PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
34010745-2	2021	When GLE was orally administered to mice, intestinal BCRP expression was significantly suppressed.	GLE	5-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	53-57
34010745-6	2021	In Caco-2 cells, GLE treatment did not affect BCRP expression, but treatment with the lysates of GLE-treated mouse feces significantly suppressed BCRP expression.	GLE	97-100	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	146-150
33602075-8	2021	Using magnetic nanoparticles polyMAG as the carrier of ABCG2-siRNA, polyMAG-ABCG2-siRNA was transfected into the Doxorubicin (DOX)-resistant breast cancer cell line MCF-7/ADR and directly into the tumors in nude mice.	polymag	29-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	55-60
33865975-2	2021	Ciprofloxacin is a known substrate of the ATP-binding cassette (ABC) transporters breast cancer resistance protein (BCRP) and multidrug resistance-associated protein 4 (MRP4).	Ciprofloxacin	0-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	116-120
33524505-0	2021	The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib.	Milciclib	148-157	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	62-67
33524505-4	2021	Upon oral administration of milciclib, its plasma exposure in Abcb1a/1b-/-, Abcg2-/-, and Abcb1a/1b;Abcg2-/- mice was similar to that found in wild-type mice.	Milciclib	28-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	76-81
33524505-4	2021	Upon oral administration of milciclib, its plasma exposure in Abcb1a/1b-/-, Abcg2-/-, and Abcb1a/1b;Abcg2-/- mice was similar to that found in wild-type mice.	Milciclib	28-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	100-105
33524505-5	2021	Milciclib showed good brain penetration even in wild-type mice (brain-to-plasma ratio of 1.2), but this was further increased by 5.2-fold when both Abcb1 and Abcg2 were ablated, and to a lesser extent in single Abcb1- or Abcg2-deficient mice.	Milciclib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	158-163
33524505-5	2021	Milciclib showed good brain penetration even in wild-type mice (brain-to-plasma ratio of 1.2), but this was further increased by 5.2-fold when both Abcb1 and Abcg2 were ablated, and to a lesser extent in single Abcb1- or Abcg2-deficient mice.	Milciclib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	221-226
33785654-4	2021	In vitro, selitrectinib was markedly transported by mouse Abcg2 and human ABCB1, and modestly by human ABCG2.	Selitrectinib	10-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	58-63
33785654-5	2021	Following oral administration at 10 mg/kg, selitrectinib brain-to-plasma ratios were increased in Abcb1a/1b-/- (2-fold) and Abcb1a/1b;Abcg2-/- (5.8-fold) compared to wild-type mice, but not in single Abcg2-/- mice.	Selitrectinib	43-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	134-139
33785654-7	2021	mAbcb1a/1b and mAbcg2 each restricted the plasma exposure of selitrectinib: with both systems absent oral availability increased by 1.7-fold.	Selitrectinib	61-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	15-21
33428896-8	2021	Concomitant oral administration of SSZ with febuxostat (FBX), which is an approved drug to inhibit BCRP, improved the distribution of SSZ to the spinal cord.	Sulfasalazine	35-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	99-103
33250293-0	2021	Analysis of the interaction between tryptophan-related compounds and ATP-binding cassette transporter G2 (ABCG2) using targeted metabolomics.	Tryptophan	36-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	69-104
33250293-0	2021	Analysis of the interaction between tryptophan-related compounds and ATP-binding cassette transporter G2 (ABCG2) using targeted metabolomics.	Tryptophan	36-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	106-111
33250293-2	2021	The in vitro and in vivo interactions between tryptophan-related compounds and ABCG2 were investigated.	Tryptophan	46-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-84
33250293-3	2021	The tryptophan metabolome was determined by liquid chromatography-tandem mass spectrometry in milk and plasma from wild-type and Abcg2-/- mice as well as dairy cows carrying the ABCG2 Y581S polymorphism (Y/S) and noncarrier animals (Y/Y).	Tryptophan	4-14	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	129-134
33785654-0	2021	ABCB1 and ABCG2 restrict brain and testis accumulation and, alongside CYP3A, limit oral availability of the novel TRK inhibitor selitrectinib.	Selitrectinib	128-141	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
33602075-8	2021	Using magnetic nanoparticles polyMAG as the carrier of ABCG2-siRNA, polyMAG-ABCG2-siRNA was transfected into the Doxorubicin (DOX)-resistant breast cancer cell line MCF-7/ADR and directly into the tumors in nude mice.	Doxorubicin	113-124	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	76-81
33510641-8	2020	Reduced activity of MRP4 by MK-571 caused significant decrease in the excretion rate (79.1%-94.6%) and efflux clearance (85.3%-98.0%) of formononetin sulfate, whereas the BCRP specific inhibitor Ko143 had no effect.	verlukast	28-34	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	171-175
33562088-8	2021	Hoechst efflux stem cell-like side population was increased in LuM1 (7.8%) compared with Colon26 (2.9%), both of which were markedly reduced by verapamil treatment, an ABCG2 inhibitor.	Verapamil	144-153	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	168-173
33573189-8	2021	Moreover, polyphenols were detected at the intracellular level or membrane-bound to cells, with evidence for breast cancer resistance protein (BCRP) efflux transporter role.	Polyphenols	10-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-141
33573189-8	2021	Moreover, polyphenols were detected at the intracellular level or membrane-bound to cells, with evidence for breast cancer resistance protein (BCRP) efflux transporter role.	Polyphenols	10-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	143-147
33513818-2	2021	P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are transport proteins localized at the BBB luminal membrane and play an important role in the clearance of amyloid-beta (Abeta).	Phenobarbital	110-117	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-58
33513818-2	2021	P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are transport proteins localized at the BBB luminal membrane and play an important role in the clearance of amyloid-beta (Abeta).	Phenobarbital	110-117	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-64
33307160-7	2021	Among the three tested AEDs, zonisamide was the only identified as BCRP substrate in vitro, as demonstrated by the net flux ratio of 2.73, which decreased 53.85% in the presence of a BCRP inhibitor, Ko143.	Zonisamide	29-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-71
33307160-7	2021	Among the three tested AEDs, zonisamide was the only identified as BCRP substrate in vitro, as demonstrated by the net flux ratio of 2.73, which decreased 53.85% in the presence of a BCRP inhibitor, Ko143.	Zonisamide	29-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	183-187
33307160-7	2021	Among the three tested AEDs, zonisamide was the only identified as BCRP substrate in vitro, as demonstrated by the net flux ratio of 2.73, which decreased 53.85% in the presence of a BCRP inhibitor, Ko143.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	199-204	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-71
33307160-7	2021	Among the three tested AEDs, zonisamide was the only identified as BCRP substrate in vitro, as demonstrated by the net flux ratio of 2.73, which decreased 53.85% in the presence of a BCRP inhibitor, Ko143.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	199-204	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	183-187
33307160-8	2021	Lacosamide revealed to inhibit BCRP in all tested concentrations (2.5-75 microM), exhibiting a significant increase (p<0.001) of the intracellular accumulation of a BCRP substrate (Hoechst 33342) in MDCK-BCRP cells.	Lacosamide	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-35
33307160-8	2021	Lacosamide revealed to inhibit BCRP in all tested concentrations (2.5-75 microM), exhibiting a significant increase (p<0.001) of the intracellular accumulation of a BCRP substrate (Hoechst 33342) in MDCK-BCRP cells.	Lacosamide	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	165-169
33307160-8	2021	Lacosamide revealed to inhibit BCRP in all tested concentrations (2.5-75 microM), exhibiting a significant increase (p<0.001) of the intracellular accumulation of a BCRP substrate (Hoechst 33342) in MDCK-BCRP cells.	bisbenzimide ethoxide trihydrochloride	181-194	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-35
33307160-8	2021	Lacosamide revealed to inhibit BCRP in all tested concentrations (2.5-75 microM), exhibiting a significant increase (p<0.001) of the intracellular accumulation of a BCRP substrate (Hoechst 33342) in MDCK-BCRP cells.	bisbenzimide ethoxide trihydrochloride	181-194	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	165-169
33307160-11	2021	These results corroborate the previous in vitro findings, suggesting that BCRP is involved in the transport of zonisamide through the BBB.	Zonisamide	111-121	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	74-78
33307160-14	2021	Altogether, these assays demonstrated that the impact of BCRP on the delivery of zonisamide to the brain is lower after intranasal administration, probably due to direct nose-to-brain transport.	Zonisamide	81-91	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	57-61
33294267-0	2020	Shikonin enhances the antitumor effect of cabazitaxel in prostate cancer stem cells and reverses cabazitaxel resistance by inhibiting ABCG2 and ALDH3A1.	shikonin	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	134-139
33153231-8	2020	Partial ABCG2 inhibition significantly increased the brain distribution of [11C]tariquidar in APP/PS1-21 and wild-type mice, but the brain distribution of [11C]tariquidar did not differ under both conditions between the two mouse strains.	[11c]tariquidar	75-90	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	8-13
33171190-0	2020	Mdr1a, Bcrp and Mrp2 regulate the efficacy and toxicity of mesaconitine and hypaconitine by altering their tissue accumulation and in vivo residence.	mesaconitine	59-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	7-11
33171190-0	2020	Mdr1a, Bcrp and Mrp2 regulate the efficacy and toxicity of mesaconitine and hypaconitine by altering their tissue accumulation and in vivo residence.	hypaconitine	76-88	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	7-11
33171190-1	2020	Mesaconitine (MA) and hypaconitine (HA) are the main bioactive/toxic alkaloids of Aconitum carmichaelii Debx, and MDR1, BCRP and MRP2 are involved in their efflux in vitro.	mesaconitine	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	120-124
33171190-1	2020	Mesaconitine (MA) and hypaconitine (HA) are the main bioactive/toxic alkaloids of Aconitum carmichaelii Debx, and MDR1, BCRP and MRP2 are involved in their efflux in vitro.	hypaconitine	22-34	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	120-124
32827538-7	2020	Administration of mangiferin not only decreased the serum urate levels in the hyperuricaemic mice but also increased the protein expression of ATP-binding cassette transporter, subfamily G, member 2 (ABCG2) and inhibited the protein expression of glucose transporter 9 (GLUT 9) in the intestine.	mangiferin	18-28	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	200-205
32827538-10	2020	Overall, promoting intestinal elimination of urate by upregulating ABCG2 expression and downregulating GLUT9 expression might be an important mechanism underlying mangiferin lowering serum uric acid levels.	Uric Acid	45-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-72
33294267-13	2020	Furthermore, shikonin suppressed the expression of ALDH3A1 and ABCG2 in prostate CSCs, which are two markers related to drug-resistance.	shikonin	13-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-68
33294267-14	2020	When inhibiting the expression of ABCG2 and ALDH3A1, the cabazitaxel resistant cells acquired more sensibility to cabazitaxel.	cabazitaxel	57-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
33294267-14	2020	When inhibiting the expression of ABCG2 and ALDH3A1, the cabazitaxel resistant cells acquired more sensibility to cabazitaxel.	cabazitaxel	114-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
33082288-5	2020	Treating cultured CSCs or 4T1 tumor-bearing mice with the nonsteroidal anti-inflammatory drug aspirin restored SMAR1 expression and ABCG2 repression and enhanced tumor sensitivity to doxorubicin.	Aspirin	94-101	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	132-137
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	Erlotinib Hydrochloride	84-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	154-159
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	tariquidar	98-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	33-38
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	tariquidar	98-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	154-159
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	Erlotinib Hydrochloride	175-184	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	33-38
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	Erlotinib Hydrochloride	84-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	33-38
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	Erlotinib Hydrochloride	175-184	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	154-159
32345621-8	2020	Moreover, the brain of adolescent mice contained higher mRNA levels of the multi-drug transporter Abcg2, which may extrude Delta9-THC from the brain, and of claudin-5, a protein that contributes to blood-brain barrier integrity.	delta9	123-129	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	98-103
33081568-4	2021	co-infusion of erlotinib and tariquidar by studying brain distribution of the model ABCB1/ABCG2 substrate [11C]erlotinib in mice and rhesus macaques with PET.	Erlotinib Hydrochloride	15-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	90-95
33081568-4	2021	co-infusion of erlotinib and tariquidar by studying brain distribution of the model ABCB1/ABCG2 substrate [11C]erlotinib in mice and rhesus macaques with PET.	tariquidar	29-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	90-95
33081568-4	2021	co-infusion of erlotinib and tariquidar by studying brain distribution of the model ABCB1/ABCG2 substrate [11C]erlotinib in mice and rhesus macaques with PET.	Erlotinib Hydrochloride	111-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	90-95
33081568-9	2021	Co-infusion of erlotinib/tariquidar may potentially allow for complete ABCB1/ABCG2 inhibition at the BBB, while simultaneously achieving brain-targeted EGFR inhibition.	Erlotinib Hydrochloride	15-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-82
33081568-9	2021	Co-infusion of erlotinib/tariquidar may potentially allow for complete ABCB1/ABCG2 inhibition at the BBB, while simultaneously achieving brain-targeted EGFR inhibition.	tariquidar	25-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-82
32850823-4	2020	Bergenin treatment increased Abcg2 expression both in the kidneys and intestine, while the expression of Slc2a9 was suppressed in the kidney and increased in the intestine.	bergenin	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-34
32087611-0	2020	OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation.	larotrectinib	77-90	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-34
32087611-0	2020	OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation.	larotrectinib	77-90	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-113
32087611-6	2020	KEY RESULTS: In vitro, larotrectinib was avidly transported by human (h)ABCB1 and mouse (m)Abcg2 efficiently by hABCG2, and modestly by hOATP1A2.	larotrectinib	23-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	91-96
32087611-10	2020	CONCLUSIONS AND IMPLICATIONS: ABCG2 and especially ABCB1 limit the oral availability and brain and testis penetration of larotrectinib, while OATP1A/1B transporters restrict its systemic exposure by mediating hepatic uptake, thus allowing hepatobiliary excretion.	larotrectinib	121-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-35
31729540-10	2020	After tariquidar administration, brain uptake increased 3-fold and 8-fold in wild-type and Abcg2-/- mice, respectively, but did not increase further in Abcb1a/b-/- mice.	tariquidar	6-16	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	91-96
32347580-5	2020	The results of immunohistochemistry revealed that the ABCG2 protein expression in the small and large intestine was significantly upregulated after the GFJ administration.	4-[1-(5,8-difluoroquinolin-4-yl)-2-methyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzimidazol-6-yl]-3-fluoropyridin-2-amine	152-155	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
32849930-5	2020	Apatinib inhibited the expressions of ABCG2, CD24, ICAM-1, OCT4, and SOX2 and upregulated the expressions of CD44, CD13, and FOXD3.	apatinib	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-43
32345621-8	2020	Moreover, the brain of adolescent mice contained higher mRNA levels of the multi-drug transporter Abcg2, which may extrude Delta9-THC from the brain, and of claudin-5, a protein that contributes to blood-brain barrier integrity.	Dronabinol	130-133	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	98-103
32488095-3	2020	We explore mechanisms by generating a mouse model of the orthologous Q140K Abcg2 variant and find male mice have significant hyperuricemia and metabolic alterations, but only subtle alterations of renal urate excretion and ABCG2 abundance.	Uric Acid	203-208	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-80
32205262-0	2020	Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity.	Gefitinib	39-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	124-129
32205262-8	2020	Hoechst 33342, a specific substrate of ATP Binding Cassette Subfamily G Member 2 (ABCG2), was used to determine the effects of MTE on activities of ABCG2 in tumor cells.	bisbenzimide ethoxide trihydrochloride	0-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-80
32205262-8	2020	Hoechst 33342, a specific substrate of ATP Binding Cassette Subfamily G Member 2 (ABCG2), was used to determine the effects of MTE on activities of ABCG2 in tumor cells.	bisbenzimide ethoxide trihydrochloride	0-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-87
32205262-8	2020	Hoechst 33342, a specific substrate of ATP Binding Cassette Subfamily G Member 2 (ABCG2), was used to determine the effects of MTE on activities of ABCG2 in tumor cells.	bisbenzimide ethoxide trihydrochloride	0-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	148-153
32205262-8	2020	Hoechst 33342, a specific substrate of ATP Binding Cassette Subfamily G Member 2 (ABCG2), was used to determine the effects of MTE on activities of ABCG2 in tumor cells.	methylthioethanol	127-130	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-87
32205262-8	2020	Hoechst 33342, a specific substrate of ATP Binding Cassette Subfamily G Member 2 (ABCG2), was used to determine the effects of MTE on activities of ABCG2 in tumor cells.	methylthioethanol	127-130	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	148-153
32234426-0	2020	Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.	tivozanib	22-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	76-81
32234426-3	2020	Tivozanib was transported by human ABCB1 and mouse Abcg2 in polarized MDCK-II cells.	tivozanib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-56
32239172-13	2020	We conclude that iron/heme overload in HH increases xanthine oxidase activity and also promotes p53 degradation resulting in decreased ABCG2 expression.	Iron	17-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	135-140
32528828-3	2020	In this study, rociletinib (CO-1686), a mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was found to significantly improve the efficacy of ABCG2 substrate chemotherapeutic agents in the transporter-overexpressing cancer cells in vitro and in MDR tumor xenografts in nude mice, without incurring additional toxicity.	rociletinib	15-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	181-186
32528828-3	2020	In this study, rociletinib (CO-1686), a mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was found to significantly improve the efficacy of ABCG2 substrate chemotherapeutic agents in the transporter-overexpressing cancer cells in vitro and in MDR tumor xenografts in nude mice, without incurring additional toxicity.	rociletinib	28-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	181-186
32528828-4	2020	Mechanistic studies revealed that in ABCG2-overexpressing cancer cells, rociletinib inhibited ABCG2-mediated drug efflux and increased intracellular accumulation of ABCG2 probe substrates.	rociletinib	72-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-42
32528828-4	2020	Mechanistic studies revealed that in ABCG2-overexpressing cancer cells, rociletinib inhibited ABCG2-mediated drug efflux and increased intracellular accumulation of ABCG2 probe substrates.	rociletinib	72-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	94-99
32528828-4	2020	Mechanistic studies revealed that in ABCG2-overexpressing cancer cells, rociletinib inhibited ABCG2-mediated drug efflux and increased intracellular accumulation of ABCG2 probe substrates.	rociletinib	72-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	94-99
32528828-5	2020	Moreover, rociletinib, inhibited the ATPase activity, and competed with [125I] iodoarylazidoprazosin (IAAP) photolabeling of ABCG2.	rociletinib	10-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	125-130
32528828-5	2020	Moreover, rociletinib, inhibited the ATPase activity, and competed with [125I] iodoarylazidoprazosin (IAAP) photolabeling of ABCG2.	azidoprazosin	79-100	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	125-130
32528828-5	2020	Moreover, rociletinib, inhibited the ATPase activity, and competed with [125I] iodoarylazidoprazosin (IAAP) photolabeling of ABCG2.	azidoprazosin	102-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	125-130
32528828-8	2020	Our results collectively showed that rociletinib reversed ABCG2-mediated MDR by inhibiting ABCG2 efflux function, thus increasing the cellular accumulation of the transporter substrate anticancer drugs.	rociletinib	37-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	58-63
32528828-8	2020	Our results collectively showed that rociletinib reversed ABCG2-mediated MDR by inhibiting ABCG2 efflux function, thus increasing the cellular accumulation of the transporter substrate anticancer drugs.	rociletinib	37-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	91-96
32217099-2	2020	The aim of this study was to investigate whether the widely used anti-inflammatory drug meloxicam is an Abcg2 sustrate, and how this transporter affects its systemic distribution.	Meloxicam	88-97	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-109
32217099-3	2020	Using polarized ABCG2-transduced cell lines, we found that meloxicam is efficiently transported by murine Abcg2 and human ABCG2.	Meloxicam	59-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	16-21
32217099-3	2020	Using polarized ABCG2-transduced cell lines, we found that meloxicam is efficiently transported by murine Abcg2 and human ABCG2.	Meloxicam	59-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	106-111
32217099-4	2020	After oral administration of meloxicam, the area under the plasma concentration-time curve in Abcg2-/- mice was 2-fold higher than in wild type mice (146.06 +- 10.57 microg h/ml versus 73.80 +- 10.00 microg h/ml).	Meloxicam	29-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	94-99
32217099-5	2020	Differences in meloxicam distribution were reported for several tissues after oral and intravenous administration, with a 20-fold higher concentration in the brain of Abcg2-/- after oral administration.	Meloxicam	15-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	167-172
32217099-7	2020	We conclude that Abcg2 is an important determinant of the plasma and brain distribution of meloxicam and is clearly involved in its secretion into milk.	Meloxicam	91-100	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	17-22
32239172-13	2020	We conclude that iron/heme overload in HH increases xanthine oxidase activity and also promotes p53 degradation resulting in decreased ABCG2 expression.	Heme	22-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	135-140
31968215-13	2020	In mice, the brain uptake of each alkaloid measured by in situ brain perfusion was suppressed by diphenhydramine when the transport capacity of P-gp/Bcrp at the BBB was chemically inhibited.	Diphenhydramine	97-112	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	149-153
32167760-0	2020	beta-Sitosterol Reverses Multidrug Resistance via BCRP Suppression by Inhibiting the p53-MDM2 Interaction in Colorectal Cancer.	gamma-sitosterol	0-15	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-54
32300151-6	2020	Our results demonstrate that the delivery of ispinesib is restricted by P-gp and Bcrp efflux at BBB.	ispinesib	45-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	81-85
32300151-8	2020	We further find that elacridar-a P-gp and Bcrp inhibitor-improves brain accumulation of ispinesib, resulting in remarkably reduced tumor growth and extended survival in a rodent model of glioblastoma.	ispinesib	88-97	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	42-46
32167760-3	2020	Here, we demonstrated that beta-sitosterol, the most common dietary phytosterol, recovers oxaliplatin (OXA) sensitivity in drug-resistant colorectal cancer (CRC) cells by inhibiting breast cancer resistance protein (BCRP) expression.	gamma-sitosterol	27-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	182-214
32167760-3	2020	Here, we demonstrated that beta-sitosterol, the most common dietary phytosterol, recovers oxaliplatin (OXA) sensitivity in drug-resistant colorectal cancer (CRC) cells by inhibiting breast cancer resistance protein (BCRP) expression.	gamma-sitosterol	27-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	216-220
32167760-3	2020	Here, we demonstrated that beta-sitosterol, the most common dietary phytosterol, recovers oxaliplatin (OXA) sensitivity in drug-resistant colorectal cancer (CRC) cells by inhibiting breast cancer resistance protein (BCRP) expression.	Oxaliplatin	90-101	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	182-214
32167760-3	2020	Here, we demonstrated that beta-sitosterol, the most common dietary phytosterol, recovers oxaliplatin (OXA) sensitivity in drug-resistant colorectal cancer (CRC) cells by inhibiting breast cancer resistance protein (BCRP) expression.	Oxaliplatin	103-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	182-214
32167760-3	2020	Here, we demonstrated that beta-sitosterol, the most common dietary phytosterol, recovers oxaliplatin (OXA) sensitivity in drug-resistant colorectal cancer (CRC) cells by inhibiting breast cancer resistance protein (BCRP) expression.	Oxaliplatin	103-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	216-220
32167760-4	2020	We further showed evidence that beta-sitosterol could activate p53 by disrupting the p53-MDM2 interaction, leading to an increase in p53 translocation to the nucleus and silencing the nuclear factor-kappaB (NF-kappaB) pathway, which is necessary for BCRP expression.	gamma-sitosterol	32-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	250-254
32167760-6	2020	These results revealed that beta-sitosterol is able to mediate the p53/NF-kappaB/BCRP signaling axis to regulate the response of CRC to chemotherapy.	gamma-sitosterol	28-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	81-85
31733931-7	2020	Following culturing for 7 days, the SSCs were treated with Ko143 (a specific inhibitor of ABCG2) for 1 h, and the ROS level and expression of bcl-2, bax, and p53 were analyzed.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	59-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	90-95
31733931-13	2020	The expression of ABCG2 in the SSCs cultured at 2.5% O2 was higher than in the other O2 groups.	Superoxides	85-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	18-23
31304590-3	2020	In vitro, galunisertib was vigorously transported by human ABCB1, and moderately by mouse Abcg2.	LY-2157299	10-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	90-95
31304590-5	2020	Galunisertib brain-to-plasma ratios were increased by ~24-fold in Abcb1a/1b-/- and Abcb1a/1b;Abcg2-/- mice compared to wild-type mice, but not in single Abcg2-/- mice, whereas galunisertib oral availability was not markedly affected.	LY-2157299	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	93-98
31304590-5	2020	Galunisertib brain-to-plasma ratios were increased by ~24-fold in Abcb1a/1b-/- and Abcb1a/1b;Abcg2-/- mice compared to wild-type mice, but not in single Abcg2-/- mice, whereas galunisertib oral availability was not markedly affected.	LY-2157299	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	153-158
31304590-6	2020	However, recovery of galunisertib in the small intestinal lumen was strongly reduced in Abcb1a/1b-/- and Abcb1a/1b;Abcg2-/- mice.	LY-2157299	21-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	115-120
31304590-7	2020	Oral coadministration of the ABCB1/ABCG2 inhibitor elacridar boosted galunisertib brain accumulation in wild-type mice to equal the levels seen in Abcb1a/1b;Abcg2-/- mice.	LY-2157299	69-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-40
31733931-15	2020	In conclusion, moderate to low O2 tension increases ABCG2 expression to maintain mild ROS levels, triggers the expression of the anti-apoptotic genes, suppresses the proapoptotic gene pathway, and further promotes the proliferation of mouse SSCs in vitro.	Superoxides	31-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-57
31733931-13	2020	The expression of ABCG2 in the SSCs cultured at 2.5% O2 was higher than in the other O2 groups.	Superoxides	53-55	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	18-23
31915017-8	2020	RESULTS: In vitro, intracellular teri concentration in T cells was 2.5-fold higher in abcg2-KO mice than in wt mice.	teriflunomide	33-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	86-91
31915017-9	2020	Teri-induced inhibition of T cell proliferation was two fold increased in abcg2-KO cells compared to wt cells.	teri	0-4	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	74-79
31915017-0	2020	Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis.	teriflunomide	60-73	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-56
31915017-1	2020	BACKGROUND: The multi-drug resistance transporter ABCG2, a member of the ATP-binding cassette (ABC) transporter family, mediates the efflux of different immunotherapeutics used in multiple sclerosis (MS), e.g., teriflunomide (teri), cladribine, and mitoxantrone, across cell membranes and organelles.	teriflunomide	211-224	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-55
31915017-1	2020	BACKGROUND: The multi-drug resistance transporter ABCG2, a member of the ATP-binding cassette (ABC) transporter family, mediates the efflux of different immunotherapeutics used in multiple sclerosis (MS), e.g., teriflunomide (teri), cladribine, and mitoxantrone, across cell membranes and organelles.	teriflunomide	211-215	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-55
31790256-6	2020	PET data in transporter knockout mice revealed that both ABCB1 and ABCG2 mediated biliary excretion of [11C]tariquidar.	Carbon-11	104-107	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-72
31915017-1	2020	BACKGROUND: The multi-drug resistance transporter ABCG2, a member of the ATP-binding cassette (ABC) transporter family, mediates the efflux of different immunotherapeutics used in multiple sclerosis (MS), e.g., teriflunomide (teri), cladribine, and mitoxantrone, across cell membranes and organelles.	Cladribine	233-243	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-55
31915017-1	2020	BACKGROUND: The multi-drug resistance transporter ABCG2, a member of the ATP-binding cassette (ABC) transporter family, mediates the efflux of different immunotherapeutics used in multiple sclerosis (MS), e.g., teriflunomide (teri), cladribine, and mitoxantrone, across cell membranes and organelles.	Mitoxantrone	249-261	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-55
31915017-3	2020	In this study, we aimed at investigating the functional impact of abcg2 modulation on teri-induced effects in vitro and in vivo.	teriflunomide	86-90	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	66-71
31640252-14	2019	In summary, RES529, the first dual TORC1/TORC2 dissociative inhibitor, lacking affinity for ABCB1/ABCG2 and having good brain penetration, was active in GBM preclinical/murine models giving credence to its use in clinical trial for patients with GBM treated in association with anti-angiogenetic compounds.	resorcinarene	12-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	98-103
31759109-4	2020	Upon oral administration of 10 mg/kg fisogatinib, its brain accumulation was substantially increased in Abcb1a/1b-/- (6.3-fold) and Abcb1a/1b;Abcg2-/- mice (7.2-fold) compared to wild-type mice, but not in single Abcg2-/- mice.	BLU-554	37-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	142-147
31759109-4	2020	Upon oral administration of 10 mg/kg fisogatinib, its brain accumulation was substantially increased in Abcb1a/1b-/- (6.3-fold) and Abcb1a/1b;Abcg2-/- mice (7.2-fold) compared to wild-type mice, but not in single Abcg2-/- mice.	BLU-554	37-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	213-218
31709896-7	2020	Conclusions: In summary, the ABCG2 inhibitor, botryllamide G, increases brain exposure to lapatinib in mice lacking Abcb1, although the combination of botryllamide G and tariquidar increases brain exposure in wild-type mice only briefly (1 h).	lapatinib	90-99	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-34
32015688-0	2020	Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic Mice.	empagliflozin	0-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	58-63
32015688-7	2020	Furthermore, in both kidney and ileum, empagliflozin obviously promoted protein expression of uric acid (UA) transporter ABCG2, p-AMPK, p-AKT and p-CREB.	empagliflozin	39-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-126
32015688-7	2020	Furthermore, in both kidney and ileum, empagliflozin obviously promoted protein expression of uric acid (UA) transporter ABCG2, p-AMPK, p-AKT and p-CREB.	Uric Acid	94-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-126
32015688-7	2020	Furthermore, in both kidney and ileum, empagliflozin obviously promoted protein expression of uric acid (UA) transporter ABCG2, p-AMPK, p-AKT and p-CREB.	Uric Acid	105-107	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-126
32015688-11	2020	Taken together, our study demonstrated that empagliflozin treatment played an essential role in attenuating HUA by upregulation of ABCG2 via AMPK/AKT/CREB signaling pathway.	empagliflozin	44-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	131-136
31709896-0	2020	Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain.	botryllamide G	0-14	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-26
31709896-0	2020	Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain.	lapatinib	51-60	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-26
31709896-2	2020	The present study ascertained whether the natural product botryllamide G is viable for in vivo inhibition of ABCG2 using lapatinib as a probe for ABCB1 and ABCG2-mediated efflux from the brain.	botryllamide G	58-72	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-114
31709896-2	2020	The present study ascertained whether the natural product botryllamide G is viable for in vivo inhibition of ABCG2 using lapatinib as a probe for ABCB1 and ABCG2-mediated efflux from the brain.	botryllamide G	58-72	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	156-161
31709896-7	2020	Conclusions: In summary, the ABCG2 inhibitor, botryllamide G, increases brain exposure to lapatinib in mice lacking Abcb1, although the combination of botryllamide G and tariquidar increases brain exposure in wild-type mice only briefly (1 h).	botryllamide G	46-60	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-34
33198612-0	2020	Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Mediate the Disposition of Leonurine-10-O-beta-glucuronide.	leonurine-10-o-beta-glucuronide	95-126	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-32
33198612-2	2020	OBJECTIVE: To explore the effects of breast cancer resistance protein (Bcrp) and multidrug resistance protein 2 (Mrp2) on the disposition of L-10-G.	l-10-g	141-147	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-69
33198612-2	2020	OBJECTIVE: To explore the effects of breast cancer resistance protein (Bcrp) and multidrug resistance protein 2 (Mrp2) on the disposition of L-10-G.	l-10-g	141-147	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-75
33198612-5	2020	RESULTS: After intravenous injection with Leo, the AUC0-  values of L-10-G in Bcrp1-/- and Mrp2-/- mice were 1.55-fold and 16.80-fold higher, respectively, than those in wild-type FVB mice (P < 0.05).	leonurine	42-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	78-83
33198612-10	2020	CONCLUSION: Both Bcrp and Mrp2 are involved in the disposition of L-10-G, and Mrp2 exhibits a superior influence.	l-10-g	66-72	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	17-21
31619389-9	2019	These results indicate additional efflux transporters other than P-gp and Bcrp may be limiting distribution of SAR405838 to the brain.	SAR405838	111-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	74-78
31399506-2	2019	The results indicate that Bcrp acts as a canalicular efflux mediator for DCF, as wild-type (WT) mice had biliary excretion values that were 2.2- to 2.6-fold greater than Bcrp KO mice, although DCF plasma levels were not affected.	Diclofenac	73-76	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-30
31399506-2	2019	The results indicate that Bcrp acts as a canalicular efflux mediator for DCF, as wild-type (WT) mice had biliary excretion values that were 2.2- to 2.6-fold greater than Bcrp KO mice, although DCF plasma levels were not affected.	Diclofenac	193-196	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-30
31399506-3	2019	The loss of Bcrp resulted in a 1.8- to 3.2-fold increase of diclofenac acyl glucuronide (DCF-AG) plasma concentrations in KO animals compared with WT mice, while the biliary excretion of DCF-AG increased 1.4-fold in WT versus KO mice.	1-O-(2-((2',6'-dichlorophenyl)amino)phenylacetyl)glucopyranuronic acid	60-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	12-16
31399506-3	2019	The loss of Bcrp resulted in a 1.8- to 3.2-fold increase of diclofenac acyl glucuronide (DCF-AG) plasma concentrations in KO animals compared with WT mice, while the biliary excretion of DCF-AG increased 1.4-fold in WT versus KO mice.	dcf-ag	89-95	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	12-16
31399506-3	2019	The loss of Bcrp resulted in a 1.8- to 3.2-fold increase of diclofenac acyl glucuronide (DCF-AG) plasma concentrations in KO animals compared with WT mice, while the biliary excretion of DCF-AG increased 1.4-fold in WT versus KO mice.	dcf-ag	187-193	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	12-16
31175939-3	2019	In vitro, human ABCB1 and mouse Abcg2 modestly transported osimertinib.	osimertinib	59-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-37
31175939-0	2019	Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).	osimertinib	22-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	111-116
31163185-5	2019	In the present study, the effect of 14 TKIs on Pgp-, Bcrp1-, and BCRP-mediated afatinib efflux was investigated in vitro.	Afatinib	79-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	65-69
31163185-6	2019	Nilotinib was a potent inhibitor of Pgp, Bcrp1, and BCRP, with EC50 values of 2.22, 2.47, and 0.692 muM, respectively.	nilotinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-46
31163185-6	2019	Nilotinib was a potent inhibitor of Pgp, Bcrp1, and BCRP, with EC50 values of 2.22, 2.47, and 0.692 muM, respectively.	nilotinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-56
31527775-9	2019	Excretion of NP-59 into bile via BCRP was observed in normal mice with and without Ko143 in the biological distribution and SPECT imaging.	Adosterol	13-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	33-37
31512001-0	2019	Metabolome Analysis Reveals Dermal Histamine Accumulation in Murine Dermatitis Provoked by Genetic Deletion of P-Glycoprotein and Breast Cancer Resistance Protein.	Histamine	35-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	130-162
31512001-6	2019	This hypothesis was supported by the metabolome analysis which revealed that concentration of histamine and other dermatitis-associated metabolites like urate and serotonin in the dermatitis skin, but not normal skin, of Mdr1a/1b/Bcrp-/- mice was higher than that of wild-type mice.	Histamine	94-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	230-234
31512001-6	2019	This hypothesis was supported by the metabolome analysis which revealed that concentration of histamine and other dermatitis-associated metabolites like urate and serotonin in the dermatitis skin, but not normal skin, of Mdr1a/1b/Bcrp-/- mice was higher than that of wild-type mice.	Uric Acid	153-158	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	230-234
31512001-6	2019	This hypothesis was supported by the metabolome analysis which revealed that concentration of histamine and other dermatitis-associated metabolites like urate and serotonin in the dermatitis skin, but not normal skin, of Mdr1a/1b/Bcrp-/- mice was higher than that of wild-type mice.	Serotonin	163-172	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	230-234
30317661-5	2019	In a mouse xenograft model, knockdown of CCN2 expression increased the therapeutic effect of doxorubicin, which was reversed by ABCG2 overexpression.	Doxorubicin	93-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	128-133
30953637-8	2019	Moreover, the combination of SN-38 and sunitinib caused synergism on colon cancer cells, with significant inhibition of the ABCG2 gene expression and an increase of SN-38 intracellular concentrations.	Irinotecan	29-34	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	124-129
30953637-8	2019	Moreover, the combination of SN-38 and sunitinib caused synergism on colon cancer cells, with significant inhibition of the ABCG2 gene expression and an increase of SN-38 intracellular concentrations.	Sunitinib	39-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	124-129
31175939-0	2019	Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).	Ro 21-5104	60-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	111-116
30897286-3	2019	In the present study, we tested the in vivo effects of two HDAC inhibitors, valproic acid (VPA; 400 mg/kg) and apicidin (5 mg/kg), on Mdr1 and Bcrp transporter expression in brain regions of adult male mice injected intraperitoneally daily for 7 days.	Valproic Acid	76-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	143-147
30897286-3	2019	In the present study, we tested the in vivo effects of two HDAC inhibitors, valproic acid (VPA; 400 mg/kg) and apicidin (5 mg/kg), on Mdr1 and Bcrp transporter expression in brain regions of adult male mice injected intraperitoneally daily for 7 days.	Valproic Acid	91-94	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	143-147
30897286-3	2019	In the present study, we tested the in vivo effects of two HDAC inhibitors, valproic acid (VPA; 400 mg/kg) and apicidin (5 mg/kg), on Mdr1 and Bcrp transporter expression in brain regions of adult male mice injected intraperitoneally daily for 7 days.	apicidin	111-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	143-147
30576553-0	2019	Placental BCRP/ABCG2 Transporter Prevents Fetal Exposure to the Estrogenic Mycotoxin Zearalenone.	Zearalenone	85-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-14
31015586-5	2019	However, MK-571 (MRP inhibitor) and novobiocin (BCRP inhibitor) substantially increased the rate of ALDH-positive CT26 cells based on either Aldefluor or AldeRed588 assays.	Novobiocin	36-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	48-52
30790712-5	2019	BPA increased all-trans-retinoic acid concentration and expression of Adh1, Aox1 and Cyp1a2 (biosynthesis of retinoic acid), while reduced Mrp3 (efflux from hepatocyte to blood), increased Bcrp expression (biliary excretion) and changed the retinoid-dependent signalling system after reducing expression of Rxrbeta and increasing that of Fgf21.	bisphenol A	0-3	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	189-193
30858238-0	2019	Role of ABCG2 in Secretion into Milk of the Anti-Inflammatory Flunixin and Its Main Metabolite: In Vitro-In Vivo Correlation in Mice and Cows.	flunixin	62-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	8-13
30858238-7	2019	The objective of this work was to study the role of ABCG2 in the secretion into milk of flunixin and its main metabolite, 5-hydroxyflunixin, using Abcg2(-/-) mice, and to investigate the implication of the Y581S polymorphism in the secretion of these compounds into cow milk.	flunixin	88-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-57
30576553-0	2019	Placental BCRP/ABCG2 Transporter Prevents Fetal Exposure to the Estrogenic Mycotoxin Zearalenone.	Zearalenone	85-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	15-20
30576553-2	2019	Previous research has pointed to the estrogenic mycotoxin zearalenone as a potential substrate for BCRP.	Zearalenone	58-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	99-103
30576553-3	2019	Here, we sought to assess the role of the BCRP transporter in the transplacental disposition of zearalenone during pregnancy.	Zearalenone	96-107	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	42-46
30576553-5	2019	In both models, the presence of BCRP protein increased the basolateral-to-apical transport and reduced the apical-to-basolateral transport of zearalenone over a 2-h period.	Zearalenone	142-153	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-36
30576553-9	2019	In Bcrp-/- mice, the free fetal concentrations of zearalenone, alpha-zearalenol, and beta-zearalenol were increased by 115%, 84%, and 150%, respectively, when compared with wild-type mice.	Zearalenone	50-61	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	3-7
30576553-9	2019	In Bcrp-/- mice, the free fetal concentrations of zearalenone, alpha-zearalenol, and beta-zearalenol were increased by 115%, 84%, and 150%, respectively, when compared with wild-type mice.	zearalenol	63-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	3-7
30576553-9	2019	In Bcrp-/- mice, the free fetal concentrations of zearalenone, alpha-zearalenol, and beta-zearalenol were increased by 115%, 84%, and 150%, respectively, when compared with wild-type mice.	zearalenol	85-100	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	3-7
30576553-10	2019	Concentrations of free zearalenone and alpha-zearalenol were elevated 145% and 78% in Bcrp-/- placentas, respectively, when compared with wild-type placentas.	Zearalenone	23-34	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	86-90
30576553-10	2019	Concentrations of free zearalenone and alpha-zearalenol were elevated 145% and 78% in Bcrp-/- placentas, respectively, when compared with wild-type placentas.	zearalenol	39-55	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	86-90
30576553-11	2019	Taken together, these data indicate that the placental BCRP transporter functions to reduce the fetal accumulation of zearalenone, which may impact susceptibility to developmental toxicities associated with in utero zearalenone exposure.	Zearalenone	118-129	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	55-59
30576553-11	2019	Taken together, these data indicate that the placental BCRP transporter functions to reduce the fetal accumulation of zearalenone, which may impact susceptibility to developmental toxicities associated with in utero zearalenone exposure.	Zearalenone	216-227	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	55-59
30701287-0	2019	ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	77-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-32
30701287-0	2019	ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation.	dss	82-85	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-32
30701287-6	2019	The results suggest that Mdr1a/1b, Bcrp1 and Mrp2 contributed to biliary excretion and Mrp3 to sinusoidal secretion of the pre-carcinogenic metabolite N2-OH-PhIP.	2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	151-161	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-40
30602435-4	2019	administration of ET and 4-ME, the area under the plasma concentration-time curve from time 0 to the last data point or infinity values of ET, 4-ME, and their glucuronides (ET-G and 4-ME-G) were remarkably and significantly increased in most Bcrp1-/- and Mrp2-/- mice compared with those in wild-type FVB mice (P &lt; 0.05).	4-methylesculetin	25-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	242-247
30694684-0	2019	Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib.	Carbon-11	145-148	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-29
30694684-0	2019	Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib.	Carbon-11	145-148	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	128-133
30694684-0	2019	Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib.	Erlotinib Hydrochloride	149-158	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-29
30694684-0	2019	Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib.	Erlotinib Hydrochloride	149-158	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	128-133
30602435-4	2019	administration of ET and 4-ME, the area under the plasma concentration-time curve from time 0 to the last data point or infinity values of ET, 4-ME, and their glucuronides (ET-G and 4-ME-G) were remarkably and significantly increased in most Bcrp1-/- and Mrp2-/- mice compared with those in wild-type FVB mice (P &lt; 0.05).	4-methylesculetin	143-147	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	242-247
30602435-4	2019	administration of ET and 4-ME, the area under the plasma concentration-time curve from time 0 to the last data point or infinity values of ET, 4-ME, and their glucuronides (ET-G and 4-ME-G) were remarkably and significantly increased in most Bcrp1-/- and Mrp2-/- mice compared with those in wild-type FVB mice (P &lt; 0.05).	et-g	173-177	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	242-247
30602435-4	2019	administration of ET and 4-ME, the area under the plasma concentration-time curve from time 0 to the last data point or infinity values of ET, 4-ME, and their glucuronides (ET-G and 4-ME-G) were remarkably and significantly increased in most Bcrp1-/- and Mrp2-/- mice compared with those in wild-type FVB mice (P &lt; 0.05).	4-methylesculetin	143-147	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	242-247
30602435-6	2019	In Caco-2 monolayers, the efflux and clearance rates of ET-G and 4-ME-G were markedly reduced by the BCRP inhibitor Ko143 and MRP2 inhibitor MK571 on the apical side (P &lt; 0.05).	et-g	56-60	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-105
30602435-6	2019	In Caco-2 monolayers, the efflux and clearance rates of ET-G and 4-ME-G were markedly reduced by the BCRP inhibitor Ko143 and MRP2 inhibitor MK571 on the apical side (P &lt; 0.05).	4-methylesculetin	65-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-105
30602435-6	2019	In Caco-2 monolayers, the efflux and clearance rates of ET-G and 4-ME-G were markedly reduced by the BCRP inhibitor Ko143 and MRP2 inhibitor MK571 on the apical side (P &lt; 0.05).	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	116-121	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-105
30602435-7	2019	In an intestinal perfusion study, the excretion of ET-G was significantly decreased in perfusate and increased in plasma in Bcrp1-/- mice compared with those in wild-type FVB mice (P &lt; 0.05).	et-g	51-55	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	124-129
30602435-10	2019	In conclusion, BCRP and MRP2 are involved in excreting ET-G and 4-ME-G. ET and 4-ME are most likely absorbed via passive diffusion in the intestines.	et-g	55-59	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	15-19
30602435-10	2019	In conclusion, BCRP and MRP2 are involved in excreting ET-G and 4-ME-G. ET and 4-ME are most likely absorbed via passive diffusion in the intestines.	4-methylesculetin	64-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	15-19
30602435-10	2019	In conclusion, BCRP and MRP2 are involved in excreting ET-G and 4-ME-G. ET and 4-ME are most likely absorbed via passive diffusion in the intestines.	esculetin	55-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	15-19
30602435-10	2019	In conclusion, BCRP and MRP2 are involved in excreting ET-G and 4-ME-G. ET and 4-ME are most likely absorbed via passive diffusion in the intestines.	4-methylesculetin	79-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	15-19
30221549-2	2019	One of the most widely used drugs, doxorubicin (Dox) is a substrate of three different ATP-binding cassette (ABC) transporters, namely, ABCB1, ABCG2 and ABCC1, predominantly contributing to MDR phenotype in cancer.	Doxorubicin	35-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	143-148
30221549-2	2019	One of the most widely used drugs, doxorubicin (Dox) is a substrate of three different ATP-binding cassette (ABC) transporters, namely, ABCB1, ABCG2 and ABCC1, predominantly contributing to MDR phenotype in cancer.	Doxorubicin	48-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	143-148
30553002-0	2019	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.	quizartinib	125-136	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	66-70
30622172-8	2019	In vivo studies in mice show that the brain distribution of CCT196969, LY3009120, and MLN2480 is limited, and is enhanced in transgenic mice lacking P-gp and Bcrp.	1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(3-oxo-3,4-dihydropyrido(3,2-b)pyrazin-8-yloxy)phenyl)urea	60-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	158-162
30622172-8	2019	In vivo studies in mice show that the brain distribution of CCT196969, LY3009120, and MLN2480 is limited, and is enhanced in transgenic mice lacking P-gp and Bcrp.	LY3009120	71-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	158-162
30622172-8	2019	In vivo studies in mice show that the brain distribution of CCT196969, LY3009120, and MLN2480 is limited, and is enhanced in transgenic mice lacking P-gp and Bcrp.	tak-580	86-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	158-162
30553002-0	2019	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.	quizartinib	125-136	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-76
30553002-3	2019	Quizartinib was transported by human ABCB1 in vitro, and by mouse (m)Abcb1 and mAbcg2 in vivo.	quizartinib	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-85
30553002-4	2019	Upon oral administration, the brain accumulation of quizartinib was 6-fold decreased by mAbcb1 and 2-fold by mAbcg2 (together: 12-fold).	quizartinib	52-63	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-115
30339949-7	2019	RESULTS: Mouse liver homogenization by Potter-Elvehjem homogenizer in combination with sucrose-cushion ultracentrifugation and PM enrichment with Tween 40 resulted in two times higher transporter protein quantity (Breast cancer resistance protein (Bcrp) 18.0 fmol/mug protein) in comparison with the PM samples isolated by extraction kit (Bcrp 9.8 fmol/mug protein).	Sucrose	87-94	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	214-246
30339949-7	2019	RESULTS: Mouse liver homogenization by Potter-Elvehjem homogenizer in combination with sucrose-cushion ultracentrifugation and PM enrichment with Tween 40 resulted in two times higher transporter protein quantity (Breast cancer resistance protein (Bcrp) 18.0 fmol/mug protein) in comparison with the PM samples isolated by extraction kit (Bcrp 9.8 fmol/mug protein).	polysorbate 40	146-154	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	214-246
30339949-7	2019	RESULTS: Mouse liver homogenization by Potter-Elvehjem homogenizer in combination with sucrose-cushion ultracentrifugation and PM enrichment with Tween 40 resulted in two times higher transporter protein quantity (Breast cancer resistance protein (Bcrp) 18.0 fmol/mug protein) in comparison with the PM samples isolated by extraction kit (Bcrp 9.8 fmol/mug protein).	polysorbate 40	146-154	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	248-252
30339949-7	2019	RESULTS: Mouse liver homogenization by Potter-Elvehjem homogenizer in combination with sucrose-cushion ultracentrifugation and PM enrichment with Tween 40 resulted in two times higher transporter protein quantity (Breast cancer resistance protein (Bcrp) 18.0 fmol/mug protein) in comparison with the PM samples isolated by extraction kit (Bcrp 9.8 fmol/mug protein).	polysorbate 40	146-154	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	339-343
30243825-13	2019	RESULTS: HQ, AS-IV, CS and FMNT significantly upregulated the P-gp and BCRP expression in the liver of wild-type mice.	7,3'-dihydroxy-4'-methoxyisoflavone	20-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-75
30243825-19	2019	HQ and these compounds also significantly enhanced the efflux activity of P-gp and BCRP, and the increased intracellular ATP levels were likely involved in the increased P-gp and BCRP function.	Adenosine Triphosphate	121-124	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	179-183
30247919-3	2018	Using in vitro transport assays and genetically modified mouse models, we investigated whether the multidrug efflux transporters ABCB1 and ABCG2 and the multidrug-metabolizing CYP3A enzyme family can affect the oral bioavailability and tissue disposition of ibrutinib and ibrutinib-DiOH.	ibrutinib	258-267	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	139-144
30415015-2	2018	Inhibition of ABCB1 and ABCG2 at the mouse BBB improved the BBB permeation of erlotinib but could not be achieved in humans.	Erlotinib Hydrochloride	78-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-29
30247919-3	2018	Using in vitro transport assays and genetically modified mouse models, we investigated whether the multidrug efflux transporters ABCB1 and ABCG2 and the multidrug-metabolizing CYP3A enzyme family can affect the oral bioavailability and tissue disposition of ibrutinib and ibrutinib-DiOH.	ibrutinib	272-281	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	139-144
30247919-3	2018	Using in vitro transport assays and genetically modified mouse models, we investigated whether the multidrug efflux transporters ABCB1 and ABCG2 and the multidrug-metabolizing CYP3A enzyme family can affect the oral bioavailability and tissue disposition of ibrutinib and ibrutinib-DiOH.	dioh	282-286	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	139-144
30247919-4	2018	In vitro, ibrutinib was transported moderately by human ABCB1 and mouse Abcg2 but not detectably by human ABCG2.	ibrutinib	10-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	72-77
30176366-7	2018	Ko143 (a BCRP-selective inhibitor) at 20 muM significantly decreased the excretion rate of liquiritigenin sulfate (&gt;42.5%, p &lt; 0.001).	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	0-5	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	9-13
30111622-0	2018	Pheophorbide A: Fluorescent Bcrp Substrate to Measure Oral Drug-Drug Interactions in Real-Time In Vivo.	pheophorbide a	0-14	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	28-32
30111622-1	2018	We investigated whether pheophorbide A (PhA) could serve as a selective breast cancer resistance protein (BCRP) substrate (victim) to screen in vivo using fluorescent live animal imaging for transporter-mediated interactions with orally administered inhibitors (perpetrators), and whether that could be coupled with serum sampling to measure the systemic concentration of PhA with a fast-throughput in vitro fluorescent assay.	pheophorbide a	24-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	72-104
30111622-1	2018	We investigated whether pheophorbide A (PhA) could serve as a selective breast cancer resistance protein (BCRP) substrate (victim) to screen in vivo using fluorescent live animal imaging for transporter-mediated interactions with orally administered inhibitors (perpetrators), and whether that could be coupled with serum sampling to measure the systemic concentration of PhA with a fast-throughput in vitro fluorescent assay.	pheophorbide a	24-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	106-110
30176366-12	2018	BCRP and MRP4 should be the key factors for the cellular excretion of liquiritigenin sulfate.	liquiritigenin sulfate	70-92	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
30176366-7	2018	Ko143 (a BCRP-selective inhibitor) at 20 muM significantly decreased the excretion rate of liquiritigenin sulfate (&gt;42.5%, p &lt; 0.001).	liquiritigenin sulfate	91-113	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	9-13
30176366-9	2018	Furthermore, knockdown of BCRP led to moderate reduction in sulfate excretion (15.9%-16.9%, p &lt; 0.05).	Sulfates	60-67	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-30
30253203-4	2018	Following oral brigatinib administration (10 mg/kg), brain accumulation was dramatically increased in Abcb1a/1b-/- (19.3-fold) and Abcb1a/1b;Abcg2-/-(41.8-fold), but not in single Abcg2-/- mice compared to wild-type mice.	brigatinib	15-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	141-146
30253203-4	2018	Following oral brigatinib administration (10 mg/kg), brain accumulation was dramatically increased in Abcb1a/1b-/- (19.3-fold) and Abcb1a/1b;Abcg2-/-(41.8-fold), but not in single Abcg2-/- mice compared to wild-type mice.	brigatinib	15-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	180-185
30253203-3	2018	In vitro, brigatinib was exceptionally well transported by human ABCB1 and mouse Abcg2, and efficiently by human ABCG2.	brigatinib	10-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	81-86
30253203-11	2018	ABCB1 and ABCG2 thus limit brain accumulation, toxicity, and systemic exposure of brigatinib, whereas CYP3 A also markedly restricts its oral availability.	brigatinib	82-92	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
29964089-4	2018	Here, we treated pregnant Abcg2 Cre/Cre RosaLSL-YFP mice with a single injection of 4-hydroxytamoxifen at embryonic day 7.5.	hydroxytamoxifen	84-102	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-31
29744867-4	2018	In vitro, human ABCB1 and mouse Abcg2 modestly transported lorlatinib.	lorlatinib	59-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-37
29767557-8	2018	Conversely, mRNA expression levels in kidney of genes encoding solute and water transporters in the proximal tubule ( Abcg2 and Slc34a1) and collecting duct ( Aqp2, Scnn1a, and Scnn1b) remained comparable between control and iKsp- Pkd1-/- mice, although a water reabsorption defect was observed in iKsp- Pkd1-/- mice.	Water	74-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	118-123
29098941-9	2018	This result was supported by a Cpd-1 and Bcrp inhibitor ML753286 drug-drug interaction (DDI) study in mice.	ML753286	56-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-45
30115694-7	2018	ABCG2 and RASA1 were identified only from de novo transposon insertions acquired during AZD4547 treatment, demonstrating that insertional mutagenesis in mice is an effective tool for identifying potential mechanisms of resistance to targeted cancer therapies.Significance: These findings demonstrate that a combined approach of transcriptomics and insertional mutagenesis in vivo is an effective method for identifying potential targets to overcome resistance to therapy in the clinic.	AZD4547	88-95	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
29683403-6	2018	The BCRP functionality was identified by flow cytometric analysis of mitoxantrone accumulation and fluorescence microscopic analysis of Hoechst 33342 accumulation using Ko-143 as BCRP inhibitor.	Mitoxantrone	69-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	4-8
30104076-0	2018	Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate.	Adenosine Triphosphate	20-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-87
30104076-0	2018	Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate.	Adenosine Triphosphate	44-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-87
30104076-0	2018	Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate.	Artesunate	165-175	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-87
30104076-1	2018	The present study investigated the correlation between the abnormal expression of adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) in esophageal cancer and the drug resistance of esophageal cancer, the reversal effect in drug resistance of artesunate (Art), and the mechanism underlying esophageal cancer using nude mice with subcutaneous xenograft as an animal model.	Adenosine Triphosphate	82-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	144-149
30104076-1	2018	The present study investigated the correlation between the abnormal expression of adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) in esophageal cancer and the drug resistance of esophageal cancer, the reversal effect in drug resistance of artesunate (Art), and the mechanism underlying esophageal cancer using nude mice with subcutaneous xenograft as an animal model.	Adenosine Triphosphate	106-109	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	144-149
30104076-1	2018	The present study investigated the correlation between the abnormal expression of adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) in esophageal cancer and the drug resistance of esophageal cancer, the reversal effect in drug resistance of artesunate (Art), and the mechanism underlying esophageal cancer using nude mice with subcutaneous xenograft as an animal model.	Artesunate	260-270	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	144-149
30104076-1	2018	The present study investigated the correlation between the abnormal expression of adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) in esophageal cancer and the drug resistance of esophageal cancer, the reversal effect in drug resistance of artesunate (Art), and the mechanism underlying esophageal cancer using nude mice with subcutaneous xenograft as an animal model.	Artesunate	272-275	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	144-149
29683403-6	2018	The BCRP functionality was identified by flow cytometric analysis of mitoxantrone accumulation and fluorescence microscopic analysis of Hoechst 33342 accumulation using Ko-143 as BCRP inhibitor.	bisbenzimide ethoxide trihydrochloride	136-149	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	4-8
29683403-6	2018	The BCRP functionality was identified by flow cytometric analysis of mitoxantrone accumulation and fluorescence microscopic analysis of Hoechst 33342 accumulation using Ko-143 as BCRP inhibitor.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	169-175	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	4-8
29683403-6	2018	The BCRP functionality was identified by flow cytometric analysis of mitoxantrone accumulation and fluorescence microscopic analysis of Hoechst 33342 accumulation using Ko-143 as BCRP inhibitor.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	169-175	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	179-183
29683403-9	2018	The verapamil induced a higher cellular uptake of Rhodamine 123, and Ko-143 significantly elevated cellular accumulation of mitoxantrone and Hoechst 33342, suggesting the P-gp and BCRP functionality shown by bEnd3 cells.	Verapamil	4-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	180-184
29683403-9	2018	The verapamil induced a higher cellular uptake of Rhodamine 123, and Ko-143 significantly elevated cellular accumulation of mitoxantrone and Hoechst 33342, suggesting the P-gp and BCRP functionality shown by bEnd3 cells.	Mitoxantrone	124-136	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	180-184
29683403-9	2018	The verapamil induced a higher cellular uptake of Rhodamine 123, and Ko-143 significantly elevated cellular accumulation of mitoxantrone and Hoechst 33342, suggesting the P-gp and BCRP functionality shown by bEnd3 cells.	bisbenzimide ethoxide trihydrochloride	141-154	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	180-184
30042379-0	2018	Identification of ABCG2 as an Exporter of Uremic Toxin Indoxyl Sulfate in Mice and as a Crucial Factor Influencing CKD Progression.	Indican	55-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	18-23
29852323-0	2018	Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2.	Temozolomide	53-65	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	93-98
29674491-4	2018	The PK data demonstrated a significantly increased oral bioavailability and serum exposure of ketamine in dKO &gt; Pgp KO &gt; Bcrp KO mice compared with WT mice.	Ketamine	94-102	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	127-131
29674491-5	2018	Intraperitoneal ketamine-induced dLORR was significantly longer in dKO &gt; Pgp KO &gt; Bcrp KO &gt; WT mice compared with WT mice.	Ketamine	16-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	88-92
29674491-6	2018	Inhibition of Bcrp and Pgp in WT mice using the dual Pgp/Bcrp inhibitor elacridar increased the ketamine-induced dLORR compared with vehicle-treated mice.	Ketamine	96-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	14-18
29674491-6	2018	Inhibition of Bcrp and Pgp in WT mice using the dual Pgp/Bcrp inhibitor elacridar increased the ketamine-induced dLORR compared with vehicle-treated mice.	Ketamine	96-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	57-61
29674491-8	2018	In total, these results demonstrate that ketamine appears to be a dual Pgp/Bcrp substrate whose PK and pharmacodynamics are affected by Pgp and Bcrp-mediated efflux.	Ketamine	41-49	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-79
29674491-8	2018	In total, these results demonstrate that ketamine appears to be a dual Pgp/Bcrp substrate whose PK and pharmacodynamics are affected by Pgp and Bcrp-mediated efflux.	Ketamine	41-49	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	144-148
29852323-3	2018	We have studied the effect of P-gp and BCRP on the pharmacokinetics and pharmacodynamics of temozolomide, making use of a comprehensive set of in vitro transport experiments and in vivo pharmacokinetic and antitumor efficacy experiments using wild-type, Abcg2-/-, Abcb1a/b-/-, and Abcb1a/b;Abcg2-/- mice.	Temozolomide	92-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-43
29852323-3	2018	We have studied the effect of P-gp and BCRP on the pharmacokinetics and pharmacodynamics of temozolomide, making use of a comprehensive set of in vitro transport experiments and in vivo pharmacokinetic and antitumor efficacy experiments using wild-type, Abcg2-/-, Abcb1a/b-/-, and Abcb1a/b;Abcg2-/- mice.	Temozolomide	92-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	254-259
29852323-3	2018	We have studied the effect of P-gp and BCRP on the pharmacokinetics and pharmacodynamics of temozolomide, making use of a comprehensive set of in vitro transport experiments and in vivo pharmacokinetic and antitumor efficacy experiments using wild-type, Abcg2-/-, Abcb1a/b-/-, and Abcb1a/b;Abcg2-/- mice.	Temozolomide	92-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	290-295
29852323-4	2018	We here show that the combined deletion of Abcb1a/b and Abcg2 increases the brain penetration of temozolomide by 1.5-fold compared to wild-type controls (P &lt; .001) without changing the systemic drug exposure.	Temozolomide	97-109	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	56-61
29852323-5	2018	Moreover, the same increase was achieved when temozolomide was given to wild-type mice in combination with the dual P-gp/BCRP inhibitor elacridar (GF120918).	Temozolomide	46-58	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
29852323-5	2018	Moreover, the same increase was achieved when temozolomide was given to wild-type mice in combination with the dual P-gp/BCRP inhibitor elacridar (GF120918).	Elacridar	136-145	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
29852323-5	2018	Moreover, the same increase was achieved when temozolomide was given to wild-type mice in combination with the dual P-gp/BCRP inhibitor elacridar (GF120918).	Elacridar	147-155	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
29852323-6	2018	The antitumor efficacy of temozolomide against three different intracranial tumor models was significantly enhanced when Abcb1a/b and Abcg2 were genetically deficient or pharmacologically inhibited in recipient mice.	Temozolomide	26-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	134-139
29175983-8	2018	Results: Brain uptake of 11C-erlotinib was 2.6-fold higher in Abcb1a/b;Abcg2 knockout mice than in WT mice, measured as percentage injected dose per gram of tissue (P = 0.01).	Erlotinib Hydrochloride	25-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-76
29147815-4	2018	Methods We have here conducted a comprehensive set of in vitro and in vivo experiments to determine to what extent two dominant efflux transporters in the BBB, P-gp (ABCB1) and BCRP (ABCG2), exhibit affinity towards AZD1775 and PD0166285 and restrict their brain penetration.	adavosertib	216-223	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	177-181
29147815-4	2018	Methods We have here conducted a comprehensive set of in vitro and in vivo experiments to determine to what extent two dominant efflux transporters in the BBB, P-gp (ABCB1) and BCRP (ABCG2), exhibit affinity towards AZD1775 and PD0166285 and restrict their brain penetration.	adavosertib	216-223	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	183-188
29147815-4	2018	Methods We have here conducted a comprehensive set of in vitro and in vivo experiments to determine to what extent two dominant efflux transporters in the BBB, P-gp (ABCB1) and BCRP (ABCG2), exhibit affinity towards AZD1775 and PD0166285 and restrict their brain penetration.	PD 0166285	228-237	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	177-181
29147815-4	2018	Methods We have here conducted a comprehensive set of in vitro and in vivo experiments to determine to what extent two dominant efflux transporters in the BBB, P-gp (ABCB1) and BCRP (ABCG2), exhibit affinity towards AZD1775 and PD0166285 and restrict their brain penetration.	PD 0166285	228-237	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	183-188
29147815-5	2018	Results Using these studies, we demonstrate that AZD1775 is efficiently transported by both P-gp and BCRP, whereas PD0166285 is only a substrate of P-gp.	adavosertib	49-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-105
29175983-14	2018	Conclusion: When Abcb1 and Abcg2 were disrupted in mice, brain uptake of 11C-erlotinib increased both at a tracer dose and at a pharmacologic dose.	Erlotinib Hydrochloride	73-86	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-32
29574357-0	2018	Repression of adenosine triphosphate-binding cassette transporter ABCG2 by estrogen increases intracellular glutathione in brain endothelial cells following ischemic reperfusion injury.	Glutathione	108-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	66-71
29574357-5	2018	When bEnd.3 cells were transfected with ABCG2 small interfering RNA, ischemia-induced cell death was reduced, and the intracellular concentration of glutathione, an antioxidant that is transported by ABCG2, was increased.	Glutathione	149-160	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	40-45
29574357-5	2018	When bEnd.3 cells were transfected with ABCG2 small interfering RNA, ischemia-induced cell death was reduced, and the intracellular concentration of glutathione, an antioxidant that is transported by ABCG2, was increased.	Glutathione	149-160	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	200-205
29360507-2	2018	Previous in vitro data indicate that Ko143 binds specifically to ABCG2/Abcg2, suggesting a potential utility of Ko143 as a positron emission tomography (PET) tracer to assess the density (abundance) of ABCG2 in different tissues.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	37-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	65-70
29277460-10	2018	RESULTS: The Aconitum alkaloids significantly up-regulated MRP2 and BCRP expression, accompanied by a marked increase in nuclear factor E2-related factor-2 (Nrf2) expression in the jejunum, ileum, and colon of FVB mice, in the order AC &lt; BAC &lt; aconine.	aconitum alkaloids	13-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	68-72
29440450-2	2018	In vivo pharmacokinetic studies in wild-type and transporter knockout mice showed that two major BBB efflux transporters, P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp), cooperate to modulate the brain exposure of ponatinib.	ponatinib	233-242	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	182-186
29440450-4	2018	The triple knockout mice had a greater than an additive increase in the brain exposure of ponatinib when compared with single knockout mice [Bcrp1(-/-) or Mdr1a/b(-/-)], suggesting functional compensation of transporter-mediated drug efflux.	ponatinib	90-99	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	141-151
28485193-7	2018	ML753286 is a potent inhibitor for BCRP, but not for P-glycoprotein (P-gp), organic anion-transporting polypeptide (OATP) or major cytochrome P450s (CYPs).	ML753286	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-39
28485193-10	2018	Bcrp inhibition affects oral absorption and clearance of sulfasalazine in rodents.	Sulfasalazine	57-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
28485193-13	2018	These findings confirm that ML753286 is a useful selective inhibitor to evaluate BCRP/Bcrp activity in vitro and in rodent model systems.	ML753286	28-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	81-85
28485193-13	2018	These findings confirm that ML753286 is a useful selective inhibitor to evaluate BCRP/Bcrp activity in vitro and in rodent model systems.	ML753286	28-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	86-90
29144552-3	2018	The objective of this study was to develop a sensitive, reliable and validated ultra-high-performance liquid chromatography with tandem mass spectrometry (UHPLC-MS/MS) method to simultaneously quantify tilianin and its main metabolites and to determine its pharmacokinetics in wild-type and breast cancer resistance protein knockout (Bcrp1-/-) FVB mice.	tilianin	202-210	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	334-339
29144552-8	2018	Moreover, systemic exposure of acacetin-7-sulfate was significantly higher in Bcrp1 (-/-) FVB mice compared with wild-type FVB mice.	acacetin-7-sulfate	31-49	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	78-83
29144552-9	2018	In conclusion, the fully validated UHPLC-MS/MS method was sensitive, reliable, and was successfully applied to assess the pharmacokinetics of tilianin in wild-type and Bcrp1 (-/-) FVB mice.	tilianin	142-150	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	168-173
29762857-13	2018	The expression of ABCG2 protein and ABCG2 mRNA decreased after treatment with acridone.	acridone	78-86	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	18-23
29762857-13	2018	The expression of ABCG2 protein and ABCG2 mRNA decreased after treatment with acridone.	acridone	78-86	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-41
29762857-14	2018	CONCLUSIONS: We showed that acridone could induce cell apoptosis, inhibited ABCG2 (ATP-binding cassette sub-family G member 2) protein and adjusted hormone level.	acridone	28-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	76-81
29762857-14	2018	CONCLUSIONS: We showed that acridone could induce cell apoptosis, inhibited ABCG2 (ATP-binding cassette sub-family G member 2) protein and adjusted hormone level.	acridone	28-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	83-125
29360507-7	2018	[11C]Ko143-derived radioactivity underwent both hepatobiliary and urinary excretion, with Abcg2 playing a possible role in mediating the transport of radiolabeled metabolites of [11C]Ko143 from the kidney into urine.	Carbon-11	179-182	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	90-95
29360507-7	2018	[11C]Ko143-derived radioactivity underwent both hepatobiliary and urinary excretion, with Abcg2 playing a possible role in mediating the transport of radiolabeled metabolites of [11C]Ko143 from the kidney into urine.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	183-188	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	90-95
29425861-0	2018	Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice.	5,7-dimethoxyflavone	10-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
29425861-0	2018	Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice.	Sorafenib	62-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
29425861-4	2018	5,7-Dimethoxyflavone (5,7-DMF) is a natural flavonoid which was recently reported to be a potent BCRP inhibitor.	5,7-dimethoxyflavone	0-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	97-101
29425861-4	2018	5,7-Dimethoxyflavone (5,7-DMF) is a natural flavonoid which was recently reported to be a potent BCRP inhibitor.	5,7-dimethoxyflavone	22-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	97-101
29425861-4	2018	5,7-Dimethoxyflavone (5,7-DMF) is a natural flavonoid which was recently reported to be a potent BCRP inhibitor.	Flavonoids	44-53	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	97-101
29425861-5	2018	In the current study, the effect of 5,7-DMF on the disposition of sorafenib, a TKI which is a good substrate of BCRP, was investigated both in vitro in efflux transporter expressing cells and in vivo in mice.	Sorafenib	66-75	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	112-116
29425861-6	2018	5,7-DMF significantly inhibited Bcrp1-mediated sorafenib efflux in a concentration dependent manner in MDCK/Bcrp1 cells, with EC50 value of 8.78 muM.	5,7-dimethoxyflavone	0-7	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-37
29425861-6	2018	5,7-DMF significantly inhibited Bcrp1-mediated sorafenib efflux in a concentration dependent manner in MDCK/Bcrp1 cells, with EC50 value of 8.78 muM.	5,7-dimethoxyflavone	0-7	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-113
29425861-6	2018	5,7-DMF significantly inhibited Bcrp1-mediated sorafenib efflux in a concentration dependent manner in MDCK/Bcrp1 cells, with EC50 value of 8.78 muM.	Sorafenib	47-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-37
29425861-6	2018	5,7-DMF significantly inhibited Bcrp1-mediated sorafenib efflux in a concentration dependent manner in MDCK/Bcrp1 cells, with EC50 value of 8.78 muM.	Sorafenib	47-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-113
29425861-10	2018	Our results indicated that 5,7-DMF may represent a novel and very promising chemosensitizing agent for BCRP-mediated anticancer drug resistance due to its low toxicity and potent BCRP inhibition.	5,7-dimethoxyflavone	27-34	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	103-107
29425861-10	2018	Our results indicated that 5,7-DMF may represent a novel and very promising chemosensitizing agent for BCRP-mediated anticancer drug resistance due to its low toxicity and potent BCRP inhibition.	5,7-dimethoxyflavone	27-34	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	179-183
29518608-6	2018	Potassium oxonate-treated mice showed significantly high mRNA levels of ATP-binding cassette, subfamily G, membrane 2 (ABCG2), organic anion transporter 1 (OAT1), OAT3, organic cation transporter 1 (OCT1) and organic cation/carnitine transporter 1 (OCTN1) in renal tissue samples, which were reversed by RIP3-deficiency.	potassium oxonate	0-17	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	72-117
29518608-6	2018	Potassium oxonate-treated mice showed significantly high mRNA levels of ATP-binding cassette, subfamily G, membrane 2 (ABCG2), organic anion transporter 1 (OAT1), OAT3, organic cation transporter 1 (OCT1) and organic cation/carnitine transporter 1 (OCTN1) in renal tissue samples, which were reversed by RIP3-deficiency.	potassium oxonate	0-17	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	119-124
29360507-2	2018	Previous in vitro data indicate that Ko143 binds specifically to ABCG2/Abcg2, suggesting a potential utility of Ko143 as a positron emission tomography (PET) tracer to assess the density (abundance) of ABCG2 in different tissues.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	37-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-76
29360507-2	2018	Previous in vitro data indicate that Ko143 binds specifically to ABCG2/Abcg2, suggesting a potential utility of Ko143 as a positron emission tomography (PET) tracer to assess the density (abundance) of ABCG2 in different tissues.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	37-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	202-207
29360507-2	2018	Previous in vitro data indicate that Ko143 binds specifically to ABCG2/Abcg2, suggesting a potential utility of Ko143 as a positron emission tomography (PET) tracer to assess the density (abundance) of ABCG2 in different tissues.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	112-117	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	65-70
29360507-2	2018	Previous in vitro data indicate that Ko143 binds specifically to ABCG2/Abcg2, suggesting a potential utility of Ko143 as a positron emission tomography (PET) tracer to assess the density (abundance) of ABCG2 in different tissues.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	112-117	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-76
29155017-0	2018	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.	encorafenib	134-145	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	66-70
29233733-12	2018	Diosgenin and Tigogenin increased uric acid excretion via ATP binding cassette subfamily G member 2 (ABCG2).	Uric Acid	34-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	58-99
29233733-12	2018	Diosgenin and Tigogenin increased uric acid excretion via ATP binding cassette subfamily G member 2 (ABCG2).	Uric Acid	34-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-106
29233733-14	2018	Tigogenin, a metabolite of Dioscin, was identified as an active substance with antihyperuricemic activity in vivo, through inhibition of URAT1 and promotion of ABCG2.	sarsasapogenin	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	160-165
29155017-0	2018	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.	encorafenib	134-145	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-76
29155017-3	2018	In polarized MDCK-II cells, encorafenib was efficiently transported by canine and human ABCB1 and ABCG2 and by mouse Abcg2.	encorafenib	28-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	117-122
29155017-4	2018	Upon oral administration to wild-type, Abcb1a/1b-/-, Abcg2-/-, and Abcb1a/1b;Abcg2-/- mice, encorafenib was absorbed very quickly and to very high plasma levels, but without clear changes in oral availability between the strains.	encorafenib	92-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	53-58
29155017-4	2018	Upon oral administration to wild-type, Abcb1a/1b-/-, Abcg2-/-, and Abcb1a/1b;Abcg2-/- mice, encorafenib was absorbed very quickly and to very high plasma levels, but without clear changes in oral availability between the strains.	encorafenib	92-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-82
29155017-5	2018	Upon oral or intravenous administration, encorafenib brain accumulation was markedly increased in Abcb1a/1b;Abcg2-/- mice and to a lesser extent in Abcb1a/1b-/- mice.	encorafenib	41-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-113
29155017-7	2018	Upon intravenous administration, Abcb1a/1b;Abcg2-/- mice showed somewhat reduced plasma elimination of encorafenib compared to wild-type mice, and lower accumulation of the drug in the intestinal tract, suggesting a limited role for these transporters in intestinal elimination of the drug.	encorafenib	103-114	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	43-48
28990372-0	2018	ATP Binding Cassette Sub-family Member 2 (ABCG2) and Xenobiotic Exposure During Early Mouse Embryonic Stem Cell Differentiation.	Adenosine Triphosphate	0-3	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	42-47
29292449-3	2018	We hypothesized here that Abcg2 could influence the levels of lignans and their derived metabolites in target tissues.	Lignans	62-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-31
29292449-7	2018	Particularly relevant was the detection of 24-fold and 8-fold higher concentrations of enterolactone-sulfate and enterolactone-glucuronide, respectively, in the kidney of Abcg2-/- compared with wild-type mice.	enterolactone-sulfate	87-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	171-176
29292449-7	2018	Particularly relevant was the detection of 24-fold and 8-fold higher concentrations of enterolactone-sulfate and enterolactone-glucuronide, respectively, in the kidney of Abcg2-/- compared with wild-type mice.	enterolactone-glucuronide	113-138	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	171-176
29292449-8	2018	In conclusion, our study showed that lignans and their derived metabolites were in vivo substrates of Abcg2, which affected their plasma and tissue levels.	Lignans	37-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	102-107
29292449-9	2018	These results highlight the role of Abcg2 in influencing the health-beneficial properties of dietary lignans.	Lignans	101-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-41
28990372-7	2018	ABCG2 activity was assessed using a Pheophorbide a-based fluorescent assay.	pheophorbide a	36-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
28990372-10	2018	Treatment with K0143, an inhibitor of ABCG2, had no effect on proliferation or differentiation.	k0143	15-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-43
28990372-12	2018	Exposure to K0143 in combination with chemicals predicted by ToxCast to regulate ABCG2 expression did not alter xenobiotic-induced toxicity.	k0143	12-17	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	81-86
29181098-3	2017	The present study identified a SP in the mouse HF expressing the ABCG2 transporter and MTS24 surface marker.	sp	31-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	65-70
28921565-3	2018	The BBB is equipped with a range of ATP-dependent efflux transport proteins, of which P-gp (ABCB1) and BCRP (ABCG2) are the two most dominant for drug efflux from the brain.	Adenosine Triphosphate	36-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	103-107
28921565-3	2018	The BBB is equipped with a range of ATP-dependent efflux transport proteins, of which P-gp (ABCB1) and BCRP (ABCG2) are the two most dominant for drug efflux from the brain.	Adenosine Triphosphate	36-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-114
28921565-6	2018	PD0325901 displayed more promising characteristics than trametinib (GSK1120212), binimetinib (MEK162), selumetinib (AZD6244), and pimasertib (AS703026): PD0325901 was the weakest substrate of P-gp and BCRP in vitro, its brain penetration was only marginally higher in Abcb1a/b;Abcg2-/- mice, and efficient target inhibition in the brain could be achieved at clinically relevant plasma levels.	mirdametinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	201-205
28921565-6	2018	PD0325901 displayed more promising characteristics than trametinib (GSK1120212), binimetinib (MEK162), selumetinib (AZD6244), and pimasertib (AS703026): PD0325901 was the weakest substrate of P-gp and BCRP in vitro, its brain penetration was only marginally higher in Abcb1a/b;Abcg2-/- mice, and efficient target inhibition in the brain could be achieved at clinically relevant plasma levels.	mirdametinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	277-282
29181098-5	2017	Consistent with their SP characteristic, they demonstrated elevated expression of ABCG2 transporter, which participates in the dye efflux.	sp	22-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-87
29291022-11	2017	In line with these, treatment of NRF2-silenced SKOV3 with the miR-206 inhibitor elevated BCRP levels and consequently made these cells more resistant to doxorubicin treatment.	Doxorubicin	153-164	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	89-93
29180684-5	2017	The permeation of SLM and SLOH through the brain endothelium was affected by the efflux transporters (P-gp and BCRP) and influx transporter (OATP2B1).	sloh	26-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	111-115
28790147-0	2017	Hepatocyte-Specific Deletion of EGFR in Mice Reduces Hepatic Abcg2 Transport Activity Measured by [11C]erlotinib and Positron Emission Tomography.	Carbon-11	99-102	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	61-66
28830790-2	2017	The potent anticancer agent topotecan is a substrate of efflux transporters BCRP and P-gp, which are expressed at the BRB to restrict vitreous and retinal distribution of xenobiotics.	Topotecan	28-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	76-80
28830790-3	2017	In this work we have studied vitreous and retinal distribution, tumor accumulation and antitumor activity of topotecan, using pantoprazole as inhibitor of BCRP and P-gp.	Topotecan	109-118	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	155-159
28830790-3	2017	In this work we have studied vitreous and retinal distribution, tumor accumulation and antitumor activity of topotecan, using pantoprazole as inhibitor of BCRP and P-gp.	Pantoprazole	126-138	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	155-159
28949254-8	2017	Ko143 and YHO-13177 significantly inhibited the BCRP-mediated Hoechst 33342 transport in the 3D organoids.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	0-5	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	48-52
28949254-8	2017	Ko143 and YHO-13177 significantly inhibited the BCRP-mediated Hoechst 33342 transport in the 3D organoids.	YHO-13177	10-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	48-52
28949254-8	2017	Ko143 and YHO-13177 significantly inhibited the BCRP-mediated Hoechst 33342 transport in the 3D organoids.	bisbenzimide ethoxide trihydrochloride	62-75	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	48-52
28880088-0	2017	Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).	ponatinib	22-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	162-166
28880088-0	2017	Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).	ponatinib	22-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	167-172
28880088-0	2017	Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).	UNII-5EMP4AZ4U5	59-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	162-166
28880088-0	2017	Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).	UNII-5EMP4AZ4U5	59-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	167-172
28880088-2	2017	Using in vitro transport assays and knockout mouse models, we investigated whether the multidrug efflux transporters ABCB1 and ABCG2 transport ponatinib and whether they, or the drug-metabolizing enzyme CYP3A, affect the oral availability and brain accumulation of ponatinib and its active N-desmethyl metabolite (DMP).	ponatinib	143-152	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	127-132
28880088-3	2017	In vitro, mouse Abcg2 and human ABCB1 modestly transported ponatinib.	ponatinib	59-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	16-21
28880088-4	2017	In mice, both Abcb1 and Abcg2 markedly restricted brain accumulation of ponatinib and DMP, but not ponatinib oral availability.	ponatinib	72-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-29
28790147-3	2017	In this study, we used positron emission tomography and magnetic resonance imaging to compare disposition of the model Abcg2 substrate [11C]erlotinib in a mouse model of hepatocyte-specific deletion of EGFR (EGFR hep mice, n = 5) with EGFRfl/fl control mice (n = 6), which have normal EGFR expression levels in all tissues.	Carbon-11	136-139	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	119-124
28790147-3	2017	In this study, we used positron emission tomography and magnetic resonance imaging to compare disposition of the model Abcg2 substrate [11C]erlotinib in a mouse model of hepatocyte-specific deletion of EGFR (EGFR hep mice, n = 5) with EGFRfl/fl control mice (n = 6), which have normal EGFR expression levels in all tissues.	Erlotinib Hydrochloride	140-149	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	119-124
29212198-6	2017	Most importantly, we showed that isoliquiritigenin potentiated chemotherapy along with downregulated expression of an ABC transporter that is associated with drug resistance, ABCG2.	isoliquiritigenin	33-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	175-180
28919747-10	2017	Taken together, liposomal encapsulation of DTX and ABCG2-siRNA improved the anti-tumor effects of treatment with free DTX in Hep-2 cell lines, and conjugation of GE11 peptides to liposomal constructs enhanced anti-tumor efficacies and specificities in laryngeal cancer cells.	Docetaxel	118-121	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-56
29212189-0	2017	Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies.	quizartinib	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-34
29212189-4	2017	While non-toxic to cell lines, quizartinib at 3 muM showed significant reversal effect on wild-type and mutant ABCG2 (R482T)-mediated MDR, and only a moderate reversal effect on mutant ABCG2 (R482G)-mediated MDR.	quizartinib	31-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	111-116
29212189-4	2017	While non-toxic to cell lines, quizartinib at 3 muM showed significant reversal effect on wild-type and mutant ABCG2 (R482T)-mediated MDR, and only a moderate reversal effect on mutant ABCG2 (R482G)-mediated MDR.	quizartinib	31-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-190
29212189-5	2017	Results also showed that quizartinib reversed MDR not by reducing the expression of ABCG2 protein, but by antagonizing the drug efflux function and increasing the intracellular accumulation of substrate anticancer drugs in ABCG2-overexpressing cells.	quizartinib	25-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-89
29212189-5	2017	Results also showed that quizartinib reversed MDR not by reducing the expression of ABCG2 protein, but by antagonizing the drug efflux function and increasing the intracellular accumulation of substrate anticancer drugs in ABCG2-overexpressing cells.	quizartinib	25-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	223-228
29212189-6	2017	Importantly, quizartinib at 30 mg/kg strongly enhanced the effect of topotecan (3 mg/kg) in ABCG2-overexpressing (H460/MX20) xenografts in athymic nude mice.	quizartinib	13-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-97
29212189-6	2017	Importantly, quizartinib at 30 mg/kg strongly enhanced the effect of topotecan (3 mg/kg) in ABCG2-overexpressing (H460/MX20) xenografts in athymic nude mice.	Topotecan	69-78	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-97
29212189-7	2017	These results demonstrated that quizartinib potentiates the antineoplastic activity of wild-type and R482T mutant ABCG2 substrates.	quizartinib	32-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	114-119
28587984-4	2017	The aim of the present study was to characterize roles of ABCB1 and ABCG2 in the transmembrane transport of Huperzine A and identify a rate limiting step in its brain distribution.	huperzine A	108-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	68-73
28445053-6	2017	We confirmed that sulfate conjugate is breast cancer resistance protein (BCRP) substrate using the intestinal perfusion model and pharmacokinetics studies in Bcrp1-/- mice.	Sulfates	18-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-71
28445053-6	2017	We confirmed that sulfate conjugate is breast cancer resistance protein (BCRP) substrate using the intestinal perfusion model and pharmacokinetics studies in Bcrp1-/- mice.	Sulfates	18-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	73-77
28445053-6	2017	We confirmed that sulfate conjugate is breast cancer resistance protein (BCRP) substrate using the intestinal perfusion model and pharmacokinetics studies in Bcrp1-/- mice.	Sulfates	18-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	158-163
28445053-11	2017	In contrast, plasma level of C-3"-S was increased to 40-fold (p &lt; 0.01) in Bcrp1-/- mice.	c-3"-s	29-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	78-83
28479358-8	2017	The present findings thus indicate that P-glycoprotein and BCRP are involved in the accumulation of regorafenib and its active metabolites in the skin, by affecting either their systemic exposure or their plasma distribution in the circulating blood.	regorafenib	100-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	59-63
28456721-5	2017	GF120918, a dual inhibitor of P-gp and Bcrp, significantly decreased Kp,cortex and Kp,cerebellum only in Mrp4-/- mice.	Elacridar	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-43
28591733-0	2017	ABCG2 downregulation in glioma stem cells enhances the therapeutic efficacy of demethoxycurcumin.	demethoxycurcumin	79-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
28421306-6	2017	AUC of acacetin-7-glucuronide (Aca-7-Glu) was 2-fold and 6-fold higher in Bcrp1 (-/-) mice and Mrp2 (-/-) mice, respectively.	Acacetin 7-glucuronide	7-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	74-79
28421306-7	2017	AUC of acacetin-5-glucuronide (Aca-5-Glu) was 2-fold higher in Bcrp1 (-/-) mice.	acacetin-5-glucuronide	7-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-68
28421306-11	2017	CONCLUSIONS: BCRP and MRP2 regulated the in vivo disposition of acacetin glucuronides.	acacetin glucuronides	64-85	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	13-17
28479358-0	2017	Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites.	regorafenib	136-147	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-83
28479358-2	2017	The purpose of this study is to clarify possible involvement of P-glycoprotein and breast cancer resistance protein (BCRP) in the dermal accumulation of regorafenib and its active metabolites M-2 and M-5.	regorafenib	153-164	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	83-115
28479358-2	2017	The purpose of this study is to clarify possible involvement of P-glycoprotein and breast cancer resistance protein (BCRP) in the dermal accumulation of regorafenib and its active metabolites M-2 and M-5.	regorafenib	153-164	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	117-121
28785115-6	2017	Milk BA concentrations were lower in Abcg2 -/- than in wild-type mice.	Bile Acids and Salts	5-7	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-42
28207160-0	2017	Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor.	Irinotecan	45-55	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-80
28591733-1	2017	We analyzed the role of ABCG2, a drug transporter, in determining the sensitivity of glioma stem cells (GSCs) to demethoxycurcumin (DMC).	demethoxycurcumin	113-130	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-29
28591733-1	2017	We analyzed the role of ABCG2, a drug transporter, in determining the sensitivity of glioma stem cells (GSCs) to demethoxycurcumin (DMC).	demethoxycurcumin	132-135	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-29
28591733-3	2017	Modulation of ABCG2 levels in GSCs by transfection of ABCG2 shRNA or a lentiviral vector encoding ABCG2 revealed an inverse relation between ABCG2 levels and DMC-induced GSC growth inhibition.	demethoxycurcumin	158-161	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	14-19
28591733-3	2017	Modulation of ABCG2 levels in GSCs by transfection of ABCG2 shRNA or a lentiviral vector encoding ABCG2 revealed an inverse relation between ABCG2 levels and DMC-induced GSC growth inhibition.	demethoxycurcumin	158-161	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
28591733-3	2017	Modulation of ABCG2 levels in GSCs by transfection of ABCG2 shRNA or a lentiviral vector encoding ABCG2 revealed an inverse relation between ABCG2 levels and DMC-induced GSC growth inhibition.	demethoxycurcumin	158-161	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
28591733-3	2017	Modulation of ABCG2 levels in GSCs by transfection of ABCG2 shRNA or a lentiviral vector encoding ABCG2 revealed an inverse relation between ABCG2 levels and DMC-induced GSC growth inhibition.	demethoxycurcumin	158-161	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
28591733-4	2017	Suppressing ABCG2 increased DMC-induced apoptosis and G0/G1 cell cycle arrest in GSCs.	demethoxycurcumin	28-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	12-17
28591733-7	2017	These findings demonstrate that ABCG2 expression is critical for DMC resistance in GSCs and is a potential therapeutic target for GBM.	demethoxycurcumin	65-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-37
28288939-4	2017	We used in vitro transport assays to assess human (h)ABCB1-, hABCG2- or murine (m)Abcg2-mediated transport of afatinib.	Afatinib	110-118	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-87
28540728-6	2017	Compared with that in wild-type Friend Virus B (FVB) mice, plasma exposure of acacetin-7-sulfate decreased significantly in multidrug resistance protein 1 knockout (Mrp1-/-) mice vut increased clearly in breast cancer resistance protein knockout (Bcrp-/-) mice.	acacetin-7-sulfate	78-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	247-251
28540728-7	2017	In Caco-2 monolayers, the efflux and clearance of acacetin-7-sulfate was reduced distinctly by the BCRP inhibitor Ko143 on the apical side and by the MRP1 inhibitor MK571 on the basolateral side.	acacetin-7-sulfate	50-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	99-103
28540728-7	2017	In Caco-2 monolayers, the efflux and clearance of acacetin-7-sulfate was reduced distinctly by the BCRP inhibitor Ko143 on the apical side and by the MRP1 inhibitor MK571 on the basolateral side.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	114-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	99-103
28540728-9	2017	Acacetin-7-sulfate was found to be transported mainly by BCRP and MRP1.	acacetin-7-sulfate	0-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	57-61
28540728-10	2017	Hence, SULT1A1, BCRP, and MRP1 are responsible for acacetin-7-sulfate exposure in vivo.	acacetin-7-sulfate	51-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	16-20
28288939-0	2017	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.	Afatinib	88-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
28288939-0	2017	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.	Afatinib	88-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
28288939-6	2017	Afatinib was transported well by hABCB1, hABCG2 and mAbcg2 in vitro.	Afatinib	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-58
28288939-7	2017	Upon oral administration of afatinib, Abcg2-/-, Abcb1a/1b-/- and Abcb1a/1b-/-;Abcg2-/- mice displayed a 4.2-, 2.4- and 7-fold increased afatinib plasma AUC0-24 compared with wild-type mice.	Afatinib	28-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-43
28288939-7	2017	Upon oral administration of afatinib, Abcg2-/-, Abcb1a/1b-/- and Abcb1a/1b-/-;Abcg2-/- mice displayed a 4.2-, 2.4- and 7-fold increased afatinib plasma AUC0-24 compared with wild-type mice.	Afatinib	28-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	78-83
28288939-7	2017	Upon oral administration of afatinib, Abcg2-/-, Abcb1a/1b-/- and Abcb1a/1b-/-;Abcg2-/- mice displayed a 4.2-, 2.4- and 7-fold increased afatinib plasma AUC0-24 compared with wild-type mice.	Afatinib	136-144	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-43
28288939-10	2017	Abcg2 and Abcb1a/1b restrict oral availability and brain accumulation of afatinib.	Afatinib	73-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
28503421-0	2017	Differential expression of breast cancer-resistance protein, lung resistance protein, and multidrug resistance protein 1 in retinas of streptozotocin-induced diabetic mice.	Streptozocin	135-149	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-59
28232025-0	2017	Enhancing the anti-multiple myeloma efficiency in a cancer stem cell xenograft model by conjugating the ABCG2 antibody with microbubbles for a targeted delivery of ultrasound mediated epirubicin.	Epirubicin	184-194	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-109
28232025-3	2017	In this study, we used the targeting microbubbles (MBs) conjugated with anti-ABCG2 monoclonal antibody (mAb) for ultrasound mediated epirubicin (EPI) delivery to evaluate the therapeutic effectiveness of the novel agent in MM CSC xenograft model.	Epirubicin	133-143	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-82
28209803-7	2017	The results are summarized as follows: 1) the membrane protein expression levels correlate with the corrected efflux ratios of substrates for human BCRP and murine BCRP1 within the efflux ratios investigated; 2) we demonstrate good concordance in rank order between the BCRP and BCRP1-mediated efflux ratios for 12 drugs; and 3) we propose an approach to contextualize in vitro BCRP transport data of discovery compounds by comparing them to the in vitro and in vivo transport data of the reference drug dantrolene and taking into account interbatch variation in BCRP expression.	Dantrolene	504-514	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	164-169
28209803-7	2017	The results are summarized as follows: 1) the membrane protein expression levels correlate with the corrected efflux ratios of substrates for human BCRP and murine BCRP1 within the efflux ratios investigated; 2) we demonstrate good concordance in rank order between the BCRP and BCRP1-mediated efflux ratios for 12 drugs; and 3) we propose an approach to contextualize in vitro BCRP transport data of discovery compounds by comparing them to the in vitro and in vivo transport data of the reference drug dantrolene and taking into account interbatch variation in BCRP expression.	Dantrolene	504-514	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	164-168
28209803-7	2017	The results are summarized as follows: 1) the membrane protein expression levels correlate with the corrected efflux ratios of substrates for human BCRP and murine BCRP1 within the efflux ratios investigated; 2) we demonstrate good concordance in rank order between the BCRP and BCRP1-mediated efflux ratios for 12 drugs; and 3) we propose an approach to contextualize in vitro BCRP transport data of discovery compounds by comparing them to the in vitro and in vivo transport data of the reference drug dantrolene and taking into account interbatch variation in BCRP expression.	Dantrolene	504-514	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	164-168
28209803-7	2017	The results are summarized as follows: 1) the membrane protein expression levels correlate with the corrected efflux ratios of substrates for human BCRP and murine BCRP1 within the efflux ratios investigated; 2) we demonstrate good concordance in rank order between the BCRP and BCRP1-mediated efflux ratios for 12 drugs; and 3) we propose an approach to contextualize in vitro BCRP transport data of discovery compounds by comparing them to the in vitro and in vivo transport data of the reference drug dantrolene and taking into account interbatch variation in BCRP expression.	Dantrolene	504-514	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	164-168
28111265-6	2017	In this study, we systematically examined and compared the roles of P-gp and BCRP in determining maternal brain and fetal distribution of norbuprenorphine using transporter knockout mouse models.	norbuprenorphine	138-154	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-81
28093289-0	2017	R- and S-Warfarin Were Transported by Breast Cancer Resistance Protein: From In Vitro to Pharmacokinetic-Pharmacodynamic Studies.	r-	0-2	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-70
28093289-0	2017	R- and S-Warfarin Were Transported by Breast Cancer Resistance Protein: From In Vitro to Pharmacokinetic-Pharmacodynamic Studies.	Warfarin	8-17	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-70
28093289-3	2017	We hypothesized that the transport of warfarin anion across cell membrane was mediated by breast cancer resistance protein (BCRP), an efflux transporter having a variety of acidic substrates.	Warfarin	38-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	90-122
28093289-3	2017	We hypothesized that the transport of warfarin anion across cell membrane was mediated by breast cancer resistance protein (BCRP), an efflux transporter having a variety of acidic substrates.	Warfarin	38-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	124-128
28093289-4	2017	This study aimed at verifying that warfarin was a substrate of BCRP.	Warfarin	35-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-67
28093289-7	2017	Transport assay showed that the intracellular concentrations of R- and S-warfarin in MDCKII-BCRP were significantly lower than those in MDCKII.	Warfarin	73-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-96
28093289-8	2017	In addition, Ko143, a potent BCRP inhibitor, significantly inhibited the efflux transport of R- and S-warfarin in MDCKII-BCRP, but not in MDCKII.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	13-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-33
28093289-8	2017	In addition, Ko143, a potent BCRP inhibitor, significantly inhibited the efflux transport of R- and S-warfarin in MDCKII-BCRP, but not in MDCKII.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	13-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
28093289-8	2017	In addition, Ko143, a potent BCRP inhibitor, significantly inhibited the efflux transport of R- and S-warfarin in MDCKII-BCRP, but not in MDCKII.	Warfarin	102-110	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-33
28093289-8	2017	In addition, Ko143, a potent BCRP inhibitor, significantly inhibited the efflux transport of R- and S-warfarin in MDCKII-BCRP, but not in MDCKII.	Warfarin	102-110	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
28093289-9	2017	Pharmacokinetic study showed that the plasma concentrations of R- and S-warfarin in Bcrp-/- mice were significantly higher than those in wild-type mice at 6 h after dosing.	Warfarin	72-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-88
28093289-11	2017	In conclusion, R- and S-warfarin were transported by BCRP.	r- and s-warfarin	15-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	53-57
28111265-9	2017	The maternal plasma AUCs of norbuprenorphine in Abcb1a-/-/1b-/- and Abcb1a-/-/1b-/-/Abcg2-/- mice were ~2 times greater than that in wild-type mice.	norbuprenorphine	28-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-89
28111265-15	2017	BCRP is not as important as P-gp in determining both the systemic and tissue exposure to norbuprenorphine.	norbuprenorphine	89-105	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
28242377-3	2017	Skin and plasma concentrations of dexamethasone after dermal application were reduced in P-gp and BCRP triple-knockout (Mdr1a/1b/Bcrp-/-) mice.	Dexamethasone	34-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	98-102
28242377-3	2017	Skin and plasma concentrations of dexamethasone after dermal application were reduced in P-gp and BCRP triple-knockout (Mdr1a/1b/Bcrp-/-) mice.	Dexamethasone	34-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	129-133
28242377-5	2017	Involvement of these transporters in dermal transport of dexamethasone was also supported by the observation of a higher epidermal concentration in Mdr1a/1b/Bcrp-/- than wild-type mice during intravenous infusion.	Dexamethasone	57-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	157-161
28242377-6	2017	Transdermal absorption after dermal application of prednisolone, but not methylprednisolone or ethinyl estradiol, was also lower in Mdr1a/1b/Bcrp-/- than in wild-type mice.	Prednisolone	51-63	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	141-145
28242377-7	2017	Transport studies in epithelial cell lines transfected with P-gp or BCRP showed that dexamethasone and prednisolone are substrates of P-gp, but are minimally transported by BCRP.	Dexamethasone	85-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	68-72
28242377-7	2017	Transport studies in epithelial cell lines transfected with P-gp or BCRP showed that dexamethasone and prednisolone are substrates of P-gp, but are minimally transported by BCRP.	Dexamethasone	85-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	173-177
28242377-7	2017	Transport studies in epithelial cell lines transfected with P-gp or BCRP showed that dexamethasone and prednisolone are substrates of P-gp, but are minimally transported by BCRP.	Prednisolone	103-115	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	68-72
28242377-7	2017	Transport studies in epithelial cell lines transfected with P-gp or BCRP showed that dexamethasone and prednisolone are substrates of P-gp, but are minimally transported by BCRP.	Prednisolone	103-115	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	173-177
27193034-3	2017	Here, we define a role for peroxisome proliferator-activated receptor alpha in regulating the expression of three ATP-driven drug efflux transporters at the rat and mouse blood-brain barriers: P-glycoprotein (Abcb1), breast cancer resistance protein (Bcrp/Abcg2), and multidrug resistance-associated protein 2 (Mrp2/Abcc2).	Adenosine Triphosphate	114-117	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	251-255
28417924-10	2017	Investigation with real time quantitative PCR analysis revealed the limiting expression of chemo-resistant genes (ABCG2 and MDR1) after applying PLGA NPs as a drug delivery system for PTX.	Paclitaxel	184-187	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	114-119
27193034-3	2017	Here, we define a role for peroxisome proliferator-activated receptor alpha in regulating the expression of three ATP-driven drug efflux transporters at the rat and mouse blood-brain barriers: P-glycoprotein (Abcb1), breast cancer resistance protein (Bcrp/Abcg2), and multidrug resistance-associated protein 2 (Mrp2/Abcc2).	Adenosine Triphosphate	114-117	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	256-261
28216407-4	2017	Here we use genetic deletions in MDR1a/b/BCRP of mice to test MDR function in ovarian somatic cells and find that mdr1a/b/bcrp-/- mice had significantly increased sensitivity to cyclophosphamide.	Cyclophosphamide	178-194	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	122-126
27553832-6	2017	Moreover, ABCG2 transports NVP-BEZ235 and AZD8055, but not ZSTK474 or rapamycin.	dactolisib	31-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
27553832-6	2017	Moreover, ABCG2 transports NVP-BEZ235 and AZD8055, but not ZSTK474 or rapamycin.	(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	42-49	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
27553832-7	2017	Concordantly, Abcb1a/b-/-;Abcg2-/- mice revealed increased brain penetration of rapamycin (13-fold), AZD8055 (7.7-fold), and NVP-BEZ235 (4.5-fold), but not ZSTK474 relative to WT mice.	Sirolimus	80-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-31
27553832-7	2017	Concordantly, Abcb1a/b-/-;Abcg2-/- mice revealed increased brain penetration of rapamycin (13-fold), AZD8055 (7.7-fold), and NVP-BEZ235 (4.5-fold), but not ZSTK474 relative to WT mice.	(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	101-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-31
27553832-7	2017	Concordantly, Abcb1a/b-/-;Abcg2-/- mice revealed increased brain penetration of rapamycin (13-fold), AZD8055 (7.7-fold), and NVP-BEZ235 (4.5-fold), but not ZSTK474 relative to WT mice.	dactolisib	129-135	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-31
28118809-7	2017	FECH expression was initially found downregulated both in L-02 cells and mouse livers and expression levels of ALAS1 and BCRP were elevated in L-02 cells after INH/RFP treatment, indicating FECH inhibition and ALAS1 induction might confer a synergistic effect on PPIX accumulation.	protoporphyrin IX	263-267	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
27454381-0	2017	The Function of SDF-1-CXCR4 Axis in SP Cells-Mediated Protective Role for Renal Ischemia/Reperfusion Injury by SHH/GLI1-ABCG2 Pathway.	sp	36-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	120-125
27454381-8	2017	Mechanism analysis corroborated that SDF-1/CXCR4 further induced the expression of ATP-binding cassette transporter ABCG2, an essential element for SP-mediated kidney regeneration after renal I/R injury.	sp	148-150	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	116-121
27454381-12	2017	Together, this research suggests that SDF-1/CXCR4 axis might act, via Shh-Gli1-ABCG2 signaling, as a positive regulator of SP cell-based therapies for renal I/R by Shh-Gli 1-ABCG2 signaling.	sp	123-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-84
27856956-8	2017	Furthermore, Ko143 reduced tumor growth rates in mice implanted with ABCG2-expressing CWR-R1 cells.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	13-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	69-74
27856956-9	2017	In addition, Ko143-treated mice had more differentiated tumors as evidenced by an increased percentage of CK8+/AR+ luminal cells and decreased percentage of ABCG2-expressing cells.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	13-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	157-162
27454381-12	2017	Together, this research suggests that SDF-1/CXCR4 axis might act, via Shh-Gli1-ABCG2 signaling, as a positive regulator of SP cell-based therapies for renal I/R by Shh-Gli 1-ABCG2 signaling.	sp	123-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	174-179
28082903-7	2016	Indeed, our in vivo study demonstrated that orally administered febuxostat inhibited the intestinal Abcg2 and, thereby, increased the intestinal absorption of an ABCG2 substrate sulfasalazine in wild-type mice, but not in Abcg2 knockout mice.	Febuxostat	64-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	100-105
28082903-7	2016	Indeed, our in vivo study demonstrated that orally administered febuxostat inhibited the intestinal Abcg2 and, thereby, increased the intestinal absorption of an ABCG2 substrate sulfasalazine in wild-type mice, but not in Abcg2 knockout mice.	Febuxostat	64-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	162-167
28082903-7	2016	Indeed, our in vivo study demonstrated that orally administered febuxostat inhibited the intestinal Abcg2 and, thereby, increased the intestinal absorption of an ABCG2 substrate sulfasalazine in wild-type mice, but not in Abcg2 knockout mice.	Febuxostat	64-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	222-227
28082903-7	2016	Indeed, our in vivo study demonstrated that orally administered febuxostat inhibited the intestinal Abcg2 and, thereby, increased the intestinal absorption of an ABCG2 substrate sulfasalazine in wild-type mice, but not in Abcg2 knockout mice.	Sulfasalazine	178-191	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	162-167
27482605-1	2016	S-Adenosyl-l-methionine (SAM) dependent xanthosine methyltransferase (XMT) is the key enzyme that catalyzes the first methyl transfer in the caffeine biosynthesis pathway to produce the intermediate 7-methylxanthosine (7mXR).	Methionine	12-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	220-223
27495788-1	2016	PURPOSE: Pharmacokinetic interaction of sunitinib with diclofenac, paracetamol, mefenamic acid and ibuprofen was evaluated due to their P450 mediated metabolism and OATP1B1, OATP1B3, ABCB1, ABCG2 transporters overlapping features.	Sunitinib	40-49	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	190-195
27495788-1	2016	PURPOSE: Pharmacokinetic interaction of sunitinib with diclofenac, paracetamol, mefenamic acid and ibuprofen was evaluated due to their P450 mediated metabolism and OATP1B1, OATP1B3, ABCB1, ABCG2 transporters overlapping features.	Ibuprofen	99-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	190-195
27638506-6	2016	GDC-0084 was tested in vitro to assess its sensitivity to the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) and in vivo in mice to evaluate its effects on the PI3K pathway in intact brain.	GDC-0084	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-140
27638506-6	2016	GDC-0084 was tested in vitro to assess its sensitivity to the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) and in vivo in mice to evaluate its effects on the PI3K pathway in intact brain.	GDC-0084	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	142-146
27482605-1	2016	S-Adenosyl-l-methionine (SAM) dependent xanthosine methyltransferase (XMT) is the key enzyme that catalyzes the first methyl transfer in the caffeine biosynthesis pathway to produce the intermediate 7-methylxanthosine (7mXR).	Caffeine	141-149	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	220-223
27482605-1	2016	S-Adenosyl-l-methionine (SAM) dependent xanthosine methyltransferase (XMT) is the key enzyme that catalyzes the first methyl transfer in the caffeine biosynthesis pathway to produce the intermediate 7-methylxanthosine (7mXR).	9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7-methyl-2,6-dioxo-2,3,6,9-tetrahydro-1H-purin-7-ium	199-217	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	220-223
27293996-12	2016	The anti-ABCG2 scFv antibody possesses good tumoraffin and antitumor activity and may therefore be an effective therapeutic agent for lung adenocarcinoma that is dependent on ABCG2 for drug resistance and survival.	tumoraffin	44-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	9-14
27393480-13	2016	The BCRP inhibitor Ko143 decreased the glucuronide conjugate efflux.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	19-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	4-8
27393480-13	2016	The BCRP inhibitor Ko143 decreased the glucuronide conjugate efflux.	Glucuronides	39-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	4-8
27393480-14	2016	Therefore, kaempferol is mainly exposed as K-3-G in vivo, which is driven by phase II metabolic enzymes and efflux transporters (i.e., BCRP and MRPs).	kaempferol	11-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	135-139
27207776-6	2016	Importantly, treatment of both S120 sublines with known ABCG2 inhibitors (fumitremorgin C, Ko143, and YHO-13351) restored toxicity of SN-38, and the combination of YHO-13351 with IMMU-132 increased the median survival of mice bearing NCI-N87-S120 xenografts.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	91-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	56-61
27207776-6	2016	Importantly, treatment of both S120 sublines with known ABCG2 inhibitors (fumitremorgin C, Ko143, and YHO-13351) restored toxicity of SN-38, and the combination of YHO-13351 with IMMU-132 increased the median survival of mice bearing NCI-N87-S120 xenografts.	Irinotecan	134-139	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	56-61
27207776-6	2016	Importantly, treatment of both S120 sublines with known ABCG2 inhibitors (fumitremorgin C, Ko143, and YHO-13351) restored toxicity of SN-38, and the combination of YHO-13351 with IMMU-132 increased the median survival of mice bearing NCI-N87-S120 xenografts.	YHO-13351	102-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	56-61
26883271-0	2016	ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.	Dasatinib	38-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
26883271-2	2016	We investigated whether the ABC efflux transporters ABCG2 and ABCB1 expressed in the blood-brain barrier (BBB), are limiting the efficacy of dasatinib in the treatment of glioma using genetic and pharmacologic approaches.	Dasatinib	141-150	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-57
26604245-8	2016	The steady-state brain distribution of GSK2126458 was 8-fold higher in the P-gp/Bcrp knockout mice compared with the wild type.	omipalisib	39-49	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	80-84
27028005-4	2016	Effects on transporter expression and function of the imidazole fungicide prochloraz, previously reported to influence BCRP in mammary cells, was investigated on transporter expression and function in the two cell lines.	prochloraz	74-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	119-123
26853103-4	2016	In the present study, we show that in vitro models of the placenta possess ABCG2 activity and can specifically transport D-luciferin, the endogenous substrate of firefly luciferase.	D-luciferin	121-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-80
26853103-6	2016	We found that coadministering the ABCG2 inhibitors Ko143 and gefitinib with D-luciferin increased bioluminescent signal from fetuses and placentae, whereas the control P-gp inhibitor DCPQ had no effect.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	51-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
26853103-6	2016	We found that coadministering the ABCG2 inhibitors Ko143 and gefitinib with D-luciferin increased bioluminescent signal from fetuses and placentae, whereas the control P-gp inhibitor DCPQ had no effect.	Gefitinib	61-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
26853103-6	2016	We found that coadministering the ABCG2 inhibitors Ko143 and gefitinib with D-luciferin increased bioluminescent signal from fetuses and placentae, whereas the control P-gp inhibitor DCPQ had no effect.	D-luciferin	76-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
26853103-6	2016	We found that coadministering the ABCG2 inhibitors Ko143 and gefitinib with D-luciferin increased bioluminescent signal from fetuses and placentae, whereas the control P-gp inhibitor DCPQ had no effect.	dcpq	183-187	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
26507673-6	2016	Studies of [(3) H]-mitoxantrone and [(3) H]-zidovudine transport suggested, respectively, that Bcrp efflux was less involved at the BRB than BBB, whereas Mrps were significantly and similarly involved at both barriers.	[(3) h]-mitoxantrone	11-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	95-99
26507673-6	2016	Studies of [(3) H]-mitoxantrone and [(3) H]-zidovudine transport suggested, respectively, that Bcrp efflux was less involved at the BRB than BBB, whereas Mrps were significantly and similarly involved at both barriers.	[(3) h]-zidovudine	36-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	95-99
26353857-0	2016	Targeting CD133(+) laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles.	Silicon Dioxide	140-146	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	91-96
26465636-4	2015	Ex vivo quantitative real-time PCR and immunoblot analyses showed significant up-regulation of Abcg2/Bcrp mRNA and protein levels in CD-1 mouse brain capillaries incubated with clofibrate, a Pparalpha ligand.	Clofibrate	177-187	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	95-100
27424909-2	2016	D-Luciferin is specifically transported by ABCG2 found on the apical side of endothelial cells at the BBB.	D-luciferin	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	43-48
27424909-4	2016	Therefore bioluminescence imaging (BLI) correlates with ABCG2 function at the BBB and this can be measured by administering luciferin in a mouse model that expresses luciferase in the brain parenchyma.	D-luciferin	124-133	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	56-61
26465636-4	2015	Ex vivo quantitative real-time PCR and immunoblot analyses showed significant up-regulation of Abcg2/Bcrp mRNA and protein levels in CD-1 mouse brain capillaries incubated with clofibrate, a Pparalpha ligand.	Clofibrate	177-187	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-105
26465636-5	2015	Fluorescence-based transport assays in CD-1 and C57BL/6 brain capillaries showed that exposure to clofibrate significantly increased Bcrp transport activity.	Clofibrate	98-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	133-137
26465636-7	2015	In vivo, we found: i) significant Bcrp protein up-regulation in clofibrate-dosed CD-1 and C57BL/6 capillary lysates, but no effect in Pparalpha knockout capillary lysates, and ii) significantly increased Bcrp transport activity in capillaries isolated from clofibrate-treated mice.	Clofibrate	64-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
26465636-9	2015	We propose the involvement of the following pathways in clofibrate-mediated induction of the drug transporter Abcg2/Bcrp mRNA, protein expression and function by the nuclear receptor Pparalpha, in mouse brain capillary endothelial cells.	Clofibrate	56-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-115
26359257-9	2015	CONCLUSION: ABCG2, ABCB1, and possibly other transporters influence in vivo disposition of (11)C-erlotinib and thereby affect its distribution to normal and potentially also tumor tissue.	Erlotinib Hydrochloride	91-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	12-17
26359257-11	2015	The inhibition of ABCB1 and ABCG2 is a promising approach to enhance brain distribution of erlotinib to increase its efficacy in the treatment of brain tumors.	Erlotinib Hydrochloride	91-100	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	28-33
26465636-9	2015	We propose the involvement of the following pathways in clofibrate-mediated induction of the drug transporter Abcg2/Bcrp mRNA, protein expression and function by the nuclear receptor Pparalpha, in mouse brain capillary endothelial cells.	Clofibrate	56-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	116-120
26465636-10	2015	Upon activation with clofibrate (Pparalpha, ligand), Pparalpha complex translocates from the cytoplasm into the nucleus and further recruits coactivators and transcription machinery which induce the transcription of Abcg2 gene and ultimately results in upregulation of Bcrp protein expression and function.	Clofibrate	21-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	216-221
26465636-10	2015	Upon activation with clofibrate (Pparalpha, ligand), Pparalpha complex translocates from the cytoplasm into the nucleus and further recruits coactivators and transcription machinery which induce the transcription of Abcg2 gene and ultimately results in upregulation of Bcrp protein expression and function.	Clofibrate	21-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	269-273
26398480-6	2015	Additionally, OCT4B1 was able to reduce sensitivity to oxaliplatin by altering the expression of two important mediators in drug resistance, P-gp and ABCG2 [ATP-binding cassette, sub-family G (WHITE), member 2].	Oxaliplatin	55-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	150-155
26398480-6	2015	Additionally, OCT4B1 was able to reduce sensitivity to oxaliplatin by altering the expression of two important mediators in drug resistance, P-gp and ABCG2 [ATP-binding cassette, sub-family G (WHITE), member 2].	Oxaliplatin	55-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	157-209
26361725-0	2015	Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).	ceritinib	45-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	138-142
26361725-0	2015	Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).	ceritinib	45-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	143-148
26361725-5	2015	Ceritinib was very efficiently transported by hABCB1, and efficiently by hABCG2 and mAbcg2 in vitro, and transport was specifically inhibited by the ABCB1 inhibitor zosuquidar and ABCG2 inhibitor Ko143, respectively.	ceritinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	74-79
26361725-1	2015	We aimed to clarify the roles of the multidrug transporters ABCB1 and ABCG2 in oral availability and brain accumulation of ceritinib, an oral anaplastic lymphoma kinase (ALK) inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) after progression on crizotinib.	ceritinib	123-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	70-75
26361725-5	2015	Ceritinib was very efficiently transported by hABCB1, and efficiently by hABCG2 and mAbcg2 in vitro, and transport was specifically inhibited by the ABCB1 inhibitor zosuquidar and ABCG2 inhibitor Ko143, respectively.	Zosuquidar	165-175	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	74-79
26361725-7	2015	The brain concentrations increased another ~ 3-fold (to &gt;90-fold) in Abcb1a/1b;Abcg2(-/-) mice, indicating that there was a significant additional effect of Abcg2-mediated transport of ceritinib as well in vivo.	ceritinib	188-197	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	160-165
26361725-9	2015	Our data suggest that coadministration of ceritinib with a dual ABCB1 and ABCG2 inhibitor may improve treatment of brain (micro) metastases positioned behind a functionally intact blood-brain barrier, and possibly also of tumors resistant to ceritinib due to ABCB1 or ABCG2 overexpression.	ceritinib	42-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	74-79
26361725-9	2015	Our data suggest that coadministration of ceritinib with a dual ABCB1 and ABCG2 inhibitor may improve treatment of brain (micro) metastases positioned behind a functionally intact blood-brain barrier, and possibly also of tumors resistant to ceritinib due to ABCB1 or ABCG2 overexpression.	ceritinib	42-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	268-273
26361725-3	2015	Transport of ceritinib by human (h) ABCB1 or hABCG2 or mouse (m) Abcg2 was assessed in vitro.	ceritinib	13-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	65-70
26515463-8	2015	Mechanistic studies demonstrated that A-803467 (7.5 muM) significantly increased the intracellular accumulation of [(3)H]-mitoxantrone by inhibiting the transport activity of ABCG2, without altering its expression levels.	[(3)h]-mitoxantrone	115-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	175-180
26515463-10	2015	In a murine model system, combination treatment of A-803467 (35 mg/kg) and topotecan (3 mg/kg) significantly inhibited the tumor growth in mice xenografted with ABCG2-overexpressing cancer cells.	Topotecan	75-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	161-166
26515463-2	2015	The diverse range of substrates of ABCG2 includes many antineoplastic agents such as topotecan, doxorubicin and mitoxantrone.	Topotecan	85-94	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-40
26264927-7	2015	administration of [(18)F]-gefitinib (1mg/kg), PET-CT imaging showed 2.3-fold increased brain levels of [(18)F]-gefitinib in Abcb1a/1b;Abcg2(-/-) mice, compared to wild-type.	Gefitinib	26-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	134-139
26515463-2	2015	The diverse range of substrates of ABCG2 includes many antineoplastic agents such as topotecan, doxorubicin and mitoxantrone.	Doxorubicin	96-107	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-40
26515463-2	2015	The diverse range of substrates of ABCG2 includes many antineoplastic agents such as topotecan, doxorubicin and mitoxantrone.	Mitoxantrone	112-124	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-40
26515463-7	2015	We found that at non-toxic concentrations, A-803467 could significantly increase the cellular sensitivity to ABCG2 substrates in drug-resistant cells overexpressing either wild-type or mutant ABCG2.	A 803467	43-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-114
26515463-7	2015	We found that at non-toxic concentrations, A-803467 could significantly increase the cellular sensitivity to ABCG2 substrates in drug-resistant cells overexpressing either wild-type or mutant ABCG2.	A 803467	43-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	192-197
26515463-8	2015	Mechanistic studies demonstrated that A-803467 (7.5 muM) significantly increased the intracellular accumulation of [(3)H]-mitoxantrone by inhibiting the transport activity of ABCG2, without altering its expression levels.	A 803467	38-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	175-180
26281846-8	2015	Since D-luciferin is a substrate of ABCG2, the feasibility of improving D-luciferin brain accumulation (and luciferase signal) was tested by coadministering the dual ABCB1/ABCG2 inhibitor elacridar.	D-luciferin	6-17	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-41
26264927-9	2015	Furthermore, enhanced brain accumulation of [(18)F]-gefitinib after administration of the ABCB1 and ABCG2 inhibitor elacridar (10 mg/kg) could be quantified with PET-CT imaging.	[(18)f]-gefitinib	44-61	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	100-105
26264927-0	2015	PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.	Gefitinib	28-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	70-75
26264927-10	2015	CONCLUSIONS: PET-CT imaging with [(18)F]-gefitinib is a powerful tool to non-invasively assess potential ABCB1- and ABCG2-mediated drug-drug interactions (DDIs) in vivo.	Gefitinib	41-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	116-121
26264927-0	2015	PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.	Gefitinib	28-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-82
26264927-2	2015	In this study we developed a PET-CT imaging method for non-invasive, quantitative analysis of the effect of ABCB1 and ABCG2 on brain penetration of the anti-cancer drug gefitinib, and demonstrated the applicability of this method for identification and quantification of potential modulators of ABCB1 and ABCB2 using the dual inhibitor elacridar.	Gefitinib	169-178	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	118-123
25868794-4	2015	All EZH2 inhibitors are transported by P-gp and BCRP, although in vitro the transporter affinity of GSK126 was obscured by very low membrane permeability.	GSK-2816126	100-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	48-52
25868794-8	2015	Moreover, the oral bioavailability of GSK126 is only 0.2% in WT mice, which increases to 14.4% in Abcb1;Abcg2 knockout mice.	GSK-2816126	38-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-109
26199091-4	2015	By screening ABC substrates against mouse G3 medulloblastoma tumorspheres in vitro, we found that Abcg2 inhibition could potentiate responses to the clinically used drug topotecan, producing a more than 9-fold suppression of cell proliferation.	Topotecan	170-179	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	98-103
26317243-1	2015	We aimed to clarify the roles of the multidrug-detoxifying proteins ABCB1, ABCG2, ABCC2, and CYP3A in oral availability and brain accumulation of cabazitaxel, a taxane developed for improved therapy of docetaxel-resistant prostate cancer.	cabazitaxel	146-157	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-80
26317243-1	2015	We aimed to clarify the roles of the multidrug-detoxifying proteins ABCB1, ABCG2, ABCC2, and CYP3A in oral availability and brain accumulation of cabazitaxel, a taxane developed for improved therapy of docetaxel-resistant prostate cancer.	taxane	161-167	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-80
26123925-11	2015	CONCLUSION: Thus, the brain penetration of palbociclib is restricted by P-gp and BCRP, which may restrict the efficacy against GBM and DIPG.	Dipinacoline glutamate	135-139	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	81-85
26199091-5	2015	Extended studies in vivo in this model confirmed that Abcg2 inhibition was sufficient to enhance antiproliferative responses to topotecan, producing a significant survival advantage compared with subjects treated with topotecan alone.	Topotecan	128-137	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
26199091-5	2015	Extended studies in vivo in this model confirmed that Abcg2 inhibition was sufficient to enhance antiproliferative responses to topotecan, producing a significant survival advantage compared with subjects treated with topotecan alone.	Topotecan	218-227	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
25972455-8	2015	CONCLUSIONS: GDC-0980 is subject to active efflux by P-gp and BCRP at the BBB, while brain penetrance of GNE-317 is independent of efflux, which translates into enhanced inhibition of PI3K/mTOR signaling.	1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one	13-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	62-66
26516354-1	2015	BACKGROUND: Active efflux of irinotecan by ATP-binding cassette (ABC)-transporters, in particular ABCB1 and ABCG2, is a well-established drug resistance mechanism in vitro and in pre-clinical mouse models, but its relevance in colorectal cancer (CRC) patients is unknown.	Irinotecan	29-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-113
26071310-0	2015	Oleic acid increases intestinal absorption of the BCRP/ABCG2 substrate, mitoxantrone, in mice.	Oleic Acid	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-54
26071310-0	2015	Oleic acid increases intestinal absorption of the BCRP/ABCG2 substrate, mitoxantrone, in mice.	Oleic Acid	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	55-60
26071310-0	2015	Oleic acid increases intestinal absorption of the BCRP/ABCG2 substrate, mitoxantrone, in mice.	Oleic Acid	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	72-84
26071310-3	2015	Here, we investigated the effect of oleic acid on intestinal absorption of MXR in mice.	Oleic Acid	36-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-78
26071310-8	2015	Absorption of MXR increased after exposure to oleic acid at all doses, and also after exposure to Ko143.	Oleic Acid	46-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	14-17
26071310-8	2015	Absorption of MXR increased after exposure to oleic acid at all doses, and also after exposure to Ko143.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	98-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	14-17
26071310-9	2015	Intestinal BCRP gene expression tended to increase 120min after oleic acid exposure.	Oleic Acid	64-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	11-15
26071310-10	2015	Our results in mice demonstrate that oleic acid decreases BCRP-mediated efflux, causing increased intestinal MXR absorption in mice.	Oleic Acid	37-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	58-62
26071310-10	2015	Our results in mice demonstrate that oleic acid decreases BCRP-mediated efflux, causing increased intestinal MXR absorption in mice.	Oleic Acid	37-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-112
25936263-7	2015	All derivatives containing carboxylic acid at the position-17(2) were noted to be substrate for the ABCG2 (a member of the ATP binding cassette transporters) protein explaining their low retention in lung tumor cells expressing this transporter.	Carboxylic Acids	27-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	100-105
26274818-4	2015	The major findings were that in total brains on postnatal day (PN) 4 triple antenatal dexamethasone treatment significantly downregulated the tight junction protein claudin-5, the endothelial marker Pecam-1/CD31, the glucocorticoid receptor, the NR1 subunit of the N-methyl-D-aspartate receptor, and Abc transporters (Abcb1a, Abcg2 Abcc4).	Dexamethasone	86-99	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	326-331
26011058-1	2015	Tyrosine kinase inhibitor sunitinib (used in GIST, advanced RCC, and pancreatic neuroendocrine tumors) undergoes CYP3A4 metabolism and is an ABCB1B and ABCG2 efflux transporters substrate.	Sunitinib	26-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	152-157
25914040-10	2015	It restored fructose-induced dysregulation of renal urate transporter 1 (URAT1), glucose transporter 9 (GLUT9), ATP-binding cassette subfamily G member 2 (ABCG2) and organic anion transporter 1 (OAT1), as well as organic cation transporter 1 (OCT1) and OCT2 in mice.	Fructose	12-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	112-153
25914040-10	2015	It restored fructose-induced dysregulation of renal urate transporter 1 (URAT1), glucose transporter 9 (GLUT9), ATP-binding cassette subfamily G member 2 (ABCG2) and organic anion transporter 1 (OAT1), as well as organic cation transporter 1 (OCT1) and OCT2 in mice.	Fructose	12-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	155-160
25563977-0	2015	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).	regorafenib	33-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	96-100
25563977-0	2015	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).	regorafenib	33-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-106
25563977-3	2015	METHODS: We used in vitro transport assays to assess human (h)ABCB1- or hABCG2- or murine (m)Abcg2-mediated active transport at high and low concentrations of regorafenib.	regorafenib	159-170	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	93-98
25563977-6	2015	Abcg2 and to a lesser extent Abcb1a/1b limited brain and testis accumulation of regorafenib and metabolite M2 (brain only) in mice.	regorafenib	80-91	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
25563977-9	2015	CONCLUSIONS: Brain and testis accumulation of regorafenib and brain accumulation of metabolite M2 are restricted by Abcg2 and Abcb1a/1b.	regorafenib	46-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	116-121
25915534-4	2015	Trametinib significantly potentiated the effects of two ABCB1 substrates vincristine and doxorubicin on inhibition of growth, arrest of cell cycle and induction of apoptosis in cancer cells overexpressed ABCB1, but not ABCC1 and ABCG2.	trametinib	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	229-234
25823393-1	2015	INTRODUCTION: Transport of 2-[(18)F]fluoro-2-deoxy-d-glucose ([(18)F]FDG) by the multidrug efflux transporters P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier (BBB) may confound the interpretation of [(18)F]FDG brain PET data.	Fluorine	33-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	172-177
25823393-1	2015	INTRODUCTION: Transport of 2-[(18)F]fluoro-2-deoxy-d-glucose ([(18)F]FDG) by the multidrug efflux transporters P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier (BBB) may confound the interpretation of [(18)F]FDG brain PET data.	fluoro-2-deoxy-d-glucose	36-60	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	172-177
25380981-2	2015	METHODS: The correlation of the changes of the area under the plasma concentration-time curve (AUC) caused by ABCG2 421C&gt;A with those caused by the Bcrp knockout in mice, or BCRP inhibition in monkeys, was investigated using well-known BCRP substrates (rosuvastatin, pitavastatin, fluvastatin, and sulfasalazine).	Rosuvastatin Calcium	256-268	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-115
25567291-1	2015	Multi-drug resistance (MDR)-ATP binding cassette (ABC) transporters, ABCB1, ABCC1, and ABCG2 participate in the efflux of steroid hormones, estrogens, and androgens, which regulate prostate development and differentiation.	Steroids	122-138	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-92
25755207-11	2015	CETA confirmed transport of pilocarpine by PGP and BCRP.	Pilocarpine	28-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-55
25755207-12	2015	Pilocarpine is a substrate of PGP and BCRP at the rodent blood-brain barrier, which restricts its convulsive action.	Pilocarpine	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-42
25380981-2	2015	METHODS: The correlation of the changes of the area under the plasma concentration-time curve (AUC) caused by ABCG2 421C&gt;A with those caused by the Bcrp knockout in mice, or BCRP inhibition in monkeys, was investigated using well-known BCRP substrates (rosuvastatin, pitavastatin, fluvastatin, and sulfasalazine).	pitavastatin	270-282	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-115
25380981-2	2015	METHODS: The correlation of the changes of the area under the plasma concentration-time curve (AUC) caused by ABCG2 421C&gt;A with those caused by the Bcrp knockout in mice, or BCRP inhibition in monkeys, was investigated using well-known BCRP substrates (rosuvastatin, pitavastatin, fluvastatin, and sulfasalazine).	Fluvastatin	284-295	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-115
25380981-2	2015	METHODS: The correlation of the changes of the area under the plasma concentration-time curve (AUC) caused by ABCG2 421C&gt;A with those caused by the Bcrp knockout in mice, or BCRP inhibition in monkeys, was investigated using well-known BCRP substrates (rosuvastatin, pitavastatin, fluvastatin, and sulfasalazine).	Sulfasalazine	301-314	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-115
26477273-6	2015	An inhibitor against URATv1, benzbromarone, abolished the urate effects, whereas an inhibitor against ABCG2, KO143, augmented them.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	109-114	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	102-107
25663899-4	2015	The results revealed that Dox treatment induced a significant increase in the breast cancer resistance protein (ABCG2) gene transcription and protein expression.	Doxorubicin	26-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	112-117
25663899-6	2015	Functionally, the role of ABCG2 in the resistance to sunitinib was confirmed by the use of the ABCG2 inhibitors fumitremorgin C and diethylstilbestrol, which blocked cell resistance.	Sunitinib	53-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-31
25663899-6	2015	Functionally, the role of ABCG2 in the resistance to sunitinib was confirmed by the use of the ABCG2 inhibitors fumitremorgin C and diethylstilbestrol, which blocked cell resistance.	Sunitinib	53-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	95-100
25663899-6	2015	Functionally, the role of ABCG2 in the resistance to sunitinib was confirmed by the use of the ABCG2 inhibitors fumitremorgin C and diethylstilbestrol, which blocked cell resistance.	Diethylstilbestrol	132-150	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-31
25663899-6	2015	Functionally, the role of ABCG2 in the resistance to sunitinib was confirmed by the use of the ABCG2 inhibitors fumitremorgin C and diethylstilbestrol, which blocked cell resistance.	Diethylstilbestrol	132-150	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	95-100
25499818-2	2015	Furthermore, nuciferine reversed expression alteration of renal urate transporter 1 (URAT1), glucose transporter 9 (GLUT9), ATP-binding cassette, subfamily G, membrane 2 (ABCG2), organic anion transporter 1 (OAT1), organic cation transporter 1 (OCT1), and organic cation/carnitine transporters 1/2 (OCTN1/2) in hyperuricemic mice.	nuciferine	13-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	124-169
25499818-2	2015	Furthermore, nuciferine reversed expression alteration of renal urate transporter 1 (URAT1), glucose transporter 9 (GLUT9), ATP-binding cassette, subfamily G, membrane 2 (ABCG2), organic anion transporter 1 (OAT1), organic cation transporter 1 (OCT1), and organic cation/carnitine transporters 1/2 (OCTN1/2) in hyperuricemic mice.	nuciferine	13-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	171-176
25791223-5	2015	In addition, Bcrp function was assessed by transport experiments with mitoxantrone (MX) in undifferentiated HC11 cells, in HC11 cells subjected to Bcrp RNA interference (RNAi), as well as in HC11 cells stimulated to differentiate by treatment with lactogenic hormones.	Mitoxantrone	70-82	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	13-17
25791223-9	2015	The Bcrp inhibitor elacridar (GF120918) reduced secretion and increased accumulation of MX in both undifferentiated and differentiated HC11 cells.	Elacridar	30-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	4-8
25474134-0	2014	MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts.	Irinotecan	44-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	89-94
24962512-3	2015	PURPOSE: We aimed to establish whether the multidrug efflux transporters ABCG2 (BCRP) and ABCB1 (P-gp, MDR1) affect the oral availability and brain penetration of rucaparib in mice.	rucaparib	163-172	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	73-78
24962512-3	2015	PURPOSE: We aimed to establish whether the multidrug efflux transporters ABCG2 (BCRP) and ABCB1 (P-gp, MDR1) affect the oral availability and brain penetration of rucaparib in mice.	rucaparib	163-172	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	80-84
24962512-4	2015	RESULTS: In vitro, rucaparib was efficiently transported by both human ABCB1 and ABCG2, and very efficiently by mouse Abcg2.	rucaparib	19-28	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	118-123
25452783-12	2015	The expression levels of HIF-2, ABCG2 and Oct-4 mRNA and protein were high in the blank control group, and were further increased in the 5-Fu group.	Fluorouracil	137-141	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-37
25474134-0	2014	MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts.	Irinotecan	56-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	89-94
25474134-4	2014	Combination of 10 mg/kg MBL-II-141 with the anticancer agent CPT-11 completely blocked the growth of 90% freshly implanted ABCG2-positive tumors.	Irinotecan	61-67	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	123-128
25474134-9	2014	MBL-II-141 induced a potent sensitization of ABCG2-positive xenografts to CPT-11 through in vivo ABCG2 inhibition.	Irinotecan	74-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	45-50
25474134-9	2014	MBL-II-141 induced a potent sensitization of ABCG2-positive xenografts to CPT-11 through in vivo ABCG2 inhibition.	Irinotecan	74-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	97-102
24666334-2	2014	We investigated how deficiencies in P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) affect the pharmacokinetics of atypical antipsychotics aripiprazole and its active metabolite (dehydroaripiprazole) using normal Friend leukemia virus strain B (FVB) mice, BCRP knockout (Bcrp[-/-]) mice, and P-gp and BCRP triple knockout (Mdr1a/1b[-/-]Bcrp[-/-]) mice.	dehydroaripiprazole	197-216	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	96-100
25451572-0	2014	The role of the efflux carriers Abcg2 and Abcc2 for the hepatobiliary elimination of benzo[a]pyrene and its metabolites in mice.	Benzo(a)pyrene	85-99	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-37
25451572-4	2014	After intravenous application of [(3)H]BP the hepatobiliary excretion was significantly reduced in these mice: whereas wild type mice excreted on average 25.4% of the applied dose into the bile over 90min, Abcg2(-/-) knockout mice only excreted 10.7% and Abcc2(-/-) knockout mice 8.6%.	[(3)h]bp	33-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	206-211
25451572-5	2014	As a consequence, [(3)H]BP concentrations were in general higher in the plasma and in most of the organs of the Abcg2 and Abcc2 knockout mice.	Benzo(a)pyrene	24-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	112-117
25451572-7	2014	Subjects with reduced ABCG2 or ABCC2 expression might have higher oral bioavailability for BP due to a reduced excretion and so might be more susceptible to BP-induced carcinogenesis.	Benzo(a)pyrene	91-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-27
25451572-7	2014	Subjects with reduced ABCG2 or ABCC2 expression might have higher oral bioavailability for BP due to a reduced excretion and so might be more susceptible to BP-induced carcinogenesis.	Benzo(a)pyrene	157-159	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-27
25574474-4	2014	METHODS: Here, we prove that a P-gp/BCRP-driven pharmacoresistance limits the bioavailability of ALS therapeutics using riluzole, the only FDA-approved drug for ALS and a substrate of P-gp and BCRP.	Riluzole	120-128	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-40
25574474-4	2014	METHODS: Here, we prove that a P-gp/BCRP-driven pharmacoresistance limits the bioavailability of ALS therapeutics using riluzole, the only FDA-approved drug for ALS and a substrate of P-gp and BCRP.	Riluzole	120-128	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	193-197
25574474-6	2014	RESULTS: We show that riluzole, which normally is not effective when given at onset of symptoms, is now effective in the ALS mice when administered in combination with the P-gp/BCRP inhibitor elacridar.	Riluzole	22-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	177-181
25243894-2	2014	The objectives of this study were to determine in vitro and in vivo if cobimetinib is a substrate of P-glycoprotein (P-gp) and/or breast cancer resistance protein (Bcrp1) and to assess the implications of efflux on cobimetinib pharmacokinetics (PK), brain penetration, and target modulation.	cobimetinib	71-82	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	164-169
25243894-3	2014	Cell lines transfected with P-gp or Bcrp1 established that cobimetinib was a substrate of P-gp but not a substrate of Bcrp1.	cobimetinib	59-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-41
25243894-5	2014	After an oral 10 mg/kg dose of cobimetinib, the mean total brain to plasma ratio (Kp) at 6 h postdose was 0.3 and 0.2 in WT and Bcrp1(-/-) mice, respectively.	cobimetinib	31-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	128-133
25243894-8	2014	By MALDI imaging, the cobimetinib signal intensity was relatively high and was dispersed throughout the brain of Mdr1a/1b/Bcrp1(-/-) KO mice compared to low/undetectable signal intensity in WT mice.	cobimetinib	22-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	122-127
24980806-8	2014	The net efflux ratio of GA (C15:1) and GA (C17:1) in both cell models was greater than 2 and markedly reduced by the presence of Cyclosporin A (CsA) or GF120918, inhibitors of P-gp and BCRP, suggesting that GAs are P-gp and BCRP substrates.	ginkgolic acid	24-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-189
24980806-8	2014	The net efflux ratio of GA (C15:1) and GA (C17:1) in both cell models was greater than 2 and markedly reduced by the presence of Cyclosporin A (CsA) or GF120918, inhibitors of P-gp and BCRP, suggesting that GAs are P-gp and BCRP substrates.	ginkgolic acid	24-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	224-228
24980806-8	2014	The net efflux ratio of GA (C15:1) and GA (C17:1) in both cell models was greater than 2 and markedly reduced by the presence of Cyclosporin A (CsA) or GF120918, inhibitors of P-gp and BCRP, suggesting that GAs are P-gp and BCRP substrates.	ginkgolic acid	39-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-189
24980806-8	2014	The net efflux ratio of GA (C15:1) and GA (C17:1) in both cell models was greater than 2 and markedly reduced by the presence of Cyclosporin A (CsA) or GF120918, inhibitors of P-gp and BCRP, suggesting that GAs are P-gp and BCRP substrates.	ginkgolic acid	39-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	224-228
24980806-8	2014	The net efflux ratio of GA (C15:1) and GA (C17:1) in both cell models was greater than 2 and markedly reduced by the presence of Cyclosporin A (CsA) or GF120918, inhibitors of P-gp and BCRP, suggesting that GAs are P-gp and BCRP substrates.	Cyclosporine	144-147	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-189
24980806-8	2014	The net efflux ratio of GA (C15:1) and GA (C17:1) in both cell models was greater than 2 and markedly reduced by the presence of Cyclosporin A (CsA) or GF120918, inhibitors of P-gp and BCRP, suggesting that GAs are P-gp and BCRP substrates.	Cyclosporine	144-147	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	224-228
24980806-8	2014	The net efflux ratio of GA (C15:1) and GA (C17:1) in both cell models was greater than 2 and markedly reduced by the presence of Cyclosporin A (CsA) or GF120918, inhibitors of P-gp and BCRP, suggesting that GAs are P-gp and BCRP substrates.	Elacridar	152-160	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-189
24980806-8	2014	The net efflux ratio of GA (C15:1) and GA (C17:1) in both cell models was greater than 2 and markedly reduced by the presence of Cyclosporin A (CsA) or GF120918, inhibitors of P-gp and BCRP, suggesting that GAs are P-gp and BCRP substrates.	Elacridar	152-160	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	224-228
24980806-9	2014	The results from a rat bioavailability study also showed that co-administrating CsA intravenously (20mg/kg) could significantly increase GA (C15:1) and GA (C17:1) AUC0-t by 1.46-fold and 1.53-fold and brain concentration levels of 1.43-fold and 1.51-fold, respectively, due to the inhibition of P-gp and BCRP efflux transporters by CsA.	Cyclosporine	80-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	304-308
25122876-6	2014	Genetic labeling of lung MSC in mice enabled determination of terminal lineage and localization of ABCG2 cells following intratracheal administration of bleomycin to elicit fibrotic lung injury.	Bleomycin	153-162	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	99-104
25175747-6	2014	The milk-to-plasma concentration ratio (M/P) values of cimetidine and acyclovir were significantly decreased in Bcrp knockout and Oct1/2 double-knockout (DKO) mice compared with control FVB mice, whereas the M/P values of terbutaline and metformin were significantly decreased in Oct1/2 DKO mice alone.	Cimetidine	55-65	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	112-116
25175747-6	2014	The milk-to-plasma concentration ratio (M/P) values of cimetidine and acyclovir were significantly decreased in Bcrp knockout and Oct1/2 double-knockout (DKO) mice compared with control FVB mice, whereas the M/P values of terbutaline and metformin were significantly decreased in Oct1/2 DKO mice alone.	Acyclovir	70-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	112-116
25078948-0	2014	"Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".	taxane	106-112	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-56
24666334-0	2014	Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole.	Aripiprazole	109-121	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	53-85
24666334-0	2014	Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole.	dehydroaripiprazole	126-145	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	53-85
24666334-2	2014	We investigated how deficiencies in P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) affect the pharmacokinetics of atypical antipsychotics aripiprazole and its active metabolite (dehydroaripiprazole) using normal Friend leukemia virus strain B (FVB) mice, BCRP knockout (Bcrp[-/-]) mice, and P-gp and BCRP triple knockout (Mdr1a/1b[-/-]Bcrp[-/-]) mice.	Aripiprazole	157-169	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	62-94
24666334-2	2014	We investigated how deficiencies in P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) affect the pharmacokinetics of atypical antipsychotics aripiprazole and its active metabolite (dehydroaripiprazole) using normal Friend leukemia virus strain B (FVB) mice, BCRP knockout (Bcrp[-/-]) mice, and P-gp and BCRP triple knockout (Mdr1a/1b[-/-]Bcrp[-/-]) mice.	Aripiprazole	157-169	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	96-100
24666334-4	2014	While plasma concentrations of aripiprazole and dehydroaripiprazole after oral administration were slightly higher in both Bcrp(-/-) and Mdr1a/1b(-/-)/Bcrp(-/-) mice than in normal FVB mice, the difference was not marked.	Aripiprazole	31-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	123-127
24666334-4	2014	While plasma concentrations of aripiprazole and dehydroaripiprazole after oral administration were slightly higher in both Bcrp(-/-) and Mdr1a/1b(-/-)/Bcrp(-/-) mice than in normal FVB mice, the difference was not marked.	Aripiprazole	31-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	151-155
24666334-4	2014	While plasma concentrations of aripiprazole and dehydroaripiprazole after oral administration were slightly higher in both Bcrp(-/-) and Mdr1a/1b(-/-)/Bcrp(-/-) mice than in normal FVB mice, the difference was not marked.	dehydroaripiprazole	48-67	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	123-127
24666334-4	2014	While plasma concentrations of aripiprazole and dehydroaripiprazole after oral administration were slightly higher in both Bcrp(-/-) and Mdr1a/1b(-/-)/Bcrp(-/-) mice than in normal FVB mice, the difference was not marked.	dehydroaripiprazole	48-67	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	151-155
24666334-6	2014	This finding suggests that BCRP may be involved in the intestinal absorption of aripiprazole in mice, albeit with minimal contribution to absorption at best.	Aripiprazole	80-92	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-31
24666334-8	2014	In contrast, the brain-to-plasma concentration ratio (Kp,brain) for aripiprazole and dehydroaripiprazole after oral administration was significantly higher in Mdr1a/1b(-/-)/Bcrp(-/-) mice than in normal mice, whereas Bcrp(-/-) mice exhibited Kp,brain values similar to those in normal mice.	Aripiprazole	68-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	173-177
24666334-8	2014	In contrast, the brain-to-plasma concentration ratio (Kp,brain) for aripiprazole and dehydroaripiprazole after oral administration was significantly higher in Mdr1a/1b(-/-)/Bcrp(-/-) mice than in normal mice, whereas Bcrp(-/-) mice exhibited Kp,brain values similar to those in normal mice.	Aripiprazole	68-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	217-221
24666334-8	2014	In contrast, the brain-to-plasma concentration ratio (Kp,brain) for aripiprazole and dehydroaripiprazole after oral administration was significantly higher in Mdr1a/1b(-/-)/Bcrp(-/-) mice than in normal mice, whereas Bcrp(-/-) mice exhibited Kp,brain values similar to those in normal mice.	dehydroaripiprazole	85-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	173-177
24666334-8	2014	In contrast, the brain-to-plasma concentration ratio (Kp,brain) for aripiprazole and dehydroaripiprazole after oral administration was significantly higher in Mdr1a/1b(-/-)/Bcrp(-/-) mice than in normal mice, whereas Bcrp(-/-) mice exhibited Kp,brain values similar to those in normal mice.	dehydroaripiprazole	85-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	217-221
24727496-5	2014	Delivery of paraquat dichloride (PQ), a systemic oxidative stress-inducing agent, to mice confirmed that Abcg2 provides a survival benefit.	Paraquat dichloride	12-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	105-110
25071019-4	2014	AuNPs inhibit cisplatin induced EMT, decrease the side population cells and key stem cell markers such as ALDH1, CD44, CD133, Sox2, MDR1 and ABCG2 in ovarian cancer cells.	Cisplatin	14-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	141-146
24948812-2	2014	We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2].	sulforaphane	39-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	298-330
24948812-2	2014	We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2].	sulforaphane	39-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	332-336
24948812-2	2014	We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2].	sulforaphane	39-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	339-344
24727322-1	2014	PURPOSE: To clarify the role of ABCB1, ABCG2, and CYP3A in blood and brain exposure of everolimus using knockout mouse models.	Everolimus	87-97	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
24727322-3	2014	RESULTS: Following everolimus administration, brain concentrations and brain-to-liver ratios were substantially increased in Abcb1a/1b(-/-)and Abcb1a/1b;Abcg2(-/-), but not Abcg2(-/-)mice.	Everolimus	19-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	153-158
24727322-3	2014	RESULTS: Following everolimus administration, brain concentrations and brain-to-liver ratios were substantially increased in Abcb1a/1b(-/-)and Abcb1a/1b;Abcg2(-/-), but not Abcg2(-/-)mice.	Everolimus	19-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	173-178
24875464-9	2014	In vitro studies indicated that trametinib is a substrate for both P-glycoprotein (P-gp) and Bcrp, efflux transporters found at the blood-brain barrier.	trametinib	32-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	93-97
24948812-2	2014	We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2].	sulforaphane	53-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	298-330
24948812-2	2014	We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2].	sulforaphane	53-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	332-336
24948812-2	2014	We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2].	sulforaphane	53-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	339-344
24948812-2	2014	We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2].	Adenosine Triphosphate	131-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	298-330
24948812-2	2014	We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2].	Adenosine Triphosphate	131-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	332-336
24948812-2	2014	We show here that Nrf2 activation with sulforaphane (SFN) in vivo or in vitro increases expression and transport activity of three ATP-driven drug efflux pumps at the blood-brain barrier [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2), Abcc2; and breast cancer resistance protein (Bcrp), Abcg2].	Adenosine Triphosphate	131-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	339-344
24727496-5	2014	Delivery of paraquat dichloride (PQ), a systemic oxidative stress-inducing agent, to mice confirmed that Abcg2 provides a survival benefit.	pq	33-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	105-110
24727496-6	2014	When exposed to PQ, reporter mice showed an increase in the Abcg2 lineage.	pq	16-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-65
24727496-10	2014	The contribution of the Abcg2 lineage to the vasculature in the heart is increased after PQ delivery.	pq	89-91	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-29
25028581-4	2014	Abcg2 mRNA expression was enhanced in bone marrow hemopoietic progenitor cells from mice that were treated with phenylhydrazine (PHZ).	phenylhydrazine	112-127	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
25028581-4	2014	Abcg2 mRNA expression was enhanced in bone marrow hemopoietic progenitor cells from mice that were treated with phenylhydrazine (PHZ).	phenylhydrazine	129-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
25028581-8	2014	Abcg2 appears to act principally as a safety valve regulating porphyrin levels during the early stages of erythropoiesis and its role in systemic haem metabolism and erythrophagocytosis, in particular, awaits further clarification.	Porphyrins	62-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
24565910-11	2014	In addition, telatinib (15 mg/kg) with doxorubicin (1.8 mg/kg) significantly decreased the growth rate and tumor size of ABCG2 overexpressing tumors in a xenograft nude mouse model.	telatinib	13-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-126
24647572-9	2014	Importantly, ABT-888 does enhance TMZ efficacy in Pten deficient glioblastoma allografts and spontaneous tumors, even in Abcb1/Abcg2 proficient wild-type mice.	veliparib	13-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	127-132
24565910-11	2014	In addition, telatinib (15 mg/kg) with doxorubicin (1.8 mg/kg) significantly decreased the growth rate and tumor size of ABCG2 overexpressing tumors in a xenograft nude mouse model.	Doxorubicin	39-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-126
24568887-8	2014	This paper is the first to report that enterolactone is a transported substrate and therefore most probably a competitive inhibitor of ABCG2, which suggests it has a role in the interindividual variations in the disposition of enterolactone and its secretion into milk.	2,3-bis(3'-hydroxybenzyl)butyrolactone	39-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	135-140
24568887-8	2014	This paper is the first to report that enterolactone is a transported substrate and therefore most probably a competitive inhibitor of ABCG2, which suggests it has a role in the interindividual variations in the disposition of enterolactone and its secretion into milk.	2,3-bis(3'-hydroxybenzyl)butyrolactone	227-240	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	135-140
24037730-2	2014	We used knockout mice to study the roles of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) in plasma pharmacokinetics and brain accumulation of oral crizotinib, and the feasibility of improving crizotinib kinetics using coadministration of the dual ABCB1/ABCG2 inhibitor elacridar.	Crizotinib	170-180	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	105-110
23384250-1	2014	ATP-Binding Cassette transporters such as ABCG2 confer resistance to various anticancer drugs including irinotecan and its active metabolite, SN38.	Irinotecan	104-114	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	42-47
23384250-3	2014	A proof-of-concept study has been carried out for studying the effect of a new ABCG2 transporter inhibitor, MBLI87 combined to irinotecan in mice xenografted with cells overexpressing ABCG2.	9-oxo-9,10-dihydroacridine-4-carboxylic acid 3,4-dimethoxyphenethyl amide	108-114	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-84
23384250-3	2014	A proof-of-concept study has been carried out for studying the effect of a new ABCG2 transporter inhibitor, MBLI87 combined to irinotecan in mice xenografted with cells overexpressing ABCG2.	9-oxo-9,10-dihydroacridine-4-carboxylic acid 3,4-dimethoxyphenethyl amide	108-114	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	184-189
24037730-0	2014	Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.	Crizotinib	72-82	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	171-176
24334255-0	2014	Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	92-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
24334255-0	2014	Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	98-145	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
24334255-2	2014	The food-derived carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) is transported by BCRP, MDR1, and MRP2.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	34-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-105
24940679-0	2014	ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion.	Uric Acid	34-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
24497321-7	2014	This characteristic allows for SP cells to be isolated based upon their capacity to efflux the dye Hoechst 33342, through a mechanism driven by a membrane transporter, the breast cancer resistance protein (BCRP1/ABCG2).	TFF2 protein, human	31-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	206-211
24497321-7	2014	This characteristic allows for SP cells to be isolated based upon their capacity to efflux the dye Hoechst 33342, through a mechanism driven by a membrane transporter, the breast cancer resistance protein (BCRP1/ABCG2).	TFF2 protein, human	31-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	212-217
24497321-7	2014	This characteristic allows for SP cells to be isolated based upon their capacity to efflux the dye Hoechst 33342, through a mechanism driven by a membrane transporter, the breast cancer resistance protein (BCRP1/ABCG2).	bisbenzimide ethoxide trihydrochloride	99-112	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	206-211
24497321-7	2014	This characteristic allows for SP cells to be isolated based upon their capacity to efflux the dye Hoechst 33342, through a mechanism driven by a membrane transporter, the breast cancer resistance protein (BCRP1/ABCG2).	bisbenzimide ethoxide trihydrochloride	99-112	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	212-217
24940679-5	2014	The export process by mouse Abcg2 was ATP-dependent and not saturable under the physiological concentration of urate.	Adenosine Triphosphate	38-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	28-33
24940679-5	2014	The export process by mouse Abcg2 was ATP-dependent and not saturable under the physiological concentration of urate.	Uric Acid	111-116	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	28-33
24738341-0	2014	Gamma-Fe2O3 nanoparticles increase therapeutic efficacy of combination with paclitaxel and anti-ABCG2 monoclonal antibody on multiple myeloma cancer stem cells in mouse model.	gamma-fe2o3	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	96-101
24940679-1	2014	ATP-binding cassette transporter G2 (ABCG2), also known as breast cancer resistance protein (BCRP), is identified as a high-capacity urate exporter and its dysfunction has an association with serum uric acid (SUA) levels and gout/hyperuricemia risk.	Uric Acid	198-207	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-35
24940679-7	2014	SUA of Abcg2-knockout mice was significantly higher than that of control mice.	sua	0-3	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	7-12
24940679-11	2014	Decreased intestinal excretion could account for the increased SUA of Abcg2-knockout mice.	sua	63-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	70-75
24940679-1	2014	ATP-binding cassette transporter G2 (ABCG2), also known as breast cancer resistance protein (BCRP), is identified as a high-capacity urate exporter and its dysfunction has an association with serum uric acid (SUA) levels and gout/hyperuricemia risk.	Uric Acid	198-207	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-42
24940679-1	2014	ATP-binding cassette transporter G2 (ABCG2), also known as breast cancer resistance protein (BCRP), is identified as a high-capacity urate exporter and its dysfunction has an association with serum uric acid (SUA) levels and gout/hyperuricemia risk.	Uric Acid	198-207	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	59-91
24940679-1	2014	ATP-binding cassette transporter G2 (ABCG2), also known as breast cancer resistance protein (BCRP), is identified as a high-capacity urate exporter and its dysfunction has an association with serum uric acid (SUA) levels and gout/hyperuricemia risk.	Uric Acid	198-207	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	93-97
24940679-1	2014	ATP-binding cassette transporter G2 (ABCG2), also known as breast cancer resistance protein (BCRP), is identified as a high-capacity urate exporter and its dysfunction has an association with serum uric acid (SUA) levels and gout/hyperuricemia risk.	sua	209-212	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-35
24940679-1	2014	ATP-binding cassette transporter G2 (ABCG2), also known as breast cancer resistance protein (BCRP), is identified as a high-capacity urate exporter and its dysfunction has an association with serum uric acid (SUA) levels and gout/hyperuricemia risk.	sua	209-212	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-42
24940679-1	2014	ATP-binding cassette transporter G2 (ABCG2), also known as breast cancer resistance protein (BCRP), is identified as a high-capacity urate exporter and its dysfunction has an association with serum uric acid (SUA) levels and gout/hyperuricemia risk.	sua	209-212	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	59-91
24940679-1	2014	ATP-binding cassette transporter G2 (ABCG2), also known as breast cancer resistance protein (BCRP), is identified as a high-capacity urate exporter and its dysfunction has an association with serum uric acid (SUA) levels and gout/hyperuricemia risk.	sua	209-212	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	93-97
24940679-3	2014	In this study, we investigated how ABCG2 dysfunction affected the urate excretion pathways.	Uric Acid	66-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-40
24940679-4	2014	First, we revealed that mouse Abcg2 mediates urate transport using the membrane vesicle system.	Uric Acid	45-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-35
24297888-6	2013	Here we show that D-luciferin, the endogenous substrate of firefly luciferase, is a specific substrate for ABCG2.	D-luciferin	18-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	107-112
24297888-8	2013	Bioluminescence signal in the brain of mice increased with coadministration of the ABCG2 inhibitors Ko143, gefitinib, and nilotinib, but not an ABCB1 inhibitor.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	100-105	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	83-88
24297888-8	2013	Bioluminescence signal in the brain of mice increased with coadministration of the ABCG2 inhibitors Ko143, gefitinib, and nilotinib, but not an ABCB1 inhibitor.	Gefitinib	107-116	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	83-88
24297888-8	2013	Bioluminescence signal in the brain of mice increased with coadministration of the ABCG2 inhibitors Ko143, gefitinib, and nilotinib, but not an ABCB1 inhibitor.	nilotinib	122-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	83-88
24130050-0	2013	Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.	Tunicamycin	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-82
24113148-5	2013	Furthermore, the distribution of sunitinib to the brain increased after administration of selective P-glycoprotein (P-gp) or breast cancer resistance protein (Bcrp) pharmacological inhibitors and a dual inhibitor, elacridar, comparable to that of the corresponding transgenic genotype.	Sunitinib	33-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	125-157
24113148-5	2013	Furthermore, the distribution of sunitinib to the brain increased after administration of selective P-glycoprotein (P-gp) or breast cancer resistance protein (Bcrp) pharmacological inhibitors and a dual inhibitor, elacridar, comparable to that of the corresponding transgenic genotype.	Sunitinib	33-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	159-163
24130050-8	2013	Tunicamycin combined with cisplatin (CDDP) inhibited proliferating cell nuclear antigen (PCNA) expression and increased the cleavage of PARP; this effect was partially rescued by the overexpression of ABCG2 or Akt-myr.	Cisplatin	37-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	201-206
24130050-11	2013	In summary, our results suggest that tunicamycin may reverse the drug resistance and improve the efficacy of combination treatments for hepatocellular carcinomas by targeting the DPAGT1/Akt/ABCG2 pathway.	Tunicamycin	37-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	190-195
24130050-0	2013	Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.	Cisplatin	24-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-82
24130050-6	2013	The N-linked glycosylation (NLG) inhibitor tunicamycin dramatically reduced ABCG2 expression, altered its subcellular localization, and reversed its drug efflux effect in multiple hepatocellular carcinoma cell lines.	Tunicamycin	43-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	76-81
24130050-8	2013	Tunicamycin combined with cisplatin (CDDP) inhibited proliferating cell nuclear antigen (PCNA) expression and increased the cleavage of PARP; this effect was partially rescued by the overexpression of ABCG2 or Akt-myr.	Tunicamycin	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	201-206
24130050-8	2013	Tunicamycin combined with cisplatin (CDDP) inhibited proliferating cell nuclear antigen (PCNA) expression and increased the cleavage of PARP; this effect was partially rescued by the overexpression of ABCG2 or Akt-myr.	Cisplatin	26-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	201-206
24014645-4	2013	BPA solely inhibited BCRP activity, whereas TBBPA, PFOA, and PFOS inhibited all transporters tested.	bisphenol A	0-3	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-25
23868912-5	2013	To this end, we developed and characterized a new mouse Abcg2-expressing subline that demonstrated efflux of known fluorescent ABCG2 substrates and increased resistance to mitoxantrone, which is reduced in the presence of the ABCG2 inhibitor Ko143.	Mitoxantrone	172-184	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	226-231
23665398-0	2013	Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP).	Tryptophan	25-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	107-139
23665398-0	2013	Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP).	Tryptophan	25-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	141-145
23665398-5	2013	A transport assay, using membrane vesicles of cells overexpressing the transporters, revealed that uric acid inhibited substrate-specific transport by BCRP at clinically relevant concentrations (calculated IC50 value: 365+-13muM), as was previously reported for MRP4.	Uric Acid	99-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	151-155
23665398-6	2013	Moreover, we identified kynurenic acid as a novel substrate for MRP4 and BCRP.	Kynurenic Acid	24-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	73-77
23665398-10	2013	Based on our results, we postulate that elevated uric acid levels hamper MRP4 and BCRP functioning, thereby promoting the retention of other potentially toxic substrates, including kynurenic acid, which could contribute to the development of CKD.	Uric Acid	49-58	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-86
23868912-5	2013	To this end, we developed and characterized a new mouse Abcg2-expressing subline that demonstrated efflux of known fluorescent ABCG2 substrates and increased resistance to mitoxantrone, which is reduced in the presence of the ABCG2 inhibitor Ko143.	Mitoxantrone	172-184	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	56-61
23868912-5	2013	To this end, we developed and characterized a new mouse Abcg2-expressing subline that demonstrated efflux of known fluorescent ABCG2 substrates and increased resistance to mitoxantrone, which is reduced in the presence of the ABCG2 inhibitor Ko143.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	242-247	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	56-61
23868912-5	2013	To this end, we developed and characterized a new mouse Abcg2-expressing subline that demonstrated efflux of known fluorescent ABCG2 substrates and increased resistance to mitoxantrone, which is reduced in the presence of the ABCG2 inhibitor Ko143.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	242-247	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	226-231
23868912-7	2013	We identified a new human and mouse ABCG2 substrate, a porphyrin analog, purpurin-18 (Pp-18), which is not a substrate for P-glycoprotein or multidrug resistance protein 1.	Porphyrins	55-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-41
23868912-7	2013	We identified a new human and mouse ABCG2 substrate, a porphyrin analog, purpurin-18 (Pp-18), which is not a substrate for P-glycoprotein or multidrug resistance protein 1.	purpurin 18	73-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-41
23868912-7	2013	We identified a new human and mouse ABCG2 substrate, a porphyrin analog, purpurin-18 (Pp-18), which is not a substrate for P-glycoprotein or multidrug resistance protein 1.	purpurin 18	86-91	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-41
23868912-8	2013	The ability of inhibitors to block efflux activity of ABCG2 was assessed using Pp-18.	purpurin 18	79-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
23868912-10	2013	Chrysin, benzoflavone, and cyclosporin A inhibited Pp-18 efflux in both human and mouse ABCG2.	chrysin	0-7	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	88-93
23868912-10	2013	Chrysin, benzoflavone, and cyclosporin A inhibited Pp-18 efflux in both human and mouse ABCG2.	Benzoflavones	9-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	88-93
23868912-10	2013	Chrysin, benzoflavone, and cyclosporin A inhibited Pp-18 efflux in both human and mouse ABCG2.	Cyclosporine	27-40	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	88-93
23868912-10	2013	Chrysin, benzoflavone, and cyclosporin A inhibited Pp-18 efflux in both human and mouse ABCG2.	purpurin 18	51-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	88-93
23827160-4	2013	In vitro, CYT387 was efficiently transported by both human MDR1 and BCRP, and very efficiently by mouse Bcrp1 and its transport could be inhibited by specific MDR1 inhibitor, zosuquidar and/or specific BCRP inhibitor, Ko143.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	10-16	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-109
23897419-1	2013	Venlafaxine, and to a lesser extent desvenlafaxine, has previously been shown to induce the expression of the drug efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in whole cells and alter the cellular permeability of a known drug efflux probe (rhodamine 123).	Venlafaxine Hydrochloride	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	161-193
23897419-1	2013	Venlafaxine, and to a lesser extent desvenlafaxine, has previously been shown to induce the expression of the drug efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in whole cells and alter the cellular permeability of a known drug efflux probe (rhodamine 123).	Venlafaxine Hydrochloride	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	195-199
23897419-1	2013	Venlafaxine, and to a lesser extent desvenlafaxine, has previously been shown to induce the expression of the drug efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in whole cells and alter the cellular permeability of a known drug efflux probe (rhodamine 123).	Desvenlafaxine Succinate	36-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	161-193
23897419-1	2013	Venlafaxine, and to a lesser extent desvenlafaxine, has previously been shown to induce the expression of the drug efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in whole cells and alter the cellular permeability of a known drug efflux probe (rhodamine 123).	Desvenlafaxine Succinate	36-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	195-199
23897419-1	2013	Venlafaxine, and to a lesser extent desvenlafaxine, has previously been shown to induce the expression of the drug efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in whole cells and alter the cellular permeability of a known drug efflux probe (rhodamine 123).	Rhodamines	282-291	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	161-193
23897419-1	2013	Venlafaxine, and to a lesser extent desvenlafaxine, has previously been shown to induce the expression of the drug efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in whole cells and alter the cellular permeability of a known drug efflux probe (rhodamine 123).	Rhodamines	282-291	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	195-199
23897419-3	2013	P-gp and BCRP expression was significantly upregulated in the intestine, following a treatment with venlafaxine (2.6- and 6.7-fold, respectively) or desvenlafaxine (2.3- and 4.8-fold, respectively).	Venlafaxine Hydrochloride	100-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	9-13
23845421-2	2013	There is some evidence in literature that verapamil inhibits two other ABC transporters expressed at the BBB, i.e. multidrug resistance protein 1 (MRP1) and breast cancer resistance protein (BCRP).	Verapamil	42-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	191-195
23845421-4	2013	The aim of this study was to assess the selectivity of verapamil, in nanomolar concentrations, for Pgp over MRP1 and BCRP.	Verapamil	55-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	117-121
23315030-1	2013	We explored whether barasertib (AZD1152), a selective Aurora B kinase inhibitor, is a substrate for P-glycoprotein (Pgp, MDR1), breast cancer resistance protein (BCRP), and multidrug resistance protein 2 (MRP2) in vitro.	2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate	20-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	128-160
23315030-1	2013	We explored whether barasertib (AZD1152), a selective Aurora B kinase inhibitor, is a substrate for P-glycoprotein (Pgp, MDR1), breast cancer resistance protein (BCRP), and multidrug resistance protein 2 (MRP2) in vitro.	2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate	20-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	162-166
23315030-1	2013	We explored whether barasertib (AZD1152), a selective Aurora B kinase inhibitor, is a substrate for P-glycoprotein (Pgp, MDR1), breast cancer resistance protein (BCRP), and multidrug resistance protein 2 (MRP2) in vitro.	2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate	32-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	128-160
23315030-1	2013	We explored whether barasertib (AZD1152), a selective Aurora B kinase inhibitor, is a substrate for P-glycoprotein (Pgp, MDR1), breast cancer resistance protein (BCRP), and multidrug resistance protein 2 (MRP2) in vitro.	2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate	32-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	162-166
23315030-6	2013	In Sf9-BCRP membrane vesicles, both barasertib and barasertib-hQPA significantly inhibited the BCRP-mediated transport of methotrexate.	Methotrexate	122-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	7-11
23315030-6	2013	In Sf9-BCRP membrane vesicles, both barasertib and barasertib-hQPA significantly inhibited the BCRP-mediated transport of methotrexate.	Methotrexate	122-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	95-99
23315030-8	2013	In vivo, systemic exposure as well as bioavailability, brain penetration, kidney and liver distribution and myelotoxicity of barasertib-hQPA were statistically significantly increased in Bcrp1(-/-)/Mdr1a/1b(-/-) compared with wild type mice (p&lt;0.001).	AZD 1152-HQPA	125-140	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	187-192
23315030-10	2013	In vivo, genetic deletion of P-gp and BCRP in mice significantly affected pharmacokinetics, tissue distribution and myelotoxicity of barasertib-hQPA.	AZD 1152-HQPA	133-148	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-42
23897419-3	2013	P-gp and BCRP expression was significantly upregulated in the intestine, following a treatment with venlafaxine (2.6- and 6.7-fold, respectively) or desvenlafaxine (2.3- and 4.8-fold, respectively).	Desvenlafaxine Succinate	149-163	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	9-13
23897419-4	2013	In addition, venlafaxine increased the BCRP expression in the brain (40%) and liver (60%), whereas desvenlafaxine had no effect on drug efflux transporter levels in these tissues.	Venlafaxine Hydrochloride	13-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-43
23827160-4	2013	In vitro, CYT387 was efficiently transported by both human MDR1 and BCRP, and very efficiently by mouse Bcrp1 and its transport could be inhibited by specific MDR1 inhibitor, zosuquidar and/or specific BCRP inhibitor, Ko143.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	10-16	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	202-206
23827160-4	2013	In vitro, CYT387 was efficiently transported by both human MDR1 and BCRP, and very efficiently by mouse Bcrp1 and its transport could be inhibited by specific MDR1 inhibitor, zosuquidar and/or specific BCRP inhibitor, Ko143.	Zosuquidar	175-185	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-109
23827160-4	2013	In vitro, CYT387 was efficiently transported by both human MDR1 and BCRP, and very efficiently by mouse Bcrp1 and its transport could be inhibited by specific MDR1 inhibitor, zosuquidar and/or specific BCRP inhibitor, Ko143.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	218-223	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	202-206
23827160-5	2013	CYT387 (10 mg/kg) was orally administered to wild-type (WT), Bcrp1(-/-), Mdr1a/1b(-/-) and Bcrp1;Mdr1a/1b(-/-) mice and plasma and brain concentrations were analyzed.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-6	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	61-66
23827160-5	2013	CYT387 (10 mg/kg) was orally administered to wild-type (WT), Bcrp1(-/-), Mdr1a/1b(-/-) and Bcrp1;Mdr1a/1b(-/-) mice and plasma and brain concentrations were analyzed.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-6	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	91-96
23843632-0	2013	Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.	Dasatinib	143-152	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-76
23712697-6	2013	The Kp,brain of anastrozole and vorozole were increased by 12- and 3.3-fold, respectively, in Mdr1a/b/Bcrp(-/-) mice.	Anastrozole	16-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	102-106
23843632-0	2013	Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.	Sunitinib	169-178	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-76
23712697-6	2013	The Kp,brain of anastrozole and vorozole were increased by 12- and 3.3-fold, respectively, in Mdr1a/b/Bcrp(-/-) mice.	vorozole	32-40	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	102-106
24009622-3	2013	We showed that a low concentration of ethanol, which inhibits many membrane proteins, inhibits ABCG2 in lung cancer SP cells.	Ethanol	38-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	95-100
23319174-4	2013	RESULTS: STZ treatment up-regulated expression of Mrp1-5, Mdr1, Abcg5, Abcg8, Bcrp, and Bsep mRNA and/or protein in the livers of non-pregnant mice.	Streptozocin	9-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	78-82
23588114-5	2013	In contrast, the plasma concentration profiles of phenytoin, lamotrigine, topiramate, tiagabine, and levetiracetam in the Mdr1a/1b(-/-)/Bcrp(-/-) mice were significantly lower than the corresponding ones in the wild-type mice.	Phenytoin	50-59	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	136-140
23634795-7	2013	After 2 weeks of culture with EtBr both cell lines showed increased expression of the stemness-related genes ABCG2, Oct3/4, Nanog1/Nanogp8, and CD44.	Ethidium	30-34	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-114
23634795-9	2013	In conclusion, blocking mtDNA replication by EtBr induces increased expression of stemness genes, such as Oct3/4, Nanog, CD44, and ABCG2, in addition to the immune regulator B7-H3 in PC-3 and DU145 prostate cancer cell lines.	Ethidium	45-49	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	131-136
23620484-4	2013	Using cell lines expressing the aforementioned transporters, we showed that the lipophilic AR-67 lactone form is a substrate for efflux transporters BCRP and MDR1.	Lactones	97-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	149-153
23620484-6	2013	Notably, both BCRP and MDR1 conferred resistance to AR-67 lactone.	7-tert-butyldimethylsilyl-10-hydroxycamptothecin	52-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	14-18
23620484-6	2013	Notably, both BCRP and MDR1 conferred resistance to AR-67 lactone.	Lactones	58-65	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	14-18
23620484-9	2013	In conclusion, BCRP- and MDR1-mediated efflux of AR-67 lactone confers resistance to AR-67, but OATP1B3-mediated uptake of the AR-67 carboxylate does not sensitize OATP1B3-expressing tumor cells.	Lactones	55-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	15-19
23620484-9	2013	In conclusion, BCRP- and MDR1-mediated efflux of AR-67 lactone confers resistance to AR-67, but OATP1B3-mediated uptake of the AR-67 carboxylate does not sensitize OATP1B3-expressing tumor cells.	Argon	49-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	15-19
24009622-5	2013	We found that 5% ethanol did not reduce ABCG2 protein levels, but significantly reduced ABCG2 protein function by a Hoechst 33342 extrusion assay, an ATPase activity assay, and transmission electron microscopy.	Ethanol	17-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	88-93
24009622-5	2013	We found that 5% ethanol did not reduce ABCG2 protein levels, but significantly reduced ABCG2 protein function by a Hoechst 33342 extrusion assay, an ATPase activity assay, and transmission electron microscopy.	bisbenzimide ethoxide trihydrochloride	116-129	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	88-93
23635651-8	2013	It is concluded that Abcg2 has the most significant effect on topotecan elimination, whereas both Abcb1 and Abcc2 have overlapping functions with Abcg2.	Topotecan	62-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-26
23583082-10	2013	In the PET study in mice, the radioactivity levels in the brain, liver, and small intestine were slightly increased by inhibition of the Pgp/Bcrp function for more than 30 min after [(11)C]irinotecan injection.	Irinotecan	189-199	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	141-145
23583082-11	2013	This result demonstrated that in vivo behavior of [(11)C] irinotecan and radioactive metabolites are influenced by the Pgp/Bcrp function.	Carbon-11	50-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	123-127
23583082-11	2013	This result demonstrated that in vivo behavior of [(11)C] irinotecan and radioactive metabolites are influenced by the Pgp/Bcrp function.	Irinotecan	58-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	123-127
23588114-5	2013	In contrast, the plasma concentration profiles of phenytoin, lamotrigine, topiramate, tiagabine, and levetiracetam in the Mdr1a/1b(-/-)/Bcrp(-/-) mice were significantly lower than the corresponding ones in the wild-type mice.	Levetiracetam	101-114	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	136-140
23518403-4	2013	The targeting berberine liposomes were shown to cross the CSC membrane, inhibit ABC transporters (ABCC1, ABCC2, ABCC3, ABCG2) and selectively accumulate in the mitochondria.	Berberine	14-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	119-124
23454352-0	2013	P-glycoprotein (Mdr1a/1b) and breast cancer resistance protein (Bcrp) decrease the uptake of hydrophobic alkyl triphenylphosphonium cations by the brain.	alkyl triphenylphosphonium	105-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-62
23454352-0	2013	P-glycoprotein (Mdr1a/1b) and breast cancer resistance protein (Bcrp) decrease the uptake of hydrophobic alkyl triphenylphosphonium cations by the brain.	alkyl triphenylphosphonium	105-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	64-68
23613808-9	2013	Finally, the single and combined administration of 10 and 30 mg/kg MK571 and the specific breast cancer resistance protein (BCRP) inhibitor KO143 showed no reduction of LPS-induced TNFalpha release into the BALF compared to vehicle treated control animals.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	140-145	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	124-128
23422148-1	2013	AIM: Recently, sildenafil was reported to be an inhibitor of P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) in vitro.	Sildenafil Citrate	15-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	127-131
23422148-1	2013	AIM: Recently, sildenafil was reported to be an inhibitor of P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) in vitro.	Sildenafil Citrate	15-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	132-137
23422148-6	2013	On the other hand, sildenafil increased the plasma levels of the cytotoxic drugs, but not by inhibition of Abcb1 or Abcg2, since this effect was also seen in Abcb1;Abcg2 knockout mice.	Sildenafil Citrate	19-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	164-169
23422148-7	2013	The brain penetration of sildenafil was more than 20-fold higher in Abcb1;Abcg2 mice versus wild-type mice, indicating that sildenafil is a good substrate of the two transporters.	Sildenafil Citrate	25-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	74-79
23422148-7	2013	The brain penetration of sildenafil was more than 20-fold higher in Abcb1;Abcg2 mice versus wild-type mice, indicating that sildenafil is a good substrate of the two transporters.	Sildenafil Citrate	124-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	74-79
23422148-10	2013	CONCLUSION: These results demonstrate that the potency and specificity of sildenafil as an inhibitor of ABCB1 and ABCG2 is not sufficient to warrant further clinical testing of this agent in combination with anticancer drugs.	Sildenafil Citrate	74-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	114-119
23461902-0	2013	Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.	Camptothecin	115-127	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-35
23461902-10	2013	CONCLUSION: Abcc4 limits the brain penetration of camptothecin analogues and teams up with Abcb1a/b and Abcg2 to form a robust cooperative drug efflux system.	Camptothecin	50-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-109
23287578-0	2013	Evaluation of breast cancer resistance protein function in hepatobiliary and renal excretion using PET with 11C-SC-62807.	11c-sc	108-114	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	14-46
23435180-0	2013	Hepatic and renal Bcrp transporter expression in mice treated with perfluorooctanoic acid.	perfluorooctanoic acid	67-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	18-22
23435180-7	2013	Immunofluorescent staining confirmed enhanced canalicular Bcrp staining in liver sections from PFOA-treated mice.	perfluorooctanoic acid	95-99	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	58-62
23435180-8	2013	The kidney expression of cytochrome P450 4a14 mRNA, but not Bcrp, was increased in mice treated with PFOA.	perfluorooctanoic acid	101-105	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-64
23435180-9	2013	Micromolar concentrations of PFOA decreased human BCRP ATPase activity and inhibited BCRP-mediated transport in inverted membrane vesicles.	perfluorooctanoic acid	29-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-54
23435180-9	2013	Micromolar concentrations of PFOA decreased human BCRP ATPase activity and inhibited BCRP-mediated transport in inverted membrane vesicles.	perfluorooctanoic acid	29-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	85-89
23435180-10	2013	Together, these studies demonstrate that PFOA induces hepatic Bcrp expression in mice and may inhibit human BCRP transporter function at concentrations that exceed levels observed in humans.	perfluorooctanoic acid	41-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	62-66
23435180-10	2013	Together, these studies demonstrate that PFOA induces hepatic Bcrp expression in mice and may inhibit human BCRP transporter function at concentrations that exceed levels observed in humans.	perfluorooctanoic acid	41-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-112
22958812-0	2013	Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.	Rivaroxaban	108-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	33-65
22958812-0	2013	Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.	Rivaroxaban	108-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-72
22958812-3	2013	As renal rivaroxaban clearance exceeds glomerular filtration rate, we suggested that active secretion by efflux transporters P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP) contributes to rivaroxaban clearance.	Rivaroxaban	9-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	151-183
22958812-3	2013	As renal rivaroxaban clearance exceeds glomerular filtration rate, we suggested that active secretion by efflux transporters P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP) contributes to rivaroxaban clearance.	Rivaroxaban	9-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-189
22958812-3	2013	As renal rivaroxaban clearance exceeds glomerular filtration rate, we suggested that active secretion by efflux transporters P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP) contributes to rivaroxaban clearance.	Rivaroxaban	206-217	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	151-183
22958812-3	2013	As renal rivaroxaban clearance exceeds glomerular filtration rate, we suggested that active secretion by efflux transporters P-glycoprotein (MDR1) and breast cancer resistance protein (BCRP) contributes to rivaroxaban clearance.	Rivaroxaban	206-217	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-189
22958812-4	2013	The ability of MDR1 and BCRP efflux transporters to mediate rivaroxaban transport in vitro was assessed in polarized cell monolayers.	Rivaroxaban	60-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-28
22958812-7	2013	However, rivaroxaban clearance was significantly reduced in Mdr1a/Mdr1b(-/-)/Bcrp(-/-) mice.	Rivaroxaban	9-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-81
23249624-9	2013	Dabrafenib plasma exposure was ~2-fold greater in Mdr1 a/b(-/-)Bcrp1(-/-) mice as compared with wild-type with an oral dose (25 mg/kg); however, the brain distribution was increased by ~10-fold with a resulting K(p) of 0.25.	dabrafenib	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-68
23432917-9	2013	In animals injected with Abeta1-40-Cy5.5, the deficiency in either Abcb1 or Abcg2 resulted in significant increases in fluorescence concentration in the head ROIs 2 hours after injection compared to wild-type animals.	cyanine dye 5	35-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	76-81
22958812-8	2013	Interestingly, rivaroxaban brain-to-plasma ratio did not differ in mice lacking only Mdr1a or Bcrp, but more than two times higher in the Mdr1a/Mdr1b(-/-)/Bcrp(-/-) mice.	Rivaroxaban	15-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	155-159
22958812-9	2013	Rivaroxaban is a shared substrate of MDR1 and BCRP.	Rivaroxaban	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	46-50
22958812-10	2013	In vivo, MDR and BCRP function synergistically to modulate rivaroxaban disposition and appear to be particularly relevant to limiting its central nervous system entry.	Rivaroxaban	59-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	17-21
22958812-11	2013	These data have important implications for safety and efficacy of anticoagulation therapy with rivaroxaban as many drugs in clinical use are known MDR1 inhibitors and loss-of-function polymorphisms in BCRP are common.	Rivaroxaban	95-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	201-205
23333829-5	2013	KEY FINDINGS: BCRP inhibitor Ko143 (50 muM and 100 muM) significantly increased the intestinal absorption amount in jejunum, ileum and colon (p&lt;0.05).	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	29-34	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	14-18
23333829-7	2013	Furthermore, the plasma concentration MED-5 and tolmetin, metabolites of MED-15, increased 2-fold and 4-fold, respectively, in Bcrp1 knockout mice compared with wild-type mice after the single-pass perfusion of small intestine with MED-15.	Tolmetin glycinamide	38-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	127-132
23333829-7	2013	Furthermore, the plasma concentration MED-5 and tolmetin, metabolites of MED-15, increased 2-fold and 4-fold, respectively, in Bcrp1 knockout mice compared with wild-type mice after the single-pass perfusion of small intestine with MED-15.	Tolmetin	48-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	127-132
23333829-8	2013	SIGNIFICANCE: It may be concluded that BCRP plays an important role in the intestinal efflux of MED-5 and limits the bioavailability after oral administration of MED-15.	Tolmetin glycinamide	96-101	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-43
23063411-0	2013	Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.	Dactinomycin	104-117	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	57-62
23291288-1	2013	The fumitremorgin C analogue Ko143 is a potent and selective inhibitor of the ATP-binding cassette transporter ABCG2.	tryptoquivaline	4-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	111-116
23291288-1	2013	The fumitremorgin C analogue Ko143 is a potent and selective inhibitor of the ATP-binding cassette transporter ABCG2.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	29-34	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	111-116
23089896-2	2013	Skin and plasma concentrations of rhodamine123 (Rho123) after dermal application were reduced in P-gp knockout (mdr1a/1b-/-) mice and were below the detection limit in P-gp and BCRP triple-knockout (mdr1a/1b/bcrp-/-) mice.	Rhodamine 123	34-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	177-181
23089896-2	2013	Skin and plasma concentrations of rhodamine123 (Rho123) after dermal application were reduced in P-gp knockout (mdr1a/1b-/-) mice and were below the detection limit in P-gp and BCRP triple-knockout (mdr1a/1b/bcrp-/-) mice.	Rhodamine 123	34-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	208-212
23063650-0	2013	Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models.	nilotinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	68-73
23063650-1	2013	A panel of clinically used tyrosine kinase inhibitors were compared and nilotinib was found to most potently sensitize specific anticancer agents by blocking the functions of ABCB1/P-glycoprotein, ABCG2/BCRP and ABCC10/MRP7 transporters involved in multi-drug resistance.	nilotinib	72-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	197-202
23063650-1	2013	A panel of clinically used tyrosine kinase inhibitors were compared and nilotinib was found to most potently sensitize specific anticancer agents by blocking the functions of ABCB1/P-glycoprotein, ABCG2/BCRP and ABCC10/MRP7 transporters involved in multi-drug resistance.	nilotinib	72-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	203-207
23063650-2	2013	Nilotinib appreciably enhanced the antitumor response of (1) paclitaxel in the ABCB1- and novel ABCC10-xenograft models, and (2) doxorubicin in a novel ABCG2-xenograft model.	nilotinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	152-157
23063650-2	2013	Nilotinib appreciably enhanced the antitumor response of (1) paclitaxel in the ABCB1- and novel ABCC10-xenograft models, and (2) doxorubicin in a novel ABCG2-xenograft model.	Doxorubicin	129-140	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	152-157
22785334-0	2013	Studies on the intestinal absorption characteristics of sulfasalazine, a breast cancer resistance protein (BCRP) substrate.	Sulfasalazine	56-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	73-105
22785334-0	2013	Studies on the intestinal absorption characteristics of sulfasalazine, a breast cancer resistance protein (BCRP) substrate.	Sulfasalazine	56-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	107-111
22785334-1	2013	Oral sulfasalazine (SASP) is now used clinically as a probe substrate of a breast cancer resistance protein (BCRP) activity; however the intestinal absorption characteristics of SASP are not well understood.	Sulfasalazine	5-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-107
23014761-6	2013	We show that erlotinib transport across an intact BBB is significantly restricted due to P-gp- and Bcrp-mediated efflux transport.	Erlotinib Hydrochloride	13-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	99-103
22785334-1	2013	Oral sulfasalazine (SASP) is now used clinically as a probe substrate of a breast cancer resistance protein (BCRP) activity; however the intestinal absorption characteristics of SASP are not well understood.	Sulfasalazine	5-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-113
23014761-8	2013	Inhibition of P-gp and Bcrp by the dual inhibitor elacridar dramatically increased erlotinib delivery to the tumor core, rim, and normal brain.	Erlotinib Hydrochloride	83-92	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	23-27
22785334-3	2013	The everted ileum was incubated with SASP in the absence or presence of the Bcrp inhibitor Ko134.	ko134	91-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	76-80
22774772-0	2012	Pharmacological characterization of the peripheral FAAH inhibitor URB937 in female rodents: interaction with the Abcg2 transporter in the blood-placenta barrier.	URB937	66-72	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	113-118
23285492-0	2004	(11)C-Labeled rhodamine-123 The P-glycoprotein (P-gp; also known as MDR1 or ABCB1) is a member of the ATP-binding cassette transporter family of proteins (the multi-drug resistance (MDR) protein and the breast cancer resistance protein (BCRP) are the other two members of this group of proteins) that is responsible for the rapid transportation of drugs across the cell membrane (uptake and efflux) (1).	Rhodamine 123	14-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	237-241
22750234-4	2012	The use of different specific inhibitors of these transporters as well as knockout mice enabled us to conclude that MRP2 and BCRP are involved in the extrusion of trans-resveratrol glucuronide and sulfate to the intestinal lumen without the participation of P-gp.	trans-resveratrol glucuronide	163-192	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	125-129
22750234-4	2012	The use of different specific inhibitors of these transporters as well as knockout mice enabled us to conclude that MRP2 and BCRP are involved in the extrusion of trans-resveratrol glucuronide and sulfate to the intestinal lumen without the participation of P-gp.	Sulfates	197-204	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	125-129
23020847-2	2012	We aimed to establish whether oral availability and brain penetration of vemurafenib could be restricted by the multidrug efflux transporters P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2), as these might limit therapeutic efficacy, especially against brain metastases.	Vemurafenib	73-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	208-212
23020847-0	2012	Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.	Vemurafenib	68-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	164-169
23020847-2	2012	We aimed to establish whether oral availability and brain penetration of vemurafenib could be restricted by the multidrug efflux transporters P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2), as these might limit therapeutic efficacy, especially against brain metastases.	Vemurafenib	73-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	213-218
23020847-3	2012	In vitro, vemurafenib was efficiently transported by both human ABCB1 and ABCG2, and very efficiently by mouse Abcg2, but not by mouse Abcc2.	Vemurafenib	10-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	111-116
23020847-4	2012	Upon oral administration of vemurafenib (5 mg/kg), Abcb1a/1b(-/-) mice had a 1.6-fold increased, Abcg2(-/-) mice a 2.3-fold increased, and Abcb1a/1b(-/-);Abcg2(-/-) mice a 6.6-fold increased plasma AUC, respectively, compared to wild-type (WT) mice, indicating a marked and additive role of these transporters in limiting vemurafenib oral availability.	Vemurafenib	28-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	97-102
23020847-4	2012	Upon oral administration of vemurafenib (5 mg/kg), Abcb1a/1b(-/-) mice had a 1.6-fold increased, Abcg2(-/-) mice a 2.3-fold increased, and Abcb1a/1b(-/-);Abcg2(-/-) mice a 6.6-fold increased plasma AUC, respectively, compared to wild-type (WT) mice, indicating a marked and additive role of these transporters in limiting vemurafenib oral availability.	Vemurafenib	28-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	154-159
23020847-6	2012	Oral coadministration of the dual ABCB1 and ABCG2 inhibitor elacridar almost completely eliminated the roles of Abcb1 and Abcg2 in restricting oral availability and brain accumulation of vemurafenib.	Vemurafenib	187-198	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	122-127
22828996-2	2012	In this study, we developed a positron emission tomography (PET) protocol to visualize Bcrp function at the murine BBB, based on the dual P-glycoprotein (P-gp)/Bcrp substrate radiotracer [(11)C]tariquidar in combination with the Bcrp inhibitor Ko143.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	244-249	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-91
22728310-4	2012	It was found that Dox decreased the numbers of BMSCs (ABCG2(+)) and the sphere formation in a dose-dependent fashion in isolated bone marrow cells.	Doxorubicin	18-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
22688250-8	2012	However, dual P-gp/Bcrp1 inhibition by elacridar (GF120918), significantly enhanced pazopanib brain penetration by ~5-fold without altering its plasma concentrations.	pazopanib	84-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	19-24
22688250-0	2012	Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.	pazopanib	31-40	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	64-69
22828996-5	2012	After 15 mg/kg Ko143, the maximum increase in [(11)C]tariquidar brain uptake relative to baseline scans was 6.3-fold in Mdr1a/b((-/-)) mice with a half-maximum effect dose of 4.98 mg/kg and 3.6-fold in tariquidar (8 mg/kg) pretreated wild-type mice, suggesting that the presented protocol is sensitive to visualize a range of different functional Bcrp activities at the murine BBB.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	15-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	347-351
22688250-9	2012	Thus, even though Bcrp1 showed higher affinity towards pazopanib in vitro, in vivo at the mouse BBB both P-gp and Bcrp1 act in concert to limit brain accumulation of pazopanib.	pazopanib	55-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	18-23
22688250-9	2012	Thus, even though Bcrp1 showed higher affinity towards pazopanib in vitro, in vivo at the mouse BBB both P-gp and Bcrp1 act in concert to limit brain accumulation of pazopanib.	pazopanib	166-175	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	18-23
22688250-0	2012	Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.	Canertinib	91-101	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	64-69
22688250-9	2012	Thus, even though Bcrp1 showed higher affinity towards pazopanib in vitro, in vivo at the mouse BBB both P-gp and Bcrp1 act in concert to limit brain accumulation of pazopanib.	pazopanib	166-175	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	114-119
22688250-0	2012	Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.	Erlotinib Hydrochloride	105-114	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	64-69
22736306-0	2012	Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein.	Genistein	68-77	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-32
22688250-1	2012	Primary objective of this investigation was to delineate the differential impact of efflux transporters P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) on brain disposition and plasma pharmacokinetics of pazopanib.	pazopanib	235-244	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	170-175
22688250-1	2012	Primary objective of this investigation was to delineate the differential impact of efflux transporters P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) on brain disposition and plasma pharmacokinetics of pazopanib.	pazopanib	235-244	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	176-181
22688250-3	2012	In vitro assays with MDCKII cell monolayers suggested that pazopanib is a high affinity substrate for Bcrp1 and a moderate substrate for P-gp.	pazopanib	59-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	102-107
22736306-0	2012	Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein.	Genistein	68-77	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
22736306-1	2012	It was recently proposed that the improved oral bioavailability of genistein aglycone and conjugates in Bcrp1(-/-) mice is mainly due to increased intestinal absorption of aglycone and subsequent elevated exposure to conjugation enzymes.	CHEBI:166892	77-85	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-109
22736306-1	2012	It was recently proposed that the improved oral bioavailability of genistein aglycone and conjugates in Bcrp1(-/-) mice is mainly due to increased intestinal absorption of aglycone and subsequent elevated exposure to conjugation enzymes.	CHEBI:166892	172-180	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-109
22736306-3	2012	Separately, we showed that 5- to 10-fold increases in exposures of conjugates and somewhat lower fold increases (&lt;2-fold) in exposures of aglycone were apparent after both oral and intraperitoneal administration in Bcrp1(-/-) mice.	CHEBI:166892	141-149	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	218-223
22736306-4	2012	In contrast, the intestinal and biliary excretion of genistein conjugates significantly decreased in Bcrp1(-/-) mice without corresponding changes in aglycone excretion.	Genistein	53-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-106
22736306-7	2012	Because genistein glucuronidation rates were 110% (liver) and 50% (colon) higher and genistein sulfation rates were 40% (liver) and 42% (colon) lower in Bcrp1(-/-) mice, the changes in genistein exposures are not mainly due to changes in enzyme activities.	Genistein	85-94	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	153-158
22736306-7	2012	Because genistein glucuronidation rates were 110% (liver) and 50% (colon) higher and genistein sulfation rates were 40% (liver) and 42% (colon) lower in Bcrp1(-/-) mice, the changes in genistein exposures are not mainly due to changes in enzyme activities.	Genistein	85-94	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	153-158
22266045-4	2012	Three candidate apical GSH transporters in the lung are CFTR, BCRP, and MRP2, but their potential roles in ELF GSH transport in response to CS have not been investigated.	Glutathione	23-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	62-66
22633931-0	2012	Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.	vandetanib	60-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	151-156
22633931-0	2012	Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.	vandetanib	60-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	157-162
22633931-1	2012	The objectives of this study were (i) to characterize the interaction of vandetanib with P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1) in vitro and in vivo (ii) to study the modulation of P-gp and BCRP mediated efflux of vandetanib with specific transport inhibitors and m-TOR inhibitors, everolimus and temsirolimus.	vandetanib	73-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	149-154
22633931-1	2012	The objectives of this study were (i) to characterize the interaction of vandetanib with P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1) in vitro and in vivo (ii) to study the modulation of P-gp and BCRP mediated efflux of vandetanib with specific transport inhibitors and m-TOR inhibitors, everolimus and temsirolimus.	vandetanib	73-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	218-222
22633931-1	2012	The objectives of this study were (i) to characterize the interaction of vandetanib with P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1) in vitro and in vivo (ii) to study the modulation of P-gp and BCRP mediated efflux of vandetanib with specific transport inhibitors and m-TOR inhibitors, everolimus and temsirolimus.	vandetanib	242-252	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	149-154
22633931-1	2012	The objectives of this study were (i) to characterize the interaction of vandetanib with P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1) in vitro and in vivo (ii) to study the modulation of P-gp and BCRP mediated efflux of vandetanib with specific transport inhibitors and m-TOR inhibitors, everolimus and temsirolimus.	Everolimus	310-320	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	149-154
22633931-1	2012	The objectives of this study were (i) to characterize the interaction of vandetanib with P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1) in vitro and in vivo (ii) to study the modulation of P-gp and BCRP mediated efflux of vandetanib with specific transport inhibitors and m-TOR inhibitors, everolimus and temsirolimus.	temsirolimus	325-337	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	149-154
22633931-4	2012	In vitro studies suggested that vandetanib is a high affinity substrate of Bcrp1 but is not transported by P-gp.	vandetanib	32-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-80
22633931-5	2012	Interestingly, in vivo brain distribution studies in FVB wild type mice indicated that vandetanib penetration into the brain is restricted by both Bcrp1 and P-gp mediated active efflux at the blood brain barrier (BBB).	vandetanib	87-97	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	147-152
22633931-6	2012	Co-administration of elacridar, a dual P-gp/BCRP inhibitor increased the brain to plasma concentration ratio of vandetanib upto 5 fold.	vandetanib	112-122	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-48
22578166-2	2012	ABCG2 is a transporter protein expressed in the brain and involved in GSH transport.	Glutathione	70-73	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
22454535-0	2012	Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).	Vemurafenib	131-142	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-69
22454535-0	2012	Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).	Vemurafenib	131-142	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-76
22454535-0	2012	Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).	Vemurafenib	144-151	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-76
22454535-2	2012	The objective of this study was to investigate the role of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in the distribution of vemurafenib to the central nervous system.	Vemurafenib	148-159	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	85-117
22454535-2	2012	The objective of this study was to investigate the role of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in the distribution of vemurafenib to the central nervous system.	Vemurafenib	148-159	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	119-123
22454535-8	2012	These data indicate that the brain distribution of vemurafenib is severely restricted at the blood-brain barrier because of active efflux by both P-gp and BCRP.	Vemurafenib	51-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	155-159
22699078-9	2012	Axitinib, alone and in combination with 5-FU, reduced ABCG2 expression in the tumor tissue, and 5-FU has no such effect.	Axitinib	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
22699078-9	2012	Axitinib, alone and in combination with 5-FU, reduced ABCG2 expression in the tumor tissue, and 5-FU has no such effect.	Fluorouracil	40-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
22266779-3	2012	The effect of Bcrp and Pgp on digoxin exposures in brain and CSF was investigated in wild-type mice in the presence of the inhibitors.	Digoxin	30-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	14-18
22266779-4	2012	In vivo studies showed dantrolene exposures in brain and CSF, but not the blood, increased in Bcrp(-/-) and Mdr1a/1b(-/-)/Bcrp(-/-) mice, or in the presence of the Bcrp inhibitors Ko143 or GF120918.	Dantrolene	23-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	94-98
22266779-4	2012	In vivo studies showed dantrolene exposures in brain and CSF, but not the blood, increased in Bcrp(-/-) and Mdr1a/1b(-/-)/Bcrp(-/-) mice, or in the presence of the Bcrp inhibitors Ko143 or GF120918.	Dantrolene	23-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	122-126
22266779-4	2012	In vivo studies showed dantrolene exposures in brain and CSF, but not the blood, increased in Bcrp(-/-) and Mdr1a/1b(-/-)/Bcrp(-/-) mice, or in the presence of the Bcrp inhibitors Ko143 or GF120918.	Dantrolene	23-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	122-126
22266779-6	2012	Results from the present study demonstrated that inhibition of Bcrp and Pgp increased not only the exposures of dantrolene and digoxin in brain, but also the exposures in CSF.	Dantrolene	112-122	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-67
22266779-6	2012	Results from the present study demonstrated that inhibition of Bcrp and Pgp increased not only the exposures of dantrolene and digoxin in brain, but also the exposures in CSF.	Digoxin	127-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-67
22707564-4	2012	In vitro, ABCG2 transports several sulfate conjugates at high rates.	Sulfates	35-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
22707564-6	2012	Levels of many sulfate conjugates were up to 15-fold higher in plasma and urine of Abcg2-/- than of wild-type mice, with the opposite effect seen in bile.	Sulfates	15-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	83-88
22707564-8	2012	We confirmed that these sulfate conjugates were ABCG2 substrates using transportomics, a method that uses vesicular transport assays to screen for substrates of ABC transporters in body fluids.	Sulfates	24-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	48-53
22707564-9	2012	In conclusion, our results show that ABCG2 limits the systemic exposure to many different phytoestrogens, a class of compounds to which mammals are exposed on a daily basis via food of plant origin, by directing their sulfate conjugates for excretion via the feces.	Sulfates	218-225	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-42
22549112-7	2012	In nude mice bearing ABCG2-overexpressing S1-M1-80 xenografts, axitinib significantly enhanced the antitumor activity of topotecan without causing additional toxicity.	Axitinib	63-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-26
22667338-10	2012	SP cells were detected at a frequency of 4.4% and expressed stem/progenitor markers, Abcb1b, Abcg2, Sca1, Notch1, Notch4, Hes1, and Jag1 in microarray analysis.	sp	0-2	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	93-98
22508302-8	2012	TCBZSO administration also inhibited nitrofurantoin Abcg2-mediated secretion into milk by more than 2-fold and increased plasma levels of the sulfonamide sulfasalazine by more than 1.5-fold in mice.	triclabendazole sulfoxide	0-6	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-57
22508302-8	2012	TCBZSO administration also inhibited nitrofurantoin Abcg2-mediated secretion into milk by more than 2-fold and increased plasma levels of the sulfonamide sulfasalazine by more than 1.5-fold in mice.	Nitrofurantoin	37-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-57
22682531-13	2012	The DNA-binding dye DyeCycle Violet was used to set up the side population (SP) assay aimed at identifying subpopulations of OSE cells with chemoresistance phenotype associated with ABCG2 transporter activity.	DyeCycle Violet	20-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	182-187
22396548-7	2012	ATF4 bound time-dependently to the cAMP response element within the exon 1B promoter region of the Abcg2 gene, thereby causing the oscillation of BCRP protein abundance and its efflux pump function.	Cyclic AMP	35-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	99-104
22396548-7	2012	ATF4 bound time-dependently to the cAMP response element within the exon 1B promoter region of the Abcg2 gene, thereby causing the oscillation of BCRP protein abundance and its efflux pump function.	Cyclic AMP	35-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	146-150
22323823-3	2012	This study investigated the influence of two important efflux transporters at the blood-brain barrier, P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp), on the delivery of cediranib to the central nervous system.	cediranib	189-198	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	129-161
22323823-3	2012	This study investigated the influence of two important efflux transporters at the blood-brain barrier, P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp), on the delivery of cediranib to the central nervous system.	cediranib	189-198	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	163-167
22323823-4	2012	In vitro studies indicated that cediranib is a dual substrate for both P-gp and Bcrp.	cediranib	32-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	80-84
22473008-5	2012	Paradoxically, ABCG2 export dysfunction significantly increases urinary urate excretion and risk ratio of urate overproduction.	Uric Acid	72-77	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	15-20
22473008-5	2012	Paradoxically, ABCG2 export dysfunction significantly increases urinary urate excretion and risk ratio of urate overproduction.	Uric Acid	106-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	15-20
22473008-6	2012	Abcg2-knockout mice show increased serum uric acid levels and renal urate excretion, and decreased intestinal urate excretion.	Uric Acid	41-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
22266045-5	2012	In vitro, the inhibition of CFTR, BCRP, or MRP2 resulted in decreased GSH efflux in response to cigarette smoke extract.	Glutathione	70-73	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
22134889-1	2012	The side population phenotype is associated with the Hoechst dye efflux activity of the Abcg2 transporter and identifies hematopoietic stem cells (HSCs) in the bone marrow.	hoechst dye	53-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	88-93
20963470-0	2012	Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.	Erlotinib Hydrochloride	62-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-114
20963470-8	2012	In Bcrp1(-/-) mice, were P-gp is present, a more pronounced 3.8-fold decrease to 13.0 +- 0.70, mug/g*h (P &lt; 0.01) was observed, which is close to the 4.5-fold decrease in the AUC(brain) of erlotinib found in WT mice where both drug transporters are present (11.0 +- 1.35, P &lt; 0.01).	Erlotinib Hydrochloride	192-201	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	3-8
20963470-9	2012	The plasma clearance of erlotinib was similar in mice deficient for P-gp and/or Bcrp1 compared with wild-type mice.	Erlotinib Hydrochloride	24-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	80-85
20963470-11	2012	CONCLUSIONS: Both P-gp and Bcrp1 reduce the brain penetration of erlotinib.	Erlotinib Hydrochloride	65-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-32
22116099-6	2012	In vitro experiments demonstrated that ABCG2 regulates transport of glutathione, an important endogenous antioxidant, from microvascular endothelial cells.	Glutathione	68-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
22116099-7	2012	Besides, glutathione transported from microvascular endothelial cells in ABCG2-dependent manner ameliorated oxidative stress-induced cardiomyocyte hypertrophy.	Glutathione	9-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	73-78
22238213-0	2012	P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.	Sunitinib	110-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	61-66
22238213-0	2012	P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.	SU 12662	131-151	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	61-66
22238213-3	2012	In vitro, N-desethyl sunitinib was a good transport substrate of human ABCB1 and ABCG2 and murine Abcg2, but not ABCC2 or Abcc2.	SU 12662	10-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	98-103
22238213-4	2012	At 5 muM, ABCB1 and ABCG2 contributed almost equally to N-desethyl sunitinib transport.	SU 12662	56-76	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	20-25
22238213-6	2012	However, brain accumulation of N-desethyl sunitinib was markedly increased (13.7-fold) in Abcb1a/1b(-/-)/Abcg2(-/-) mice, but not in Abcb1a/1b(-/-) or Abcg2(-/-) mice.	SU 12662	31-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	105-110
22238213-6	2012	However, brain accumulation of N-desethyl sunitinib was markedly increased (13.7-fold) in Abcb1a/1b(-/-)/Abcg2(-/-) mice, but not in Abcb1a/1b(-/-) or Abcg2(-/-) mice.	SU 12662	31-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	151-156
22238213-7	2012	In the absence of the ABCB1 and ABCG2 inhibitor elacridar, brain concentrations of N-desethyl sunitinib were detectable only in Abcb1a/1b(-/-)/Abcg2(-/-) mice after sunitinib administration.	SU 12662	83-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	143-148
22238213-7	2012	In the absence of the ABCB1 and ABCG2 inhibitor elacridar, brain concentrations of N-desethyl sunitinib were detectable only in Abcb1a/1b(-/-)/Abcg2(-/-) mice after sunitinib administration.	Sunitinib	94-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	143-148
22238213-9	2012	In conclusion, brain accumulation of N-desethyl sunitinib is effectively restricted by both Abcb1 and Abcg2.	SU 12662	37-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	102-107
22335402-0	2012	Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.	Sorafenib	151-160	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	93-98
22335402-5	2012	The brain efflux index method, combined with the organotypic brain slices, was used to determine the net contribution of P-gp and BCRP to the total clearance of sorafenib out of the brain and show that its efflux at the BBB is mediated primarily by BCRP.	Sorafenib	161-170	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	130-134
22335402-5	2012	The brain efflux index method, combined with the organotypic brain slices, was used to determine the net contribution of P-gp and BCRP to the total clearance of sorafenib out of the brain and show that its efflux at the BBB is mediated primarily by BCRP.	Sorafenib	161-170	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	249-253
22335402-6	2012	Sorafenib clearance out of the brain decreased 2-fold in the Bcrp1(-/-) mice and 2.5-fold in the Mdr1a/1b(-/-)Bcrp1(-/-) mice.	Sorafenib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	61-66
22335402-6	2012	Sorafenib clearance out of the brain decreased 2-fold in the Bcrp1(-/-) mice and 2.5-fold in the Mdr1a/1b(-/-)Bcrp1(-/-) mice.	Sorafenib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-115
22335402-9	2012	In conclusion, this study explains the cooperation of P-gp and BCRP by analysis of the efflux clearance of sorafenib and correlating it to the "mechanisms" that determine the clearance, i.e., affinity and capacity.	Sorafenib	107-116	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-67
22096226-10	2012	Compared with wild-type mice, obstructive cholestasis in pregnant Abcg2(-/-) knockout mice induced similar bile acid accumulation in maternal serum but higher accumulation in placenta, fetal serum, and liver.	Bile Acids and Salts	107-116	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	66-71
22134889-7	2012	Stem cell tracing patterns were seen in the small intestine and in seminiferous tubules in the testis 20 months after Tam treatment, proving that stem cells from these organs express Abcg2.	Tamoxifen	118-121	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	183-188
21351087-0	2012	Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.	Sunitinib	22-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-115
22673043-7	2012	The maximum concentration and AUC(0-4) of sunitinib were significantly higher in Abcg2(-/-), Abcb1a/1b(-/-) and Abcb1a/1b;Abcg2(-/-) mice than wild-type mice when sunitinib was given orally but not intraperitoneally.	Sunitinib	42-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	81-86
22673043-7	2012	The maximum concentration and AUC(0-4) of sunitinib were significantly higher in Abcg2(-/-), Abcb1a/1b(-/-) and Abcb1a/1b;Abcg2(-/-) mice than wild-type mice when sunitinib was given orally but not intraperitoneally.	Sunitinib	42-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	122-127
21351087-2	2012	We aimed to investigate the in vivo roles of the ATP-binding cassette drug efflux transporters ABCB1 and ABCG2 in plasma pharmacokinetics and brain accumulation of oral sunitinib, and the feasibility of improving sunitinib kinetics using oral coadministration of the dual ABCB1/ABCG2 inhibitor elacridar.	Adenosine Triphosphate	49-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	105-110
21351087-2	2012	We aimed to investigate the in vivo roles of the ATP-binding cassette drug efflux transporters ABCB1 and ABCG2 in plasma pharmacokinetics and brain accumulation of oral sunitinib, and the feasibility of improving sunitinib kinetics using oral coadministration of the dual ABCB1/ABCG2 inhibitor elacridar.	Adenosine Triphosphate	49-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	278-283
21351087-2	2012	We aimed to investigate the in vivo roles of the ATP-binding cassette drug efflux transporters ABCB1 and ABCG2 in plasma pharmacokinetics and brain accumulation of oral sunitinib, and the feasibility of improving sunitinib kinetics using oral coadministration of the dual ABCB1/ABCG2 inhibitor elacridar.	Sunitinib	169-178	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	105-110
21351087-2	2012	We aimed to investigate the in vivo roles of the ATP-binding cassette drug efflux transporters ABCB1 and ABCG2 in plasma pharmacokinetics and brain accumulation of oral sunitinib, and the feasibility of improving sunitinib kinetics using oral coadministration of the dual ABCB1/ABCG2 inhibitor elacridar.	Sunitinib	213-222	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	105-110
21351087-2	2012	We aimed to investigate the in vivo roles of the ATP-binding cassette drug efflux transporters ABCB1 and ABCG2 in plasma pharmacokinetics and brain accumulation of oral sunitinib, and the feasibility of improving sunitinib kinetics using oral coadministration of the dual ABCB1/ABCG2 inhibitor elacridar.	Sunitinib	213-222	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	278-283
21351087-4	2012	In vitro, sunitinib was a good substrate of murine (mu)ABCG2 and a moderate substrate of human (hu)ABCB1 and huABCG2.	Sunitinib	10-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	55-60
21351087-6	2012	Brain accumulation of sunitinib was markedly (23-fold) increased in Abcb1a/b/Abcg2(-/-)  mice, but only slightly (2.3-fold) in Abcb1a/b(-/-)  mice, and not in Abcg2(-/-)  mice.	Sunitinib	22-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-82
21351087-6	2012	Brain accumulation of sunitinib was markedly (23-fold) increased in Abcb1a/b/Abcg2(-/-)  mice, but only slightly (2.3-fold) in Abcb1a/b(-/-)  mice, and not in Abcg2(-/-)  mice.	Sunitinib	22-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	159-164
21351087-7	2012	Importantly, a clinically realistic coadministration of oral elacridar and oral sunitinib to wild-type mice resulted in markedly increased sunitinib brain accumulation, equaling levels in Abcb1a/1b/Abcg2(-/-)  mice.	Sunitinib	80-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	198-203
22391220-6	2012	We showed that ABCG2 and Abcg4 mediate the cellular efflux of [3H] Abeta1-40.	Tritium	63-65	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	15-20
22391220-9	2012	Perfusing the brains of Abcb1/Abcg2- and Abca1-deficient mice with [3H] Abeta1-40 plus probucol significantly increased the Clup of Abeta.	Tritium	68-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-35
22348008-8	2012	Bcrp1 knockout mice exhibited significantly decreased intestinal secretion and an increased plasma concentration of uric acid.	Uric Acid	116-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
23028879-0	2012	EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.	EZN-2208	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-35
23028879-0	2012	EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.	Topotecan	45-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-35
23028879-3	2012	Here, we tested the pegylated SN38 compound EZN-2208 as a novel approach to treat BRCA1-mutated tumors that express ABCG2.	EZN-2208	44-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	116-121
23028879-4	2012	We found that EZN-2208 therapy resulted in more pronounced and durable responses of ABCG2-positive tumors than topotecan or irinotecan therapy.	EZN-2208	14-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-89
23028879-5	2012	We also evaluated tumor-specific ABCG2 inhibition by Ko143 in Abcg2(-/-) host animals that carried tumors with topotecan-induced ABCG2 expression.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	53-58	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	33-38
23028879-5	2012	We also evaluated tumor-specific ABCG2 inhibition by Ko143 in Abcg2(-/-) host animals that carried tumors with topotecan-induced ABCG2 expression.	Topotecan	111-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	129-134
22536451-0	2012	Enhanced brain disposition and effects of Delta9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice.	Dronabinol	42-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-124
22536451-2	2012	The main psychoactive constituent of cannabis Delta(9)-tetrahydrocannabinol (THC) has affinity for P-gp and Bcrp, however it is unknown whether these transporters modulate the brain accumulation of THC and its functional effects on the CNS.	Dronabinol	46-75	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-112
22536451-2	2012	The main psychoactive constituent of cannabis Delta(9)-tetrahydrocannabinol (THC) has affinity for P-gp and Bcrp, however it is unknown whether these transporters modulate the brain accumulation of THC and its functional effects on the CNS.	Dronabinol	77-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-112
22536451-3	2012	Here we aim to show that mice devoid of Abcb1 and Abcg2 retain higher brain THC levels and are more sensitive to cannabinoid-induced hypothermia than wild-type (WT) mice.	Dronabinol	76-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-55
22536451-3	2012	Here we aim to show that mice devoid of Abcb1 and Abcg2 retain higher brain THC levels and are more sensitive to cannabinoid-induced hypothermia than wild-type (WT) mice.	Cannabinoids	113-124	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-55
22536451-6	2012	Brain THC concentrations were higher in both Abcb1a/b (-/-) and Abcg2 (-/-) mice than WT mice.	Dronabinol	6-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	64-69
22536451-7	2012	ABC transporter knockout mice exhibited delayed elimination of THC from the brain with the effect being more prominent in Abcg2 (-/-) mice.	Dronabinol	63-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	122-127
22536451-9	2012	These results show P-gp and Bcrp prolong the brain disposition and hypothermic effects of THC and offer a novel mechanism for both genetic vulnerability to the psychoactive effects of cannabis and drug interactions between CNS therapies and cannabis.	Dronabinol	90-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	28-32
22004608-2	2011	Nitrofurantoin transepithelial secretion was confirmed in both human BCRP and mouse bcrp-transfected MDCKII epithelia, whereas no net transepithelial secretion was observed in native or human MDR1-MDCKII epithelia.	Nitrofurantoin	0-14	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-88
21934030-4	2011	P-gp and/or Bcrp substrates, such as verapamil, loperamide, flavopiridol, genistein, quinidine, dantrolene, daidzein, cimetidine, and pefloxacin, showed a higher CSF-to-brain unbound concentration ratio (K(p,uu,CSF/brain)) compared with non-P-gp and non-Bcrp substrates.	Verapamil	37-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	12-16
21855533-4	2011	Aurones and related analogs were investigated for re-sensitization of R cells to mitoxantrone (MX, a chemotherapeutic substrate of ABCG2) in cell-based assays, accumulation of intracellular MX by cell cytometry, interaction with ABCG2 by biochemical assays and in vivo efficacy in MX resistant nude mice xenografts.	Mitoxantrone	81-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	131-136
21934030-6	2011	Furthermore, consistent with the contribution of P-gp and Bcrp to the net efflux at the BBB, K(p,uu,CSF/brain) values of the common substrates (flavopiridol and erlotinib) were markedly decreased in Mdr1a/1b(-/-)/Bcrp(-/-) mice, but only moderately or weakly in Mdr1a/1b(-/-) mice and negligibly in Bcrp(-/-) mice.	alvocidib	144-156	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	58-62
21934030-5	2011	K(p,uu,CSF/brain) values of P-gp-specific (quinidine and verapamil) and Bcrp-specific (daidzein and genistein) substrates were significantly decreased in Mdr1a/1b(-/-) and Bcrp(-/-) mice, respectively.	Quinidine	43-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	172-176
21934030-6	2011	Furthermore, consistent with the contribution of P-gp and Bcrp to the net efflux at the BBB, K(p,uu,CSF/brain) values of the common substrates (flavopiridol and erlotinib) were markedly decreased in Mdr1a/1b(-/-)/Bcrp(-/-) mice, but only moderately or weakly in Mdr1a/1b(-/-) mice and negligibly in Bcrp(-/-) mice.	alvocidib	144-156	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	213-217
21934030-6	2011	Furthermore, consistent with the contribution of P-gp and Bcrp to the net efflux at the BBB, K(p,uu,CSF/brain) values of the common substrates (flavopiridol and erlotinib) were markedly decreased in Mdr1a/1b(-/-)/Bcrp(-/-) mice, but only moderately or weakly in Mdr1a/1b(-/-) mice and negligibly in Bcrp(-/-) mice.	alvocidib	144-156	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	213-217
21934030-6	2011	Furthermore, consistent with the contribution of P-gp and Bcrp to the net efflux at the BBB, K(p,uu,CSF/brain) values of the common substrates (flavopiridol and erlotinib) were markedly decreased in Mdr1a/1b(-/-)/Bcrp(-/-) mice, but only moderately or weakly in Mdr1a/1b(-/-) mice and negligibly in Bcrp(-/-) mice.	Erlotinib Hydrochloride	161-170	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	58-62
21934030-5	2011	K(p,uu,CSF/brain) values of P-gp-specific (quinidine and verapamil) and Bcrp-specific (daidzein and genistein) substrates were significantly decreased in Mdr1a/1b(-/-) and Bcrp(-/-) mice, respectively.	Verapamil	57-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	172-176
21934030-6	2011	Furthermore, consistent with the contribution of P-gp and Bcrp to the net efflux at the BBB, K(p,uu,CSF/brain) values of the common substrates (flavopiridol and erlotinib) were markedly decreased in Mdr1a/1b(-/-)/Bcrp(-/-) mice, but only moderately or weakly in Mdr1a/1b(-/-) mice and negligibly in Bcrp(-/-) mice.	Erlotinib Hydrochloride	161-170	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	213-217
21934030-5	2011	K(p,uu,CSF/brain) values of P-gp-specific (quinidine and verapamil) and Bcrp-specific (daidzein and genistein) substrates were significantly decreased in Mdr1a/1b(-/-) and Bcrp(-/-) mice, respectively.	daidzein	87-95	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	72-76
21934030-6	2011	Furthermore, consistent with the contribution of P-gp and Bcrp to the net efflux at the BBB, K(p,uu,CSF/brain) values of the common substrates (flavopiridol and erlotinib) were markedly decreased in Mdr1a/1b(-/-)/Bcrp(-/-) mice, but only moderately or weakly in Mdr1a/1b(-/-) mice and negligibly in Bcrp(-/-) mice.	Erlotinib Hydrochloride	161-170	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	213-217
21934030-5	2011	K(p,uu,CSF/brain) values of P-gp-specific (quinidine and verapamil) and Bcrp-specific (daidzein and genistein) substrates were significantly decreased in Mdr1a/1b(-/-) and Bcrp(-/-) mice, respectively.	Genistein	100-109	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	72-76
21828252-3	2011	Breast cancer resistance protein (ABCG2/BCRP) interacts with genistein and daidzein, which are among the natural substrates of the transporter and competitively inhibit ABCG2-mediated drug efflux.	Genistein	61-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
22058337-9	2011	In all cases of iron overload, the expression of FLVCR and PCFT was upregulated and that of BCRP was downregulated.	Iron	16-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-96
21828252-3	2011	Breast cancer resistance protein (ABCG2/BCRP) interacts with genistein and daidzein, which are among the natural substrates of the transporter and competitively inhibit ABCG2-mediated drug efflux.	daidzein	75-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	169-174
21828252-4	2011	ABCG2/BCRP can also transport glucuronide and sulfate conjugates.	Glucuronides	30-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
21828252-3	2011	Breast cancer resistance protein (ABCG2/BCRP) interacts with genistein and daidzein, which are among the natural substrates of the transporter and competitively inhibit ABCG2-mediated drug efflux.	Genistein	61-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	40-44
21828252-4	2011	ABCG2/BCRP can also transport glucuronide and sulfate conjugates.	Glucuronides	30-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	6-10
21828252-3	2011	Breast cancer resistance protein (ABCG2/BCRP) interacts with genistein and daidzein, which are among the natural substrates of the transporter and competitively inhibit ABCG2-mediated drug efflux.	Genistein	61-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	169-174
21828252-4	2011	ABCG2/BCRP can also transport glucuronide and sulfate conjugates.	Sulfates	46-53	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
21828252-3	2011	Breast cancer resistance protein (ABCG2/BCRP) interacts with genistein and daidzein, which are among the natural substrates of the transporter and competitively inhibit ABCG2-mediated drug efflux.	daidzein	75-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
21828252-4	2011	ABCG2/BCRP can also transport glucuronide and sulfate conjugates.	Sulfates	46-53	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	6-10
21828252-3	2011	Breast cancer resistance protein (ABCG2/BCRP) interacts with genistein and daidzein, which are among the natural substrates of the transporter and competitively inhibit ABCG2-mediated drug efflux.	daidzein	75-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	40-44
21828252-6	2011	The results show that overall plasmatic profile is mainly governed by sulfate and glucuronide derivatives, the concentration of which was significantly increased (7- to 10-fold) in Bcrp1(-/-) mice.	Sulfates	70-77	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	181-186
21828252-6	2011	The results show that overall plasmatic profile is mainly governed by sulfate and glucuronide derivatives, the concentration of which was significantly increased (7- to 10-fold) in Bcrp1(-/-) mice.	Glucuronides	82-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	181-186
21805352-5	2011	P-gp inhibition was evaluated by calcein assay in P388/dx and L-MDR1 cells and BCRP inhibition in MDCKII-BCRP cells by pheophorbide A efflux.	pheophorbide a	119-133	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-83
21828252-9	2011	Therefore, our results indicate a direct and conclusive Bcrp1 efflux action on phase II metabolites of these isoflavones in vivo and suggest a possible novel concept for ABCG2/BCRP as part of metabolism-driven efflux transport of these conjugates.	Isoflavones	109-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	56-61
21828252-9	2011	Therefore, our results indicate a direct and conclusive Bcrp1 efflux action on phase II metabolites of these isoflavones in vivo and suggest a possible novel concept for ABCG2/BCRP as part of metabolism-driven efflux transport of these conjugates.	Isoflavones	109-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	170-175
21828252-9	2011	Therefore, our results indicate a direct and conclusive Bcrp1 efflux action on phase II metabolites of these isoflavones in vivo and suggest a possible novel concept for ABCG2/BCRP as part of metabolism-driven efflux transport of these conjugates.	Isoflavones	109-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	176-180
21949413-3	2011	In Abcg2-null mice, the SP fraction is lost in skeletal muscle, although the significance of this loss was previously unknown.	sp	24-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	3-8
21859328-2	2011	In mice, Bcrp1 (murine BCRP ortholog) mediates the transport of acyclovir into breast milk.	Acyclovir	64-73	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	9-14
21767647-0	2011	The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system.	URB937	69-75	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-34
21767647-7	2011	Accumulation of the compound in the luminal/apical side was prevented by co-administration of the selective ABCG2 inhibitor, Ko-143.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	125-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-113
21859328-2	2011	In mice, Bcrp1 (murine BCRP ortholog) mediates the transport of acyclovir into breast milk.	Acyclovir	64-73	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	23-27
21566011-2	2011	We have shown before that ABCC2, ABCC3, and ABCG2 together influence the pharmacokinetics of the anticancer and antirheumatic drug methotrexate (MTX) and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX) after intravenous MTX administration.	Methotrexate	131-143	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-49
21620826-7	2011	Furthermore, esculetin, fraxetin and fraxin increased mABCG2 mRNA expression and decreased its protein levels in renal apical membrane in hyperuricemic mice.	esculetin	13-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-60
21620826-7	2011	Furthermore, esculetin, fraxetin and fraxin increased mABCG2 mRNA expression and decreased its protein levels in renal apical membrane in hyperuricemic mice.	fraxetin	24-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-60
21620826-9	2011	Regulation of mABCG2 by cortex fraxini coumarines may be partly contributed to their beneficial actions.	Coumarins	39-49	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	14-20
21566011-2	2011	We have shown before that ABCC2, ABCC3, and ABCG2 together influence the pharmacokinetics of the anticancer and antirheumatic drug methotrexate (MTX) and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX) after intravenous MTX administration.	Methotrexate	145-148	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-49
21566011-2	2011	We have shown before that ABCC2, ABCC3, and ABCG2 together influence the pharmacokinetics of the anticancer and antirheumatic drug methotrexate (MTX) and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX) after intravenous MTX administration.	7-hydroxymethotrexate	175-196	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-49
21566011-7	2011	The absence of Abcc2 and/or Abcg2 also led to significantly increased liver and kidney levels of 7OH-MTX.	7-hydroxymethotrexate	97-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	28-33
21566011-2	2011	We have shown before that ABCC2, ABCC3, and ABCG2 together influence the pharmacokinetics of the anticancer and antirheumatic drug methotrexate (MTX) and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX) after intravenous MTX administration.	7-hydroxymethotrexate	198-205	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-49
21566011-8	2011	Our results suggest that inhibition of ABCG2 and/or ABCC2, genetic polymorphisms or mutations reducing expression or activity of these proteins may increase the oral availability of MTX.	Methotrexate	182-185	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
21566011-2	2011	We have shown before that ABCC2, ABCC3, and ABCG2 together influence the pharmacokinetics of the anticancer and antirheumatic drug methotrexate (MTX) and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX) after intravenous MTX administration.	Methotrexate	202-205	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-49
21566063-8	2011	Coadministration of irinotecan with YHO-13351 significantly increased the survival time of mice inoculated with BCRP-transduced murine leukemia P388 cells and suppressed the tumor growth in an HCT116/BCRP xenograft model, whereas irinotecan alone had little effect in these tumor models.	Irinotecan	20-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	112-116
21544799-9	2011	In a functional study, ApcMin mice received radioactively labelled 2-amino-1-methyl-6-phenylimidazo[4,5-beta] pyridine (PhIP), a food colon carcinogen and substrate of BCRP, by oral gavage with analysis of PhIP accumulation and DNA adduct formation 48 hr later.	2-amino-1-methyl-6-phenylimidazo[4,5-beta] pyridine	67-118	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	168-172
20950350-0	2011	Involvement of breast cancer resistance protein (BCRP/ABCG2) in the secretion of danofloxacin into milk: interaction with ivermectin.	danofloxacin	81-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	49-53
20950350-0	2011	Involvement of breast cancer resistance protein (BCRP/ABCG2) in the secretion of danofloxacin into milk: interaction with ivermectin.	danofloxacin	81-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
20950350-3	2011	The main purpose was to determine whether danofloxacin is an in vitro substrate for Bcrp1/BCRP and to assess its involvement in danofloxacin secretion into milk.	danofloxacin	42-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-89
20950350-3	2011	The main purpose was to determine whether danofloxacin is an in vitro substrate for Bcrp1/BCRP and to assess its involvement in danofloxacin secretion into milk.	danofloxacin	42-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	90-94
20950350-5	2011	Danofloxacin was transported in vitro by Bcrp1/BCRP, and ivermectin efficiently blocked this transport.	danofloxacin	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-46
20950350-5	2011	Danofloxacin was transported in vitro by Bcrp1/BCRP, and ivermectin efficiently blocked this transport.	danofloxacin	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	47-51
20950350-7	2011	However, the milk concentration and milk-to-plasma ratio of danofloxacin were almost twofold higher in wild-type compared with Bcrp1(-/-) mice.	danofloxacin	60-72	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	127-132
21566063-8	2011	Coadministration of irinotecan with YHO-13351 significantly increased the survival time of mice inoculated with BCRP-transduced murine leukemia P388 cells and suppressed the tumor growth in an HCT116/BCRP xenograft model, whereas irinotecan alone had little effect in these tumor models.	Irinotecan	20-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	193-204
21566063-8	2011	Coadministration of irinotecan with YHO-13351 significantly increased the survival time of mice inoculated with BCRP-transduced murine leukemia P388 cells and suppressed the tumor growth in an HCT116/BCRP xenograft model, whereas irinotecan alone had little effect in these tumor models.	YHO-13351	36-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	112-116
21566063-8	2011	Coadministration of irinotecan with YHO-13351 significantly increased the survival time of mice inoculated with BCRP-transduced murine leukemia P388 cells and suppressed the tumor growth in an HCT116/BCRP xenograft model, whereas irinotecan alone had little effect in these tumor models.	YHO-13351	36-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	193-204
21566063-8	2011	Coadministration of irinotecan with YHO-13351 significantly increased the survival time of mice inoculated with BCRP-transduced murine leukemia P388 cells and suppressed the tumor growth in an HCT116/BCRP xenograft model, whereas irinotecan alone had little effect in these tumor models.	Irinotecan	230-240	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	112-116
21279423-0	2011	5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice.	5,7-dimethoxyflavone	0-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	70-75
21602547-7	2011	In placentae derived from female fetuses, high-dose DEX significantly downregulated Abcg2 mRNA expression on E15.5 (P &lt; .05) and significantly inhibited Bcrp1 function (P &lt; .05).	Dexamethasone	52-55	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-89
21602547-7	2011	In placentae derived from female fetuses, high-dose DEX significantly downregulated Abcg2 mRNA expression on E15.5 (P &lt; .05) and significantly inhibited Bcrp1 function (P &lt; .05).	Dexamethasone	52-55	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	156-161
21602547-8	2011	Similarly, high-dose DEX significantly inhibited Bcrp1 function in the placentae derived from male fetuses (P &lt; .05).	Dexamethasone	21-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	49-54
21602547-10	2011	Further, it appears that, at the level of Abcg2 gene expression, the female-derived placentae are more susceptible to the effects of DEX than male placentae.	Dexamethasone	133-136	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	42-47
21282407-4	2011	Axitinib was a good substrate of ABCB1 and Abcg2, whereas transport activity by ABCG2 was moderate.	Axitinib	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	43-48
21282407-6	2011	Upon oral administration of axitinib, Abcg2(-/-) and Abcb1a/1b;Abcg2(-/-) mice displayed 1.7- and 1.8-fold increased axitinib areas under the plasma concentration-time curve from 0 to 4 compared with those of wild-type mice.	Axitinib	28-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-43
21282407-6	2011	Upon oral administration of axitinib, Abcg2(-/-) and Abcb1a/1b;Abcg2(-/-) mice displayed 1.7- and 1.8-fold increased axitinib areas under the plasma concentration-time curve from 0 to 4 compared with those of wild-type mice.	Axitinib	28-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-68
21282407-6	2011	Upon oral administration of axitinib, Abcg2(-/-) and Abcb1a/1b;Abcg2(-/-) mice displayed 1.7- and 1.8-fold increased axitinib areas under the plasma concentration-time curve from 0 to 4 compared with those of wild-type mice.	Axitinib	117-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-43
21282407-6	2011	Upon oral administration of axitinib, Abcg2(-/-) and Abcb1a/1b;Abcg2(-/-) mice displayed 1.7- and 1.8-fold increased axitinib areas under the plasma concentration-time curve from 0 to 4 compared with those of wild-type mice.	Axitinib	117-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-68
21282407-8	2011	In contrast, relative brain accumulation of axitinib in Abcb1a/1b(-/-) and Abcb1a/1b;Abcg2(-/-) mice was, respectively, 6.8- and 13.9-fold higher than that in wild-type mice at 1 h and 4.9- and 20.7-fold at 4 h after axitinib administration.	Axitinib	44-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	85-90
21282407-11	2011	Hence, Abcg2 has a stronger impact on axitinib oral plasma pharmacokinetics, whereas Abcb1 is the more important transporter at the blood-brain barrier.	Axitinib	38-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	7-12
21718946-0	2011	Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.	Carbon-11	101-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-70
21718946-0	2011	Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.	Topotecan	113-122	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-70
21602547-3	2011	Glucocorticoids, including dexamethasone (DEX), downregulate Bcrp1 expression and function in both breast cancer cell lines and the blood-brain barrier in vitro; whether this occurs in the placenta is not known.	Dexamethasone	27-40	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	61-66
21602547-3	2011	Glucocorticoids, including dexamethasone (DEX), downregulate Bcrp1 expression and function in both breast cancer cell lines and the blood-brain barrier in vitro; whether this occurs in the placenta is not known.	Dexamethasone	42-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	61-66
21602547-5	2011	We hypothesized that (1) exposure of pregnant mice to DEX will downregulate placental Abcg2 mRNA and Bcrp1 protein, and (2) results in increased fetal accumulation of [(3)H]mitoxantrone.	Dexamethasone	54-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	86-91
21602547-5	2011	We hypothesized that (1) exposure of pregnant mice to DEX will downregulate placental Abcg2 mRNA and Bcrp1 protein, and (2) results in increased fetal accumulation of [(3)H]mitoxantrone.	Dexamethasone	54-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-106
21279423-0	2011	5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice.	Flavonoids	34-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	70-75
21279423-0	2011	5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice.	Mitoxantrone	108-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	70-75
21279423-1	2011	PURPOSE: The objective of our study was to investigate the effect of 5,7-DMF on the accumulation of mitoxantrone (MX) in BCRP-expressing normal cells and to investigate its impact on the PK and tissue distribution of MX in mice.	5,7-dmf	69-76	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
21279423-1	2011	PURPOSE: The objective of our study was to investigate the effect of 5,7-DMF on the accumulation of mitoxantrone (MX) in BCRP-expressing normal cells and to investigate its impact on the PK and tissue distribution of MX in mice.	Mitoxantrone	100-112	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
21279423-1	2011	PURPOSE: The objective of our study was to investigate the effect of 5,7-DMF on the accumulation of mitoxantrone (MX) in BCRP-expressing normal cells and to investigate its impact on the PK and tissue distribution of MX in mice.	Mitoxantrone	114-116	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
21279423-4	2011	RESULTS: In the presence of 2.5 muM or 25 muM of 5,7-DMF, the intracellular concentration of MX was significantly increased in MDCK/Bcrp1 and MDCK/BCRP cells, but not in MDCK/Mock cells.	5,7-dmf	49-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	132-137
21279423-6	2011	The most substantial elevations of MX AUC in the presence of 5,7-DMF occurred in the liver (94.5%) and kidneys (61.9%), which is in apparent agreement with the relatively high levels of mouse Bcrp1 expression in these two tissues.	5,7-dmf	61-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	192-197
21279423-7	2011	CONCLUSIONS: Bcrp1-mediated DMF-MX interactions occur both in vitro and in vivo.	Dimethylformamide	28-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	13-18
21279423-8	2011	5,7-DMF represents a novel and very promising chemosensitizing agent for the BCRP-mediated MDR due to its low toxicity and potent BCRP inhibition.	5,7-dmf	0-7	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-81
21279423-8	2011	5,7-DMF represents a novel and very promising chemosensitizing agent for the BCRP-mediated MDR due to its low toxicity and potent BCRP inhibition.	5,7-dmf	0-7	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	130-134
21419625-0	2011	[11C]sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice.	Sorafenib	5-14	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	81-85
21309545-1	2011	P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) combination knockout mice display disproportionately increased brain penetration of shared substrates, including topotecan and several tyrosine kinase inhibitors, compared to mice deficient for only one transporter.	Topotecan	191-200	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	66-70
21419625-0	2011	[11C]sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice.	Carbon-11	1-4	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	81-85
21309545-5	2011	ABCB1 and ABCG2 contributed to similar extents to topotecan transport, which was only partly saturable.	Topotecan	50-59	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
21309545-6	2011	For sorafenib transport, ABCG2 was the major determinant at low concentrations.	Sorafenib	4-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	25-30
21309545-7	2011	However, saturation of ABCG2-mediated transport occurred at higher sorafenib concentrations, where ABCB1 was still fully active.	Sorafenib	67-76	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	23-28
21309545-8	2011	Furthermore, sunitinib was transported equally by ABCB1 and ABCG2 at low concentrations, but ABCG2-mediated transport became saturated at lower concentrations than ABCB1-mediated transport.	Sunitinib	13-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-65
21216589-1	2011	The breast cancer resistance protein ABCG2 confers cellular resistance to irinotecan (CPT-11) and its active metabolite SN-38.	Irinotecan	74-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-42
21159928-3	2011	Synthetic glucocorticoids (e.g., dexamethasone [DEX]) increase Abcg2/BCRP1 expression and function in vitro in endothelial cells derived from brain microvessels.	Dexamethasone	33-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-68
21159928-3	2011	Synthetic glucocorticoids (e.g., dexamethasone [DEX]) increase Abcg2/BCRP1 expression and function in vitro in endothelial cells derived from brain microvessels.	Dexamethasone	33-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	69-74
21159928-3	2011	Synthetic glucocorticoids (e.g., dexamethasone [DEX]) increase Abcg2/BCRP1 expression and function in vitro in endothelial cells derived from brain microvessels.	Dexamethasone	48-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-68
21159928-3	2011	Synthetic glucocorticoids (e.g., dexamethasone [DEX]) increase Abcg2/BCRP1 expression and function in vitro in endothelial cells derived from brain microvessels.	Dexamethasone	48-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	69-74
21159928-6	2011	2) Maternal treatment with DEX will up-regulate Abcg2 mRNA and BCRP1 protein expression in the fetal brain, resulting in decreased BCRP1 substrate accumulation.	Dexamethasone	27-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	48-53
21159928-6	2011	2) Maternal treatment with DEX will up-regulate Abcg2 mRNA and BCRP1 protein expression in the fetal brain, resulting in decreased BCRP1 substrate accumulation.	Dexamethasone	27-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-68
21159928-6	2011	2) Maternal treatment with DEX will up-regulate Abcg2 mRNA and BCRP1 protein expression in the fetal brain, resulting in decreased BCRP1 substrate accumulation.	Dexamethasone	27-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	131-136
21159928-10	2011	Furthermore, there is a dose-, sex-, and age-dependent effect of DEX on Abcg2 mRNA in the fetal brain in vivo, indicating a complex regulatory role of glucocorticoid during development.	Dexamethasone	65-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	72-77
21906329-4	2011	The xylose conversion in SSCF was doubled with the S. cerevisiae strain expressing mXR compared to the isogenic strain expressing the native XR, converting 76% and 38%, respectively.	Xylose	4-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	83-86
21906329-4	2011	The xylose conversion in SSCF was doubled with the S. cerevisiae strain expressing mXR compared to the isogenic strain expressing the native XR, converting 76% and 38%, respectively.	Xylose	4-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-86
21906329-5	2011	The xylitol yield was less than half using mXR in comparison with the native variant.	Xylitol	4-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	43-46
21906329-6	2011	As a result of this, the ethanol yield increased from 0.33 to 0.39 g g-1 when the native XR was replaced by mXR.	Ethanol	25-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	89-91
21906329-6	2011	As a result of this, the ethanol yield increased from 0.33 to 0.39 g g-1 when the native XR was replaced by mXR.	Ethanol	25-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-111
21906329-8	2011	The results suggest that ethanolic xylose fermentation under SSCF conditions is controlled primarily by the XR activity and to a much lesser extent by xylose transport.	Xylose	35-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-110
21216589-1	2011	The breast cancer resistance protein ABCG2 confers cellular resistance to irinotecan (CPT-11) and its active metabolite SN-38.	Irinotecan	86-92	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-42
21216589-1	2011	The breast cancer resistance protein ABCG2 confers cellular resistance to irinotecan (CPT-11) and its active metabolite SN-38.	Irinotecan	120-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-42
21216589-4	2011	Addition of MBLI-87, an acridone derivative inhibitor, significantly increased the irinotecan effect against the growth of ABCG2-expressing xenografts.	9-oxo-9,10-dihydroacridine-4-carboxylic acid 3,4-dimethoxyphenethyl amide	12-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	123-128
21216589-4	2011	Addition of MBLI-87, an acridone derivative inhibitor, significantly increased the irinotecan effect against the growth of ABCG2-expressing xenografts.	acridone	24-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	123-128
21216589-4	2011	Addition of MBLI-87, an acridone derivative inhibitor, significantly increased the irinotecan effect against the growth of ABCG2-expressing xenografts.	Irinotecan	83-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	123-128
21216589-5	2011	In vitro, MBLI-87 was as potent as GF120918 against ABCG2-mediated irinotecan efflux, and additionally was specific for ABCG2.	Irinotecan	67-77	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-57
21216589-7	2011	This suggested that MBLI-87 is an excellent candidate to prevent drug efflux by ABCG2, without altering plasma concentrations of irinotecan and SN-38 after IP (intra-peritoneal) injections.	9-oxo-9,10-dihydroacridine-4-carboxylic acid 3,4-dimethoxyphenethyl amide	20-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	80-85
21304978-10	2011	Resveratrol inhibits pluripotency maintaining factors (Nanog, Sox-2, c-Myc and Oct-4) and drug resistance gene ABCG2 in CSCs.	Resveratrol	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	111-116
20670210-10	2010	P-gp affected oral absorption and brain penetration of tandutinib to a greater extent than Bcrp, but Bcrp contribution to systemic clearance of tandutinib was greater than P-gp.	tandutinib	144-154	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-105
21185730-3	2011	In vitro accumulation assay showed that treatment with P-gp/BCRP inhibitors (1 and 2) enhanced the intracellular accumulation capacity of P-gp- and BCRP-overexpressing MES-SA/Dx5 cells.	2-(N-morpholino)ethanesulfonic acid	168-171	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-64
21088257-8	2011	In vitro, erlotinib and OSI-420 accumulation was significantly lower in cells overexpressing breast cancer resistance protein (BCRP) than in control cells.	Erlotinib Hydrochloride	10-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	93-125
21088257-8	2011	In vitro, erlotinib and OSI-420 accumulation was significantly lower in cells overexpressing breast cancer resistance protein (BCRP) than in control cells.	Erlotinib Hydrochloride	10-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	127-131
20952483-0	2011	The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.	Sorafenib	80-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	16-48
20952483-0	2011	The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.	Sorafenib	80-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-55
20952483-3	2011	This study investigated the influence of P-gp and BCRP on the central nervous system (CNS) penetration of sorafenib, a multitargeted tyrosine kinase inhibitor currently being evaluated in clinical trials for glioma.	Sorafenib	106-115	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-54
20952483-4	2011	In vitro studies showed that BCRP has a high affinity for sorafenib.	Sorafenib	58-67	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-33
20952483-8	2011	Steady-state brain-to-plasma concentration ratio of sorafenib was approximately 0.36 +- 0.056 in the Bcrp1(-/-) mice, 0.11 +- 0.021 in the Mdr1a/b(-/-) mice, and 0.91 +- 0.29 in the Mdr1a/b(-/-)Bcrp1(-/-) mice compared with 0.094 +- 0.007 in the wild-type mice.	Sorafenib	52-61	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-106
20952483-10	2011	This study shows that BCRP and P-gp together restrict the brain distribution of sorafenib with BCRP playing a dominant role in the efflux of sorafenib at the BBB.	Sorafenib	80-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-26
20952483-10	2011	This study shows that BCRP and P-gp together restrict the brain distribution of sorafenib with BCRP playing a dominant role in the efflux of sorafenib at the BBB.	Sorafenib	141-150	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-26
20952483-10	2011	This study shows that BCRP and P-gp together restrict the brain distribution of sorafenib with BCRP playing a dominant role in the efflux of sorafenib at the BBB.	Sorafenib	141-150	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	95-99
20582579-0	2010	Breast cancer resistance protein (BCRP) and sulfotransferases contribute significantly to the disposition of genistein in mouse intestine.	Genistein	109-118	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-32
20582579-0	2010	Breast cancer resistance protein (BCRP) and sulfotransferases contribute significantly to the disposition of genistein in mouse intestine.	Genistein	109-118	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
20582579-7	2010	In contrast, the excretion of genistein sulfate decreased substantially (&gt;90%) in small intestine of breast cancer resistance protein (BCRP) knockout mice and became undetectable in colon of the knockout mice.	genistein sulfate	30-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-136
20582579-7	2010	In contrast, the excretion of genistein sulfate decreased substantially (&gt;90%) in small intestine of breast cancer resistance protein (BCRP) knockout mice and became undetectable in colon of the knockout mice.	genistein sulfate	30-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	138-142
20582579-8	2010	The excretion rates of genistein glucuronide in the small intestine of BCRP knockout mice were also significant decreased (78%).	Genistein	23-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-75
20582579-8	2010	The excretion rates of genistein glucuronide in the small intestine of BCRP knockout mice were also significant decreased (78%).	Glucuronides	33-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-75
20582579-9	2010	This study shows clearly that BCRP facilitates the cellular genistein sulfate excretion by removing sulfates to prevent their backward hydrolysis and to limit substrate inhibition, indicating that BCRP plays a dominant role in genistein sulfate excretion and a significant role in genistein glucuronide excretion in the mouse intestine.	genistein sulfate	60-77	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-34
20582579-9	2010	This study shows clearly that BCRP facilitates the cellular genistein sulfate excretion by removing sulfates to prevent their backward hydrolysis and to limit substrate inhibition, indicating that BCRP plays a dominant role in genistein sulfate excretion and a significant role in genistein glucuronide excretion in the mouse intestine.	genistein sulfate	60-77	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	197-201
20582579-9	2010	This study shows clearly that BCRP facilitates the cellular genistein sulfate excretion by removing sulfates to prevent their backward hydrolysis and to limit substrate inhibition, indicating that BCRP plays a dominant role in genistein sulfate excretion and a significant role in genistein glucuronide excretion in the mouse intestine.	Sulfates	100-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-34
20582579-9	2010	This study shows clearly that BCRP facilitates the cellular genistein sulfate excretion by removing sulfates to prevent their backward hydrolysis and to limit substrate inhibition, indicating that BCRP plays a dominant role in genistein sulfate excretion and a significant role in genistein glucuronide excretion in the mouse intestine.	Sulfates	100-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	197-201
20582579-9	2010	This study shows clearly that BCRP facilitates the cellular genistein sulfate excretion by removing sulfates to prevent their backward hydrolysis and to limit substrate inhibition, indicating that BCRP plays a dominant role in genistein sulfate excretion and a significant role in genistein glucuronide excretion in the mouse intestine.	genistein sulfate	227-244	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-34
20582579-9	2010	This study shows clearly that BCRP facilitates the cellular genistein sulfate excretion by removing sulfates to prevent their backward hydrolysis and to limit substrate inhibition, indicating that BCRP plays a dominant role in genistein sulfate excretion and a significant role in genistein glucuronide excretion in the mouse intestine.	genistein sulfate	227-244	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	197-201
20582579-9	2010	This study shows clearly that BCRP facilitates the cellular genistein sulfate excretion by removing sulfates to prevent their backward hydrolysis and to limit substrate inhibition, indicating that BCRP plays a dominant role in genistein sulfate excretion and a significant role in genistein glucuronide excretion in the mouse intestine.	genistein glucuronide	281-302	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-34
20582579-9	2010	This study shows clearly that BCRP facilitates the cellular genistein sulfate excretion by removing sulfates to prevent their backward hydrolysis and to limit substrate inhibition, indicating that BCRP plays a dominant role in genistein sulfate excretion and a significant role in genistein glucuronide excretion in the mouse intestine.	genistein glucuronide	281-302	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	197-201
20670210-5	2010	In mice, after intravenous administration of tandutinib, the mean plasma AUC values in the Bcrp1(-/-) mice and Mdr1a/b(-/-) mice was 1.53- and 1.20-fold greater than that of the wild type (WT) mice, respectively.	tandutinib	45-55	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	91-96
20670210-9	2010	This finding illustrates that P-gp and Bcrp play a role in oral absorption, systemic clearance, and brain penetration of tandutinib in the rodents.	tandutinib	121-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-43
21360409-3	2011	Estradiol suppressed the protein levels of urate reabsorptive transporters urate transporter 1 and glucose transporter 9 (Urat1 and Glut9), and that of urate efflux transporter ATP-binding cassette sub-family G member 2 (Abcg2).	Estradiol	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	177-219
21360409-3	2011	Estradiol suppressed the protein levels of urate reabsorptive transporters urate transporter 1 and glucose transporter 9 (Urat1 and Glut9), and that of urate efflux transporter ATP-binding cassette sub-family G member 2 (Abcg2).	Estradiol	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	221-226
21088257-8	2011	In vitro, erlotinib and OSI-420 accumulation was significantly lower in cells overexpressing breast cancer resistance protein (BCRP) than in control cells.	silicon monoxide	24-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	93-125
21088257-8	2011	In vitro, erlotinib and OSI-420 accumulation was significantly lower in cells overexpressing breast cancer resistance protein (BCRP) than in control cells.	silicon monoxide	24-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	127-131
21088257-10	2011	The P-gp/BCRP inhibitor elacridar increased erlotinib and OSI-420 accumulation in BCRP-overexpressing cells.	Erlotinib Hydrochloride	44-53	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	9-13
21088257-10	2011	The P-gp/BCRP inhibitor elacridar increased erlotinib and OSI-420 accumulation in BCRP-overexpressing cells.	OSI-420	58-65	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	9-13
21088257-10	2011	The P-gp/BCRP inhibitor elacridar increased erlotinib and OSI-420 accumulation in BCRP-overexpressing cells.	OSI-420	58-65	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-86
21088257-12	2011	CONCLUSION: Abcg2 is the main efflux transporter preventing erlotinib and OSI-420 penetration in mouse brain.	Erlotinib Hydrochloride	60-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	12-17
21666745-9	2011	Multiple genes involved in reactive oxygen species signaling pathways (NRF2, ABCG2, GSTA2, HIF1A) were strongly associated with decreased ES cell differentiation as well.	Reactive Oxygen Species	27-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-82
21666745-9	2011	Multiple genes involved in reactive oxygen species signaling pathways (NRF2, ABCG2, GSTA2, HIF1A) were strongly associated with decreased ES cell differentiation as well.	Einsteinium	138-140	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-82
20829509-8	2010	In vitro experiments demonstrated that inhibition of BCRP1/ABCG2 resulted in accumulation of intracellular protoporphyrin IX and impaired survival of microvascular endothelial cells under oxidative stress.	protoporphyrin IX	107-124	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	53-58
21072210-7	2010	Mitoxantrone-selected cells were enriched for CSCs expressing stem cell markers ALDH, c-kit, Oct-4, and ABCG2, and efficient at forming mammospheres.	Mitoxantrone	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-109
20829509-8	2010	In vitro experiments demonstrated that inhibition of BCRP1/ABCG2 resulted in accumulation of intracellular protoporphyrin IX and impaired survival of microvascular endothelial cells under oxidative stress.	protoporphyrin IX	107-124	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	59-64
20538997-4	2010	Flow cytometry was used to determine the presence of side population (SP) cells based on the ability of ABCG2 to efflux Hoechst 33342 dye.	bisbenzimide ethoxide trihydrochloride	120-133	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-109
20538997-7	2010	RESULTS: abcg2 KO mice had a normal corneal epithelial phenotype; however, cultured abcg2 KO epithelial cells were prone to oxidative damage by mitoxantrone.	Mitoxantrone	144-156	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-89
20538997-9	2010	Coculture with the ABCG2 inhibitors reserpine and Ko143 inhibited resistance to mitoxantrone, with a statistically higher cell death ratio.	Reserpine	36-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	19-24
20538997-9	2010	Coculture with the ABCG2 inhibitors reserpine and Ko143 inhibited resistance to mitoxantrone, with a statistically higher cell death ratio.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	50-55	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	19-24
20538997-9	2010	Coculture with the ABCG2 inhibitors reserpine and Ko143 inhibited resistance to mitoxantrone, with a statistically higher cell death ratio.	Mitoxantrone	80-92	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	19-24
20684544-6	2010	PS without substitutions including pyropheophorbides and purpurinimides were generally substrates for ABCG2, but carbohydrate groups conjugated at positions 8, 12, 13, and 17 but not at position 3 abrogated ABCG2 affinity regardless of structure or linking moiety.	purpurinimides	57-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	102-107
20684544-6	2010	PS without substitutions including pyropheophorbides and purpurinimides were generally substrates for ABCG2, but carbohydrate groups conjugated at positions 8, 12, 13, and 17 but not at position 3 abrogated ABCG2 affinity regardless of structure or linking moiety.	Carbohydrates	113-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	207-212
20684544-0	2010	Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy.	chlorophyll a	52-65	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-76
20684544-10	2010	We examined the relevance of the SP to PDT resistance with ABCG2 substrates in vitro and in vivo in the murine mammary tumor 4T1.	sp	33-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	59-64
20684544-2	2010	The ATP-dependent transporter ABCG2, a multidrug resistant pump expressed at variable levels in cancerous cells, can bind and efflux a wide range of structurally different classes of compounds including several PS used preclinically and clinically such as porphyrins and chlorins.	Porphyrins	256-266	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-35
20684544-12	2010	The SP could be targeted by addition of imatinib mesylate, a tyrosine kinase inhibitor which inhibits the ATPase activity of ABCG2, and prevents efflux of substrates.	sp	4-6	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	125-130
20684544-2	2010	The ATP-dependent transporter ABCG2, a multidrug resistant pump expressed at variable levels in cancerous cells, can bind and efflux a wide range of structurally different classes of compounds including several PS used preclinically and clinically such as porphyrins and chlorins.	chlorin	271-279	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-35
20684544-12	2010	The SP could be targeted by addition of imatinib mesylate, a tyrosine kinase inhibitor which inhibits the ATPase activity of ABCG2, and prevents efflux of substrates.	Imatinib Mesylate	40-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	125-130
20216549-0	2010	17-beta-Estradiol: a powerful modulator of blood-brain barrier BCRP activity.	Estradiol	0-17	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-67
20601550-2	2010	Recent reports suggest that in addition to xenobiotics, porphyrins, and food toxins, Bcrp can also transport bile acids and, therefore, may participate in the adaptive response to cholestasis.	Bile Acids and Salts	109-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	85-89
20216549-4	2010	We show that nanomolar concentrations of 17-beta-estradiol (E2) rapidly reduced BCRP transport activity in the brain capillaries.	Estradiol	41-58	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	80-84
20607366-0	2010	In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice.	Nitrofurantoin	55-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-26
20607366-0	2010	In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice.	Nitrofurantoin	55-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-32
20607366-0	2010	In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice.	Isoflavones	77-88	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-26
20607366-0	2010	In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice.	Isoflavones	77-88	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-32
20607366-0	2010	In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice.	Genistein	89-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-26
20607366-0	2010	In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice.	Genistein	89-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-32
20607366-0	2010	In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice.	daidzein	103-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-26
20607366-0	2010	In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice.	daidzein	103-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-32
20607366-1	2010	PURPOSE: The aim of this study was to determine in vivo inhibition by the isoflavones genistein and daidzein of nitrofurantoin (NTF), a well-known substrate of the ABC transporter BCRP/ABCG2.	Isoflavones	74-85	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	180-184
20607366-1	2010	PURPOSE: The aim of this study was to determine in vivo inhibition by the isoflavones genistein and daidzein of nitrofurantoin (NTF), a well-known substrate of the ABC transporter BCRP/ABCG2.	Isoflavones	74-85	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-190
20607366-1	2010	PURPOSE: The aim of this study was to determine in vivo inhibition by the isoflavones genistein and daidzein of nitrofurantoin (NTF), a well-known substrate of the ABC transporter BCRP/ABCG2.	Genistein	86-95	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	180-184
20607366-1	2010	PURPOSE: The aim of this study was to determine in vivo inhibition by the isoflavones genistein and daidzein of nitrofurantoin (NTF), a well-known substrate of the ABC transporter BCRP/ABCG2.	Genistein	86-95	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-190
20607366-1	2010	PURPOSE: The aim of this study was to determine in vivo inhibition by the isoflavones genistein and daidzein of nitrofurantoin (NTF), a well-known substrate of the ABC transporter BCRP/ABCG2.	daidzein	100-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	180-184
20607366-1	2010	PURPOSE: The aim of this study was to determine in vivo inhibition by the isoflavones genistein and daidzein of nitrofurantoin (NTF), a well-known substrate of the ABC transporter BCRP/ABCG2.	daidzein	100-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-190
20607366-1	2010	PURPOSE: The aim of this study was to determine in vivo inhibition by the isoflavones genistein and daidzein of nitrofurantoin (NTF), a well-known substrate of the ABC transporter BCRP/ABCG2.	Nitrofurantoin	112-126	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	180-184
20607366-1	2010	PURPOSE: The aim of this study was to determine in vivo inhibition by the isoflavones genistein and daidzein of nitrofurantoin (NTF), a well-known substrate of the ABC transporter BCRP/ABCG2.	Nitrofurantoin	112-126	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-190
20607366-1	2010	PURPOSE: The aim of this study was to determine in vivo inhibition by the isoflavones genistein and daidzein of nitrofurantoin (NTF), a well-known substrate of the ABC transporter BCRP/ABCG2.	Nitrofurantoin	128-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	180-184
20607366-1	2010	PURPOSE: The aim of this study was to determine in vivo inhibition by the isoflavones genistein and daidzein of nitrofurantoin (NTF), a well-known substrate of the ABC transporter BCRP/ABCG2.	Nitrofurantoin	128-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-190
20607366-7	2010	BCRP/ABCG2-mediated secretion into milk was inhibited since milk/plasma ratios were lower in wild-type mice with isoflavones (7.1 +- 4.2 vs 4.2 +- 1.6, p &lt;= 0.05).	Isoflavones	113-124	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
20607366-7	2010	BCRP/ABCG2-mediated secretion into milk was inhibited since milk/plasma ratios were lower in wild-type mice with isoflavones (7.1 +- 4.2 vs 4.2 +- 1.6, p &lt;= 0.05).	Isoflavones	113-124	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	5-10
20607366-9	2010	CONCLUSION: Our data showed that in vivo interaction of high doses of soy isoflavones with BCRP substrates may affect plasma levels but the main effect occurs in specific target organs, in our case, liver and mammary glands.	Isoflavones	74-85	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	91-95
20626554-0	2010	ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer"s disease.	Reactive Oxygen Species	14-17	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
20522663-4	2010	After administrations to mice, GDC-0941 brain-to-plasma ratio ranged from 0.02 to 0.06 in the wild-type and Bcrp1(-/-) mice and was modestly higher in the Mdr1a/b(-/-) mice, ranging from 0.08 to 0.11.	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	31-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-113
20522663-5	2010	In contrast, GDC-0941 brain-to-plasma ratio in Mdr1a/b(-/-)/Bcrp1(-/-) triple knockout mice was 30-fold higher than in the wild-type mice.	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	13-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-65
20522663-11	2010	The concerted effects of P-gp and Bcrp1 in restricting GDC-0941 access and pathway modulation in mouse brain may have implications for the treatment of patients with brain tumors.	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	55-63	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
20626554-6	2010	ABCG2 inhibits NF-kappaB activation but has less effect on AP-1 activation induced by ROS.	Reactive Oxygen Species	86-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
20626554-4	2010	In the present study, we examine the roles and mechanism of ABCG2 on ROS generation, inflammatory gene expression and signaling, heme homeostasis and Abeta production in cell models and on inflammatory signaling and Abeta deposition in Abcg2-knockout and wild-type mice.	Reactive Oxygen Species	69-72	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-65
20626554-5	2010	Our results show that ABCG2 plays a protective role against oxidative stress by decreasing ROS generation, enhancing antioxidant capacity, regulating heme level, and inhibiting inflammatory response in cell models.	Reactive Oxygen Species	91-94	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-27
20626554-5	2010	Our results show that ABCG2 plays a protective role against oxidative stress by decreasing ROS generation, enhancing antioxidant capacity, regulating heme level, and inhibiting inflammatory response in cell models.	Heme	150-154	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-27
20621487-1	2010	The aim of this study was to develop a positron emission tomography (PET) tracer based on the dual P-glycoprotein (P-gp) breast cancer resistance protein (BCRP) inhibitor tariquidar (1) to study the interaction of 1 with P-gp and BCRP in the blood-brain barrier (BBB) in vivo.	tariquidar	171-181	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	155-159
20421331-0	2010	Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.	Gefitinib	16-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	80-112
20460386-1	2010	Breast cancer resistance protein (BCRP) is an ATP-driven efflux pump at the blood-brain barrier that limits central nervous system pharmacotherapy.	Adenosine Triphosphate	46-49	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
20460386-2	2010	Our previous studies showed rapid loss of BCRP transport activity in rat brain capillaries exposed to low concentrations of 17-beta-estradiol (E2); this occurred without acute change in BCRP protein expression.	Estradiol	124-141	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	42-46
20460386-8	2010	Lactacystin, a proteasome inhibitor, abolished E2-mediated BCRP down-regulation, suggesting internalization followed by transporter degradation.	lactacystin	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	59-63
20421331-0	2010	Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.	Gefitinib	16-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	114-119
20421331-3	2010	In this study, we investigated the influence of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) on distribution of gefitinib to the central nervous system.	Gefitinib	133-142	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	74-106
20421331-3	2010	In this study, we investigated the influence of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) on distribution of gefitinib to the central nervous system.	Gefitinib	133-142	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-112
20421331-7	2010	The B/P ratio after oral administration increased significantly when gefitinib was coadministered with the dual P-gp and BCRP inhibitor elacridar.	Gefitinib	69-78	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
20421331-10	2010	These results show that brain distribution of gefitinib is restricted due to active efflux by P-gp and BCRP.	Gefitinib	46-55	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	103-107
20610168-0	2010	Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate.	Carbon-11	93-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	49-81
20610168-2	2010	Methyl is a recently discovered BCRP-selective inhibitor, which is structurally derived from the potent P-glycoprotein (P-gp) inhibitor tariquidar.	tariquidar	136-146	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-36
20369276-3	2010	Mitoxantrone transport in the presence of flavonoids was studied in human and murine BCRP-transfected MDCK cell lines, and mitoxantrone concentrations were determined by HPLC.	Mitoxantrone	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	85-89
20369276-6	2010	Additionally, the basolateral-to-apical membrane-directed transport of mitoxantrone in murine Bcrp1- and human BCRP-expressing MDCK cells, in the presence of 2.5 microM of these flavonoids, was also significantly decreased.	Mitoxantrone	71-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	94-99
20145144-8	2010	Tumor-specific genetic ablation of Abcg2 significantly increased overall survival of topotecan-treated animals (P &lt; 0.001), confirming the in vivo relevance of ABCG2 for topotecan resistance in a novel approach.	Topotecan	85-94	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-40
20304939-0	2010	Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.	Erlotinib Hydrochloride	165-174	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	105-109
20304939-0	2010	Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.	Erlotinib Hydrochloride	165-174	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-115
20304939-0	2010	Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.	alvocidib	176-188	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	105-109
20304939-0	2010	Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.	alvocidib	176-188	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-115
20304939-0	2010	Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.	Mitoxantrone	194-206	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	105-109
20304939-0	2010	Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.	Mitoxantrone	194-206	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-115
20232796-0	2010	Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice.	Resveratrol	112-129	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	49-54
20232796-0	2010	Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice.	Resveratrol	112-129	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	55-60
20232796-2	2010	Given the important role of the breast cancer resistance protein (ABCG2/BCRP) in the efflux of conjugated forms, the present study investigates the bioavailability and tissue distribution of trans-resveratrol and its metabolites after the oral administration of 60 mg/kg in Bcrp1(-/-) mice.	Resveratrol	191-208	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	66-71
20232796-2	2010	Given the important role of the breast cancer resistance protein (ABCG2/BCRP) in the efflux of conjugated forms, the present study investigates the bioavailability and tissue distribution of trans-resveratrol and its metabolites after the oral administration of 60 mg/kg in Bcrp1(-/-) mice.	Resveratrol	191-208	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	72-76
20232796-4	2010	At 30 min after administration, intestinal content showed decreases of 71% and 97% of resveratrol glucuronide and sulfate, respectively, in Bcrp1(-/-), indicating a lower efflux from the enterocytes.	resveratrol glucuronide	86-109	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	140-145
20232796-4	2010	At 30 min after administration, intestinal content showed decreases of 71% and 97% of resveratrol glucuronide and sulfate, respectively, in Bcrp1(-/-), indicating a lower efflux from the enterocytes.	Sulfates	114-121	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	140-145
20232796-6	2010	In conclusion, Bcrp1 plays an important role in the efflux of resveratrol conjugates, contributing to their bioavailability, tissue distribution and elimination.	Resveratrol	62-73	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	15-20
20086033-8	2010	This might explain why Mrp2/Mrp3/Bcrp1(-/-) mice, which have markedly elevated levels of diclofenac acyl glucuronides in their liver, display acute, albeit very mild, hepatotoxicity.	1-O-(2-((2',6'-dichlorophenyl)amino)phenylacetyl)glucopyranuronic acid	89-117	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	33-38
20212014-2	2010	The three most prevalent ATP-binding cassette efflux transporters at the blood-brain barrier are P-glycoprotein (P-gp), multidrug resistance protein 1 (Mrp1), and breast cancer resistance protein (BCRP).	Adenosine Triphosphate	25-28	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	163-195
20212014-2	2010	The three most prevalent ATP-binding cassette efflux transporters at the blood-brain barrier are P-glycoprotein (P-gp), multidrug resistance protein 1 (Mrp1), and breast cancer resistance protein (BCRP).	Adenosine Triphosphate	25-28	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	197-201
20304939-4	2010	The C(brain)/C(plasma) and C(testis)/C(plasma) of the common substrates erlotinib, flavopiridol, and mitoxantrone were markedly increased in Mdr1a/1b(-/-)/Bcrp(-/-) mice even compared with Mdr1a/1b(-/-) and Bcrp(-/-) mice.	alvocidib	83-95	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	155-159
20086033-3	2010	We show here that loss of multidrug resistance protein 2 (MRP2/ABCC2) and breast cancer resistance protein (BCRP/ABCG2) in mice results in highly increased plasma levels of diclofenac acyl glucuronide, after both oral and intravenous administration.	1-O-(2-((2',6'-dichlorophenyl)amino)phenylacetyl)glucopyranuronic acid	173-200	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-112
20086033-3	2010	We show here that loss of multidrug resistance protein 2 (MRP2/ABCC2) and breast cancer resistance protein (BCRP/ABCG2) in mice results in highly increased plasma levels of diclofenac acyl glucuronide, after both oral and intravenous administration.	1-O-(2-((2',6'-dichlorophenyl)amino)phenylacetyl)glucopyranuronic acid	173-200	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	113-118
20086033-4	2010	The absence of Mrp2 and Bcrp1, localized at the canalicular membrane of hepatocytes, leads to impaired biliary excretion of acyl glucuronides and consequently to elevated liver and plasma levels.	acyl glucuronides	124-141	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-29
20145144-8	2010	Tumor-specific genetic ablation of Abcg2 significantly increased overall survival of topotecan-treated animals (P &lt; 0.001), confirming the in vivo relevance of ABCG2 for topotecan resistance in a novel approach.	Topotecan	173-182	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-40
19492342-4	2009	We measured the interactions of [(99m)Tc(CO)(3)-ibogaine](+) and (99m)Tc-tricarbonyl with the main BBB efflux transporters P-gp and BCRP in vitro and in vivo.	Ibogaine	48-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	132-136
20103600-3	2010	Sorafenib was moderately transported by P-gp and more efficiently by ABCG2 and Abcg2.	Sorafenib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	69-74
20103600-3	2010	Sorafenib was moderately transported by P-gp and more efficiently by ABCG2 and Abcg2.	Sorafenib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-84
20103600-7	2010	Moreover, when wild-type mice were treated with sorafenib in combination with the dual P-gp and ABCG2 inhibitor elacridar, brain accumulation was similar to that observed for Abcb1a/1b;Abcg2(-/-) mice.	Sorafenib	48-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-190
20103600-8	2010	These results show that the brain accumulation of sorafenib is primarily restricted by ABCG2.	Sorafenib	50-59	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-92
20103600-10	2010	Interestingly, for sorafenib, it is the other way around, that is, ABCG2, and not P-gp, plays the dominant role in restricting its brain accumulation.	Sorafenib	19-28	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-72
19495753-9	2010	In mouse xenograft models, TP300 showed antitumor activity against both BCRP-positive and -negative xenografts, whereas CPT-11 was less active against BCRP-positive xenografts.	TP 300	27-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	72-76
19495753-9	2010	In mouse xenograft models, TP300 showed antitumor activity against both BCRP-positive and -negative xenografts, whereas CPT-11 was less active against BCRP-positive xenografts.	Irinotecan	120-126	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	151-155
19492342-4	2009	We measured the interactions of [(99m)Tc(CO)(3)-ibogaine](+) and (99m)Tc-tricarbonyl with the main BBB efflux transporters P-gp and BCRP in vitro and in vivo.	co)(3)	41-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	132-136
19492342-4	2009	We measured the interactions of [(99m)Tc(CO)(3)-ibogaine](+) and (99m)Tc-tricarbonyl with the main BBB efflux transporters P-gp and BCRP in vitro and in vivo.	tc-tricarbonyl	70-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	132-136
19802874-0	2009	ABCG2-associated resistance to Hoechst 33342 and topotecan in a murine cell model with constitutive expression of side population characteristics.	bisbenzimide ethoxide trihydrochloride	31-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
19996279-0	2009	Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.	Methotrexate	97-109	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-37
19996279-0	2009	Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.	Methotrexate	97-109	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
19996279-0	2009	Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.	7-hydroxymethotrexate	135-156	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-37
19996279-0	2009	Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.	7-hydroxymethotrexate	135-156	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
19996279-6	2009	One hour after administration, 67% of the MTX dose was still present in livers of Abcc2;Abcc3;Abcg2-/- mice as MTX or 7OH-MTX versus 7% in wild-type, showing dramatic liver accumulation of these toxic compounds when Abcc2, Abcc3, and Abcg2 were all absent.	Methotrexate	42-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	94-99
19996279-6	2009	One hour after administration, 67% of the MTX dose was still present in livers of Abcc2;Abcc3;Abcg2-/- mice as MTX or 7OH-MTX versus 7% in wild-type, showing dramatic liver accumulation of these toxic compounds when Abcc2, Abcc3, and Abcg2 were all absent.	Methotrexate	42-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	234-239
19996279-7	2009	Furthermore, the urinary and fecal excretion of the nephrotoxic metabolite 7OH-MTX were increased 27- and 7-fold, respectively, in Abcc2;Abcc3;Abcg2-/- mice.	7-hydroxymethotrexate	75-82	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	143-148
19996279-8	2009	Thus, Abcc2, Abcc3, and Abcg2 together mediate the rapid elimination of MTX and 7OH-MTX after i.v.	Methotrexate	72-75	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-29
19996279-8	2009	Thus, Abcc2, Abcc3, and Abcg2 together mediate the rapid elimination of MTX and 7OH-MTX after i.v.	7-hydroxymethotrexate	80-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-29
19996279-10	2009	This may explain why it is still comparatively safe to use a toxic drug such as MTX in the clinic, as the risk of highly increased toxicity due to dysfunctioning of ABCC2, ABCC3, or ABCG2 alone is limited.	Methotrexate	80-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	182-187
19802874-0	2009	ABCG2-associated resistance to Hoechst 33342 and topotecan in a murine cell model with constitutive expression of side population characteristics.	Topotecan	49-58	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
19802874-1	2009	Drug resistant tumor "side-populations," enriched in cancer stem cells and identified by reduced accumulation of Hoechst 33342 under ABCG2-mediated efflux, may compromise therapeutic outcome.	bisbenzimide ethoxide trihydrochloride	113-126	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	133-138
19802874-7	2009	Hoechst 33342-resistant murine cells showed lower but significant crossresistance to topotecan, again attributable to enhanced ABCG2 expression, enabling cells to evade S-phase arrest.	bisbenzimide ethoxide trihydrochloride	0-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	127-132
19802874-7	2009	Hoechst 33342-resistant murine cells showed lower but significant crossresistance to topotecan, again attributable to enhanced ABCG2 expression, enabling cells to evade S-phase arrest.	Topotecan	85-94	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	127-132
19491323-0	2009	P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.	Dasatinib	84-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	19-51
19487254-1	2009	Breast cancer resistance protein (BCRP, ABCG2) is expressed in the hepatic canalicular membrane and mediates biliary excretion of xenobiotics including sulfate and glucuronide metabolites of some compounds.	Sulfates	152-159	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-32
19487254-1	2009	Breast cancer resistance protein (BCRP, ABCG2) is expressed in the hepatic canalicular membrane and mediates biliary excretion of xenobiotics including sulfate and glucuronide metabolites of some compounds.	Sulfates	152-159	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
19487254-1	2009	Breast cancer resistance protein (BCRP, ABCG2) is expressed in the hepatic canalicular membrane and mediates biliary excretion of xenobiotics including sulfate and glucuronide metabolites of some compounds.	Sulfates	152-159	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	40-45
19487254-1	2009	Breast cancer resistance protein (BCRP, ABCG2) is expressed in the hepatic canalicular membrane and mediates biliary excretion of xenobiotics including sulfate and glucuronide metabolites of some compounds.	Glucuronides	164-175	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-32
19487254-1	2009	Breast cancer resistance protein (BCRP, ABCG2) is expressed in the hepatic canalicular membrane and mediates biliary excretion of xenobiotics including sulfate and glucuronide metabolites of some compounds.	Glucuronides	164-175	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
19487254-1	2009	Breast cancer resistance protein (BCRP, ABCG2) is expressed in the hepatic canalicular membrane and mediates biliary excretion of xenobiotics including sulfate and glucuronide metabolites of some compounds.	Glucuronides	164-175	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	40-45
19487254-3	2009	The hypothesis that sex-dependent Bcrp expression influences the hepatobiliary disposition of phase II metabolites was tested in the present study using acetaminophen (APAP) and the generated APAP glucuronide (AG) and sulfate (AS) metabolites in single-pass in situ perfused livers from male and female wild-type and Abcg(-/-) (Bcrp-deficient) mice.	Acetaminophen	153-166	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
19487254-3	2009	The hypothesis that sex-dependent Bcrp expression influences the hepatobiliary disposition of phase II metabolites was tested in the present study using acetaminophen (APAP) and the generated APAP glucuronide (AG) and sulfate (AS) metabolites in single-pass in situ perfused livers from male and female wild-type and Abcg(-/-) (Bcrp-deficient) mice.	Acetaminophen	168-172	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
19487254-3	2009	The hypothesis that sex-dependent Bcrp expression influences the hepatobiliary disposition of phase II metabolites was tested in the present study using acetaminophen (APAP) and the generated APAP glucuronide (AG) and sulfate (AS) metabolites in single-pass in situ perfused livers from male and female wild-type and Abcg(-/-) (Bcrp-deficient) mice.	Acetaminophen	192-196	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
19487254-3	2009	The hypothesis that sex-dependent Bcrp expression influences the hepatobiliary disposition of phase II metabolites was tested in the present study using acetaminophen (APAP) and the generated APAP glucuronide (AG) and sulfate (AS) metabolites in single-pass in situ perfused livers from male and female wild-type and Abcg(-/-) (Bcrp-deficient) mice.	Glucuronides	197-208	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
19487254-3	2009	The hypothesis that sex-dependent Bcrp expression influences the hepatobiliary disposition of phase II metabolites was tested in the present study using acetaminophen (APAP) and the generated APAP glucuronide (AG) and sulfate (AS) metabolites in single-pass in situ perfused livers from male and female wild-type and Abcg(-/-) (Bcrp-deficient) mice.	Sulfates	218-225	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
19487254-3	2009	The hypothesis that sex-dependent Bcrp expression influences the hepatobiliary disposition of phase II metabolites was tested in the present study using acetaminophen (APAP) and the generated APAP glucuronide (AG) and sulfate (AS) metabolites in single-pass in situ perfused livers from male and female wild-type and Abcg(-/-) (Bcrp-deficient) mice.	Arsenic	227-229	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
19491323-2	2009	The objective of this study was to investigate the role of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in modulating the CNS penetration of dasatinib.	Dasatinib	162-171	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	85-117
19491323-2	2009	The objective of this study was to investigate the role of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in modulating the CNS penetration of dasatinib.	Dasatinib	162-171	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	119-123
19491323-3	2009	Results from the in vitro studies indicate that cellular delivery of dasatinib is significantly limited by active efflux due to both P-gp and BCRP.	Dasatinib	69-78	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	142-146
19491323-6	2009	In vivo brain distribution studies showed that the CNS distribution of dasatinib is limited, with the brain-to-plasma concentration ratios less than 0.12 in wild-type mice, which increased approximately 8-fold in Mdr1a/b(-/-) Bcrp1(-/-) mice.	Dasatinib	71-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	226-231
19491323-9	2009	These in vitro and in vivo studies demonstrate that dasatinib is a substrate for the important efflux transporters p-glycoprotein and BCRP.	Dasatinib	52-61	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	134-138
19383815-0	2009	Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.	Methotrexate	87-99	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
19508886-1	2009	The aim of this work was to clarify the role of Abcb1 and the possible involvement of Abcc2 and Abcg2 in liver, bile and brain disposition of amitriptyline (AMI).	Amitriptyline	142-155	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	96-101
19508886-1	2009	The aim of this work was to clarify the role of Abcb1 and the possible involvement of Abcc2 and Abcg2 in liver, bile and brain disposition of amitriptyline (AMI).	Amitriptyline	157-160	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	96-101
19619277-0	2009	A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models.	Chalcone	8-16	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	106-110
19619277-10	2009	JAI-51 also inhibited the activity of P-gp and BCRP, without being a substrate of these efflux pumps.	JAI-51	0-6	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	47-51
19567673-1	2009	Topotecan is a substrate of the ATP-binding cassette transporters P-glycoprotein (P-gp/MDR1) and breast cancer resistance protein (BCRP).	Topotecan	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	97-129
19567673-1	2009	Topotecan is a substrate of the ATP-binding cassette transporters P-glycoprotein (P-gp/MDR1) and breast cancer resistance protein (BCRP).	Topotecan	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	131-135
19567673-7	2009	When gefitinib (200 mg/kg) was preadministered to inhibit Bcrp1 and P-gp, the vCSF-to-plasma ratio decreased to 1.29 +/- 0.09 in wild-type mice and increased to 1.13 +/- 0.13 in Mdr1a/b(-/-)Bcrp1(-/-) mice, whereas the ECF-to-plasma ratio increased to 0.74 +/- 0.14 in wild-type and 1.07 +/- 0.03 in Mdr1a/b(-/-)Bcrp1(-/-) mice.	Gefitinib	5-14	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	58-63
19567673-7	2009	When gefitinib (200 mg/kg) was preadministered to inhibit Bcrp1 and P-gp, the vCSF-to-plasma ratio decreased to 1.29 +/- 0.09 in wild-type mice and increased to 1.13 +/- 0.13 in Mdr1a/b(-/-)Bcrp1(-/-) mice, whereas the ECF-to-plasma ratio increased to 0.74 +/- 0.14 in wild-type and 1.07 +/- 0.03 in Mdr1a/b(-/-)Bcrp1(-/-) mice.	Gefitinib	5-14	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	190-195
19567673-7	2009	When gefitinib (200 mg/kg) was preadministered to inhibit Bcrp1 and P-gp, the vCSF-to-plasma ratio decreased to 1.29 +/- 0.09 in wild-type mice and increased to 1.13 +/- 0.13 in Mdr1a/b(-/-)Bcrp1(-/-) mice, whereas the ECF-to-plasma ratio increased to 0.74 +/- 0.14 in wild-type and 1.07 +/- 0.03 in Mdr1a/b(-/-)Bcrp1(-/-) mice.	Gefitinib	5-14	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	190-195
19567673-8	2009	Preferential active transport of topotecan lactone over topotecan carboxylate was shown in vivo by vCSF lactone-to-carboxylate area under the curve ratios for wild-type, Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)Bcrp1(-/-) mice of 5.69 +/- 0.83, 3.85 +/- 0.64, 3.61 +/- 0.46, and 0.78 +/- 0.19, respectively.	Topotecan	33-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	184-189
19567673-8	2009	Preferential active transport of topotecan lactone over topotecan carboxylate was shown in vivo by vCSF lactone-to-carboxylate area under the curve ratios for wild-type, Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)Bcrp1(-/-) mice of 5.69 +/- 0.83, 3.85 +/- 0.64, 3.61 +/- 0.46, and 0.78 +/- 0.19, respectively.	Topotecan	33-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	212-217
19567673-8	2009	Preferential active transport of topotecan lactone over topotecan carboxylate was shown in vivo by vCSF lactone-to-carboxylate area under the curve ratios for wild-type, Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)Bcrp1(-/-) mice of 5.69 +/- 0.83, 3.85 +/- 0.64, 3.61 +/- 0.46, and 0.78 +/- 0.19, respectively.	Lactones	43-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	184-189
19567673-8	2009	Preferential active transport of topotecan lactone over topotecan carboxylate was shown in vivo by vCSF lactone-to-carboxylate area under the curve ratios for wild-type, Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)Bcrp1(-/-) mice of 5.69 +/- 0.83, 3.85 +/- 0.64, 3.61 +/- 0.46, and 0.78 +/- 0.19, respectively.	Lactones	43-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	212-217
19567673-9	2009	Our results suggest that Bcrp1 and P-gp transport topotecan into vCSF and out of brain parenchyma through the blood-brain barrier.	Topotecan	50-59	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	25-30
19393620-2	2009	These cells are isolated based on the side population (SP) phenotype, a Hoechst 3342 dye efflux property believed to be conferred by ABCG2.	hoechst 3342	72-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	133-138
18820913-0	2009	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer.	Fluorouracil	57-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	8-12
18820913-5	2009	METHODS: PA317/Tet-on/TRE-BCRP cell induced with doxycycline was used to screen the possible substrates of BCRP by MTT assay.	pa317	9-14	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	107-111
18820913-5	2009	METHODS: PA317/Tet-on/TRE-BCRP cell induced with doxycycline was used to screen the possible substrates of BCRP by MTT assay.	tetramethylenedisulfotetramine	15-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	107-111
18820913-5	2009	METHODS: PA317/Tet-on/TRE-BCRP cell induced with doxycycline was used to screen the possible substrates of BCRP by MTT assay.	Doxycycline	49-60	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-30
18820913-5	2009	METHODS: PA317/Tet-on/TRE-BCRP cell induced with doxycycline was used to screen the possible substrates of BCRP by MTT assay.	Doxycycline	49-60	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	107-111
18820913-5	2009	METHODS: PA317/Tet-on/TRE-BCRP cell induced with doxycycline was used to screen the possible substrates of BCRP by MTT assay.	monooxyethylene trimethylolpropane tristearate	115-118	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-30
18820913-5	2009	METHODS: PA317/Tet-on/TRE-BCRP cell induced with doxycycline was used to screen the possible substrates of BCRP by MTT assay.	monooxyethylene trimethylolpropane tristearate	115-118	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	107-111
18820913-7	2009	RESULTS: Mitoxantrone, 5-Fu, adriamycin, Methotrexate, Pirarubicin, and Etoposide were identified as substrates of BCRP.	Mitoxantrone	9-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	115-119
18820913-7	2009	RESULTS: Mitoxantrone, 5-Fu, adriamycin, Methotrexate, Pirarubicin, and Etoposide were identified as substrates of BCRP.	Fluorouracil	23-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	115-119
18820913-7	2009	RESULTS: Mitoxantrone, 5-Fu, adriamycin, Methotrexate, Pirarubicin, and Etoposide were identified as substrates of BCRP.	Doxorubicin	29-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	115-119
18820913-7	2009	RESULTS: Mitoxantrone, 5-Fu, adriamycin, Methotrexate, Pirarubicin, and Etoposide were identified as substrates of BCRP.	Methotrexate	41-53	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	115-119
18820913-7	2009	RESULTS: Mitoxantrone, 5-Fu, adriamycin, Methotrexate, Pirarubicin, and Etoposide were identified as substrates of BCRP.	pirarubicin	55-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	115-119
18820913-7	2009	RESULTS: Mitoxantrone, 5-Fu, adriamycin, Methotrexate, Pirarubicin, and Etoposide were identified as substrates of BCRP.	Etoposide	72-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	115-119
18820913-9	2009	5-Fu was identified as substrate of BCRP for the first time.	Fluorouracil	0-4	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-40
18820913-10	2009	The further study showed that the intracellular retention dose of 5-Fu and the 5-Fu induced cellular apoptosis all decreased when BCRP highly expressed.	Fluorouracil	66-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	130-134
18820913-10	2009	The further study showed that the intracellular retention dose of 5-Fu and the 5-Fu induced cellular apoptosis all decreased when BCRP highly expressed.	Fluorouracil	79-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	130-134
18820913-11	2009	Furthermore, 5-Fu accumulation and 5-Fu induced DNA damage increased when BCRP was silenced by RNAi in breast cancer cells.	Fluorouracil	13-17	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	74-78
18820913-11	2009	Furthermore, 5-Fu accumulation and 5-Fu induced DNA damage increased when BCRP was silenced by RNAi in breast cancer cells.	Fluorouracil	35-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	74-78
18820913-12	2009	CONCLUSIONS: 5-Fluorouracil may be a specific substrate which can be bound by BCRP.	Fluorouracil	13-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	78-82
18820913-13	2009	BCRP can predict the sensitivity of breast cancer to 5-Fu.	Fluorouracil	53-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
18820913-14	2009	And BCRP-targeted therapy will reverse the resistance of breast cancer to 5-Fu.	Fluorouracil	74-78	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	4-8
19508886-9	2009	At the hepato-biliary interface, we showed the involvement of Abcb1, Abcc2 and Abcg2; indeed, AMI concentration was increased in liver and decreased in bile, where quinidine is the strongest inhibitor, followed by probenecid and novobiocin.	Quinidine	164-173	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-84
19591692-1	2009	BACKGROUND: Imatinib, a tyrosine kinase inhibitor currently approved for treatment of several malignancies, has been shown to be a substrate for multiple efflux-transporter proteins, including ABCB1 (P-glycoprotein) and ABCG2 (BCRP).	Imatinib Mesylate	12-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	220-225
19591692-1	2009	BACKGROUND: Imatinib, a tyrosine kinase inhibitor currently approved for treatment of several malignancies, has been shown to be a substrate for multiple efflux-transporter proteins, including ABCB1 (P-glycoprotein) and ABCG2 (BCRP).	Imatinib Mesylate	12-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	227-231
19428349-2	2009	Milbemycin moxidectin ([(3)H]-moxidectin) was tested for its ability to be transported across MCDK-II epithelial monolayer cultures transfected with BCRP.	milbemycin moxidectin	0-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	149-153
19428349-6	2009	The transport was blocked by an acridone derivative, a novel BCRP inhibitor.	acridone	32-40	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	61-65
19383815-5	2009	RESULTS: Compared with wild-type, the plasma areas under the curve (AUC) for MTX were 1.6-fold and 2.0-fold higher in Abcg2(-/-) and Abcc2(-/-) mice, respectively, and 3.3-fold increased in Abcc2;Abcg2(-/-) mice.	Methotrexate	77-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	118-123
19383815-5	2009	RESULTS: Compared with wild-type, the plasma areas under the curve (AUC) for MTX were 1.6-fold and 2.0-fold higher in Abcg2(-/-) and Abcc2(-/-) mice, respectively, and 3.3-fold increased in Abcc2;Abcg2(-/-) mice.	Methotrexate	77-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	196-201
19383815-6	2009	The biliary excretion of MTX was 23-fold reduced in Abcc2;Abcg2(-/-) mice, and the MTX levels in the small intestine were dramatically decreased.	Methotrexate	25-28	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	58-63
19383815-10	2009	We additionally found that in the absence of Abcc2, Abcg2 mediated substantial urinary excretion of MTX and 7OH-MTX.	Methotrexate	100-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-57
19383815-10	2009	We additionally found that in the absence of Abcc2, Abcg2 mediated substantial urinary excretion of MTX and 7OH-MTX.	7-hydroxymethotrexate	108-115	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-57
19383815-11	2009	CONCLUSIONS: Abcc2 and Abcg2 together are major determinants of MTX and 7OH-MTX pharmacokinetics.	Methotrexate	64-67	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	23-28
19383815-11	2009	CONCLUSIONS: Abcc2 and Abcg2 together are major determinants of MTX and 7OH-MTX pharmacokinetics.	7-hydroxymethotrexate	72-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	23-28
19383815-0	2009	Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.	Methotrexate	87-99	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-46
19383815-0	2009	Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.	7-hydroxymethotrexate	130-151	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
19383815-0	2009	Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.	7-hydroxymethotrexate	130-151	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-46
19383815-2	2009	We investigated the possibly overlapping roles of Abcg2 and Abcc2 in the elimination of the anticancer drug methotrexate (MTX) and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX).	Methotrexate	108-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-55
19383815-2	2009	We investigated the possibly overlapping roles of Abcg2 and Abcc2 in the elimination of the anticancer drug methotrexate (MTX) and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX).	Methotrexate	122-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-55
19383815-2	2009	We investigated the possibly overlapping roles of Abcg2 and Abcc2 in the elimination of the anticancer drug methotrexate (MTX) and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX).	7-hydroxymethotrexate	152-173	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	50-55
19383815-3	2009	EXPERIMENTAL DESIGN: We generated and characterized Abcc2;Abcg2(-/-) mice, and used these to determine the overlapping roles of Abcc2 and Abcg2 in the elimination of MTX and 7OH-MTX after i.v.	Methotrexate	166-169	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	138-143
19324269-2	2009	Recent studies confirmed that gefitinib interacted with the breast cancer resistance protein (BCRP) at submicromolar concentrations, whereas other multidrug transporters, including P-glycoprotein (P-gp), showed much lower reactivity toward gefitinib.	Gefitinib	30-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-92
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	alvocidib	12-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
19276246-0	2009	Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.	Dasatinib	22-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-115
19276246-1	2009	PURPOSE: Imatinib, a BCR-ABL tyrosine kinase inhibitor, is a substrate of the efflux transporters P-glycoprotein (P-gp; ABCB1) and ABCG2 (breast cancer resistance protein), and its brain accumulation is restricted by both transporters.	Imatinib Mesylate	9-17	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	131-136
19276246-2	2009	For dasatinib, an inhibitor of SCR/BCR-ABL kinases, in vivo interactions with P-gp and ABCG2 are not fully established yet.	Dasatinib	4-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-92
19276246-9	2009	Moreover, coadministration to wild-type mice of dasatinib with the dual P-gp and ABCG2 inhibitor elacridar resulted in a similar dasatinib brain accumulation as observed for Abcb1a/1b;Abcg2(-/-) mice.	Dasatinib	48-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	81-86
19276246-9	2009	Moreover, coadministration to wild-type mice of dasatinib with the dual P-gp and ABCG2 inhibitor elacridar resulted in a similar dasatinib brain accumulation as observed for Abcb1a/1b;Abcg2(-/-) mice.	Dasatinib	48-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	184-189
19114588-0	2009	Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol.	Resveratrol	144-155	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	11-43
19114588-0	2009	Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol.	Resveratrol	144-155	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	45-49
19114588-0	2009	Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol.	Resveratrol	144-155	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-56
19114588-8	2009	BCRP transports Res-3-G and resveratrol sulfates in vitro, and its absence in mice results in high plasma levels of resveratrol-di-sulfate, a resveratrol metabolite hardly detectable in the plasma of wild-type mice and in an increased disposal of resveratrol via the urine.	res-3-g	16-23	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
19114588-8	2009	BCRP transports Res-3-G and resveratrol sulfates in vitro, and its absence in mice results in high plasma levels of resveratrol-di-sulfate, a resveratrol metabolite hardly detectable in the plasma of wild-type mice and in an increased disposal of resveratrol via the urine.	resveratrol sulfates	28-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
19114588-8	2009	BCRP transports Res-3-G and resveratrol sulfates in vitro, and its absence in mice results in high plasma levels of resveratrol-di-sulfate, a resveratrol metabolite hardly detectable in the plasma of wild-type mice and in an increased disposal of resveratrol via the urine.	resveratrol-di-sulfate	116-138	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
19114588-8	2009	BCRP transports Res-3-G and resveratrol sulfates in vitro, and its absence in mice results in high plasma levels of resveratrol-di-sulfate, a resveratrol metabolite hardly detectable in the plasma of wild-type mice and in an increased disposal of resveratrol via the urine.	Resveratrol	28-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
19114588-8	2009	BCRP transports Res-3-G and resveratrol sulfates in vitro, and its absence in mice results in high plasma levels of resveratrol-di-sulfate, a resveratrol metabolite hardly detectable in the plasma of wild-type mice and in an increased disposal of resveratrol via the urine.	Resveratrol	116-127	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	alvocidib	12-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	126-130
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	Imatinib Mesylate	26-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	Imatinib Mesylate	26-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	126-130
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	Imatinib Mesylate	45-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	Imatinib Mesylate	45-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	126-130
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid	55-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid	55-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	126-130
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	Prazosin	70-78	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
19225039-2	2009	Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were determined.	Prazosin	70-78	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	126-130
19225039-3	2009	Flavopiridol and prazosin were identified as substrates for both mouse Bcrp and Mdr1a with greater transport associated with Bcrp.	alvocidib	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-75
19225039-3	2009	Flavopiridol and prazosin were identified as substrates for both mouse Bcrp and Mdr1a with greater transport associated with Bcrp.	alvocidib	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	125-129
19225039-3	2009	Flavopiridol and prazosin were identified as substrates for both mouse Bcrp and Mdr1a with greater transport associated with Bcrp.	Prazosin	17-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	71-75
19225039-3	2009	Flavopiridol and prazosin were identified as substrates for both mouse Bcrp and Mdr1a with greater transport associated with Bcrp.	Prazosin	17-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	125-129
19324269-5	2009	Co-injection with gefitinib (over 50 mg/kg), a nonspecific P-gp modulator cyclosporin A (50 mg/kg), and the dual P-gp and BCRP modulator GF120918 (over 5 mg/kg) induced an increase in the brain uptake of [(11)C]gefitinib in mice 30 min after injection.	Elacridar	137-145	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	122-126
19324269-8	2009	In conclusion, [(11)C]gefitinib is a promising PET tracer to evaluate the penetration of gefitinib into the brain by combined therapy with P-gp or BCRP modulators, and into brain tumors.	Gefitinib	22-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	147-151
19324269-8	2009	In conclusion, [(11)C]gefitinib is a promising PET tracer to evaluate the penetration of gefitinib into the brain by combined therapy with P-gp or BCRP modulators, and into brain tumors.	Gefitinib	89-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	147-151
19324269-2	2009	Recent studies confirmed that gefitinib interacted with the breast cancer resistance protein (BCRP) at submicromolar concentrations, whereas other multidrug transporters, including P-glycoprotein (P-gp), showed much lower reactivity toward gefitinib.	Gefitinib	30-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	94-98
19324269-2	2009	Recent studies confirmed that gefitinib interacted with the breast cancer resistance protein (BCRP) at submicromolar concentrations, whereas other multidrug transporters, including P-glycoprotein (P-gp), showed much lower reactivity toward gefitinib.	Gefitinib	240-249	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	94-98
19156141-7	2009	In mice bearing wild-type (wt) and BCRP-expressing tumours on either flank, both STX140 and mitoxantrone inhibited the growth of the MCF-7wt xenografts, but only STX140 inhibited growth of the MCF-7.MR tumours.	2-methoxyestradiol-3,17-O,O-bis(sulfamate)	81-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-39
19146924-4	2009	We have investigated riluzole as a breast cancer resistance protein (BCRP) substrate by studying its brain transport in CF1 mdr1a (-/-) mice and its intracellular uptake on BeWo cells (human placental choriocarcinoma cell line).	Riluzole	21-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-67
19146924-4	2009	We have investigated riluzole as a breast cancer resistance protein (BCRP) substrate by studying its brain transport in CF1 mdr1a (-/-) mice and its intracellular uptake on BeWo cells (human placental choriocarcinoma cell line).	Riluzole	21-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	69-73
19146924-7	2009	After repeated doses of riluzole, BCRP activity was increased in CF1 mdr1a (-/-) mice, riluzole uptake was decrease and both BCRP expression and activity were increased in BeWo cells.	Riluzole	24-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
19146924-7	2009	After repeated doses of riluzole, BCRP activity was increased in CF1 mdr1a (-/-) mice, riluzole uptake was decrease and both BCRP expression and activity were increased in BeWo cells.	Riluzole	24-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	125-129
19156141-7	2009	In mice bearing wild-type (wt) and BCRP-expressing tumours on either flank, both STX140 and mitoxantrone inhibited the growth of the MCF-7wt xenografts, but only STX140 inhibited growth of the MCF-7.MR tumours.	Mitoxantrone	92-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-39
19156141-8	2009	In conclusion, STX140, a promising orally bioavailable anti-cancer agent in pre-clinical development, is highly efficacious in BCRP-expressing xenografts.	2-methoxyestradiol-3,17-O,O-bis(sulfamate)	15-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	127-131
19156141-9	2009	This is despite an increase in BCRP expression in A2780 cells in vitro after chronic dosing with STX140.	2-methoxyestradiol-3,17-O,O-bis(sulfamate)	97-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-35
18841445-0	2009	Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice.	Curcumin	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
19056914-0	2009	An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016).	Lapatinib	159-168	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-83
19056914-5	2009	In contrast, Mdr1a/b(-/-)/Bcrp1(-/-) triple knockout mice had a 40-fold higher brain-to-plasma ratio (ratio range from 1.2 to 1.7), suggesting that Pgp and Bcrp work in concert to limit the brain-to-plasma ratio of lapatinib in mice.	Lapatinib	215-224	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-31
19056914-5	2009	In contrast, Mdr1a/b(-/-)/Bcrp1(-/-) triple knockout mice had a 40-fold higher brain-to-plasma ratio (ratio range from 1.2 to 1.7), suggesting that Pgp and Bcrp work in concert to limit the brain-to-plasma ratio of lapatinib in mice.	Lapatinib	215-224	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-30
18449471-0	2009	The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.	Imatinib Mesylate	138-146	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-35
18449471-0	2009	The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.	Imatinib Mesylate	138-146	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-42
18449471-0	2009	The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.	Imatinib Mesylate	138-146	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	53-57
18449471-1	2009	Imatinib is transported by P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), however, the exact impact of these transporters on absorption, distribution, metabolism and excretion (ADME) of imatinib is not fully understood due to incomplete data.	Imatinib Mesylate	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	53-85
18449471-1	2009	Imatinib is transported by P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), however, the exact impact of these transporters on absorption, distribution, metabolism and excretion (ADME) of imatinib is not fully understood due to incomplete data.	Imatinib Mesylate	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-91
18449471-1	2009	Imatinib is transported by P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), however, the exact impact of these transporters on absorption, distribution, metabolism and excretion (ADME) of imatinib is not fully understood due to incomplete data.	Imatinib Mesylate	206-214	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	53-85
18449471-1	2009	Imatinib is transported by P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), however, the exact impact of these transporters on absorption, distribution, metabolism and excretion (ADME) of imatinib is not fully understood due to incomplete data.	Imatinib Mesylate	206-214	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-91
18449471-2	2009	We have performed a comprehensive ADME study of imatinib given as single agent or in combination with the well known BCRP/P-gp inhibitors, elacridar and pantoprazole, in wild-type and P-gp and/or BCRP knockout mice.	Imatinib Mesylate	48-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	196-200
18449471-5	2009	Both elacridar and pantoprazole significantly increased the AUC of orally administered imatinib in wild-type but also in P-gp/BCRP knockout mice.	Pantoprazole	19-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	126-130
18449471-5	2009	Both elacridar and pantoprazole significantly increased the AUC of orally administered imatinib in wild-type but also in P-gp/BCRP knockout mice.	Imatinib Mesylate	87-95	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	126-130
18449471-8	2009	In conclusion, P-gp and BCRP have only a modest effect on the ADME of imatinib in comparison to metabolic elimination.	Imatinib Mesylate	70-78	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-28
18449471-10	2009	The considerable drug-drug interaction observed with elacridar or pantoprazole is only partly mediated by inhibition of P-gp and BCRP and far more by the inhibition of other elimination pathways.	Pantoprazole	66-78	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	129-133
18841445-7	2009	Based on studies in wild type and abcg2-/- mice, we observed that oral curcumin increased Cmax and relative bioavailability of sulfasalazine by selectively inhibiting ABCG2 function.	Curcumin	71-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
18841445-7	2009	Based on studies in wild type and abcg2-/- mice, we observed that oral curcumin increased Cmax and relative bioavailability of sulfasalazine by selectively inhibiting ABCG2 function.	Curcumin	71-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	167-172
18841445-7	2009	Based on studies in wild type and abcg2-/- mice, we observed that oral curcumin increased Cmax and relative bioavailability of sulfasalazine by selectively inhibiting ABCG2 function.	Sulfasalazine	127-140	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	167-172
18841445-10	2009	5:1995-2006, 2006) and provides the first in vivo evidence for the inhibition by curcumin of ABCG2-mediated efflux of sulfasalazine in mice.	Curcumin	81-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	93-98
18841445-10	2009	5:1995-2006, 2006) and provides the first in vivo evidence for the inhibition by curcumin of ABCG2-mediated efflux of sulfasalazine in mice.	Sulfasalazine	118-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	93-98
18841445-11	2009	Based on these studies, we propose that non-toxic concentrations of curcumin may be used to enhance drug exposure when the rate-limiting step of drug absorption and/or tissue distribution is impacted by ABCG2.	Curcumin	68-76	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	203-208
18841445-0	2009	Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice.	Curcumin	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	40-45
18841445-1	2009	PURPOSE: To evaluate the in vivo efficacy of curcumin as an inhibitor of the multidrug-resistance-linked ATP Binding Cassette (ABC) drug transporter, ABCG2.	Curcumin	45-53	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	150-155
18841445-2	2009	METHODS: Photoaffinity labeling with [125I]-iodoarylazidoprazosin was used to characterize the interaction of sulfasalazine, a substrate of the mouse ABCG2, with human ABCG2.	azidoprazosin	37-65	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	150-155
18841445-2	2009	METHODS: Photoaffinity labeling with [125I]-iodoarylazidoprazosin was used to characterize the interaction of sulfasalazine, a substrate of the mouse ABCG2, with human ABCG2.	Sulfasalazine	110-123	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	150-155
19118589-5	2009	In addition, several other physiological functions of ABCG2 have been observed, including extrusion of porphyrins and/or porphyrin conjugates from hematopoietic cells, liver and harderian gland, as well as secretion of vitamin B(2) (riboflavin) and possibly other vitamins (biotin, vitamin K) into breast milk.	Riboflavin	219-231	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
19118589-5	2009	In addition, several other physiological functions of ABCG2 have been observed, including extrusion of porphyrins and/or porphyrin conjugates from hematopoietic cells, liver and harderian gland, as well as secretion of vitamin B(2) (riboflavin) and possibly other vitamins (biotin, vitamin K) into breast milk.	Vitamin K	282-291	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
19118589-5	2009	In addition, several other physiological functions of ABCG2 have been observed, including extrusion of porphyrins and/or porphyrin conjugates from hematopoietic cells, liver and harderian gland, as well as secretion of vitamin B(2) (riboflavin) and possibly other vitamins (biotin, vitamin K) into breast milk.	Riboflavin	233-243	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
19118589-5	2009	In addition, several other physiological functions of ABCG2 have been observed, including extrusion of porphyrins and/or porphyrin conjugates from hematopoietic cells, liver and harderian gland, as well as secretion of vitamin B(2) (riboflavin) and possibly other vitamins (biotin, vitamin K) into breast milk.	Biotin	274-280	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
18719241-1	2008	Previous experiments demonstrated that the biliary excretion of harmol sulfate (HS) was mediated by breast cancer resistance protein (Bcrp) and not by multidrug resistance-associated protein (Mrp)2 or P-glycoprotein in mice.	harmol sulfate	64-78	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	100-132
19732493-1	2009	PURPOSE: The activities of breast cancer resistance protein (Bcrp/ABCG2) as well as P-glycoprotein (P-gp) and drug-metabolizing enzymes can be inhibited by several flavonoids or drugs in rats.	Flavonoids	164-174	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	61-65
19732493-2	2009	However, the species, gender and regional differences of effects of flavonoids on Bcrp/ABCG2 in rats and mice remain unclear, although Bcrp, like P-gp, is also important in controlling drug absorption and disposition.	Flavonoids	68-78	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-86
19732493-4	2009	We examined the pharmacokinetics of nitrofurantoin, a specific Bcrp substrate, in rats and mice treated with chrysin.	Nitrofurantoin	36-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-67
19732493-8	2009	CONCLUSIONS: These results suggest that chrysin-nitrofurantoin interactions occur in the small intestine in rats, but not in mice, possibly due to the higher levels of Bcrp expression in the small intestine in rats, compared with those in mice.	chrysin-nitrofurantoin	40-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	168-172
19732497-0	2009	Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.	Bromocriptine	81-94	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
19732497-7	2009	Conversely, ABCG2 expression studied on brain capillaries from MPTP-treated mice was decreased (1.3-fold, p less than 0.05) and ABCB1 expression increased (1.43-fold, p less than 0.05) as an off-setting of brain transport.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	63-67	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	12-17
19047120-1	2008	PURPOSE: Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members.	Topotecan	9-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	86-118
19047120-1	2008	PURPOSE: Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members.	Topotecan	9-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	120-124
19047120-6	2008	RESULTS: Lapatinib increased topotecan accumulation in BCRP- or Pgp-expressing cells in vitro, and the combination showed enhanced efficacy in HER2+ BT474 xenografts.	Lapatinib	9-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	55-59
19047120-6	2008	RESULTS: Lapatinib increased topotecan accumulation in BCRP- or Pgp-expressing cells in vitro, and the combination showed enhanced efficacy in HER2+ BT474 xenografts.	Topotecan	29-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	55-59
18799806-1	2008	Genetic knockout mice studies suggested ATP-binding cassette transporter family G member 2 (ABCG2)/Abcg2 translocates nitrofurantoin at the mammary-blood barrier, resulting in drug accumulation in milk.	Nitrofurantoin	118-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-97
18799806-1	2008	Genetic knockout mice studies suggested ATP-binding cassette transporter family G member 2 (ABCG2)/Abcg2 translocates nitrofurantoin at the mammary-blood barrier, resulting in drug accumulation in milk.	Nitrofurantoin	118-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	99-104
18719241-1	2008	Previous experiments demonstrated that the biliary excretion of harmol sulfate (HS) was mediated by breast cancer resistance protein (Bcrp) and not by multidrug resistance-associated protein (Mrp)2 or P-glycoprotein in mice.	harmol sulfate	64-78	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	134-138
18719241-1	2008	Previous experiments demonstrated that the biliary excretion of harmol sulfate (HS) was mediated by breast cancer resistance protein (Bcrp) and not by multidrug resistance-associated protein (Mrp)2 or P-glycoprotein in mice.	harmol sulfate	80-82	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	100-132
18719241-1	2008	Previous experiments demonstrated that the biliary excretion of harmol sulfate (HS) was mediated by breast cancer resistance protein (Bcrp) and not by multidrug resistance-associated protein (Mrp)2 or P-glycoprotein in mice.	harmol sulfate	80-82	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	134-138
18719241-4	2008	As expected, in mouse liver perfusions, the biliary excretion of HS was decreased approximately 3.5-fold by GF120918, consistent with previous reports of Bcrp-mediated HS biliary excretion.	harmol sulfate	65-67	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	154-158
18787193-4	2008	Abcg2 belongs to the ATP-binding cassette (ABC) transporter superfamily and constitutes the molecular basis for the dye efflux, hence the SP phenotype, in hematopoietic stem cells.	sp	138-140	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
18787193-5	2008	Although Abcg2 is also expressed in cardiac SP (cSP) cells, its role in regulating the SP phenotype and function of cSP cells is unknown.	sp	44-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	9-14
18787193-10	2008	In summary, for the first time, we reveal a functional role for Abcg2 in modulating the proliferation, differentiation, and survival of adult cSP cells that goes beyond its distinct role in Hoechst dye efflux.	hoechst dye	190-201	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	64-69
18443033-0	2008	Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse.	abacavir	137-145	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	68-73
18765824-2	2008	In cells transfected with DNA constructs resulting in overexpression of human or mouse ABCG2, we found resistance against cladribine, clofarabine, fludarabine, 6-mercaptopurine, and 6-mercaptopurine riboside in both MDCKII and HEK293 cells and against gemcitabine only in HEK293 cells.	Cladribine	122-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-92
18765824-2	2008	In cells transfected with DNA constructs resulting in overexpression of human or mouse ABCG2, we found resistance against cladribine, clofarabine, fludarabine, 6-mercaptopurine, and 6-mercaptopurine riboside in both MDCKII and HEK293 cells and against gemcitabine only in HEK293 cells.	Clofarabine	134-145	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-92
18765824-2	2008	In cells transfected with DNA constructs resulting in overexpression of human or mouse ABCG2, we found resistance against cladribine, clofarabine, fludarabine, 6-mercaptopurine, and 6-mercaptopurine riboside in both MDCKII and HEK293 cells and against gemcitabine only in HEK293 cells.	fludarabine	147-158	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-92
18765824-2	2008	In cells transfected with DNA constructs resulting in overexpression of human or mouse ABCG2, we found resistance against cladribine, clofarabine, fludarabine, 6-mercaptopurine, and 6-mercaptopurine riboside in both MDCKII and HEK293 cells and against gemcitabine only in HEK293 cells.	Mercaptopurine	160-176	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-92
18765824-2	2008	In cells transfected with DNA constructs resulting in overexpression of human or mouse ABCG2, we found resistance against cladribine, clofarabine, fludarabine, 6-mercaptopurine, and 6-mercaptopurine riboside in both MDCKII and HEK293 cells and against gemcitabine only in HEK293 cells.	Thioinosine	182-207	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-92
18765824-2	2008	In cells transfected with DNA constructs resulting in overexpression of human or mouse ABCG2, we found resistance against cladribine, clofarabine, fludarabine, 6-mercaptopurine, and 6-mercaptopurine riboside in both MDCKII and HEK293 cells and against gemcitabine only in HEK293 cells.	gemcitabine	252-263	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-92
18523872-5	2008	RESULTS: The Bcrp inhibitor Ko143 blocked topotecan and ABZSO transport in a concentration-dependent manner.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	28-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	13-17
18523872-5	2008	RESULTS: The Bcrp inhibitor Ko143 blocked topotecan and ABZSO transport in a concentration-dependent manner.	Topotecan	42-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	13-17
18523872-6	2008	P-gp inhibitors ivermectin, LY335979, PSC833, and the P-gp/Bcrp inhibitor ritonavir did not influence Bcrp mediated topotecan transport, however, blocked ABZSO transport.	Ritonavir	74-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	59-63
18443033-2	2008	We have previously shown that zidovudine (AZT) and abacavir (ABC) are in vitro substrates for the efflux transport protein breast cancer resistance protein (Bcrp) 1.	Zidovudine	30-40	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	123-164
18443033-2	2008	We have previously shown that zidovudine (AZT) and abacavir (ABC) are in vitro substrates for the efflux transport protein breast cancer resistance protein (Bcrp) 1.	Zidovudine	42-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	123-164
18443033-2	2008	We have previously shown that zidovudine (AZT) and abacavir (ABC) are in vitro substrates for the efflux transport protein breast cancer resistance protein (Bcrp) 1.	abacavir	51-59	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	123-164
18443033-5	2008	The AUC(plasma) of abacavir was 20% lower in the Bcrp1-/- mice, whereas the AUC(brain) was 20% greater.	abacavir	19-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	49-54
18443033-6	2008	This difference resulted in a 1.5-fold increase in abacavir brain exposure in the Bcrp1-/- mice.	abacavir	51-59	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-87
18443033-10	2008	Brain/plasma concentration ratios in both the wild-type and Bcrp1-/- mice were increased by the P-glycoprotein inhibitors LY335979 and GF120918, but not by BCRP-selective inhibitors.	zosuquidar trihydrochloride	122-130	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-65
18443033-10	2008	Brain/plasma concentration ratios in both the wild-type and Bcrp1-/- mice were increased by the P-glycoprotein inhibitors LY335979 and GF120918, but not by BCRP-selective inhibitors.	Elacridar	135-143	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-65
18443033-12	2008	However, for abacavir, deletion of Bcrp1 reduces plasma exposure and enhances brain penetration.	abacavir	13-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-40
18322075-3	2008	In addition, the K(p,brain) of triamterene and the K(p,testis) of 4"-hydroxyl PhIP were also significantly increased in Bcrp(-/-) mice.	Triamterene	31-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	120-124
18723475-0	2008	Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.	Erlotinib Hydrochloride	80-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-65
18723475-6	2008	In vitro, erlotinib was actively transported by P-gp and BCRP/Bcrp1.	Erlotinib Hydrochloride	10-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	57-61
18723475-6	2008	In vitro, erlotinib was actively transported by P-gp and BCRP/Bcrp1.	Erlotinib Hydrochloride	10-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	62-67
18723475-8	2008	In vivo, systemic exposure (P = 0.01) as well as bioavailability of erlotinib after oral administration (5 mg/kg) were statistically significantly increased in Bcrp1/Mdr1a/1b(-/-) knockout mice (60.4%) compared with WT mice (40.0%; P = 0.02).	Erlotinib Hydrochloride	68-77	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	160-165
18723475-9	2008	CONCLUSION: Erlotinib is transported efficiently by P-gp and BCRP/Bcrp1 in vitro.	Erlotinib Hydrochloride	12-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	61-65
18723475-9	2008	CONCLUSION: Erlotinib is transported efficiently by P-gp and BCRP/Bcrp1 in vitro.	Erlotinib Hydrochloride	12-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	66-71
18723475-10	2008	In vivo, absence of P-gp and Bcrp1 significantly affected the oral bioavailability of erlotinib.	Erlotinib Hydrochloride	86-95	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-34
18322075-5	2008	In vitro transcellular transport experiments using cell lines expressing mouse Bcrp or P-glycoprotein (Mdr1a/Abcb1a) showed that, among the tested Bcrp substrates, PhIP, MeIQx, prazosin, and triamterene are common substrates of Bcrp and P-glycoprotein.	Triamterene	191-202	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-83
18322075-4	2008	The effect of functional impairment of Bcrp on the brain uptake of PhIP, dantrolene, and daidzein in Bcrp(-/-) mice determined using in situ brain perfusion was weaker than that observed on the K(p) values.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	67-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-43
18322075-5	2008	In vitro transcellular transport experiments using cell lines expressing mouse Bcrp or P-glycoprotein (Mdr1a/Abcb1a) showed that, among the tested Bcrp substrates, PhIP, MeIQx, prazosin, and triamterene are common substrates of Bcrp and P-glycoprotein.	Triamterene	191-202	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	147-151
18322075-5	2008	In vitro transcellular transport experiments using cell lines expressing mouse Bcrp or P-glycoprotein (Mdr1a/Abcb1a) showed that, among the tested Bcrp substrates, PhIP, MeIQx, prazosin, and triamterene are common substrates of Bcrp and P-glycoprotein.	Triamterene	191-202	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	147-151
18322075-4	2008	The effect of functional impairment of Bcrp on the brain uptake of PhIP, dantrolene, and daidzein in Bcrp(-/-) mice determined using in situ brain perfusion was weaker than that observed on the K(p) values.	Dantrolene	73-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-43
18322075-4	2008	The effect of functional impairment of Bcrp on the brain uptake of PhIP, dantrolene, and daidzein in Bcrp(-/-) mice determined using in situ brain perfusion was weaker than that observed on the K(p) values.	daidzein	89-97	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-43
18322075-5	2008	In vitro transcellular transport experiments using cell lines expressing mouse Bcrp or P-glycoprotein (Mdr1a/Abcb1a) showed that, among the tested Bcrp substrates, PhIP, MeIQx, prazosin, and triamterene are common substrates of Bcrp and P-glycoprotein.	2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	170-175	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-83
18322075-5	2008	In vitro transcellular transport experiments using cell lines expressing mouse Bcrp or P-glycoprotein (Mdr1a/Abcb1a) showed that, among the tested Bcrp substrates, PhIP, MeIQx, prazosin, and triamterene are common substrates of Bcrp and P-glycoprotein.	Prazosin	177-185	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-83
18322075-5	2008	In vitro transcellular transport experiments using cell lines expressing mouse Bcrp or P-glycoprotein (Mdr1a/Abcb1a) showed that, among the tested Bcrp substrates, PhIP, MeIQx, prazosin, and triamterene are common substrates of Bcrp and P-glycoprotein.	Prazosin	177-185	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	147-151
18322075-5	2008	In vitro transcellular transport experiments using cell lines expressing mouse Bcrp or P-glycoprotein (Mdr1a/Abcb1a) showed that, among the tested Bcrp substrates, PhIP, MeIQx, prazosin, and triamterene are common substrates of Bcrp and P-glycoprotein.	Prazosin	177-185	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	147-151
18094612-1	2008	PURPOSE: Chronic imatinib exposure has been shown to result in upregulation of the ABCB1 (P-glycoprotein) and ABCG2 (BCRP) transporters in vitro, for which imatinib is a substrate.	Imatinib Mesylate	17-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-115
18356544-5	2008	Overexpression of Abcg2 results in an increased ability to consume hydrogen peroxide and is associated with increased levels of alpha-glutathione reductase protein expression.	Hydrogen Peroxide	67-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	18-23
18356544-6	2008	Importantly, overexpression of Abcg2 also conferred a cell survival benefit following exposure to hydrogen peroxide.	Hydrogen Peroxide	98-115	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-36
18094612-1	2008	PURPOSE: Chronic imatinib exposure has been shown to result in upregulation of the ABCB1 (P-glycoprotein) and ABCG2 (BCRP) transporters in vitro, for which imatinib is a substrate.	Imatinib Mesylate	17-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	117-121
18094612-1	2008	PURPOSE: Chronic imatinib exposure has been shown to result in upregulation of the ABCB1 (P-glycoprotein) and ABCG2 (BCRP) transporters in vitro, for which imatinib is a substrate.	Imatinib Mesylate	156-164	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-115
18094612-1	2008	PURPOSE: Chronic imatinib exposure has been shown to result in upregulation of the ABCB1 (P-glycoprotein) and ABCG2 (BCRP) transporters in vitro, for which imatinib is a substrate.	Imatinib Mesylate	156-164	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	117-121
17914640-7	2007	In addition, the result that the SP phenotype of ICM cells disappeared when the inhibitor verapamil was added into medium implies that the SP phenotype is directly associated with ABCG2.	sp	139-141	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	180-185
18079276-0	2008	The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study.	Glyburide	80-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	4-36
18079276-0	2008	The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study.	Glyburide	80-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-43
18079276-0	2008	The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study.	Glyburide	80-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-49
18079276-9	2008	GLB was administered by retro-orbital injection to the wild-type and Bcrp1(-/-) pregnant mice.	Glyburide	0-3	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	69-74
18039806-8	2008	The K(p,brain) value of oseltamivir in multidrug-resistant (Mdr) 1a/1b P-gp knockout mice was 5.5-fold higher than that in wild-type mice and comparable with that obtained by pretreatment with GF120918, whereas it was unchanged in Bcrp knockout mice.	Oseltamivir	24-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	231-235
17913796-5	2008	N-(4-[2-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) (10 muM) was employed to inhibit P-gp and Bcrp.	Elacridar	126-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	178-182
17785426-0	2007	Breast cancer resistance protein 1 limits fetal distribution of nitrofurantoin in the pregnant mouse.	Nitrofurantoin	64-78	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-32
17914640-7	2007	In addition, the result that the SP phenotype of ICM cells disappeared when the inhibitor verapamil was added into medium implies that the SP phenotype is directly associated with ABCG2.	sp	33-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	180-185
17914640-7	2007	In addition, the result that the SP phenotype of ICM cells disappeared when the inhibitor verapamil was added into medium implies that the SP phenotype is directly associated with ABCG2.	Verapamil	90-99	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	180-185
17682070-0	2007	Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).	Sulfates	159-166	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-64
17975156-0	2007	P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.	Topotecan	133-142	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	19-51
17975156-5	2007	RESULTS: The area under the plasma and tissue concentration-time curve (AUC) of topotecan in brains of Mdr1a/b(-/-) and Bcrp1(-/-) mice was only 1.5-fold higher compared with WT mice, but in Mdr1a/b(-/-)Bcrp1(-/-) mice, where both transporters are absent, the AUC increased by 12-fold.	Topotecan	80-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	120-125
17975156-5	2007	RESULTS: The area under the plasma and tissue concentration-time curve (AUC) of topotecan in brains of Mdr1a/b(-/-) and Bcrp1(-/-) mice was only 1.5-fold higher compared with WT mice, but in Mdr1a/b(-/-)Bcrp1(-/-) mice, where both transporters are absent, the AUC increased by 12-fold.	Topotecan	80-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	203-208
17975156-8	2007	The P-gp/BCRP inhibitor elacridar fully inhibited P-gp-mediated transport of topotecan, whereas inhibition of Bcrp1-mediated transport by elacridar was minimal.	Topotecan	77-86	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	9-13
17975156-9	2007	CONCLUSIONS: Our results using Mdr1a/b(-/-)Bcrp1(-/-) mice clearly show the effect of Bcrp1 at the BBB and also show how two drug transporters act in concert to limit the brain penetration of topotecan.	Topotecan	192-201	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	86-91
17682070-0	2007	Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).	Glucuronides	171-182	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	65-70
17682070-0	2007	Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).	Sulfates	159-166	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	65-70
17682070-0	2007	Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).	Edaravone	198-207	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-64
17682070-0	2007	Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).	Glucuronides	171-182	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-64
17682070-0	2007	Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).	Edaravone	198-207	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	65-70
17644650-1	2007	The effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of the phytoestrogens daidzein, genistein, and coumestrol was investigated using Bcrp(-/-) mice.	daidzein	101-109	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	48-52
17682070-5	2007	Increased ATP-dependent uptake of edaravone sulfate but not edaravone glucuronide was observed in BCRP-expressing membrane vesicles compared with control vesicles (Km = 16.5 microM).	Adenosine Triphosphate	10-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	98-102
17682070-5	2007	Increased ATP-dependent uptake of edaravone sulfate but not edaravone glucuronide was observed in BCRP-expressing membrane vesicles compared with control vesicles (Km = 16.5 microM).	(5-methyl-2-phenylpyrazol-3-yl) hydrogen sulfate	34-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	98-102
17682070-8	2007	The functional importance of BCRP and MRP4 in the urinary excretion of edaravone sulfate and edaravone glucuronide, respectively, was investigated using Bcrp and Mrp4 knockout mice.	(5-methyl-2-phenylpyrazol-3-yl) hydrogen sulfate	71-88	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-33
17682070-8	2007	The functional importance of BCRP and MRP4 in the urinary excretion of edaravone sulfate and edaravone glucuronide, respectively, was investigated using Bcrp and Mrp4 knockout mice.	Norantipyrine glucuronide	93-114	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-33
17682070-11	2007	Our results suggest that Bcrp and Mrp4 are partly involved in the luminal efflux of edaravone sulfate and edaravone glucuronide, respectively.	(5-methyl-2-phenylpyrazol-3-yl) hydrogen sulfate	84-101	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	25-29
17682070-11	2007	Our results suggest that Bcrp and Mrp4 are partly involved in the luminal efflux of edaravone sulfate and edaravone glucuronide, respectively.	Norantipyrine glucuronide	106-127	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	25-29
17644650-1	2007	The effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of the phytoestrogens daidzein, genistein, and coumestrol was investigated using Bcrp(-/-) mice.	Genistein	111-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	48-52
17639028-0	2007	Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones.	Fluoroquinolones	94-110	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	49-54
17639028-3	2007	In the present study, we examined the involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion of fluoroquinolones (grepafloxacin, ulifloxacin, ciprofloxacin, and ofloxacin).	Fluoroquinolones	127-143	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-91
17639028-3	2007	In the present study, we examined the involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion of fluoroquinolones (grepafloxacin, ulifloxacin, ciprofloxacin, and ofloxacin).	Fluoroquinolones	127-143	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-97
17639028-3	2007	In the present study, we examined the involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion of fluoroquinolones (grepafloxacin, ulifloxacin, ciprofloxacin, and ofloxacin).	grepafloxacin	145-158	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-91
17639028-3	2007	In the present study, we examined the involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion of fluoroquinolones (grepafloxacin, ulifloxacin, ciprofloxacin, and ofloxacin).	grepafloxacin	145-158	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-97
17639028-3	2007	In the present study, we examined the involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion of fluoroquinolones (grepafloxacin, ulifloxacin, ciprofloxacin, and ofloxacin).	ulifloxacin	160-171	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-91
17639028-3	2007	In the present study, we examined the involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion of fluoroquinolones (grepafloxacin, ulifloxacin, ciprofloxacin, and ofloxacin).	ulifloxacin	160-171	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-97
17639028-3	2007	In the present study, we examined the involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion of fluoroquinolones (grepafloxacin, ulifloxacin, ciprofloxacin, and ofloxacin).	Ciprofloxacin	173-186	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-91
17639028-3	2007	In the present study, we examined the involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion of fluoroquinolones (grepafloxacin, ulifloxacin, ciprofloxacin, and ofloxacin).	Ofloxacin	177-186	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-91
17639028-3	2007	In the present study, we examined the involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion of fluoroquinolones (grepafloxacin, ulifloxacin, ciprofloxacin, and ofloxacin).	Ofloxacin	177-186	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-97
17639028-7	2007	The cumulative biliary excretion of fluoroquinolones was significantly reduced in Bcrp(-/-) mice, resulting in a reduction of the biliary excretion clearances to 86, 50, 40, and 16 of the control values, for ciprofloxacin, grepafloxacin, ofloxacin, and ulifloxacin, respectively.	Fluoroquinolones	36-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-86
17639028-7	2007	The cumulative biliary excretion of fluoroquinolones was significantly reduced in Bcrp(-/-) mice, resulting in a reduction of the biliary excretion clearances to 86, 50, 40, and 16 of the control values, for ciprofloxacin, grepafloxacin, ofloxacin, and ulifloxacin, respectively.	Ciprofloxacin	208-221	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-86
17639028-7	2007	The cumulative biliary excretion of fluoroquinolones was significantly reduced in Bcrp(-/-) mice, resulting in a reduction of the biliary excretion clearances to 86, 50, 40, and 16 of the control values, for ciprofloxacin, grepafloxacin, ofloxacin, and ulifloxacin, respectively.	grepafloxacin	223-236	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-86
17639028-7	2007	The cumulative biliary excretion of fluoroquinolones was significantly reduced in Bcrp(-/-) mice, resulting in a reduction of the biliary excretion clearances to 86, 50, 40, and 16 of the control values, for ciprofloxacin, grepafloxacin, ofloxacin, and ulifloxacin, respectively.	Ofloxacin	212-221	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-86
17639028-7	2007	The cumulative biliary excretion of fluoroquinolones was significantly reduced in Bcrp(-/-) mice, resulting in a reduction of the biliary excretion clearances to 86, 50, 40, and 16 of the control values, for ciprofloxacin, grepafloxacin, ofloxacin, and ulifloxacin, respectively.	ulifloxacin	253-264	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-86
17639028-8	2007	Preinfusion of sulfobromophthalein significantly inhibited the biliary excretion of grepafloxacin in Bcrp(-/-) mice.	Sulfobromophthalein	15-34	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-105
17639028-8	2007	Preinfusion of sulfobromophthalein significantly inhibited the biliary excretion of grepafloxacin in Bcrp(-/-) mice.	grepafloxacin	84-97	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-105
17639028-9	2007	There was no change in the tissue/plasma concentration ratios of fluoroquinolones in the liver or brain, whereas those in the kidney were increased 3.6- and 1.5-fold for ciprofloxacin and grepafloxacin, respectively, in Bcrp(-/-) mice but were unchanged for ofloxacin and ulifloxacin.	Ciprofloxacin	170-183	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	220-224
17639028-9	2007	There was no change in the tissue/plasma concentration ratios of fluoroquinolones in the liver or brain, whereas those in the kidney were increased 3.6- and 1.5-fold for ciprofloxacin and grepafloxacin, respectively, in Bcrp(-/-) mice but were unchanged for ofloxacin and ulifloxacin.	grepafloxacin	188-201	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	220-224
17639028-10	2007	The present study shows that BCRP mediates the biliary excretion of fluoroquinolones and suggests that it is also involved in the tubular secretion of ciprofloxacin and grepafloxacin.	Fluoroquinolones	68-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-33
17639028-10	2007	The present study shows that BCRP mediates the biliary excretion of fluoroquinolones and suggests that it is also involved in the tubular secretion of ciprofloxacin and grepafloxacin.	Ciprofloxacin	151-164	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-33
17639028-10	2007	The present study shows that BCRP mediates the biliary excretion of fluoroquinolones and suggests that it is also involved in the tubular secretion of ciprofloxacin and grepafloxacin.	grepafloxacin	169-182	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-33
17644650-1	2007	The effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of the phytoestrogens daidzein, genistein, and coumestrol was investigated using Bcrp(-/-) mice.	Coumestrol	126-136	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	48-52
17644650-1	2007	The effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of the phytoestrogens daidzein, genistein, and coumestrol was investigated using Bcrp(-/-) mice.	Coumestrol	126-136	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	53-58
17644650-3	2007	After oral administration, the plasma levels of daidzein and genistein were increased in Bcrp(-/-) mice, but only a minimal change was observed for coumestrol.	daidzein	48-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	89-93
17644650-3	2007	After oral administration, the plasma levels of daidzein and genistein were increased in Bcrp(-/-) mice, but only a minimal change was observed for coumestrol.	Genistein	61-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	89-93
17644650-1	2007	The effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of the phytoestrogens daidzein, genistein, and coumestrol was investigated using Bcrp(-/-) mice.	daidzein	101-109	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	53-58
17380257-2	2007	P-glycoprotein (P-gp, rodent Mdr1a/1b or Abcb1a/1b) and Breast cancer resistance protein (rodent Bcrp1 or Abcg2) were suggested to restrict the delivery of imatinib to the brain.	Imatinib Mesylate	156-164	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	97-102
17524480-4	2007	We hypothesised that there are changes in placental Bcrp1 (the mouse orthologue of human BCRP) expression during pregnancy and that these correlate with changes in progesterone production that occur in late gestation.	Progesterone	164-176	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-57
17576841-0	2007	Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.	Spiramycin	64-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	25-29
17576841-3	2007	Bcrp was proposed to be the primary pathway for spiramycin secretion into breast milk.	Spiramycin	48-58	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
17576841-8	2007	Interestingly, biliary recovery of spiramycin in Bcrp-knockout mice was increased in both the absence and presence of GW918 compared to wild-type mice.	Spiramycin	35-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	49-53
17696988-0	2007	Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.	Imatinib Mesylate	102-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	47-52
17696988-6	2007	Perfusing imatinib with the p-gp/Bcrp1 inhibitor, elacridar, enhanced the brain uptake of imatinib in wild-type (4.1-fold) and Mdr1a/1b(-/-) mice (1.2-fold).	Imatinib Mesylate	10-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	33-38
17696988-6	2007	Perfusing imatinib with the p-gp/Bcrp1 inhibitor, elacridar, enhanced the brain uptake of imatinib in wild-type (4.1-fold) and Mdr1a/1b(-/-) mice (1.2-fold).	Imatinib Mesylate	90-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	33-38
17696988-10	2007	CGP74588 uptake was 1.5 times greater in Bcrp1(-/-) mice than in wild-type mice.	CGP 74588	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-46
17696988-11	2007	These data suggest that imatinib transport at the mouse BBB is limited by p-gp and probably by Bcrp1, and that CGP74588 transport is restricted by Bcrp1.	Imatinib Mesylate	24-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	95-100
17584961-1	2007	Side population (SP) cells are characterized by their ability to efflux the vital dye Hoechst 33342 (Sigma-Aldrich, St. Louis, MO) due to expression of the ATP binding cassette (ABC)-dependent transporter ABCG2, and are highly enriched for stem/progenitor cell activity.	bisbenzimide ethoxide trihydrochloride	86-99	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	205-210
17380257-2	2007	P-glycoprotein (P-gp, rodent Mdr1a/1b or Abcb1a/1b) and Breast cancer resistance protein (rodent Bcrp1 or Abcg2) were suggested to restrict the delivery of imatinib to the brain.	Imatinib Mesylate	156-164	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	106-111
17380257-7	2007	Blockade of both P-gp and Bcrp1 by elacridar (&gt;3 mg/kg) produced significantly greater brain penetration of imatinib (9.3-fold) and its metabolites (2.8-fold).	Imatinib Mesylate	111-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-31
17380257-10	2007	CONCLUSIONS: Imatinib and its metabolites penetrate into the brain poorly and their penetration is limited by P-gp and (probably) Bcrp1.	Imatinib Mesylate	13-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	130-135
17380257-11	2007	Administering imatinib together with P-gp (and Bcrp1) transporter inhibitors such as elacridar may improve the delivery of imatinib to the brain, making it potentially more effective against malignant gliomas.	Imatinib Mesylate	123-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	47-52
17638908-0	2007	Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution.	purine	54-60	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-40
17638908-2	2007	An unexpectedly low concentration of the purine nucleotide analogue, 9-(2-(phosphonomethoxy)ethyl)-adenine (PMEA), and up-regulation of Abcg2 in some tissues of the Mrp4 KO mouse prompted us to evaluate the possibility that Abcg2 might transport purine-derived drugs.	adefovir	108-112	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	224-229
17638908-0	2007	Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution.	purine	54-60	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-45
17638908-2	2007	An unexpectedly low concentration of the purine nucleotide analogue, 9-(2-(phosphonomethoxy)ethyl)-adenine (PMEA), and up-regulation of Abcg2 in some tissues of the Mrp4 KO mouse prompted us to evaluate the possibility that Abcg2 might transport purine-derived drugs.	purine	41-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	224-229
17638908-2	2007	An unexpectedly low concentration of the purine nucleotide analogue, 9-(2-(phosphonomethoxy)ethyl)-adenine (PMEA), and up-regulation of Abcg2 in some tissues of the Mrp4 KO mouse prompted us to evaluate the possibility that Abcg2 might transport purine-derived drugs.	adefovir	69-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	224-229
17638908-4	2007	Moreover, a specific Abcg2 inhibitor, fumitremorgin C, both increased PMEA accumulation and reversed Abcg2-mediated PMEA resistance.	adefovir	70-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-26
17446265-9	2007	Taken together, these results suggest that Pluronic P85 and Tween 20 can improve the oral bioavailability of BCRP substrates by inhibiting BCRP function in the small intestine.	Poloxamer	43-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-113
17638908-4	2007	Moreover, a specific Abcg2 inhibitor, fumitremorgin C, both increased PMEA accumulation and reversed Abcg2-mediated PMEA resistance.	adefovir	116-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-26
17638908-4	2007	Moreover, a specific Abcg2 inhibitor, fumitremorgin C, both increased PMEA accumulation and reversed Abcg2-mediated PMEA resistance.	adefovir	116-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	101-106
17638908-6	2007	Abcg2 contributed to PMEA accumulation in a variety of tissues, but in some tissues, this contribution was only revealed by the concurrent absence of Mrp4.	adefovir	21-25	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
17638908-7	2007	Abcg2 also transported and conferred resistance to additional purine analogues, such as the antineoplastic, 2-chloro-2"-deoxyadenosine (cladribine) and puromycin, a protein synthesis inhibitor that is often used as a dominant selectable marker.	purine	62-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
17638908-7	2007	Abcg2 also transported and conferred resistance to additional purine analogues, such as the antineoplastic, 2-chloro-2"-deoxyadenosine (cladribine) and puromycin, a protein synthesis inhibitor that is often used as a dominant selectable marker.	Cladribine	108-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
17638908-7	2007	Abcg2 also transported and conferred resistance to additional purine analogues, such as the antineoplastic, 2-chloro-2"-deoxyadenosine (cladribine) and puromycin, a protein synthesis inhibitor that is often used as a dominant selectable marker.	Cladribine	136-146	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
17638908-7	2007	Abcg2 also transported and conferred resistance to additional purine analogues, such as the antineoplastic, 2-chloro-2"-deoxyadenosine (cladribine) and puromycin, a protein synthesis inhibitor that is often used as a dominant selectable marker.	Puromycin	152-161	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
17638908-8	2007	Purine analogues interact with ABCG2 by a site distinct from the prazosin binding site as shown by their inability to displace the substrate analogue and photoaffinity tag [(125)I]iodoarylazidoprazosin.	purine	0-6	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-36
17638908-9	2007	These studies show that Abcg2, like Mrp4, transports and confers resistance to purine nucleoside analogues and suggest that these two transporters work in parallel to affect drug cytotoxicity and tissue distribution.	Purine Nucleosides	79-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-29
17638908-10	2007	This new knowledge will facilitate an understanding of how Abcg2 and Mrp4, separately and in combination, protect against purine analogue host toxicity as well as resistance to chemotherapy.	purine	122-128	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	59-64
17446265-9	2007	Taken together, these results suggest that Pluronic P85 and Tween 20 can improve the oral bioavailability of BCRP substrates by inhibiting BCRP function in the small intestine.	Poloxamer	43-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	139-143
17446265-9	2007	Taken together, these results suggest that Pluronic P85 and Tween 20 can improve the oral bioavailability of BCRP substrates by inhibiting BCRP function in the small intestine.	Polysorbates	60-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-113
17446265-9	2007	Taken together, these results suggest that Pluronic P85 and Tween 20 can improve the oral bioavailability of BCRP substrates by inhibiting BCRP function in the small intestine.	Polysorbates	60-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	139-143
17314268-0	2007	Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX.	protoporphyrin IX	120-137	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
17314268-0	2007	Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX.	protoporphyrin IX	120-137	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	40-45
17314268-7	2007	Bcrp1(-/-) harderian gland displayed a highly increased accumulation of PPIX glycoconjugates, and a similar shift was seen in Bcrp1(-/-) liver.	protoporphyrin IX	72-76	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
17314268-8	2007	Tear- and hepatobiliary excretion data suggest that Bcrp1 controls intracellular levels of PPIX by mediating high affinity transport of its glycoconjugates and possibly low-affinity transport of unconjugated PPIX.	protoporphyrin IX	91-95	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-57
17314268-8	2007	Tear- and hepatobiliary excretion data suggest that Bcrp1 controls intracellular levels of PPIX by mediating high affinity transport of its glycoconjugates and possibly low-affinity transport of unconjugated PPIX.	protoporphyrin IX	208-212	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-57
17229149-6	2007	Similarly, cGMP transport into vesicles from Abcc4-/- and Abcg2-/- mice was 42% and 51% of that into wild-type mouse vesicles, respectively, whereas cGMP transport into vesicles from Abcc4(-/-)/Abcg2(-/-) mice was near background.	Cyclic GMP	11-15	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	58-63
17353350-1	2007	Breast cancer resistance protein (Bcrp/Abcg2) is a member of the ATP-binding cassette transporter family with the ability to transport a variety of sulfate conjugates.	Sulfates	148-155	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
17353350-1	2007	Breast cancer resistance protein (Bcrp/Abcg2) is a member of the ATP-binding cassette transporter family with the ability to transport a variety of sulfate conjugates.	Sulfates	148-155	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
17353350-4	2007	Functional analysis of Bcrp was performed in everted intestinal sacs using 4-methylumbelliferone (4MU).	Hymecromone	75-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	23-27
17353350-4	2007	Functional analysis of Bcrp was performed in everted intestinal sacs using 4-methylumbelliferone (4MU).	Hymecromone	98-101	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	23-27
17353350-5	2007	The mucosal secretion clearance of 4MU sulfate formed in the enterocytes was markedly reduced in the jejunum, ileum, and colon of Bcrp (-/-) mice in comparison with wild-type mice, whereas a slight and nonsignificant reduction was observed in the duodenum.	4-methylumbelliferyl sulfate	35-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	130-134
17353350-7	2007	In addition, the mucosal secretion clearance of minoxidil sulfate, an active metabolite of minoxidil, was also significantly reduced in the intestine of Bcrp (-/-) mice.	minoxidil sulfate ester	48-65	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	153-157
17353350-7	2007	In addition, the mucosal secretion clearance of minoxidil sulfate, an active metabolite of minoxidil, was also significantly reduced in the intestine of Bcrp (-/-) mice.	Minoxidil	48-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	153-157
17093005-0	2007	Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect.	troglitazone sulfate	111-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	49-53
17093005-0	2007	Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect.	troglitazone sulfate	111-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
17093005-0	2007	Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect.	Troglitazone	111-123	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	49-53
17093005-0	2007	Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect.	Troglitazone	111-123	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	54-59
17093005-3	2007	The basal-to-apical transport of TGZS was enhanced in organic anion transporting polypeptide 1B1-expressing Madin-Darby canine kidney II cells by infection of recombinant adenovirus harboring human BCRP and mouse Bcrp cDNA.	troglitazone sulfate	33-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	213-217
17093005-4	2007	TGZS was given to wild-type and Bcrp (-/-) mice by constant infusion.	troglitazone sulfate	0-4	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-36
17093006-5	2007	In Madin-Darby canine kidney cells expressing human BCRP or murine Bcrp1, the polarized transport of nitrofurantoin was effectively inhibited by chrysin at concentrations of 20 and 100 microM.	Nitrofurantoin	101-115	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-72
17093006-12	2007	Taken together, these results indicate that the flavonoid chrysin significantly inhibits nitrofurantoin transport mediated by human BCRP and murine Bcrp1.	Flavonoids	48-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	148-153
17038670-4	2007	The ATP-binding cassette transporter Abcg2/Bcrp1 contributes to the specification of the SP phenotype and is proposed as a universal marker for stem/progenitor cells.	sp	89-91	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-42
17038670-4	2007	The ATP-binding cassette transporter Abcg2/Bcrp1 contributes to the specification of the SP phenotype and is proposed as a universal marker for stem/progenitor cells.	sp	89-91	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	43-48
17538966-5	2007	In mouse liver, the CDE, DDC, and APAP protocols all induced CKs and ABCG2-positive oval cells.	Zalcitabine	25-28	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	69-74
17093006-12	2007	Taken together, these results indicate that the flavonoid chrysin significantly inhibits nitrofurantoin transport mediated by human BCRP and murine Bcrp1.	Nitrofurantoin	89-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	148-153
17145775-0	2007	Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.	Riboflavin	82-92	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-27
17145775-2	2007	We here demonstrate that BCRP is responsible for pumping riboflavin (vitamin B(2)) into milk, thus supplying the young with this important nutrient.	Riboflavin	57-67	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	25-29
17145775-2	2007	We here demonstrate that BCRP is responsible for pumping riboflavin (vitamin B(2)) into milk, thus supplying the young with this important nutrient.	Riboflavin	69-78	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	25-29
17145775-3	2007	In Bcrp1(-/-) mice, milk secretion of riboflavin was reduced &gt;60-fold compared to that in wild-type mice.	Riboflavin	38-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	3-8
17145775-4	2007	Yet, under laboratory conditions, Bcrp1(-/-) pups showed no riboflavin deficiency due to concomitant milk secretion of its cofactor flavin adenine dinucleotide, which was not affected.	Flavin-Adenine Dinucleotide	132-159	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
17145775-8	2007	Indeed, Bcrp1 activity increased excretion of riboflavin into the intestine and decreased its systemic availability in adult mice.	Riboflavin	46-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	8-13
17229149-7	2007	The knockout mice were used to show that Abcg2-mediated cGMP transport occurred with lower affinity but higher Vmax than Abcc4-mediated transport.	Cyclic GMP	56-60	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-46
17229149-8	2007	Involvement of Abcg2 in cGMP transport by Abcc4-/- erythrocyte vesicles was supported by higher transport at pH 5.5 than at pH 7.4, a characteristic of Abcg2-mediated transport.	Cyclic GMP	24-28	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	15-20
17229149-8	2007	Involvement of Abcg2 in cGMP transport by Abcc4-/- erythrocyte vesicles was supported by higher transport at pH 5.5 than at pH 7.4, a characteristic of Abcg2-mediated transport.	Cyclic GMP	24-28	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	152-157
17229149-9	2007	The relative contribution of ABCC4/Abcc4 and ABCG2/Abcg2 in cGMP transport was confirmed with a new inhibitor of ABCC4 transport, the protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride.	Cyclic GMP	60-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	45-50
17229149-9	2007	The relative contribution of ABCC4/Abcc4 and ABCG2/Abcg2 in cGMP transport was confirmed with a new inhibitor of ABCC4 transport, the protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride.	Cyclic GMP	60-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-56
17229149-9	2007	The relative contribution of ABCC4/Abcc4 and ABCG2/Abcg2 in cGMP transport was confirmed with a new inhibitor of ABCC4 transport, the protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride.	4-(2-aminoethyl)benzenesulfonylfluoride	153-193	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	45-50
17229149-9	2007	The relative contribution of ABCC4/Abcc4 and ABCG2/Abcg2 in cGMP transport was confirmed with a new inhibitor of ABCC4 transport, the protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride.	4-(2-aminoethyl)benzenesulfonylfluoride	153-193	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-56
16857726-4	2006	After a 30-micromol dose of 4-methylumbelliferone, cumulative biliary excretion of 4MUG was extensive in wild-type rat IPLs (25 +/- 3 micromol) but was negligible in TR(-) livers (0.4 +/- 0.1 micromol); coadministration of the Bcrp and P-glycoprotein inhibitor GF120918 [N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide] had no effect on 4MUG biliary excretion in wild-type rat IPLs.	Hymecromone	28-49	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	227-231
17135398-2	2007	Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP).	Adenosine Triphosphate	12-15	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	179-211
17135398-2	2007	Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP).	Adenosine Triphosphate	12-15	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	213-217
17135398-2	2007	Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP).	Hydrochlorothiazide	36-55	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	179-211
17135398-2	2007	Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP).	Hydrochlorothiazide	36-55	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	213-217
17135398-2	2007	Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP).	Hydrochlorothiazide	57-60	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	179-211
17135398-2	2007	Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP).	Hydrochlorothiazide	57-60	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	213-217
17135398-2	2007	Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP).	Furosemide	66-76	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	179-211
17135398-2	2007	Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP).	Furosemide	66-76	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	213-217
17135398-4	2007	The functional importance of MRP4 and BCRP in the urinary excretion of HCT and furosemide was investigated using gene knockout mice.	Furosemide	79-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-42
17145877-10	2006	These results are consistent with the possibility that expression of Bcrp1 and P-glycoprotein at the apical side of the choroid plexus facilitates an influx transport mechanism across the blood-cerebrospinal fluid barrier, resulting in high topotecan CSF penetration.	Topotecan	241-250	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	69-74
16959944-0	2006	The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice.	Sulfates	63-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-26
16959944-0	2006	The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice.	Sulfates	63-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	28-33
16959944-0	2006	The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice.	Glucuronides	75-86	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-26
16959944-0	2006	The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice.	Glucuronides	75-86	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	28-33
16959944-0	2006	The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice.	Acetaminophen	102-115	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-26
16959944-0	2006	The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice.	Acetaminophen	102-115	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	28-33
16959944-0	2006	The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice.	Hymecromone	117-138	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-26
16959944-0	2006	The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice.	Hymecromone	117-138	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	28-33
16959944-2	2006	Biliary clearance of the sulfate conjugates was significantly decreased in Bcrp-deficient mouse livers, resulting in negligible biliary excretion of AS, 4MUS, and HS.	Sulfates	25-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-79
16959944-3	2006	It is noteworthy that the most profound decrease in the biliary clearance of the glucuronide conjugates was observed in Bcrp-deficient mouse livers, although the biliary clearance of 4MUG was also approximately 35% lower in Mrp2-deficient mouse livers.	Glucuronides	81-92	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	120-124
16959944-7	2006	Unlike in rats, where sulfate and glucuronide conjugates were excreted into bile predominantly by Mrp2, mouse Bcrp mediated the biliary excretion of sulfate metabolites and also played a major role in the biliary excretion of the glucuronide metabolites, with some minor contribution from mouse Mrp2.	Glucuronides	34-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-114
16959944-7	2006	Unlike in rats, where sulfate and glucuronide conjugates were excreted into bile predominantly by Mrp2, mouse Bcrp mediated the biliary excretion of sulfate metabolites and also played a major role in the biliary excretion of the glucuronide metabolites, with some minor contribution from mouse Mrp2.	Sulfates	149-156	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-114
16959944-7	2006	Unlike in rats, where sulfate and glucuronide conjugates were excreted into bile predominantly by Mrp2, mouse Bcrp mediated the biliary excretion of sulfate metabolites and also played a major role in the biliary excretion of the glucuronide metabolites, with some minor contribution from mouse Mrp2.	Glucuronides	230-241	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	110-114
16857726-4	2006	After a 30-micromol dose of 4-methylumbelliferone, cumulative biliary excretion of 4MUG was extensive in wild-type rat IPLs (25 +/- 3 micromol) but was negligible in TR(-) livers (0.4 +/- 0.1 micromol); coadministration of the Bcrp and P-glycoprotein inhibitor GF120918 [N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide] had no effect on 4MUG biliary excretion in wild-type rat IPLs.	4-methylumbelliferyl glucuronide	83-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	227-231
16651435-5	2006	In our studies, pretreatment of Abcg2(-/-) and Mdr1(a/b)(-/-) mice with gefitinib increased oral absorption and decreased systemic clearance of topotecan, a model substrate, indicating that additional transporters were inhibited.	Gefitinib	72-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-37
16715370-5	2006	RESULTS: Western blotting indicated that ABCG2 was expressed as a glycosylated disulfide-linked complex in the mouse retina and in peripheral tissues, including liver, kidney, and small intestine.	Disulfides	79-88	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-46
16484343-5	2006	The Abcg2/GFP allele was also expressed in approximately 10% of lineage-negative (Lin(-)) and in 91% of SP cells using stringent conditions for the SP assay.	sp	104-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	4-9
16484343-5	2006	The Abcg2/GFP allele was also expressed in approximately 10% of lineage-negative (Lin(-)) and in 91% of SP cells using stringent conditions for the SP assay.	sp	148-150	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	4-9
16651435-5	2006	In our studies, pretreatment of Abcg2(-/-) and Mdr1(a/b)(-/-) mice with gefitinib increased oral absorption and decreased systemic clearance of topotecan, a model substrate, indicating that additional transporters were inhibited.	Topotecan	144-153	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-37
16686369-12	2006	We conclude that Bcrp (abcg2) is an important determinant for the oral bioavailability and the elimination of sulfasalazine in the mouse, and that sulfasalazine has the potential to be utilized as a specific in vivo probe of Bcrp (abcg2).	Sulfasalazine	110-123	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	17-21
16434544-0	2006	Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion.	Fluoroquinolones	57-72	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
16434544-0	2006	Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion.	Fluoroquinolones	57-72	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
16434544-2	2006	The purpose of this study was to determine whether three widely used fluoroquinolone antibiotics (ciprofloxacin, ofloxacin, and norfloxacin) are substrates of Bcrp1/BCRP and to investigate the possible role of this transporter in the in vivo pharmacokinetic profile of these compounds and their secretion into the milk.	Fluoroquinolones	69-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	159-164
16434544-2	2006	The purpose of this study was to determine whether three widely used fluoroquinolone antibiotics (ciprofloxacin, ofloxacin, and norfloxacin) are substrates of Bcrp1/BCRP and to investigate the possible role of this transporter in the in vivo pharmacokinetic profile of these compounds and their secretion into the milk.	Fluoroquinolones	69-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	165-169
16434544-2	2006	The purpose of this study was to determine whether three widely used fluoroquinolone antibiotics (ciprofloxacin, ofloxacin, and norfloxacin) are substrates of Bcrp1/BCRP and to investigate the possible role of this transporter in the in vivo pharmacokinetic profile of these compounds and their secretion into the milk.	Ciprofloxacin	98-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	159-164
16434544-2	2006	The purpose of this study was to determine whether three widely used fluoroquinolone antibiotics (ciprofloxacin, ofloxacin, and norfloxacin) are substrates of Bcrp1/BCRP and to investigate the possible role of this transporter in the in vivo pharmacokinetic profile of these compounds and their secretion into the milk.	Ciprofloxacin	98-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	165-169
16434544-2	2006	The purpose of this study was to determine whether three widely used fluoroquinolone antibiotics (ciprofloxacin, ofloxacin, and norfloxacin) are substrates of Bcrp1/BCRP and to investigate the possible role of this transporter in the in vivo pharmacokinetic profile of these compounds and their secretion into the milk.	Ofloxacin	102-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	159-164
16434544-2	2006	The purpose of this study was to determine whether three widely used fluoroquinolone antibiotics (ciprofloxacin, ofloxacin, and norfloxacin) are substrates of Bcrp1/BCRP and to investigate the possible role of this transporter in the in vivo pharmacokinetic profile of these compounds and their secretion into the milk.	Ofloxacin	102-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	165-169
16434544-2	2006	The purpose of this study was to determine whether three widely used fluoroquinolone antibiotics (ciprofloxacin, ofloxacin, and norfloxacin) are substrates of Bcrp1/BCRP and to investigate the possible role of this transporter in the in vivo pharmacokinetic profile of these compounds and their secretion into the milk.	Norfloxacin	128-139	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	159-164
16434544-2	2006	The purpose of this study was to determine whether three widely used fluoroquinolone antibiotics (ciprofloxacin, ofloxacin, and norfloxacin) are substrates of Bcrp1/BCRP and to investigate the possible role of this transporter in the in vivo pharmacokinetic profile of these compounds and their secretion into the milk.	Norfloxacin	128-139	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	165-169
16000399-7	2006	Moreover, Bcrp1 mediates transfer of [14C]IQ, [14C]Trp-P-1 and [3H]aflatoxin into milk, with 3.4+/-0.6, 2.6+/-0.3 and 3.8+/-0.5-fold higher milk to plasma ratios, respectively, in lactating wild-type versus Bcrp1-/- mice.	Carbon-14	38-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
16686369-8	2006	After intravenous administration of 5 mg/kg sulfasalazine, the AUC in Bcrp1 (abcg2)-/- KO mice was approximately 13-fold higher than that in WT mice.	Sulfasalazine	44-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	70-75
16434544-3	2006	Using polarized cell lines, we found that ciprofloxacin, ofloxacin, and norfloxacin are transported by mouse Bcrp1 and human BCRP.	Ciprofloxacin	42-55	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-114
16434544-3	2006	Using polarized cell lines, we found that ciprofloxacin, ofloxacin, and norfloxacin are transported by mouse Bcrp1 and human BCRP.	Ofloxacin	46-55	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-114
16434544-3	2006	Using polarized cell lines, we found that ciprofloxacin, ofloxacin, and norfloxacin are transported by mouse Bcrp1 and human BCRP.	Norfloxacin	72-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-114
16434544-4	2006	In vivo pharmacokinetic studies showed that the ciprofloxacin plasma concentration was more than 2-fold increased in Bcrp1(-/-) compared with wild-type mice (1.77 +/- 0.73 versus 0.85 +/- 0.39 microg/ml, p &lt; 0.01) after oral administration of ciprofloxacin (10 mg/kg).	Ciprofloxacin	48-61	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	117-122
16434544-4	2006	In vivo pharmacokinetic studies showed that the ciprofloxacin plasma concentration was more than 2-fold increased in Bcrp1(-/-) compared with wild-type mice (1.77 +/- 0.73 versus 0.85 +/- 0.39 microg/ml, p &lt; 0.01) after oral administration of ciprofloxacin (10 mg/kg).	Ciprofloxacin	246-259	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	117-122
16434544-7	2006	The milk concentration and milk/plasma ratio of ciprofloxacin were 2-fold higher in wild-type than in Bcrp1(-/-) lactating mice.	Ciprofloxacin	48-61	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	102-107
16434544-8	2006	We conclude that Bcrp1 is one of the determinants for the bioavailability of fluoroquinolones and their secretion into the milk.	Fluoroquinolones	77-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	17-22
16434545-0	2006	Altered hepatobiliary disposition of 5 (and 6)-carboxy-2",7"-dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice.	5 (and 6)-carboxy-2",7"-dichlorofluorescein	37-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-89
16434545-2	2006	After single-pass liver perfusion with 1 muM CDF diacetate for 30 min and an additional 30-min perfusion with CDF-free buffer, cumulative biliary excretion of CDF in Abcg2-/- mice was significantly higher than in wild-type mice (65 +/- 6 and 47 +/- 15% of dose, respectively, p &lt; 0.05), whereas CDF recovery in bile of Abcc2-/- mice was negligible.	cdf diacetate	45-58	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	166-171
16434545-5	2006	The rate constant governing the basolateral excretion of CDF was approximately 4-fold higher in Abcc2-/- (0.12 +/- 0.02 min(-1)) relative to wild-type (0.030 +/- 0.011 min(-1)) mice but was not altered in Abcg2-/- (0.031 +/- 0.004 min(-1)) mice.	4-AMINO-1-{5-O-[(R)-HYDROXY(PHOSPHONOOXY)PHOSPHORYL]-ALPHA-D-ARABINOFURANOSYL}PYRIMIDIN-2(1H)-ONE	57-60	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	205-210
16000399-7	2006	Moreover, Bcrp1 mediates transfer of [14C]IQ, [14C]Trp-P-1 and [3H]aflatoxin into milk, with 3.4+/-0.6, 2.6+/-0.3 and 3.8+/-0.5-fold higher milk to plasma ratios, respectively, in lactating wild-type versus Bcrp1-/- mice.	Carbon-14	47-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
16000399-7	2006	Moreover, Bcrp1 mediates transfer of [14C]IQ, [14C]Trp-P-1 and [3H]aflatoxin into milk, with 3.4+/-0.6, 2.6+/-0.3 and 3.8+/-0.5-fold higher milk to plasma ratios, respectively, in lactating wild-type versus Bcrp1-/- mice.	Tritium	64-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
16000399-7	2006	Moreover, Bcrp1 mediates transfer of [14C]IQ, [14C]Trp-P-1 and [3H]aflatoxin into milk, with 3.4+/-0.6, 2.6+/-0.3 and 3.8+/-0.5-fold higher milk to plasma ratios, respectively, in lactating wild-type versus Bcrp1-/- mice.	Aflatoxins	67-76	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
16686369-0	2006	Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.	Sulfasalazine	72-85	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
16686369-0	2006	Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.	Sulfasalazine	72-85	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
16686369-3	2006	Recent studies using the T-cell line (CEM) have shown that sulfasalazine is a substrate for the ATP-binding cassette (ABC) efflux pump ABCG2.	Sulfasalazine	59-72	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	135-140
16686369-6	2006	Accordingly, we investigated whether Bcrp (abcg2) is involved in the disposition of sulfasalazine.	Sulfasalazine	84-97	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-41
16686369-6	2006	Accordingly, we investigated whether Bcrp (abcg2) is involved in the disposition of sulfasalazine.	Sulfasalazine	84-97	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	43-48
16686369-7	2006	After oral administration of 20 mg/kg sulfasalazine, the area under the plasma concentration (AUC) time profile in Bcrp1 (abcg2)-/- knockout (KO) mice was approximately 111-fold higher than that in FVB wild-type (WT) mice.	Sulfasalazine	38-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	115-120
16686369-12	2006	We conclude that Bcrp (abcg2) is an important determinant for the oral bioavailability and the elimination of sulfasalazine in the mouse, and that sulfasalazine has the potential to be utilized as a specific in vivo probe of Bcrp (abcg2).	Sulfasalazine	110-123	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	23-28
16686369-12	2006	We conclude that Bcrp (abcg2) is an important determinant for the oral bioavailability and the elimination of sulfasalazine in the mouse, and that sulfasalazine has the potential to be utilized as a specific in vivo probe of Bcrp (abcg2).	Sulfasalazine	147-160	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	225-229
16686369-12	2006	We conclude that Bcrp (abcg2) is an important determinant for the oral bioavailability and the elimination of sulfasalazine in the mouse, and that sulfasalazine has the potential to be utilized as a specific in vivo probe of Bcrp (abcg2).	Sulfasalazine	147-160	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	231-236
16158227-8	2005	These observations are strengthened by the fact that porphyrins accumulate in tissues of the Bcrp knockout mouse.	Porphyrins	53-63	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	93-97
16686369-7	2006	After oral administration of 20 mg/kg sulfasalazine, the area under the plasma concentration (AUC) time profile in Bcrp1 (abcg2)-/- knockout (KO) mice was approximately 111-fold higher than that in FVB wild-type (WT) mice.	Sulfasalazine	38-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	122-127
16686369-8	2006	After intravenous administration of 5 mg/kg sulfasalazine, the AUC in Bcrp1 (abcg2)-/- KO mice was approximately 13-fold higher than that in WT mice.	Sulfasalazine	44-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	77-82
16686369-9	2006	Moreover, treatment of WT mice with a single oral dose of gefitinib (Iressa; 50 mg/kg), a known inhibitor of Bcrp, given 2 h prior to administering a single oral dose of sulfasalazine (20 mg/kg), resulted in a 13-fold increase in the AUC of sulfasalazine compared to the AUC in vehicle-treated mice.	Gefitinib	58-67	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-113
16367905-0	2005	Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2.	Cysteine	8-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-88
16367905-0	2005	Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2.	Cysteine	8-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	89-94
16367905-1	2005	Breast cancer resistance protein (BCRP/ABCG2) is a half-molecule ATP-binding cassette transporter that we have previously suggested might function as a homodimer, bridged by disulfide bonds.	Disulfides	174-183	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
16367905-1	2005	Breast cancer resistance protein (BCRP/ABCG2) is a half-molecule ATP-binding cassette transporter that we have previously suggested might function as a homodimer, bridged by disulfide bonds.	Disulfides	174-183	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
16367905-5	2005	PA317 cells transfected with C603S-BCRP (PA/C603S) showed either similar or only marginally lower SN-38 resistance than PA/WT cells, despite the reduced levels of BCRP dimer in these cells.	Irinotecan	98-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
16367905-5	2005	PA317 cells transfected with C603S-BCRP (PA/C603S) showed either similar or only marginally lower SN-38 resistance than PA/WT cells, despite the reduced levels of BCRP dimer in these cells.	Irinotecan	98-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-39
16367905-6	2005	Moreover, the degree of SN-38 resistance in the mutant BCRP transfectants was found to be associated with the monomer expression levels under reducing conditions.	Irinotecan	24-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	55-59
16367905-10	2005	Our findings suggest that Cys-603 is an important residue in the covalent bridge between BCRP monomers but that a functioning unit of BCRP may not necessarily require covalent linkages.	Cysteine	26-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	89-93
16179903-4	2005	Hoechst dye exclusion, mediated by the stem cell surface marker ABCG2 (ATP-binding cassette transporter, G2 subfamily), was assessed by flow cytometry in mouse tumors and WERI-Rb27 cells.	hoechst dye	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	64-69
16322314-11	2005	to mice in the presence and absence of the CYP3A and ABCG2 inhibitor, ritonavir, there was an increase in BPU plasma exposure and decrease in metabolite exposure but no overall change in cumulative exposure to BPU and the cytotoxic metabolites.	Ritonavir	70-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	53-58
16179903-10	2005	Especially significant is the expression of ABCG2 in mouse and human tumor cells, a calcium-sensitive cell surface protein that not only acts to exclude Hoechst dye, but also confers resistance to over 20 different chemotherapeutic agents.	Calcium	84-91	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-49
16179903-10	2005	Especially significant is the expression of ABCG2 in mouse and human tumor cells, a calcium-sensitive cell surface protein that not only acts to exclude Hoechst dye, but also confers resistance to over 20 different chemotherapeutic agents.	hoechst dye	153-164	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-49
15955871-4	2005	The ATP-dependent uptake of pitavastatin by human and mouse BCRP-expressing membrane vesicles was significantly higher compared with that by control vesicles with Km values of 5.73 and 4.77 microM, respectively.	Adenosine Triphosphate	4-7	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-64
15955871-4	2005	The ATP-dependent uptake of pitavastatin by human and mouse BCRP-expressing membrane vesicles was significantly higher compared with that by control vesicles with Km values of 5.73 and 4.77 microM, respectively.	pitavastatin	28-40	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	60-64
15955871-5	2005	The biliary excretion clearance of pitavastatin in Bcrp1-/- mice was decreased to one-tenth of that in control mice.	pitavastatin	35-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-56
15955871-8	2005	These data suggest that the biliary clearance of pitavastatin can be largely accounted for by BCRP in mice.	pitavastatin	49-61	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	94-98
16002779-4	2005	Whereas in bone marrow Bcrp1 was almost exclusively responsible for the SP, both transporters contributed to the SP phenotype in the mammary gland, where their combined absence resulted in a nearly complete loss of SP.	sp	72-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	23-28
16002779-5	2005	Interestingly, bone marrow of Mdr1a/1b-/- mice frequently displayed an elevated SP, which was reversible by the Bcrp1 inhibitor Ko143, suggesting that Bcrp1 can compensate for the loss of Mdr1a/1b in bone marrow.	sp	80-82	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	112-117
16002779-5	2005	Interestingly, bone marrow of Mdr1a/1b-/- mice frequently displayed an elevated SP, which was reversible by the Bcrp1 inhibitor Ko143, suggesting that Bcrp1 can compensate for the loss of Mdr1a/1b in bone marrow.	sp	80-82	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	151-156
16002779-5	2005	Interestingly, bone marrow of Mdr1a/1b-/- mice frequently displayed an elevated SP, which was reversible by the Bcrp1 inhibitor Ko143, suggesting that Bcrp1 can compensate for the loss of Mdr1a/1b in bone marrow.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	128-133	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	112-117
16002779-5	2005	Interestingly, bone marrow of Mdr1a/1b-/- mice frequently displayed an elevated SP, which was reversible by the Bcrp1 inhibitor Ko143, suggesting that Bcrp1 can compensate for the loss of Mdr1a/1b in bone marrow.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	128-133	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	151-156
15709111-0	2005	The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin.	Nitrofurantoin	138-152	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-42
15749994-6	2005	In these MDCKII cells, we showed an efficient efflux-directed transport of quercetin by mouse Bcrp1, whereas in control and MRP2-transfected cells no vectorial transport of quercetin was observed.	Quercetin	75-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	94-99
15703302-7	2005	The latter results were confirmed by flow cytometry experiments demonstrating inhibition by OXF of murine Bcrp1- and human BCRP-mediated mitoxantrone transport.	Mitoxantrone	137-149	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	106-111
15709111-0	2005	The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin.	Nitrofurantoin	138-152	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	43-48
15709111-5	2005	We investigated whether Bcrp1 is involved in the pharmacokinetic profile of nitrofurantoin and its active secretion into the milk.	Nitrofurantoin	76-90	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-29
15709111-6	2005	Using polarized cell lines, we found that nitrofurantoin is efficiently transported by murine Bcrp1 and human BCRP.	Nitrofurantoin	42-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	94-99
15709111-7	2005	After oral administration of 10 mg/kg nitrofurantoin, the area under the plasma concentrationtime curve in Bcrp1 knockout mice was almost 4-fold higher than in wild-type mice (148.8 +/- 30.4 versus 37.5 +/- 6.8 min x microg/ml); and after i.v.	Nitrofurantoin	38-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	107-112
15709111-9	2005	Hepatobiliary excretion of nitrofurantoin was almost abolished in Bcrp1 knockout mice (9.6 +/- 3.2 versus 0.2 +/- 0.1% in wild-type and Bcrp1 knockout mice, respectively).	Nitrofurantoin	27-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	66-71
15709111-9	2005	Hepatobiliary excretion of nitrofurantoin was almost abolished in Bcrp1 knockout mice (9.6 +/- 3.2 versus 0.2 +/- 0.1% in wild-type and Bcrp1 knockout mice, respectively).	Nitrofurantoin	27-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	136-141
15709111-12	2005	We conclude that Bcrp1 is an important determinant for the bioavailability of nitrofurantoin and the main mechanism involved in its hepatobiliary excretion and secretion into the milk.	Nitrofurantoin	78-92	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	17-22
15846469-0	2005	Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2).	ME 3277	42-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	152-156
15805252-5	2005	Here, we show that imatinib is efficiently transported by mouse Bcrp1 in transfected Madin-Darby canine kidney strain II (MDCKII) monolayers.	Imatinib Mesylate	19-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	64-69
15805252-7	2005	imatinib is significantly decreased 1.6-fold in Bcrp1 knockout mice compared with wild-type mice.	Imatinib Mesylate	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	48-53
15805252-9	2005	imatinib was significantly 2.5-fold increased in Bcrp1 knockout mice compared with control mice.	Imatinib Mesylate	0-8	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	49-54
15805252-10	2005	We tested the hypothesis that P-gp and BCRP inhibitors, such as elacridar and pantoprazole, improve the brain penetration of imatinib.	Pantoprazole	78-90	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-43
15805252-10	2005	We tested the hypothesis that P-gp and BCRP inhibitors, such as elacridar and pantoprazole, improve the brain penetration of imatinib.	Imatinib Mesylate	125-133	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-43
15805252-11	2005	Firstly, we showed in vitro that pantoprazole and elacridar inhibit the Bcrp1-mediated transport of imatinib in MDCKII-Bcrp1 cells.	Pantoprazole	33-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	72-77
15805252-11	2005	Firstly, we showed in vitro that pantoprazole and elacridar inhibit the Bcrp1-mediated transport of imatinib in MDCKII-Bcrp1 cells.	Pantoprazole	33-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	119-124
15805252-11	2005	Firstly, we showed in vitro that pantoprazole and elacridar inhibit the Bcrp1-mediated transport of imatinib in MDCKII-Bcrp1 cells.	Imatinib Mesylate	100-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	72-77
15805252-11	2005	Firstly, we showed in vitro that pantoprazole and elacridar inhibit the Bcrp1-mediated transport of imatinib in MDCKII-Bcrp1 cells.	Imatinib Mesylate	100-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	119-124
15805252-18	2005	Our results suggest that co-administration of BCRP and P-gp inhibitors may improve delivery of imatinib to malignant gliomas.	Imatinib Mesylate	95-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	46-50
15846469-12	2005	Furthermore, it was found that after intestinal perfusion with ME3229 for 60 min, the plasma concentrations of ME3277 and PM-5, a metabolite of ME3229, increased 2-fold and 3-fold, respectively, in Bcrp1 knockout mice.	ME 3229	63-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	198-203
15846469-12	2005	Furthermore, it was found that after intestinal perfusion with ME3229 for 60 min, the plasma concentrations of ME3277 and PM-5, a metabolite of ME3229, increased 2-fold and 3-fold, respectively, in Bcrp1 knockout mice.	ME 3277	111-117	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	198-203
15846469-12	2005	Furthermore, it was found that after intestinal perfusion with ME3229 for 60 min, the plasma concentrations of ME3277 and PM-5, a metabolite of ME3229, increased 2-fold and 3-fold, respectively, in Bcrp1 knockout mice.	ME 3229	144-150	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	198-203
15846469-0	2005	Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2).	ME 3277	42-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	157-162
15846469-14	2005	CONCLUSION: These results suggest that Bcrp1 plays an important role in the intestinal efflux of ME3277 and, probably, PM-10 and PM-11, metabolites of ME3229, and limits its BA after oral administration of ME3229.	ME 3277	97-103	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
15846469-8	2005	The aim of the present study is to examine the involvement of breast cancer resistant protein (BCRP/ABCG2) as a cause of low oral absorption of ME3229.	ME 3229	144-150	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	95-99
15846469-8	2005	The aim of the present study is to examine the involvement of breast cancer resistant protein (BCRP/ABCG2) as a cause of low oral absorption of ME3229.	ME 3229	144-150	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	100-105
15846469-14	2005	CONCLUSION: These results suggest that Bcrp1 plays an important role in the intestinal efflux of ME3277 and, probably, PM-10 and PM-11, metabolites of ME3229, and limits its BA after oral administration of ME3229.	PM-10	119-124	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
15846469-9	2005	METHODS: The transport activity of ME3277 in the presence and absence of ATP was determined using a rapid filtration method with the membrane vesicles prepared from LLC-PK1 cells expressing BCRP.	ME 3277	35-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	190-194
15846469-11	2005	RESULTS: The ATP-dependent uptake of ME3277 was greater in BCRP-expressing membrane vesicles than that in the control vesicles.	Adenosine Triphosphate	13-16	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	59-63
15846469-14	2005	CONCLUSION: These results suggest that Bcrp1 plays an important role in the intestinal efflux of ME3277 and, probably, PM-10 and PM-11, metabolites of ME3229, and limits its BA after oral administration of ME3229.	PM-11	129-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
15846469-11	2005	RESULTS: The ATP-dependent uptake of ME3277 was greater in BCRP-expressing membrane vesicles than that in the control vesicles.	ME 3277	37-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	59-63
15846469-14	2005	CONCLUSION: These results suggest that Bcrp1 plays an important role in the intestinal efflux of ME3277 and, probably, PM-10 and PM-11, metabolites of ME3229, and limits its BA after oral administration of ME3229.	ME 3229	151-157	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
15598971-0	2005	Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen.	Glucuronides	75-86	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	42-47
15846469-14	2005	CONCLUSION: These results suggest that Bcrp1 plays an important role in the intestinal efflux of ME3277 and, probably, PM-10 and PM-11, metabolites of ME3229, and limits its BA after oral administration of ME3229.	ME 3229	206-212	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-44
15546952-0	2005	Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels.	protoporphyrin IX	110-127	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	28-33
15546952-3	2005	Abcg2 null mice have increased levels of protoporphyrin IX (PPIX) in erythroid cells, yet the mechanism for this remains uncertain.	protoporphyrin IX	41-58	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
15546952-3	2005	Abcg2 null mice have increased levels of protoporphyrin IX (PPIX) in erythroid cells, yet the mechanism for this remains uncertain.	protoporphyrin IX	60-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
15546952-6	2005	Erythroid cells engineered to express ABCG2 had significantly lower intracellular levels of PPIX, suggesting the modulation of PPIX level by ABCG2.	protoporphyrin IX	92-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-43
15546952-6	2005	Erythroid cells engineered to express ABCG2 had significantly lower intracellular levels of PPIX, suggesting the modulation of PPIX level by ABCG2.	protoporphyrin IX	92-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	141-146
15546952-6	2005	Erythroid cells engineered to express ABCG2 had significantly lower intracellular levels of PPIX, suggesting the modulation of PPIX level by ABCG2.	protoporphyrin IX	127-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-43
15546952-6	2005	Erythroid cells engineered to express ABCG2 had significantly lower intracellular levels of PPIX, suggesting the modulation of PPIX level by ABCG2.	protoporphyrin IX	127-131	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	141-146
15546952-7	2005	This modulating activity was abrogated by treatment with a specific ABCG2 inhibitor, Ko143, implying that PPIX may be a direct substrate for the transporter.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	85-90	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	68-73
15546952-7	2005	This modulating activity was abrogated by treatment with a specific ABCG2 inhibitor, Ko143, implying that PPIX may be a direct substrate for the transporter.	protoporphyrin IX	106-110	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	68-73
15546952-8	2005	Taken together, our results demonstrate that ABCG2 plays a role in regulating PPIX levels during erythroid differentiation and suggest a potential role for ABCG2 as a genetic determinant in erythropoietic protoporphyria.	protoporphyrin IX	78-82	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	45-50
15598971-0	2005	Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen.	Glucuronides	75-86	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	48-53
15598971-0	2005	Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen.	Sulfates	91-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	42-47
15598971-0	2005	Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen.	Sulfates	91-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	48-53
15598971-6	2005	In contrast, the efflux of intracellularly formed 4MU-G, 4MU-S, and E3040-G in Bcrp1 (-/-) mice was significantly lower than that in normal mice.	Hymecromone	50-53	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-84
15598971-7	2005	Therefore, Bcrp1 has an important role in extruding glucuronide and sulfate conjugates formed in enterocytes into the intestinal lumen, whereas Mrp2 is responsible for the efflux of some glucuronide conjugates.	Glucuronides	52-63	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	11-16
15598971-7	2005	Therefore, Bcrp1 has an important role in extruding glucuronide and sulfate conjugates formed in enterocytes into the intestinal lumen, whereas Mrp2 is responsible for the efflux of some glucuronide conjugates.	Sulfates	68-75	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	11-16
15598971-7	2005	Therefore, Bcrp1 has an important role in extruding glucuronide and sulfate conjugates formed in enterocytes into the intestinal lumen, whereas Mrp2 is responsible for the efflux of some glucuronide conjugates.	Glucuronides	187-198	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	11-16
15567169-6	2005	Furthermore, gonadectomy and hypophysectomy experiments were conducted to determine whether sex steroids and/or growth hormone are responsible for Bcrp gender-divergent expression patterns.	Steroids	96-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	147-151
15580504-6	2005	In addition, the effect of FTC administration on the expression of BCRP in T8 tumors was also assessed by RT-PCR.	tryptoquivaline	27-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-71
15685169-2	2005	Here we show that the multidrug transporter BCRP (encoded by ABCG2) is strongly induced in the mammary gland of mice, cows and humans during lactation and that it is responsible for the active secretion of clinically and toxicologically important substrates such as the dietary carcinogen PhIP, the anticancer drug topotecan and the antiulcerative cimetidine into mouse milk.	Topotecan	315-324	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	61-66
15685169-2	2005	Here we show that the multidrug transporter BCRP (encoded by ABCG2) is strongly induced in the mammary gland of mice, cows and humans during lactation and that it is responsible for the active secretion of clinically and toxicologically important substrates such as the dietary carcinogen PhIP, the anticancer drug topotecan and the antiulcerative cimetidine into mouse milk.	Cimetidine	348-358	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	61-66
15608658-7	2005	SP cells were identified in both lineage-positive and lineage-negative population and ABCG2 expression was enriched in lineage-negative SP cells.	sp	136-138	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	86-91
15567169-7	2005	Male-predominant expression of Bcrp in rat kidney appears to be due to the suppressive effect of estradiol, and male-predominant expression of Bcrp in mouse liver appears to be due to the inductive effect of testosterone.	Estradiol	97-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-35
15567169-7	2005	Male-predominant expression of Bcrp in rat kidney appears to be due to the suppressive effect of estradiol, and male-predominant expression of Bcrp in mouse liver appears to be due to the inductive effect of testosterone.	Testosterone	208-220	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	143-147
15886885-3	2005	An SP population with Bcrp activity has been defined in a number of tissues, including mouse mammary and human breast epithelium, and it has been proposed that the SP phenotype is a universal stem cell marker.	sp	3-5	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-26
15365089-8	2005	We also identified the H(2)-receptor antagonist drug cimetidine as a novel efficiently transported substrate for human BCRP and mouse Bcrp1.	Cimetidine	53-63	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	134-139
15448171-6	2005	However, the brain uptake of [(3)H]DHEAS in Bcrp knockout mice was comparable with that in wild-type mice, and the effect of GF120918 was still observed in Bcrp knockout mice.	[(3)h]dheas	29-40	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-48
15448171-6	2005	However, the brain uptake of [(3)H]DHEAS in Bcrp knockout mice was comparable with that in wild-type mice, and the effect of GF120918 was still observed in Bcrp knockout mice.	Elacridar	125-133	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	156-160
15448171-8	2005	These results suggest that although BCRP is expressed at the BBB it plays a minor role in active efflux transport of DHEAS and mitoxantrone out of brain and that one or more GF120918-sensitive efflux transporters distinct from BCRP or P-gp contributes to the brain efflux of DHEAS and mitoxantrone.	Dehydroepiandrosterone Sulfate	117-122	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-40
15448171-8	2005	These results suggest that although BCRP is expressed at the BBB it plays a minor role in active efflux transport of DHEAS and mitoxantrone out of brain and that one or more GF120918-sensitive efflux transporters distinct from BCRP or P-gp contributes to the brain efflux of DHEAS and mitoxantrone.	Mitoxantrone	127-139	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-40
15448171-8	2005	These results suggest that although BCRP is expressed at the BBB it plays a minor role in active efflux transport of DHEAS and mitoxantrone out of brain and that one or more GF120918-sensitive efflux transporters distinct from BCRP or P-gp contributes to the brain efflux of DHEAS and mitoxantrone.	Dehydroepiandrosterone Sulfate	275-280	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-40
15448171-8	2005	These results suggest that although BCRP is expressed at the BBB it plays a minor role in active efflux transport of DHEAS and mitoxantrone out of brain and that one or more GF120918-sensitive efflux transporters distinct from BCRP or P-gp contributes to the brain efflux of DHEAS and mitoxantrone.	Mitoxantrone	285-297	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-40
15473921-0	2004	[Expression establishment and functional analysis of breast cancer resistance protein with doxycycline induced tet regulating system in mouse fibroblast cell line PA317].	Doxycycline	91-102	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	53-85
15492275-3	2004	Breast cancer resistance protein (ABCG2), a transporter that confers resistance to SN-38 (the active metabolite of irinotecan), was readily detected in six of nine xenograft models examined by immunohistochemistry.	Irinotecan	83-88	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
15492275-3	2004	Breast cancer resistance protein (ABCG2), a transporter that confers resistance to SN-38 (the active metabolite of irinotecan), was readily detected in six of nine xenograft models examined by immunohistochemistry.	Irinotecan	115-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
15492275-4	2004	In vitro gefitinib potently reversed resistance to SN-38 only in a cell line that overexpressed functional ABCG2.	Gefitinib	9-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	107-112
15492275-4	2004	In vitro gefitinib potently reversed resistance to SN-38 only in a cell line that overexpressed functional ABCG2.	Irinotecan	51-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	107-112
15448473-8	2004	To understand the mechanism responsible for SP phenotype, we performed an expression cloning and identified bcrp-1/ABCG2 gene, a member of ATP binding-cassette (ABC) transporter family.	TFF2 protein, human	44-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-114
15448473-8	2004	To understand the mechanism responsible for SP phenotype, we performed an expression cloning and identified bcrp-1/ABCG2 gene, a member of ATP binding-cassette (ABC) transporter family.	TFF2 protein, human	44-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	115-120
15448473-12	2004	By expression cloning, we identify bcrp-1/ABCG2 transporter as a molecule responsible for SP phenotype.	TFF2 protein, human	90-92	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-41
15448473-12	2004	By expression cloning, we identify bcrp-1/ABCG2 transporter as a molecule responsible for SP phenotype.	TFF2 protein, human	90-92	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	42-47
15473921-2	2004	This study was to establish the functional expression of BCRP with doxycycline (Dox) induced Tet regulating system in mouse fibroblast cell line PA317, provide an ideal experimental platform for understanding the mechanism of BCRP-mediated drug resistance, and develop effective methods to reverse the drug-resistance.	Doxycycline	67-78	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	57-61
15473921-2	2004	This study was to establish the functional expression of BCRP with doxycycline (Dox) induced Tet regulating system in mouse fibroblast cell line PA317, provide an ideal experimental platform for understanding the mechanism of BCRP-mediated drug resistance, and develop effective methods to reverse the drug-resistance.	Doxycycline	80-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	57-61
15473921-2	2004	This study was to establish the functional expression of BCRP with doxycycline (Dox) induced Tet regulating system in mouse fibroblast cell line PA317, provide an ideal experimental platform for understanding the mechanism of BCRP-mediated drug resistance, and develop effective methods to reverse the drug-resistance.	Doxycycline	80-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	226-230
15473921-0	2004	[Expression establishment and functional analysis of breast cancer resistance protein with doxycycline induced tet regulating system in mouse fibroblast cell line PA317].	tetramethylenedisulfotetramine	111-114	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	53-85
15473921-2	2004	This study was to establish the functional expression of BCRP with doxycycline (Dox) induced Tet regulating system in mouse fibroblast cell line PA317, provide an ideal experimental platform for understanding the mechanism of BCRP-mediated drug resistance, and develop effective methods to reverse the drug-resistance.	tetramethylenedisulfotetramine	93-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	57-61
15473921-2	2004	This study was to establish the functional expression of BCRP with doxycycline (Dox) induced Tet regulating system in mouse fibroblast cell line PA317, provide an ideal experimental platform for understanding the mechanism of BCRP-mediated drug resistance, and develop effective methods to reverse the drug-resistance.	tetramethylenedisulfotetramine	93-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	226-230
15473921-1	2004	BACKGROUND &amp; OBJECTIVE: Breast cancer resistance protein (BCRP), discovered in 1998, is a novel member of ATP-binding cassette (ABC) membrane transporters superfamily.	Adenosine Monophosphate	12-15	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	28-60
15473921-4	2004	The response plasmid of recombinant pTRE-BCRP was transferred into positive PA317/Tet-on cells, and stable expression of BCRP was established through hygromycin selection.	tetramethylenedisulfotetramine	82-85	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-45
15473921-1	2004	BACKGROUND &amp; OBJECTIVE: Breast cancer resistance protein (BCRP), discovered in 1998, is a novel member of ATP-binding cassette (ABC) membrane transporters superfamily.	Adenosine Monophosphate	12-15	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	62-66
15473921-4	2004	The response plasmid of recombinant pTRE-BCRP was transferred into positive PA317/Tet-on cells, and stable expression of BCRP was established through hygromycin selection.	hygromycin A	150-160	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
15044468-4	2004	However, blocking heme biosynthesis reverses the hypoxic susceptibility of Bcrp(-/-) progenitor cells, a finding that indicates that heme molecules (i.e. porphyrins) are detrimental to Bcrp(-/-) cells under hypoxia.	Heme	18-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-79
15473921-6	2004	Positive PA317/Tet-on/TRE-BCRP cells, which showed well dose-response in expression of BCRP with different concentration of Dox induction, were selected by both reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot.	pa317	9-14	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-91
15473921-6	2004	Positive PA317/Tet-on/TRE-BCRP cells, which showed well dose-response in expression of BCRP with different concentration of Dox induction, were selected by both reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot.	tetramethylenedisulfotetramine	15-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-91
15473921-6	2004	Positive PA317/Tet-on/TRE-BCRP cells, which showed well dose-response in expression of BCRP with different concentration of Dox induction, were selected by both reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot.	Doxycycline	124-127	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-30
15473921-6	2004	Positive PA317/Tet-on/TRE-BCRP cells, which showed well dose-response in expression of BCRP with different concentration of Dox induction, were selected by both reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot.	Doxycycline	124-127	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	87-91
15473921-7	2004	The inhibitory effects of mitoxantrone on positive PA317/Tet-on/TRE-BCRP cells with various concentrations of Dox induction were detected by MTT method.	Mitoxantrone	26-38	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	68-72
15473921-8	2004	Ko143, a specific inhibitor of BCRP, was used to detect the drug sensitivity of positive PA317/Tet-on/TRE-BCRP cells to mitoxantrone.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	0-5	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-35
15473921-8	2004	Ko143, a specific inhibitor of BCRP, was used to detect the drug sensitivity of positive PA317/Tet-on/TRE-BCRP cells to mitoxantrone.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	0-5	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	106-110
15473921-8	2004	Ko143, a specific inhibitor of BCRP, was used to detect the drug sensitivity of positive PA317/Tet-on/TRE-BCRP cells to mitoxantrone.	pa317	89-94	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-35
15473921-8	2004	Ko143, a specific inhibitor of BCRP, was used to detect the drug sensitivity of positive PA317/Tet-on/TRE-BCRP cells to mitoxantrone.	Mitoxantrone	120-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-35
15473921-8	2004	Ko143, a specific inhibitor of BCRP, was used to detect the drug sensitivity of positive PA317/Tet-on/TRE-BCRP cells to mitoxantrone.	Mitoxantrone	120-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	106-110
15473921-9	2004	Fluorescence intensity of remaining intracellular mitoxantrone in positive PA317/Tet-on/TRE-BCRP cells with different expression of BCRP was analyzed by flow cytometry (FCM).	Mitoxantrone	50-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-96
15473921-9	2004	Fluorescence intensity of remaining intracellular mitoxantrone in positive PA317/Tet-on/TRE-BCRP cells with different expression of BCRP was analyzed by flow cytometry (FCM).	Mitoxantrone	50-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	132-136
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	tetramethylenedisulfotetramine	33-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	45-49
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	tetramethylenedisulfotetramine	33-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-108
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	tetramethylenedisulfotetramine	33-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-108
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	Doxycycline	141-144	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	45-49
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	Doxycycline	141-144	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-108
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	Doxycycline	141-144	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-108
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	Mitoxantrone	184-196	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	45-49
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	Mitoxantrone	184-196	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-108
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	Mitoxantrone	184-196	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-108
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	Mitoxantrone	287-299	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	45-49
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	Mitoxantrone	287-299	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-108
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	Mitoxantrone	287-299	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-108
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	330-335	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	45-49
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	330-335	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-108
15473921-10	2004	RESULTS: The positive No.5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0.995, P=0.002); its drug sensitivity to mitoxantrone was significantly enhanced by Ko143 (P&lt; 0.05).	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	330-335	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	104-108
15473921-11	2004	Furthermore, different expression of BCRP induced by various concentrations of Dox caused different intracellular mitoxantrone retention in this cell clone.	Doxycycline	79-82	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-41
15473921-11	2004	Furthermore, different expression of BCRP induced by various concentrations of Dox caused different intracellular mitoxantrone retention in this cell clone.	Mitoxantrone	114-126	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-41
15473921-12	2004	CONCLUSION: Functional expression of BCRP under Dox induced Tet regulating system was successfully established in PA317 cells, which provided an ideal experimental platform for further study of BCRP.	Doxycycline	48-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-41
15473921-12	2004	CONCLUSION: Functional expression of BCRP under Dox induced Tet regulating system was successfully established in PA317 cells, which provided an ideal experimental platform for further study of BCRP.	Doxycycline	48-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	194-198
15473921-12	2004	CONCLUSION: Functional expression of BCRP under Dox induced Tet regulating system was successfully established in PA317 cells, which provided an ideal experimental platform for further study of BCRP.	tetramethylenedisulfotetramine	60-63	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-41
15473921-12	2004	CONCLUSION: Functional expression of BCRP under Dox induced Tet regulating system was successfully established in PA317 cells, which provided an ideal experimental platform for further study of BCRP.	tetramethylenedisulfotetramine	60-63	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	194-198
15319327-0	2004	Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice.	E 3040	28-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	152-157
15319327-0	2004	Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice.	E 3040	28-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	158-163
15319327-2	2004	The purpose of the present study is to investigate whether Bcrp1 could be involved in the urinary excretion of the human BCRP substrates, 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole sulfate (E3040S) and 4-methylumbelliferone sulfate (4MUS), using Bcrp1(-/-) mice.	6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole sulfate	138-216	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	59-64
15367706-5	2004	Gefitinib reversed SN-38 resistance in BCRP-transduced human myelogenous leukemia K562 (K562/BCRP) or BCRP-transduced murine lymphocytic leukemia P388 (P388/BCRP) cells but not in these parental cells.	Gefitinib	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	152-161
15313923-0	2004	Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.	Methotrexate	53-65	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	105-137
15313923-1	2004	The antifolate drug methotrexate (MTX) is transported by breast cancer resistance protein (BCRP; ABCG2) and multidrug resistance-associated protein1-4 (MRP1-4; ABCC1-4).	Methotrexate	20-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	57-89
15313923-1	2004	The antifolate drug methotrexate (MTX) is transported by breast cancer resistance protein (BCRP; ABCG2) and multidrug resistance-associated protein1-4 (MRP1-4; ABCC1-4).	Methotrexate	20-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	91-95
15313923-1	2004	The antifolate drug methotrexate (MTX) is transported by breast cancer resistance protein (BCRP; ABCG2) and multidrug resistance-associated protein1-4 (MRP1-4; ABCC1-4).	Methotrexate	20-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	97-102
15205387-6	2004	The role of Pgp and Bcrp on the systemic exposure of GV196771 was assessed by pretreatment of wild-type and Pgp-deficient mdr1a/1b(-/-) mice with a single oral dose of GF120918 (50 mg/kg; a dual Pgp and Bcrp inhibitor) or vehicle (0.5% hydroxypropylmethylcellulose and 1% Tween 80) 2 h before administration of a single oral dose of GV196771 (2 mg/kg).	UNII-49M4Q410FD	53-61	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	20-24
15319327-2	2004	The purpose of the present study is to investigate whether Bcrp1 could be involved in the urinary excretion of the human BCRP substrates, 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole sulfate (E3040S) and 4-methylumbelliferone sulfate (4MUS), using Bcrp1(-/-) mice.	4-methylumbelliferyl sulfate	230-259	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	59-64
15319327-8	2004	This is to our knowledge the first demonstration of involvement of Bcrp1 in the renal secretion of organic sulfates.	Sulfates	107-115	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-72
15319327-9	2004	However, taking the results of 4MUS into consideration, the renal secretion of organic sulfates cannot be accounted for solely by Bcrp1, and transporters other than Bcrp1 are also involved.	Sulfates	87-95	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	130-135
15367706-9	2004	Furthermore, P388/BCRP-transplanted mice treated with combination of irinotecan and gefitinib survived significantly longer than those treated with irinotecan alone or gefitinib alone.	Irinotecan	69-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	18-22
15367706-9	2004	Furthermore, P388/BCRP-transplanted mice treated with combination of irinotecan and gefitinib survived significantly longer than those treated with irinotecan alone or gefitinib alone.	Gefitinib	84-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	18-22
15313923-1	2004	The antifolate drug methotrexate (MTX) is transported by breast cancer resistance protein (BCRP; ABCG2) and multidrug resistance-associated protein1-4 (MRP1-4; ABCC1-4).	Methotrexate	34-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	57-89
15313923-1	2004	The antifolate drug methotrexate (MTX) is transported by breast cancer resistance protein (BCRP; ABCG2) and multidrug resistance-associated protein1-4 (MRP1-4; ABCC1-4).	Methotrexate	34-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	91-95
15313923-1	2004	The antifolate drug methotrexate (MTX) is transported by breast cancer resistance protein (BCRP; ABCG2) and multidrug resistance-associated protein1-4 (MRP1-4; ABCC1-4).	Methotrexate	34-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	97-102
15313923-3	2004	We hypothesized that benzimidazoles interfere with the clearance of MTX and/or 7-hydroxymethotrexate by inhibition of the ATP-binding cassette drug transporters BCRP and/or MRP2, two transporters known to transport MTX and located in apical membranes of epithelia involved in drug disposition.	Benzimidazoles	21-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	161-165
15313923-3	2004	We hypothesized that benzimidazoles interfere with the clearance of MTX and/or 7-hydroxymethotrexate by inhibition of the ATP-binding cassette drug transporters BCRP and/or MRP2, two transporters known to transport MTX and located in apical membranes of epithelia involved in drug disposition.	Methotrexate	68-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	161-165
15313923-3	2004	We hypothesized that benzimidazoles interfere with the clearance of MTX and/or 7-hydroxymethotrexate by inhibition of the ATP-binding cassette drug transporters BCRP and/or MRP2, two transporters known to transport MTX and located in apical membranes of epithelia involved in drug disposition.	7-hydroxymethotrexate	79-100	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	161-165
15313923-3	2004	We hypothesized that benzimidazoles interfere with the clearance of MTX and/or 7-hydroxymethotrexate by inhibition of the ATP-binding cassette drug transporters BCRP and/or MRP2, two transporters known to transport MTX and located in apical membranes of epithelia involved in drug disposition.	Methotrexate	215-218	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	161-165
15313923-5	2004	In Sf9-BCRP vesicles, pantoprazole and omeprazole inhibited MTX transport (IC50 13 microm and 36 microm, respectively).	Pantoprazole	22-34	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	7-11
15313923-5	2004	In Sf9-BCRP vesicles, pantoprazole and omeprazole inhibited MTX transport (IC50 13 microm and 36 microm, respectively).	Omeprazole	39-49	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	7-11
15313923-5	2004	In Sf9-BCRP vesicles, pantoprazole and omeprazole inhibited MTX transport (IC50 13 microm and 36 microm, respectively).	Methotrexate	60-63	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	7-11
15313923-7	2004	Secondly, we studied the transport of pantoprazole in MDCKII monolayers transfected with mouse Bcrp1 or human MRP2.	Pantoprazole	38-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	95-100
15313923-8	2004	Pantoprazole was actively transported by Bcrp1 but not by MRP2.	Pantoprazole	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-46
15313923-10	2004	Both in wild-type mice pretreated with pantoprazole to inhibit Bcrp1 and in Bcrp1-/- mice that lack Bcrp1, the clearance of i.v.	Pantoprazole	39-51	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-68
15313923-13	2004	The conclusion is as follows: benzimidazoles differentially affect transport of MTX mediated by BCRP and MRP2.	Benzimidazoles	30-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	96-100
15313923-13	2004	The conclusion is as follows: benzimidazoles differentially affect transport of MTX mediated by BCRP and MRP2.	Methotrexate	80-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	96-100
15313923-14	2004	Competition for BCRP may explain the clinical interaction between MTX and benzimidazoles.	Methotrexate	66-69	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	16-20
15313923-14	2004	Competition for BCRP may explain the clinical interaction between MTX and benzimidazoles.	Benzimidazoles	74-88	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	16-20
15044468-0	2004	The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme.	Heme	89-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-25
15044468-0	2004	The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme.	Heme	89-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-31
15044468-4	2004	However, blocking heme biosynthesis reverses the hypoxic susceptibility of Bcrp(-/-) progenitor cells, a finding that indicates that heme molecules (i.e. porphyrins) are detrimental to Bcrp(-/-) cells under hypoxia.	Heme	18-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-189
15044468-4	2004	However, blocking heme biosynthesis reverses the hypoxic susceptibility of Bcrp(-/-) progenitor cells, a finding that indicates that heme molecules (i.e. porphyrins) are detrimental to Bcrp(-/-) cells under hypoxia.	Heme	133-137	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-79
15044468-4	2004	However, blocking heme biosynthesis reverses the hypoxic susceptibility of Bcrp(-/-) progenitor cells, a finding that indicates that heme molecules (i.e. porphyrins) are detrimental to Bcrp(-/-) cells under hypoxia.	Heme	133-137	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	185-189
15044468-5	2004	BCRP specifically binds heme, and cells lacking BCRP accumulate porphyrins.	Heme	24-28	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
15044468-7	2004	Collectively, our findings suggest that cells can, upon hypoxic demand, use BCRP to reduce heme or porphyrin accumulation, which can be detrimental to cells.	Heme	91-95	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	76-80
15044468-7	2004	Collectively, our findings suggest that cells can, upon hypoxic demand, use BCRP to reduce heme or porphyrin accumulation, which can be detrimental to cells.	Porphyrins	99-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	76-80
14681185-2	2004	We show that mouse testicular cells also display a "Side Population" that express Bcrp1 mRNA, the ABC transporter responsible for Hoechst efflux in hematopoietic cells.	hoechst	130-137	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	82-87
14699605-1	2004	BACKGROUND: Discrimination of stem cells with flow cytometric analysis of Hoechst 33342 efflux by the ABCG2 transporter (termed the Hoechst side population, or SP technique) is a valuable methodology for identifying bone marrow progenitors enriched with stem cells.	bisbenzimide ethoxide trihydrochloride	74-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	102-107
14973080-1	2004	Pheophorbide a (PhA), a chlorophyll catabolite, was shown to be an ABCG2 substrate based on Abcg2(-/-) knockout mouse studies (J. W. Jonker et al., Proc.	pheophorbide a	0-14	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-72
14973080-1	2004	Pheophorbide a (PhA), a chlorophyll catabolite, was shown to be an ABCG2 substrate based on Abcg2(-/-) knockout mouse studies (J. W. Jonker et al., Proc.	pheophorbide a	0-14	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-97
14973080-1	2004	Pheophorbide a (PhA), a chlorophyll catabolite, was shown to be an ABCG2 substrate based on Abcg2(-/-) knockout mouse studies (J. W. Jonker et al., Proc.	chlorophyll catabolite	24-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-72
14681185-3	2004	Inhibition of Hoechst efflux by specific BCRP1 inhibitor Ko143 show that germinal "Side Population" phenotype is dependent on BCRP1 activity.	hoechst	14-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-46
14681185-3	2004	Inhibition of Hoechst efflux by specific BCRP1 inhibitor Ko143 show that germinal "Side Population" phenotype is dependent on BCRP1 activity.	hoechst	14-21	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	126-131
14681185-3	2004	Inhibition of Hoechst efflux by specific BCRP1 inhibitor Ko143 show that germinal "Side Population" phenotype is dependent on BCRP1 activity.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	57-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-46
14681185-3	2004	Inhibition of Hoechst efflux by specific BCRP1 inhibitor Ko143 show that germinal "Side Population" phenotype is dependent on BCRP1 activity.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	57-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	126-131
12626330-2	2003	SP cells can be isolated by dual-wavelength flow cytometry because of their capacity to efflux Hoechst dye, a process mediated by the ATP-binding cassette transporter breast cancer resistance protein (Bcrp) 1.	sp	0-2	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	167-208
14566825-1	2003	Breast cancer resistance protein (BCRP) is a member of ATP-binding cassette transporters that has an N-terminal ATP binding domain and a C-terminal transmembrane domain (TM).	Adenosine Triphosphate	55-58	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-32
14566825-1	2003	Breast cancer resistance protein (BCRP) is a member of ATP-binding cassette transporters that has an N-terminal ATP binding domain and a C-terminal transmembrane domain (TM).	Adenosine Triphosphate	55-58	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
14566825-2	2003	Expression of wild-type BCRP confers resistance to multiple chemotherapeutic agents such as mitoxantrone, SN-38 and topotecan, but not to doxorubicin.	Mitoxantrone	92-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-28
14566825-2	2003	Expression of wild-type BCRP confers resistance to multiple chemotherapeutic agents such as mitoxantrone, SN-38 and topotecan, but not to doxorubicin.	Irinotecan	106-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-28
14566825-2	2003	Expression of wild-type BCRP confers resistance to multiple chemotherapeutic agents such as mitoxantrone, SN-38 and topotecan, but not to doxorubicin.	Topotecan	116-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-28
14566825-6	2003	Cells transfected with N557D-BCRP cDNA showed similar resistance to mitoxantrone but lower resistance to SN-38 than the wild-type BCRP-transfected cells.	Mitoxantrone	68-80	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-33
14566825-6	2003	Cells transfected with N557D-BCRP cDNA showed similar resistance to mitoxantrone but lower resistance to SN-38 than the wild-type BCRP-transfected cells.	Irinotecan	105-110	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-33
14566825-7	2003	Cells transfected with N557E-, H630E- or H630L-BCRP cDNA showed similar degrees of resistance to mitoxantrone and SN-38.	Mitoxantrone	97-109	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	47-51
14566825-7	2003	Cells transfected with N557E-, H630E- or H630L-BCRP cDNA showed similar degrees of resistance to mitoxantrone and SN-38.	Irinotecan	114-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	47-51
14566825-9	2003	Cells transfected with R482G- or R482S-BCRP cDNA showed less intracellular accumulation of [3H]mitoxantrone than the wild-type BCRP-transfected cells.	Tritium	92-94	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-43
14566825-9	2003	Cells transfected with R482G- or R482S-BCRP cDNA showed less intracellular accumulation of [3H]mitoxantrone than the wild-type BCRP-transfected cells.	Mitoxantrone	95-107	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	39-43
14566825-10	2003	These results suggest that E446 in TM2, R482 in TM3, N557 in TM5 and H630 in TM6 play important roles in drug recognition of BCRP.	e446	27-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	125-129
14566825-10	2003	These results suggest that E446 in TM2, R482 in TM3, N557 in TM5 and H630 in TM6 play important roles in drug recognition of BCRP.	2,5-Dibromo-3-fluoropyridine	53-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	125-129
14682060-0	2003	Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone.	Mitoxantrone	121-133	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	57-62
14682060-0	2003	Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone.	Mitoxantrone	121-133	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	63-68
12851395-6	2003	Bcrp1, which encodes the Hoechst dye transporter, was translocated from the membrane to the intracellular compartment under conditions that promote the SP-depleted state.	sp	152-154	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
14559835-0	2003	The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	96-143	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-43
14559835-0	2003	The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	96-143	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-49
14579240-3	2003	ABCG2 expression is associated with the side population (SP) phenotype of Hoechst 33342 efflux.	bisbenzimide ethoxide trihydrochloride	74-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
14579240-4	2003	The substrate profile of ABCG2 includes the antineoplastic drugs primarily targeting topoisomerases, including anthracyclines and camptothecins.	Anthracyclines	111-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	25-30
14579240-4	2003	The substrate profile of ABCG2 includes the antineoplastic drugs primarily targeting topoisomerases, including anthracyclines and camptothecins.	Camptothecin	130-143	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	25-30
14579240-5	2003	More recently, pheophorbide, a chlorophyll-breakdown product, and protoporhyrin IX have been described as ABCG2 substrates, perhaps indicating a physiologic role of cytoprotection of primitive cells.	pheophorbide	15-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	106-111
14579240-5	2003	More recently, pheophorbide, a chlorophyll-breakdown product, and protoporhyrin IX have been described as ABCG2 substrates, perhaps indicating a physiologic role of cytoprotection of primitive cells.	protoporhyrin ix	66-82	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	106-111
12920197-5	2003	The basal-to-apical transport (excretion) of mitoxantrone, estrone, and 17beta-estradiol was greater in LLC/BCRP cells than in LLC-PK1 cells.	Mitoxantrone	45-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-112
12920197-5	2003	The basal-to-apical transport (excretion) of mitoxantrone, estrone, and 17beta-estradiol was greater in LLC/BCRP cells than in LLC-PK1 cells.	Estradiol	72-88	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	108-112
12920197-7	2003	Alternatively, increased excretion of estrone sulfate and 17beta-estradiol sulfate was observed in LLC/BCRP cells.	estrone sulfate	38-53	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	103-107
12920197-7	2003	Alternatively, increased excretion of estrone sulfate and 17beta-estradiol sulfate was observed in LLC/BCRP cells.	estradiol-3-sulfate	58-82	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	103-107
12626330-2	2003	SP cells can be isolated by dual-wavelength flow cytometry because of their capacity to efflux Hoechst dye, a process mediated by the ATP-binding cassette transporter breast cancer resistance protein (Bcrp) 1.	hoechst dye	95-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	167-208
12626330-10	2003	In BSMC, Bcrp1 was localized to an intracellular compartment, suggesting that the molecular site of Bcrp1 expression regulates SP phenotype.	sp	127-129	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	9-14
12626330-10	2003	In BSMC, Bcrp1 was localized to an intracellular compartment, suggesting that the molecular site of Bcrp1 expression regulates SP phenotype.	sp	127-129	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	100-105
12682043-0	2003	ABCG2 transports sulfated conjugates of steroids and xenobiotics.	Steroids	40-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
12682043-3	2003	The uptake of [3H]E1S into ABCG2-expressing membrane vesicles was stimulated by ATP, and the Km value for [3H]E1S was determined to be 16.6 microm.	Tritium	15-17	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-32
12682043-3	2003	The uptake of [3H]E1S into ABCG2-expressing membrane vesicles was stimulated by ATP, and the Km value for [3H]E1S was determined to be 16.6 microm.	Adenosine Triphosphate	80-83	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-32
12682043-3	2003	The uptake of [3H]E1S into ABCG2-expressing membrane vesicles was stimulated by ATP, and the Km value for [3H]E1S was determined to be 16.6 microm.	Tritium	107-109	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-32
12218177-0	2002	Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo.	Mitoxantrone	127-139	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
12682043-4	2003	The ABCG2-mediated transport of [3H]E1S was potently inhibited by SN-38 and many sulfate conjugates but not by glucuronide and glutathione conjugates or other anionic compounds.	Tritium	33-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	4-9
12682043-4	2003	The ABCG2-mediated transport of [3H]E1S was potently inhibited by SN-38 and many sulfate conjugates but not by glucuronide and glutathione conjugates or other anionic compounds.	Irinotecan	66-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	4-9
12682043-4	2003	The ABCG2-mediated transport of [3H]E1S was potently inhibited by SN-38 and many sulfate conjugates but not by glucuronide and glutathione conjugates or other anionic compounds.	Sulfates	81-88	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	4-9
12682043-5	2003	Other sulfate conjugates such as [3H]dehydroepiandrosterone sulfate (DHEAS) and [35S]4-methylumbelliferone sulfate (Km = 12.9 microm) and [35S]6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole (E3040) sulfate (Km = 26.9 microm) were also transported by ABCG2.	Sulfates	6-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	273-278
12682043-6	2003	Although [3H]methotrexate, [3H]17beta-estradiol-17beta-D-glucuronide, [3H]2,4-dinitrophenyl-S-glutathione, and [14C]4-methylumbelliferone glucuronide were transported by ABCG2, this took place to a much lesser extent compared with [3H]E1S.	[3h]17beta-estradiol-17beta-d-glucuronide	27-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	170-175
12682043-7	2003	It was suggested that ABCG2 preferentially transports sulfate conjugates and that E1S and DHEAS are the potential physiological substrates for this transporter.	Sulfates	54-61	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	22-27
12649196-0	2003	Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.	Etoposide	62-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	40-45
12649196-0	2003	Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.	Etoposide	62-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	46-51
12649196-1	2003	The breast cancer resistance protein [BCRP (BCRP/ABCG2)] has not previously been directly identified as a source of resistance to epipodophyllotoxins.However, when P-glycoprotein (P-gp)- and Mrp1-deficient mouse fibroblast and kidney cell lines were selected for resistance to etoposide, amplification and overexpression of Bcrp1 emerged as the dominant resistance mechanism in five of five cases.	Podophyllotoxin	130-149	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-42
12649196-1	2003	The breast cancer resistance protein [BCRP (BCRP/ABCG2)] has not previously been directly identified as a source of resistance to epipodophyllotoxins.However, when P-glycoprotein (P-gp)- and Mrp1-deficient mouse fibroblast and kidney cell lines were selected for resistance to etoposide, amplification and overexpression of Bcrp1 emerged as the dominant resistance mechanism in five of five cases.	Podophyllotoxin	130-149	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-48
12649196-1	2003	The breast cancer resistance protein [BCRP (BCRP/ABCG2)] has not previously been directly identified as a source of resistance to epipodophyllotoxins.However, when P-glycoprotein (P-gp)- and Mrp1-deficient mouse fibroblast and kidney cell lines were selected for resistance to etoposide, amplification and overexpression of Bcrp1 emerged as the dominant resistance mechanism in five of five cases.	Podophyllotoxin	130-149	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	49-54
12649196-1	2003	The breast cancer resistance protein [BCRP (BCRP/ABCG2)] has not previously been directly identified as a source of resistance to epipodophyllotoxins.However, when P-glycoprotein (P-gp)- and Mrp1-deficient mouse fibroblast and kidney cell lines were selected for resistance to etoposide, amplification and overexpression of Bcrp1 emerged as the dominant resistance mechanism in five of five cases.	Etoposide	277-286	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-42
12649196-1	2003	The breast cancer resistance protein [BCRP (BCRP/ABCG2)] has not previously been directly identified as a source of resistance to epipodophyllotoxins.However, when P-glycoprotein (P-gp)- and Mrp1-deficient mouse fibroblast and kidney cell lines were selected for resistance to etoposide, amplification and overexpression of Bcrp1 emerged as the dominant resistance mechanism in five of five cases.	Etoposide	277-286	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-48
12649196-1	2003	The breast cancer resistance protein [BCRP (BCRP/ABCG2)] has not previously been directly identified as a source of resistance to epipodophyllotoxins.However, when P-glycoprotein (P-gp)- and Mrp1-deficient mouse fibroblast and kidney cell lines were selected for resistance to etoposide, amplification and overexpression of Bcrp1 emerged as the dominant resistance mechanism in five of five cases.	Etoposide	277-286	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	49-54
12649196-4	2003	Transduced wild-type Bcrp1 cDNA mediated resistance to etoposide and teniposide in fibroblast lines and trans-epithelial etoposide transport in polarized Madin-Darby canine kidney II cells.	Etoposide	55-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-26
12649196-4	2003	Transduced wild-type Bcrp1 cDNA mediated resistance to etoposide and teniposide in fibroblast lines and trans-epithelial etoposide transport in polarized Madin-Darby canine kidney II cells.	Teniposide	69-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-26
12649196-4	2003	Transduced wild-type Bcrp1 cDNA mediated resistance to etoposide and teniposide in fibroblast lines and trans-epithelial etoposide transport in polarized Madin-Darby canine kidney II cells.	Etoposide	121-130	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	21-26
12649196-5	2003	Bcrp1-mediated etoposide resistance was reversed by two structurally different BCRP/Bcrp1 inhibitors, GF120918 and Ko143.	Etoposide	15-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
12649196-5	2003	Bcrp1-mediated etoposide resistance was reversed by two structurally different BCRP/Bcrp1 inhibitors, GF120918 and Ko143.	Etoposide	15-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-83
12649196-5	2003	Bcrp1-mediated etoposide resistance was reversed by two structurally different BCRP/Bcrp1 inhibitors, GF120918 and Ko143.	Etoposide	15-24	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-89
12649196-5	2003	Bcrp1-mediated etoposide resistance was reversed by two structurally different BCRP/Bcrp1 inhibitors, GF120918 and Ko143.	Elacridar	102-110	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
12649196-5	2003	Bcrp1-mediated etoposide resistance was reversed by two structurally different BCRP/Bcrp1 inhibitors, GF120918 and Ko143.	Elacridar	102-110	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-83
12649196-5	2003	Bcrp1-mediated etoposide resistance was reversed by two structurally different BCRP/Bcrp1 inhibitors, GF120918 and Ko143.	Elacridar	102-110	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-89
12649196-5	2003	Bcrp1-mediated etoposide resistance was reversed by two structurally different BCRP/Bcrp1 inhibitors, GF120918 and Ko143.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	115-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
12649196-5	2003	Bcrp1-mediated etoposide resistance was reversed by two structurally different BCRP/Bcrp1 inhibitors, GF120918 and Ko143.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	115-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-83
12649196-5	2003	Bcrp1-mediated etoposide resistance was reversed by two structurally different BCRP/Bcrp1 inhibitors, GF120918 and Ko143.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	115-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	84-89
12649196-6	2003	BCRP/Bcrp1 (inhibition) might thus impact on the antitumor activity and pharmacokinetics of epipodophyllotoxins.	Podophyllotoxin	92-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
12649196-6	2003	BCRP/Bcrp1 (inhibition) might thus impact on the antitumor activity and pharmacokinetics of epipodophyllotoxins.	Podophyllotoxin	92-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	5-10
12529547-6	2003	Enforced expression of the ABCG2 cDNA resulted in a robust SP phenotype and a reduction in hematopoietic maturation.	sp	59-61	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-32
12429862-2	2002	We show here that mice lacking Bcrp1Abcg2 become extremely sensitive to the dietary chlorophyll-breakdown product pheophorbide a, resulting in severe, sometimes lethal phototoxic lesions on light-exposed skin.	Chlorophyll	84-95	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-41
12429862-2	2002	We show here that mice lacking Bcrp1Abcg2 become extremely sensitive to the dietary chlorophyll-breakdown product pheophorbide a, resulting in severe, sometimes lethal phototoxic lesions on light-exposed skin.	pheophorbide a	114-128	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-41
12429862-4	2002	Bcrp1 transports pheophorbide a and is highly efficient in limiting its uptake from ingested food.	pheophorbide a	17-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
12218177-2	2002	Previous studies have implicated the ATP binding cassette transporter genes Mdr1a/1b and/or Bcrp1 in the SP phenotype.	sp	105-107	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-97
12218177-5	2002	In the bone marrow, there was a nearly absolute loss of lineage negative, c-Kit-positive, Sca-1-positive SP cells, and the residual SP cells were depleted of repopulating cells in a transplant assay, demonstrating that Bcrp1 expression is necessary for the SP phenotype in HSCs.	sp	132-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	219-224
12218177-5	2002	In the bone marrow, there was a nearly absolute loss of lineage negative, c-Kit-positive, Sca-1-positive SP cells, and the residual SP cells were depleted of repopulating cells in a transplant assay, demonstrating that Bcrp1 expression is necessary for the SP phenotype in HSCs.	sp	132-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	219-224
12218177-6	2002	Furthermore, Bcrp1 null hematopoietic cells were significantly more sensitive to mitoxantrone in drug-treated transplanted mice.	Mitoxantrone	81-93	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	13-18
12089223-1	2002	PURPOSE: We discovered that breast cancer resistance protein (BCRP), a recently identified adenosine triphosphate-binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(-/-) P-glycoprotein (P-gp) knockout and wild-type mice.	Topotecan	198-207	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	62-66
12160837-1	2002	OBJECTIVE: Several lines of evidence suggest that expression of two ABC transporters (Abcg2/Bcrp1 and mdr-1a/b) and the related abilities to efflux Hoechst 33342 (Hst) and Rhodamine-123 (Rho) are features of primitive hematopoietic cells in adult bone marrow.	bisbenzimide ethoxide trihydrochloride	148-161	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	86-91
12160837-1	2002	OBJECTIVE: Several lines of evidence suggest that expression of two ABC transporters (Abcg2/Bcrp1 and mdr-1a/b) and the related abilities to efflux Hoechst 33342 (Hst) and Rhodamine-123 (Rho) are features of primitive hematopoietic cells in adult bone marrow.	bisbenzimide ethoxide trihydrochloride	148-161	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-97
12160837-1	2002	OBJECTIVE: Several lines of evidence suggest that expression of two ABC transporters (Abcg2/Bcrp1 and mdr-1a/b) and the related abilities to efflux Hoechst 33342 (Hst) and Rhodamine-123 (Rho) are features of primitive hematopoietic cells in adult bone marrow.	Rhodamine 123	172-185	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	86-91
12160837-1	2002	OBJECTIVE: Several lines of evidence suggest that expression of two ABC transporters (Abcg2/Bcrp1 and mdr-1a/b) and the related abilities to efflux Hoechst 33342 (Hst) and Rhodamine-123 (Rho) are features of primitive hematopoietic cells in adult bone marrow.	Rhodamine 123	172-185	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-97
12089223-1	2002	PURPOSE: We discovered that breast cancer resistance protein (BCRP), a recently identified adenosine triphosphate-binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(-/-) P-glycoprotein (P-gp) knockout and wild-type mice.	Topotecan	198-207	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	28-60
11956086-0	2002	A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.	Doxorubicin	96-107	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-32
11956086-0	2002	A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.	Doxorubicin	96-107	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-39
11956086-2	2002	We find that each of three mouse cell lines independently selected for resistance to the anthracycline doxorubicin also acquired mutations in the cognate mouse transporter Bcrp1 exclusively at R482.	anthracycline doxorubicin	89-114	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	172-177
10825126-3	2000	In this study, we describe a BCRP-specific monoclonal antibody, BXP-34, obtained from mice, immunized with mitoxantrone-resistant, BCRP mRNA-positive MCF-7 MR human breast cancer cells.	Mitoxantrone	107-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	29-33
11956086-3	2002	Although the mouse Bcrp1 amino acid substitutions (M or S) are distinct from those seen in the human cell lines (G or T), they all have similar consequences: (a) greater resistance to anthracyclines (and bisantrene); (b) relatively lower resistance to topotecan; (c) greatly enhanced efflux of the dye rhodamine 123.	Anthracyclines	184-198	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	19-24
11956086-3	2002	Although the mouse Bcrp1 amino acid substitutions (M or S) are distinct from those seen in the human cell lines (G or T), they all have similar consequences: (a) greater resistance to anthracyclines (and bisantrene); (b) relatively lower resistance to topotecan; (c) greatly enhanced efflux of the dye rhodamine 123.	bisantrene	204-214	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	19-24
11956086-3	2002	Although the mouse Bcrp1 amino acid substitutions (M or S) are distinct from those seen in the human cell lines (G or T), they all have similar consequences: (a) greater resistance to anthracyclines (and bisantrene); (b) relatively lower resistance to topotecan; (c) greatly enhanced efflux of the dye rhodamine 123.	Topotecan	252-261	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	19-24
11956086-3	2002	Although the mouse Bcrp1 amino acid substitutions (M or S) are distinct from those seen in the human cell lines (G or T), they all have similar consequences: (a) greater resistance to anthracyclines (and bisantrene); (b) relatively lower resistance to topotecan; (c) greatly enhanced efflux of the dye rhodamine 123.	Rhodamine 123	302-315	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	19-24
11956086-6	2002	We found that the Bcrp1 mutations all occurred after previous amplification and overexpression of the wild-type gene under doxorubicin selection; wild-type Bcrp1 is evidently able to mediate substantial resistance to anthracyclines, and this was confirmed in Bcrp1-transduced cell lines.	Doxorubicin	123-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	18-23
11956086-6	2002	We found that the Bcrp1 mutations all occurred after previous amplification and overexpression of the wild-type gene under doxorubicin selection; wild-type Bcrp1 is evidently able to mediate substantial resistance to anthracyclines, and this was confirmed in Bcrp1-transduced cell lines.	Doxorubicin	123-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	156-161
11956086-6	2002	We found that the Bcrp1 mutations all occurred after previous amplification and overexpression of the wild-type gene under doxorubicin selection; wild-type Bcrp1 is evidently able to mediate substantial resistance to anthracyclines, and this was confirmed in Bcrp1-transduced cell lines.	Doxorubicin	123-134	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	156-161
11956086-6	2002	We found that the Bcrp1 mutations all occurred after previous amplification and overexpression of the wild-type gene under doxorubicin selection; wild-type Bcrp1 is evidently able to mediate substantial resistance to anthracyclines, and this was confirmed in Bcrp1-transduced cell lines.	Anthracyclines	217-231	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	18-23
11956086-6	2002	We found that the Bcrp1 mutations all occurred after previous amplification and overexpression of the wild-type gene under doxorubicin selection; wild-type Bcrp1 is evidently able to mediate substantial resistance to anthracyclines, and this was confirmed in Bcrp1-transduced cell lines.	Anthracyclines	217-231	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	156-161
11956086-6	2002	We found that the Bcrp1 mutations all occurred after previous amplification and overexpression of the wild-type gene under doxorubicin selection; wild-type Bcrp1 is evidently able to mediate substantial resistance to anthracyclines, and this was confirmed in Bcrp1-transduced cell lines.	Anthracyclines	217-231	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	156-161
11956086-7	2002	These observations emphasize the general importance of the arginine at amino acid 482 for substrate specificity of the transporter, while reminding us that unmutated Bcrp1 remains a potential source of resistance to anthracyclines and a potential factor in anthracycline pharmacokinetics.	Arginine	59-67	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	166-171
11956086-7	2002	These observations emphasize the general importance of the arginine at amino acid 482 for substrate specificity of the transporter, while reminding us that unmutated Bcrp1 remains a potential source of resistance to anthracyclines and a potential factor in anthracycline pharmacokinetics.	Anthracyclines	216-230	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	166-171
11956086-7	2002	These observations emphasize the general importance of the arginine at amino acid 482 for substrate specificity of the transporter, while reminding us that unmutated Bcrp1 remains a potential source of resistance to anthracyclines and a potential factor in anthracycline pharmacokinetics.	Anthracyclines	216-229	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	166-171
11807788-1	2002	Breast cancer resistance protein (BCRP) is a half-molecule ABC transporter highly expressed in mitoxantrone-resistant cells.	Mitoxantrone	95-107	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-32
11807788-1	2002	Breast cancer resistance protein (BCRP) is a half-molecule ABC transporter highly expressed in mitoxantrone-resistant cells.	Mitoxantrone	95-107	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	34-38
11807788-2	2002	In our study we established PA317 transfectants expressing Myc-tagged BCRP (MycBCRP) or HA-tagged BCRP (HABCRP).	pa317	28-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	70-74
11807788-2	2002	In our study we established PA317 transfectants expressing Myc-tagged BCRP (MycBCRP) or HA-tagged BCRP (HABCRP).	pa317	28-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	79-83
11807788-3	2002	The exogenous BCRP protein migrated as a 70-kDa protein in SDS-PAGE under reducing condition, but migrated as a 140-kDa complex in the absence of reducing agents.	Sodium Dodecyl Sulfate	59-62	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	14-18
11807788-4	2002	The 140-kDa BCRP complex was heat-stable but dissociated into 70-kDa BCRP with the addition of 2-mercaptoethanol.	Mercaptoethanol	95-112	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	12-16
11807788-4	2002	The 140-kDa BCRP complex was heat-stable but dissociated into 70-kDa BCRP with the addition of 2-mercaptoethanol.	Mercaptoethanol	95-112	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	69-73
11807788-7	2002	These results clearly indicate that BCRP forms a homodimer bridged by disulfide bonds.	Disulfides	70-79	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	36-40
11801536-0	2002	The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.	bisbenzimide ethoxide trihydrochloride	89-102	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-78
11801536-1	2002	The human ATP-binding cassette superfamily G (White) member 2 (ABCG2) gene and its murine homologue breast cancer resistance protein 1 (Bcrp1) are recently described ATP-binding cassette transporters associated with drug resistance in tumor cell lines, including the MCF-7 cell line, selected for its resistance to mitoxantrone (MCF-7/MitoR).	Mitoxantrone	315-327	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	100-134
11801536-1	2002	The human ATP-binding cassette superfamily G (White) member 2 (ABCG2) gene and its murine homologue breast cancer resistance protein 1 (Bcrp1) are recently described ATP-binding cassette transporters associated with drug resistance in tumor cell lines, including the MCF-7 cell line, selected for its resistance to mitoxantrone (MCF-7/MitoR).	Mitoxantrone	315-327	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	136-141
11140726-0	2001	Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.	indolyl diketopiperazines	62-87	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	14-18
11036110-2	2000	BCRP can render tumor cells resistant to the anticancer drugs topotecan, mitoxantrone, doxorubicin, and daunorubicin.	Topotecan	62-71	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
11036110-2	2000	BCRP can render tumor cells resistant to the anticancer drugs topotecan, mitoxantrone, doxorubicin, and daunorubicin.	Mitoxantrone	73-85	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
11036110-2	2000	BCRP can render tumor cells resistant to the anticancer drugs topotecan, mitoxantrone, doxorubicin, and daunorubicin.	Doxorubicin	87-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
11036110-2	2000	BCRP can render tumor cells resistant to the anticancer drugs topotecan, mitoxantrone, doxorubicin, and daunorubicin.	Daunorubicin	104-116	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
11036110-5	2000	Bcrp1, the murine homologue of BCRP, was expressed in the polarized mammalian cell lines LLC-PK1 and MDCK-II, and the direction of Bcrp1-mediated transport of topotecan and mitoxantrone was determined.	Topotecan	159-168	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
11036110-5	2000	Bcrp1, the murine homologue of BCRP, was expressed in the polarized mammalian cell lines LLC-PK1 and MDCK-II, and the direction of Bcrp1-mediated transport of topotecan and mitoxantrone was determined.	Topotecan	159-168	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-35
11036110-5	2000	Bcrp1, the murine homologue of BCRP, was expressed in the polarized mammalian cell lines LLC-PK1 and MDCK-II, and the direction of Bcrp1-mediated transport of topotecan and mitoxantrone was determined.	Mitoxantrone	173-185	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
11036110-5	2000	Bcrp1, the murine homologue of BCRP, was expressed in the polarized mammalian cell lines LLC-PK1 and MDCK-II, and the direction of Bcrp1-mediated transport of topotecan and mitoxantrone was determined.	Mitoxantrone	173-185	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-35
11036110-6	2000	To avoid the confounding drug transport provided by P-glycoprotein (P-gp), the roles of Bcrp1 in the bioavailability of topotecan and the effect of GF120918 were studied in both wild-type and P-gp-deficient mice and their fetuses.	Topotecan	120-129	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	88-93
11036110-10	2000	In pregnant GF120918-treated, P-gp-deficient mice, relative fetal penetration of topotecan was twofold higher than that in pregnant vehicle-treated mice, suggesting a function for BCRP in the maternal-fetal barrier of the placenta.	Topotecan	81-90	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	180-184
11036110-12	2000	We propose that strategic application of BCRP inhibitors may thus lead to more effective oral chemotherapy with topotecan or other BCRP substrate drugs.	Topotecan	112-121	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-45
12477054-2	2002	We have therefore evaluated a new tetracyclic analogue of FTC, Ko143, as a practical inhibitor of BCRP, comparing it with two other analogues in the same class and with GF120918.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	63-68	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	98-102
12477054-4	2002	Indeed, Ko143 appears to be the most potent BCRP inhibitor known thus far.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	8-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	44-48
12477054-11	2002	As such, Ko143 and other FTC analogues of this type represent valuable reagents for analysis of drug resistance mechanisms and may be candidates for development as clinical BCRP inhibitors.	3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester	9-14	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	173-177
34613635-4	2022	The reduction in ATP levels and its low affinity for the ABCB1 and ABCG2 transporters (which mediate MDR) significantly increased the retention of RuZ by MDR cancer cells.	Adenosine Triphosphate	17-20	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-72
10485464-0	1999	The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.	Topotecan	105-114	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
10485464-0	1999	The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.	Topotecan	105-114	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	20-24
10485464-0	1999	The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.	Mitoxantrone	116-128	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
10485464-0	1999	The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.	Mitoxantrone	116-128	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	20-24
10485464-0	1999	The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.	Doxorubicin	133-144	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
10485464-0	1999	The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.	Doxorubicin	133-144	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	16-19
10485464-0	1999	The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.	Doxorubicin	133-144	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	20-24
10485464-6	1999	Our data argue strongly that mouse Bcrp1 is functionally comparable with human BCRP, conferring multidrug resistance to topotecan, mitoxantrone, doxorubicin, and related compounds.	Topotecan	120-129	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-40
10485464-6	1999	Our data argue strongly that mouse Bcrp1 is functionally comparable with human BCRP, conferring multidrug resistance to topotecan, mitoxantrone, doxorubicin, and related compounds.	Mitoxantrone	131-143	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-40
10485464-6	1999	Our data argue strongly that mouse Bcrp1 is functionally comparable with human BCRP, conferring multidrug resistance to topotecan, mitoxantrone, doxorubicin, and related compounds.	Doxorubicin	145-156	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	35-40
33804018-7	2021	Moreover, the absorption rate of topotecan, a BCRP substrate, in wild-type mice pretreated with LY335979 was similar to that in mdr1a/1b knockout mice but significantly lower than that in bcrp knockout mice.	Topotecan	33-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	46-50
33804018-7	2021	Moreover, the absorption rate of topotecan, a BCRP substrate, in wild-type mice pretreated with LY335979 was similar to that in mdr1a/1b knockout mice but significantly lower than that in bcrp knockout mice.	Topotecan	33-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	188-192
33804018-7	2021	Moreover, the absorption rate of topotecan, a BCRP substrate, in wild-type mice pretreated with LY335979 was similar to that in mdr1a/1b knockout mice but significantly lower than that in bcrp knockout mice.	zosuquidar trihydrochloride	96-104	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	46-50
34613635-4	2022	The reduction in ATP levels and its low affinity for the ABCB1 and ABCG2 transporters (which mediate MDR) significantly increased the retention of RuZ by MDR cancer cells.	[(2~{R},3~{S},4~{R},5~{R})-5-[7-azanyl-5-(hydroxymethyl)benzimidazol-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl ~{N}-[(2~{S})-2-azanyl-3-oxidanyl-propanoyl]sulfamate	147-150	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-72
34952136-2	2022	Here larotrectinib pharmacokinetic behavior upon co-administration with prototypical inhibitors of the efflux transporters ABCB1/ABCG2 (elacridar), the SLCO1A/1B (OATP1A/1B) uptake transporters (rifampin), and the drug-metabolizing enzyme CYP3A (ritonavir), respectively, was investigated.	larotrectinib	5-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	129-134
34730366-3	2021	In vitro, human ABCB1 and mouse Abcg2 transported niraparib moderately.	niraparib	50-59	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-37
34730366-4	2021	Compared to wild-type mice, niraparib brain-to-plasma ratios were 6- to 7-fold increased in Abcb1a/1b-/- and Abcb1a/1b;Abcg2-/- but not in single Abcg2-/- mice, while niraparib plasma exposure at later time points was ~2-fold increased.	niraparib	28-37	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	119-124
34730366-4	2021	Compared to wild-type mice, niraparib brain-to-plasma ratios were 6- to 7-fold increased in Abcb1a/1b-/- and Abcb1a/1b;Abcg2-/- but not in single Abcg2-/- mice, while niraparib plasma exposure at later time points was ~2-fold increased.	niraparib	167-176	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	119-124
33556300-12	2021	The mRNA expression levels of ATP-binding cassette superfamily G member 2 (ABCG2, 1.39) and organic anion transport 1/2 (OAT1/2, 2.34, 2.53) in EGCG + Vc + glycerol group were notably higher than those of EGCG group (0.57, 1.13, and 1.16).	epigallocatechin gallate	144-148	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-73
33556300-12	2021	The mRNA expression levels of ATP-binding cassette superfamily G member 2 (ABCG2, 1.39) and organic anion transport 1/2 (OAT1/2, 2.34, 2.53) in EGCG + Vc + glycerol group were notably higher than those of EGCG group (0.57, 1.13, and 1.16).	epigallocatechin gallate	144-148	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-80
33556300-12	2021	The mRNA expression levels of ATP-binding cassette superfamily G member 2 (ABCG2, 1.39) and organic anion transport 1/2 (OAT1/2, 2.34, 2.53) in EGCG + Vc + glycerol group were notably higher than those of EGCG group (0.57, 1.13, and 1.16).	Glycerol	156-164	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-73
33556300-12	2021	The mRNA expression levels of ATP-binding cassette superfamily G member 2 (ABCG2, 1.39) and organic anion transport 1/2 (OAT1/2, 2.34, 2.53) in EGCG + Vc + glycerol group were notably higher than those of EGCG group (0.57, 1.13, and 1.16).	Glycerol	156-164	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-80
33556300-12	2021	The mRNA expression levels of ATP-binding cassette superfamily G member 2 (ABCG2, 1.39) and organic anion transport 1/2 (OAT1/2, 2.34, 2.53) in EGCG + Vc + glycerol group were notably higher than those of EGCG group (0.57, 1.13, and 1.16).	epigallocatechin gallate	205-209	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	30-73
33556300-12	2021	The mRNA expression levels of ATP-binding cassette superfamily G member 2 (ABCG2, 1.39) and organic anion transport 1/2 (OAT1/2, 2.34, 2.53) in EGCG + Vc + glycerol group were notably higher than those of EGCG group (0.57, 1.13, and 1.16).	epigallocatechin gallate	205-209	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	75-80
34832869-0	2021	P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO).	Selpercatinib	146-159	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	32-36
34959273-3	2021	The inhibition of BCRP was investigated for quercetin and its metabolites using BCRP/mBcrp1-overexpressing MDCKII cells by flow cytometry.	Quercetin	44-53	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	85-91
34413161-3	2021	Mice were orally administered lapatinib to inhibit BCRP in vivo, and plasma samples were assessed by liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS), with all-ion fragmentation acquisition, and quantified by LC-MS/MS.	Lapatinib	30-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-55
34413161-6	2021	Administration of lapatinib and another BCRP inhibitor febuxostat increased the area under the plasma concentration-time curve (AUC) of DS, GS, and equol sulfate (ES) by 3.6- and 1.8-, 5.6- and 4.1-, and 1.6- and 4.8-fold, respectively.	equol sulfate	148-161	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	40-44
34413161-6	2021	Administration of lapatinib and another BCRP inhibitor febuxostat increased the area under the plasma concentration-time curve (AUC) of DS, GS, and equol sulfate (ES) by 3.6- and 1.8-, 5.6- and 4.1-, and 1.6- and 4.8-fold, respectively.	Einsteinium	163-165	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	40-44
34413161-7	2021	BCRP inhibitors also increased the AUC and maximum plasma concentration of DS and ES after co-administration with each parent compound.	ds	75-77	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
34413161-7	2021	BCRP inhibitors also increased the AUC and maximum plasma concentration of DS and ES after co-administration with each parent compound.	Einsteinium	82-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
34413161-8	2021	After adding parent compounds to the apical side of induced pluripotent stem cell-derived small intestinal epithelial-like cells, DS, GS, and ES in the basal compartment significantly increased in the presence of lapatinib and febuxostat, suggesting the inhibition of intestinal BCRP.	Lapatinib	213-222	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	279-283
34413161-8	2021	After adding parent compounds to the apical side of induced pluripotent stem cell-derived small intestinal epithelial-like cells, DS, GS, and ES in the basal compartment significantly increased in the presence of lapatinib and febuxostat, suggesting the inhibition of intestinal BCRP.	Febuxostat	227-237	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	279-283
34413161-9	2021	ATP-dependent uptake of DS and ES in BCRP-expressing membrane vesicles was reduced by both inhibitors, indicating inhibition of BCRP-mediated DS and ES transport.	Adenosine Triphosphate	0-3	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-41
34413161-9	2021	ATP-dependent uptake of DS and ES in BCRP-expressing membrane vesicles was reduced by both inhibitors, indicating inhibition of BCRP-mediated DS and ES transport.	Adenosine Triphosphate	0-3	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	128-132
34413161-9	2021	ATP-dependent uptake of DS and ES in BCRP-expressing membrane vesicles was reduced by both inhibitors, indicating inhibition of BCRP-mediated DS and ES transport.	ds	24-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-41
34413161-9	2021	ATP-dependent uptake of DS and ES in BCRP-expressing membrane vesicles was reduced by both inhibitors, indicating inhibition of BCRP-mediated DS and ES transport.	ds	24-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	128-132
34413161-9	2021	ATP-dependent uptake of DS and ES in BCRP-expressing membrane vesicles was reduced by both inhibitors, indicating inhibition of BCRP-mediated DS and ES transport.	Einsteinium	31-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-41
34413161-9	2021	ATP-dependent uptake of DS and ES in BCRP-expressing membrane vesicles was reduced by both inhibitors, indicating inhibition of BCRP-mediated DS and ES transport.	Einsteinium	31-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	128-132
34413161-9	2021	ATP-dependent uptake of DS and ES in BCRP-expressing membrane vesicles was reduced by both inhibitors, indicating inhibition of BCRP-mediated DS and ES transport.	ds	142-144	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-41
34413161-9	2021	ATP-dependent uptake of DS and ES in BCRP-expressing membrane vesicles was reduced by both inhibitors, indicating inhibition of BCRP-mediated DS and ES transport.	ds	142-144	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	128-132
34413161-9	2021	ATP-dependent uptake of DS and ES in BCRP-expressing membrane vesicles was reduced by both inhibitors, indicating inhibition of BCRP-mediated DS and ES transport.	Einsteinium	149-151	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	37-41
34413161-9	2021	ATP-dependent uptake of DS and ES in BCRP-expressing membrane vesicles was reduced by both inhibitors, indicating inhibition of BCRP-mediated DS and ES transport.	Einsteinium	149-151	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	128-132
34413161-12	2021	Food-derived isoflavone sulfates were identified as useful markers for evaluating changes in BCRP-mediated transport in the small intestine by its inhibitors.	isoflavone sulfates	13-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	93-97
34746942-3	2021	The results showed that ATO significantly reduced serum UA, serum creatinine levels, inhibited XOD and ADA activities in the liver (p < 0.05), and accelerated UA excretion by downregulating the gene expression of renal mURAT1 and mGLUT9 and upregulating the gene expression of mABCG2 and mOAT1.	ato	24-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	277-283
34832869-0	2021	P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO).	Selpercatinib	146-159	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-43
34832869-3	2021	Selpercatinib was efficiently transported by hABCB1 and mAbcg2, but not hABCG2, and was not a substrate of human OATP1A2, -1B1 or -1B3 in vitro.	Selpercatinib	0-13	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	56-62
34832869-6	2021	The ABCB1/ABCG2 inhibitor elacridar boosted selpercatinib brain penetration in wild-type mice to the levels seen in Abcb1a/1b;Abcg2-/- mice.	Selpercatinib	44-57	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
34834176-0	2021	ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability.	Repotrectinib	106-119	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	10-15
34834176-3	2021	In vitro, human ABCB1 and ABCG2, and mouse Abcg2 efficiently transported repotrectinib with efflux transport ratios of 13.5, 5.6, and 40, respectively.	Repotrectinib	73-86	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	43-48
34834176-4	2021	Oral repotrectinib (10 mg/kg) showed higher plasma exposures in Abcg2-deficient mouse strains.	Repotrectinib	5-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	64-69
34834176-6	2021	Small intestinal content recovery of repotrectinib was decreased 4.9-fold in Abcb1a/1b-/- and 13.6-fold in Abcb1a/1b;Abcg2-/- mice.	Repotrectinib	37-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	117-122
34834176-10	2021	Collectively, Abcb1 and Abcg2 restrict repotrectinib brain accumulation and possibly toxicity, and control its intestinal disposition.	Repotrectinib	39-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	24-29
34834176-11	2021	Abcg2 also limits repotrectinib oral availability.	Repotrectinib	18-31	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
34572902-5	2021	VKNG-1, at 6 microM, selectively inhibited ABCG2 transporter and sensitized ABCG2-overexpressing drug-resistant cancer cells to the ABCG2 substrate anticancer drugs mitoxantrone, SN-38, and doxorubicin in ABCG2-overexpressing colon cancers.	Mitoxantrone	165-177	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	132-137
34650521-5	2021	Skin fibrosis was induced in C57BL/6J (B6) and Mdr1a/b-Bcrp triple knock-out (KO) mice by daily subcutaneous injections of bleomycin (2 IU/100 microL) for 28 days.	Bleomycin	123-132	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	55-59
34650521-11	2021	However, the skin level of MRI-1867, an MDR1 substrate, was dramatically lower in B6 mice (0.023 microM) than in Mdr1a/b-Bcrp KO mice (8.8 microM) due to a bleomycin-induced increase in efflux activity of MDR1 in fibrotic skin.	Bleomycin	156-165	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-125
34650521-13	2021	MRI-1867 treatment attenuated bleomycin-induced established skin fibrosis and the associated increase in endocannabinoids in Mdr1a/b-Bcrp KO mice but not in B6 mice.	Bleomycin	30-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	133-137
34572902-5	2021	VKNG-1, at 6 microM, selectively inhibited ABCG2 transporter and sensitized ABCG2-overexpressing drug-resistant cancer cells to the ABCG2 substrate anticancer drugs mitoxantrone, SN-38, and doxorubicin in ABCG2-overexpressing colon cancers.	Irinotecan	179-184	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	76-81
34572902-5	2021	VKNG-1, at 6 microM, selectively inhibited ABCG2 transporter and sensitized ABCG2-overexpressing drug-resistant cancer cells to the ABCG2 substrate anticancer drugs mitoxantrone, SN-38, and doxorubicin in ABCG2-overexpressing colon cancers.	Irinotecan	179-184	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	132-137
34572902-5	2021	VKNG-1, at 6 microM, selectively inhibited ABCG2 transporter and sensitized ABCG2-overexpressing drug-resistant cancer cells to the ABCG2 substrate anticancer drugs mitoxantrone, SN-38, and doxorubicin in ABCG2-overexpressing colon cancers.	Doxorubicin	190-201	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	76-81
34572902-5	2021	VKNG-1, at 6 microM, selectively inhibited ABCG2 transporter and sensitized ABCG2-overexpressing drug-resistant cancer cells to the ABCG2 substrate anticancer drugs mitoxantrone, SN-38, and doxorubicin in ABCG2-overexpressing colon cancers.	Doxorubicin	190-201	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	132-137
34572902-5	2021	VKNG-1, at 6 microM, selectively inhibited ABCG2 transporter and sensitized ABCG2-overexpressing drug-resistant cancer cells to the ABCG2 substrate anticancer drugs mitoxantrone, SN-38, and doxorubicin in ABCG2-overexpressing colon cancers.	Doxorubicin	190-201	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	205-210
34572902-9	2021	In addition, VKNG-1 enhanced the anticancer efficacy of irinotecan in ABCG2- overexpressing mouse tumor xenografts.	Irinotecan	56-66	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	70-75
34452247-2	2021	We used positron emission tomography (PET) with the metabolically stable P-gp/BCRP substrates (11C)tariquidar, (11C)erlotinib, and (11C)elacridar to assess whether a similar functional redundancy as at the BBB exists in the liver, where both transporters mediate the biliary excretion of drugs.	Carbon-11	95-98	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	78-82
34062171-0	2021	Role of the Abcg2 transporter in plasma levels and tissue accumulation of the anti-inflammatory tolfenamic acid in mice.	tolfenamic acid	96-111	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	12-17
34062171-6	2021	The in vivo effect of this transporter was tested using wild-type and Abcg2-/- mice, showing that after oral and intravenous administration of tolfenamic acid, its area under the plasma concentration-time curve in Abcg2-/- mice was between 1.7 and 1.8-fold higher compared to wild type-mice.	tolfenamic acid	143-158	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	70-75
34062171-6	2021	The in vivo effect of this transporter was tested using wild-type and Abcg2-/- mice, showing that after oral and intravenous administration of tolfenamic acid, its area under the plasma concentration-time curve in Abcg2-/- mice was between 1.7 and 1.8-fold higher compared to wild type-mice.	tolfenamic acid	143-158	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	214-219
34062171-7	2021	Abcg2-/- mice also showed higher liver and testis accumulation of tolfenamic acid after intravenous administration.	tolfenamic acid	66-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-5
34062171-8	2021	In this study, we demonstrate that tolfenamic acid is transported in vitro by Abcg2 and that its plasma levels as well as its tissue distribution are affected by Abcg2, with potential pharmacological and toxicological consequences.	tolfenamic acid	35-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	78-83
34062171-8	2021	In this study, we demonstrate that tolfenamic acid is transported in vitro by Abcg2 and that its plasma levels as well as its tissue distribution are affected by Abcg2, with potential pharmacological and toxicological consequences.	tolfenamic acid	35-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	162-167
34452247-2	2021	We used positron emission tomography (PET) with the metabolically stable P-gp/BCRP substrates (11C)tariquidar, (11C)erlotinib, and (11C)elacridar to assess whether a similar functional redundancy as at the BBB exists in the liver, where both transporters mediate the biliary excretion of drugs.	tariquidar	99-109	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	78-82
34452247-2	2021	We used positron emission tomography (PET) with the metabolically stable P-gp/BCRP substrates (11C)tariquidar, (11C)erlotinib, and (11C)elacridar to assess whether a similar functional redundancy as at the BBB exists in the liver, where both transporters mediate the biliary excretion of drugs.	Erlotinib Hydrochloride	116-125	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	78-82
34452247-6	2021	The transfer of radioactivity from liver to excreted bile was significantly lower in Abcb1a/b(-/-)Abcg2(-/-) mice and almost unchanged in Abcb1a/b(-/-) and Abcg2(-/-) mice (with the exception of (11C)erlotinib, for which biliary excretion was also significantly reduced in Abcg2(-/-) mice).	Erlotinib Hydrochloride	200-209	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	273-278
34294753-0	2021	Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations.	cannabidiolic acid	88-106	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	55-59
34074729-0	2021	BCRP/ABCG2 Transporter Regulates Accumulation of Cadmium in Kidney Cells: Role of the Q141K Variant in Modulating Nephrotoxicity.	Cadmium	49-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	0-4
34074729-0	2021	BCRP/ABCG2 Transporter Regulates Accumulation of Cadmium in Kidney Cells: Role of the Q141K Variant in Modulating Nephrotoxicity.	Cadmium	49-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	5-10
34074729-5	2021	Here, we sought to 1) evaluate the in vitro and in vivo ability of BCRP to transport cadmium and protect kidney cells from toxicity, and 2) determine whether this protection is impaired by the Q141K variant.	Cadmium	85-92	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-71
34074729-10	2021	Lastly, concentrations of cadmium in the kidneys of Bcrp KO mice were 40% higher than in WT mice, confirming that cadmium is an in vivo substrate of BCRP.	Cadmium	26-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-56
34074729-10	2021	Lastly, concentrations of cadmium in the kidneys of Bcrp KO mice were 40% higher than in WT mice, confirming that cadmium is an in vivo substrate of BCRP.	Cadmium	26-33	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	149-153
34074729-10	2021	Lastly, concentrations of cadmium in the kidneys of Bcrp KO mice were 40% higher than in WT mice, confirming that cadmium is an in vivo substrate of BCRP.	Cadmium	114-121	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	52-56
34074729-10	2021	Lastly, concentrations of cadmium in the kidneys of Bcrp KO mice were 40% higher than in WT mice, confirming that cadmium is an in vivo substrate of BCRP.	Cadmium	114-121	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	149-153
34074729-11	2021	In conclusion, BCRP prevents the accumulation of cadmium and protects against toxicity, a response that is impaired by the Q141K variant.	Cadmium	49-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	15-19
34074729-12	2021	Significance Statement The BCRP transporter lowers cellular accumulation of the toxic heavy metal cadmium.	heavy metal cadmium	86-105	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	27-31
34294753-6	2021	In vitro transwell assays identified CBDA as a substrate of the drug efflux transporter breast cancer resistance protein (BCRP), and that cannabigerol and Delta9-tetrahydrocannabinol inhibited the BCRP-mediated transport of CBDA.	cannabigerol	138-150	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	197-201
34294753-6	2021	In vitro transwell assays identified CBDA as a substrate of the drug efflux transporter breast cancer resistance protein (BCRP), and that cannabigerol and Delta9-tetrahydrocannabinol inhibited the BCRP-mediated transport of CBDA.	Dronabinol	155-182	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	88-120
34294753-6	2021	In vitro transwell assays identified CBDA as a substrate of the drug efflux transporter breast cancer resistance protein (BCRP), and that cannabigerol and Delta9-tetrahydrocannabinol inhibited the BCRP-mediated transport of CBDA.	Dronabinol	155-182	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	197-201
34294753-6	2021	In vitro transwell assays identified CBDA as a substrate of the drug efflux transporter breast cancer resistance protein (BCRP), and that cannabigerol and Delta9-tetrahydrocannabinol inhibited the BCRP-mediated transport of CBDA.	cannabidiolic acid	224-228	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	197-201
34294753-7	2021	Such a cannabinoid-cannabinoid interaction at BCRP transporters located in the intestine would inhibit efflux of CBDA, thus resulting in increased plasma concentrations.	Cannabinoids	7-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	46-50
34294753-7	2021	Such a cannabinoid-cannabinoid interaction at BCRP transporters located in the intestine would inhibit efflux of CBDA, thus resulting in increased plasma concentrations.	Cannabinoids	19-30	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	46-50
34294753-7	2021	Such a cannabinoid-cannabinoid interaction at BCRP transporters located in the intestine would inhibit efflux of CBDA, thus resulting in increased plasma concentrations.	cannabidiolic acid	113-117	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	46-50
34184879-6	2021	Optimization of 32 afforded diastereomeric oxolan-3-yl derivatives 44 and 45, which demonstrated a favorable in vitro PK profile, although they displayed species disconnects in the in vivo PK profile, and a propensity for P-gp- and/or BCRP-mediated efflux in a mouse model.	oxolan-3-yl	43-54	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	235-239
34294753-6	2021	In vitro transwell assays identified CBDA as a substrate of the drug efflux transporter breast cancer resistance protein (BCRP), and that cannabigerol and Delta9-tetrahydrocannabinol inhibited the BCRP-mediated transport of CBDA.	cannabidiolic acid	37-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	88-120
34294753-6	2021	In vitro transwell assays identified CBDA as a substrate of the drug efflux transporter breast cancer resistance protein (BCRP), and that cannabigerol and Delta9-tetrahydrocannabinol inhibited the BCRP-mediated transport of CBDA.	cannabidiolic acid	37-41	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	122-126
35427142-8	2022	ABCG2-PKU1 was labeled with Cy5.5 (Cy5.5-ABCG2) for fluorescent imaging and radiolabeled with 89Zr (89Zr-DFO-ABCG2) for immunoPET imaging following the conjugation with p-SCN-deferoxamine (DFO).	dfo	105-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	109-114
34144706-5	2021	The molecular pathway by which estradiol regulates ABCG2 expression in intestinal cells was explored.	Estradiol	31-40	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	51-56
34144706-7	2021	Administering estradiol benzoate (EB) to both male hyperuricemic mice and female mice after removing the ovaries confirmed the urate-lowering effect of estradiol, and hyperuricemia and estradiol upregulated the expression of intestinal ABCG2.	estradiol 3-benzoate	14-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	236-241
34144706-7	2021	Administering estradiol benzoate (EB) to both male hyperuricemic mice and female mice after removing the ovaries confirmed the urate-lowering effect of estradiol, and hyperuricemia and estradiol upregulated the expression of intestinal ABCG2.	estradiol 3-benzoate	34-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	236-241
34144706-7	2021	Administering estradiol benzoate (EB) to both male hyperuricemic mice and female mice after removing the ovaries confirmed the urate-lowering effect of estradiol, and hyperuricemia and estradiol upregulated the expression of intestinal ABCG2.	Estradiol	185-194	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	236-241
34144706-8	2021	Estradiol has been confirmed to promote urate transport by upregulating ABCG2 expression in intestinal urate excretion models in vivo and in vitro.	Estradiol	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	72-77
34144706-8	2021	Estradiol has been confirmed to promote urate transport by upregulating ABCG2 expression in intestinal urate excretion models in vivo and in vitro.	Uric Acid	40-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	72-77
34144706-8	2021	Estradiol has been confirmed to promote urate transport by upregulating ABCG2 expression in intestinal urate excretion models in vivo and in vitro.	Uric Acid	103-108	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	72-77
34144706-9	2021	Estradiol regulates the expression of intestinal ABCG2 through the PI3K/Akt pathway.	Estradiol	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	49-54
34144706-10	2021	CONCLUSION: Our study revealed that estradiol regulates intestinal ABCG2 through the PI3K/Akt pathway to promote urate excretion, thereby reducing serum urate levels.	Estradiol	36-45	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-72
34144706-10	2021	CONCLUSION: Our study revealed that estradiol regulates intestinal ABCG2 through the PI3K/Akt pathway to promote urate excretion, thereby reducing serum urate levels.	Uric Acid	113-118	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-72
34144706-10	2021	CONCLUSION: Our study revealed that estradiol regulates intestinal ABCG2 through the PI3K/Akt pathway to promote urate excretion, thereby reducing serum urate levels.	Uric Acid	153-158	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	67-72
34149413-6	2021	Furthermore, autophagy in ADQ-treated breast CSCs was blocked by taxol via regulation of beta-catenin/ABCG2 signaling.	ADP-glucose	26-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	102-107
34149413-6	2021	Furthermore, autophagy in ADQ-treated breast CSCs was blocked by taxol via regulation of beta-catenin/ABCG2 signaling.	Paclitaxel	65-70	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	102-107
34149413-10	2021	Collectively, this study not only reveals the chemosensitizating mechanism of ADQ in breast CSCs, but also highlights the importance of GRP78 in mediating autophagy-promoting drug resistance via beta-catenin/ABCG2 signaling.	ADP-glucose	78-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	208-213
34144706-0	2021	Estradiol regulates intestinal ABCG2 to promote urate excretion via the PI3K/Akt pathway.	Estradiol	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-36
34144706-0	2021	Estradiol regulates intestinal ABCG2 to promote urate excretion via the PI3K/Akt pathway.	Uric Acid	48-53	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	31-36
34144706-2	2021	In the current study, we aimed to confirm that estradiol can promote intestinal ATP binding cassette subfamily G member 2 (ABCG2) expression to increase urate excretion through the PI3K/Akt pathway.	Estradiol	47-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	80-121
34144706-2	2021	In the current study, we aimed to confirm that estradiol can promote intestinal ATP binding cassette subfamily G member 2 (ABCG2) expression to increase urate excretion through the PI3K/Akt pathway.	Estradiol	47-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	123-128
34144706-2	2021	In the current study, we aimed to confirm that estradiol can promote intestinal ATP binding cassette subfamily G member 2 (ABCG2) expression to increase urate excretion through the PI3K/Akt pathway.	Uric Acid	153-158	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	80-121
34144706-2	2021	In the current study, we aimed to confirm that estradiol can promote intestinal ATP binding cassette subfamily G member 2 (ABCG2) expression to increase urate excretion through the PI3K/Akt pathway.	Uric Acid	153-158	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	123-128
34484661-10	2021	Interestingly, VCM (600 mg/kg, body weight) resulted in the induction of Oct2-Mate1 and Oat1/3-Mrp2/Mrp4/Bcrp pathways.	Vancomycin	15-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	105-109
34484661-11	2021	However, VCM (400 mg/kg, body weight) caused the induction of Oct2-Mate1/Mate2 and Oat1/3-Mrp4/Bcrp pathways.	Vancomycin	9-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	95-99
35314999-6	2022	RESULTS: The estimated unbound brain to plasma concentration ratio (Kp,uu,brain) of aripiprazole was estimated as 0.67 in wild-type mice and 1.94 in abcb1a/1b/abcg2 knockout mice, suggesting the involvement of both uptake and efflux transporters in BBB permeation.	Aripiprazole	84-96	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	159-164
35192958-3	2022	In vitro, sotorasib was a potent substrate for human ABCB1 and a modest substrate for mouse Abcg2, but not for human ABCG2.	AMG-510	10-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	92-97
35192958-4	2022	In vivo, the brain-to-plasma ratio of sotorasib (40 mg/kg) was highly increased in Abcb1a/1b-/- (5.9-fold) and Abcb1a/1b;Abcg2-/- (7.6-fold) compared to wild-type mice, but not in single Abcg2-/- mice.	AMG-510	38-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	121-126
35192958-4	2022	In vivo, the brain-to-plasma ratio of sotorasib (40 mg/kg) was highly increased in Abcb1a/1b-/- (5.9-fold) and Abcb1a/1b;Abcg2-/- (7.6-fold) compared to wild-type mice, but not in single Abcg2-/- mice.	AMG-510	38-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	187-192
35192958-5	2022	Upon coadministering elacridar, an ABCB1/ABCG2 inhibitor, sotorasib brain accumulation increased 7.5-fold, approaching the levels observed in Abcb1a/1b-deficient mice.	AMG-510	58-67	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	41-46